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VI. Abstract 
Periodontitis results in destruction of tooth supporting structures, eventually leading to 
tooth loss, and it affects ~10% of the world’s population. Key to its onset and progression is 
a complex relationship between the periodontal bacteria and the host inflammatory 
response. The bacteria most associated with severe periodontitis are the so-called 
periodontal pathogens of the red complex- Tannerella forsythia, Treponema denticola, and 
Porphyromonas gingivalis. These organisms all express sialidases, which cleave sialic acid 
from host glycoproteins, and this is believed to contribute to disease. 
Considering this, the aims of this project were to further characterise the sialidases of T. 
forsythia and P. gingivalis (NanH and SiaPG), to test their inhibition with commercially 
available chemotherapeutics, and the effect this has on in vitro models of virulence. 
NanH and SiaPG were successfully purified by affinity chromatography. The enzymes were 
shown to possess a high degree of activity over various conditions and on different sialic 
acid ligands. Importantly, both sialidases could be inhibited using the commercially 
available chemotherapeutic zanamivir (supplied by GlaxoSmithKline, UK) which laid the 
groundwork for studies testing inhibition of virulence. 
The accessory enzyme NanS was shown to bolster sialic acid release from bovine salivary 
mucin by both NanH and SiaPG. This was important for nutrient acquisition, since NanS also 
enhanced the growth of P. gingivalis in defined media where serum and saliva were the 
only nutrient sources. These findings also hinted at the possibility of interspecies 
cooperation in sialic acid release from host sources. Zanamivir also inhibited biofilm 
formation of P. gingivalis on oral-relevant glycoprotein sources. 
Zanamivir was also shown to be capable of inhibiting attachment and invasion of oral 
epithelial cells by P. gingivalis, T. forsythia, and the sialidase negative pathogen 
Fusobacterium nucleatum, even when multiple species were present during infection. 
Finally NanH was shown to part-mediate pro-inflammatory signalling in oral epithelial cells 
in response to P. gingivalis LPS, and zanamivir prevented pro-inflammatory cytokine 
release in cells infected with T. forsythia. This highlighted multiple mechanisms by which 
sialidase inhibition can prevent host-pathogen interactions. 
This study broadens our understanding of the multifarious roles of bacterial sialidases in 
virulence, and indicates that their inhibition with chemotherapeutics could be a promising 
strategy for periodontitis therapy.  
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1 Chapter 1: Introduction 
1.1 Teeth and major oral diseases 
The major oral infections that affect human teeth and gums are outlined in figure 1.1 and 
range from classical tooth decay (or caries) to root canal infection and periapical abscess 
formation. Severe gum inflammation often leads to periodontitis, which will be discussed at 
length below. In short they are caused chiefly by the build up of large amounts of bacterial 
(or fungal) colonisers within the various environmental niches of the teeth, namely hard 
tooth surfaces (bathed in oral secretions), gums (gingiva) and underlying niches exposed 
once infection sets in.  One of these underlying environments is termed the periodontium, 
or supporting structures of the tooth (periodontal ligament, alveolar bone, gingiva 
cementum). In disease, this site may be colonised by various micro-organisms, leading to 
inflammation and the onset of periodontitis (figure. 1.1).  
1.1.1 Periodontitis 
Simply put, periodontitis describes a condition involving inflammation of the periodontal 
tissues, which can often lead to their destruction.  In periodontitis, gingiva recede, the 
patient suffers from loss of tooth attachment, and in severe or chronic cases, eventually 
tooth loss. This is distinct from other non-destructive periodontal diseases such as gingivitis 
(where the gingivae suffer from inflammation as a result of infection but is completely 
reversible). Clinically, periodontitis is assessed by use of a probe, which attempts to gauge 
the depth of the periodontal pocket (in millimetres); ideally from the cemento-enamel 
junction (an anatomical border where the cementum meets enamel) to the bottom of the 
periodontal pocket. This measurement is termed “Clinical Attachment Loss” (CAL). Other 
clinical assessments include the presence of periodontitis at different sites (i.e. more than 
one tooth), the proximity of multiple affected sites, and the presence of bleeding at a given 
site. In addition to the clinical presentation, the age of the patient (periodontitis usually 
affects adults, but occasionally it may affect young people as well), the rate of disease 
progression, and its response to therapy have led to the development of a classification 
system to describe periodontitis (this is summarised in table 1.1, for a complete list see 
Armitage, 1999). 
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Figure 1.1. Cross-sectional representation of a posterior tooth in health and disease. 
Various tissues that comprise the tooth and its supporting periodontium are labelled. In 
health all structures are intact, including the gingival-tooth junction which forms a tight 
seal between tooth and gum.  The major infections affecting teeth are illustrated, resulting 
from prolonged plaque biofilm build-up (green material) with caries forming during enamel 
decay and further penetration through the tooth structures in to the soft tissue and in 
some cases erupting from the apical foramen to cause periapical infections, which can also 
be contributed to by migration of subgingival biofilm bacteria in severe periodontal disease 
(indicated by arrows).  Periodontitis is illustrated with the classical gum recession, 
formation of deep periodontal pockets and a proliferation of subgingival bacteria (green 
circles).  Reproduced from “Advances in Micobial Physiology, Chapter 6: Physiological 
Adaptations of Key Oral Bacteria” (2014), volume 65, with permssion from Elsevier, license 
number 4013100857114. 
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Table 1.1. Clinical descriptive terms for periodontitis. 
(Based on the summary described in Armitage 1999.) 
 As well as its importance in assessing disease in a given patient, the ability to quantify 
periodontitis is valuable for semi-quantitative research, where CAL and the presence of 
bleeding are frequently used to divide patients/affected sites into different categories, such 
as those with “mild” “moderate” and “severe” periodontitis (Eke et al. 2012). The other 
clinical descriptions discussed above may also be included to further delineate 
periodontitis-patient groups.  
1.1.2 Periodontitis-A Considerable Burden 
Even though the contribution of periodontitis to other diseases is still under debate 
(section 1.3), it can be said with certainty that this condition has a high prevalence, with 
meta-analyses placing global prevalence at ~10-11% (Kassebaum et al. 2014; Marcenes et 
al. 2013), or 743 million people (Kassebaum et al. 2014). Periodontitis prevalence may also 
Clincal Category Sub Category
Distinguishing Features of 
Subcategory
Notes
localised 
low number of teeth/sites affected, 
in the same quadrant
generalised
multiple teeth affected, in different 
quadrants
localised 
low number of teeth/sites affected, 
in the same quadrant
generalised
mutliple teeth affected, in different 
quadrants
associated with 
hematological disorders
includes acquired neutropenia, 
leukaemia, and other blood 
disorders
associated with genetic 
disorders
includes a number of inherited 
conditions
necrotizing ulcerative 
gingivitis
necrotizing ulcerative 
periodontitis
Periodontal Abcess
gingival, periodontal, or 
pericoronal abcess
Periodontitis 
Associated with 
Endodontic Lesions
localized tooth-related 
factors that pre-dispose to 
periodontal disease
may include tooth trauma or 
abnormality, and denal 
restorations/appliances
mucogingival deformities
includes all manner of soft tissue 
deformities
occlusal trauma-damage to 
the cusp tips or incisal edge of 
teeth
may be caused by, or a causative 
factor of, periodontitis
secondary or 
primary 
respectively
Chronic Periodontitis
Aggressive 
Periodontitis 
Periodontitis As a 
Manifestation of 
Systemic Diseases
previously 
referred to as 
"juvenile 
periodontitis"
Developmental or 
Acquired Deformities 
and Conditions
Necrotizing 
Periodontal Diseases
the key difference is that tissue 
destruction in the latter condition is 
irreversible
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increase in the future, since its incidence is associated with age, and the mean age of the 
population is increasing (particularly in developed countries).  
Some evidence for an increase in periodontitis incidence over time can be seen in the USA, 
where the number of periodontitis interventions has ~doubled in two decades (Flemmig & 
Beikler 2013). Furthermore, in the UK, a recent and highly comprehensive study of oral 
health -the 2009 Adult Dental Health Survey- showed that although the prevalence of 
moderate periodontitis had reduced relative to the previous decade, the number of cases 
of severe periodontitis had increased from 6 to 9% (White et al. 2012).  
1.2 Periodontitis-Aetiology 
As described above, periodontitis is an inflammatory condition, believed to be initiated by 
gingivitis, initial inflammation resulting in conditions that favour the growth of certain more 
virulent bacteria over commensal microflora-for the purposes of this thesis (and in 
accordance with nomenclature used in other research) this latter group will be referred to 
as the periodontal pathogens. The change in conditions results in a shift in the periodontal 
microbiota, termed “dysbiosis” (discussed below, section 1.2.1) and is correlated with 
periodontitis progression, with pathogens thought to cause inflammation through a 
number of mechanisms (discussed below, section 1.2.2). However, bacteria are not the 
only factors involved in causing the inflammation that is ultimately responsible for 
periodontitis, and in fact much of the destruction is caused by the reaction of the host 
immune system itself (see below).  
1.2.1 Bacterial Colonisation of the Periodontium and its Role in Periodontitis 
One of the key aspects of microbial ecology is that bacteria do not exist as static groups of a 
single species, but as part of a dynamic ecosystem with levels of different species 
constantly changing as a result of varying conditions. The oral microbiota is no different.  
In terms of the oral cavity this diversity was first noticed by the earliest microscopy 
experiments in the late 1600s by van Leeuwenhoek, and has been used to observe 
morphologically distinct bacteria in plaque. Progressively improving techniques including 
electron microscopy provided a comprehensive picture of how different tooth surfaces are 
colonised (Listgarten 1976).  In supragingival plaque, salivary proteins coat the tooth 
surface, forming the pellicle. The pellicle permits attachment of Gram positive cocci, 
termed “early colonisers”. Later, firmicutes, including the streptococci can be seen 
distributed throughout the plaque. These are ‘intermediate colonisers’. At this stage, 
conditions vary considerably between different positions in the plaque; for example, 
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adjacent to the tooth the plaque is anaerobic compared to the external surface. This 
change in conditions is thought to facilitate proliferation of ‘late colonisers’, including 
pathogens associated with severe periodontitis. 
Sub-gingival plaque formation in the gingival crevice (figure 1.1) eventually initiates 
periodontal disease. The role of bacteria as aetiological agents in gingivitis is well 
characterised: for example Porphyromonas gingivalis has been shown to be present in a 
high proportion of gingivitis cases, and in approximately one third of severe cases of 
periodontal disease (Rôças et al. 2001). In periodontitis, the role of specific organisms is 
less clear-cut than in other infectious diseases: Symptoms have not been confined to a 
single organism but rather complexes of organisms, and the same bacterial species may be 
present in different hosts with or without periodontal disease. This highlights the 
importance of other factors in the onset and progression of periodontal disease. 
However, periodontitis, like gingivitis is marked by a shift in the microbial population, a fact 
that was noted during the classic studies of Loe and colleagues in the 1960s (Theilade et al. 
1966; Loe et al. 1965), but built upon in terms of periodontal disease in the classic studies 
by Socransky and colleagues in the late 1990s  (Ximénez-Fyvie et al. 2000; Socransky et al. 
1998)  and later built upon by many others. These authors used the then-new technique, 
DNA hybridization checkerboard analysis to quantify the levels of different bacteria in sub- 
and supra-gingival plaque of healthy and diseased periodontium from large patient cohorts. 
Overall bacterial load was increased in disease cases, and the proportion of different 
species between health and disease was also affected: Streptococci, Veillonella, and 
Capnocytophaga species were associated with healthy periodontium, while Campylobacter 
and Fusobacterium species were associated with disease, and most associated with severe 
disease were P. gingivalis, Tannerella forsythia (formerly Tannerella forsythensis and 
Bacteroides forsythus) and the spirochaete Treponema denticola. 
Furthermore, cluster analysis was used to identify these bacteria as members of different 
consortia associated with periodontal disease progression, giving rise to the concept of 
colour coded bacterial complexes associated with health and disease (figure 1.2); the 
proportion of the periodontal microbiota accounted for by the different complexes varies 
between health and disease, with a higher proportion of what were termed orange and red 
complex organisms (figure 1.2) associated with more severe disease. The emergence of 
next-generation sequencing technologies has further validated this association (Liu et al. 
2012, Jünemann et al. 2012),  and shown the presence of novel non-culturable organisms 
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belonging to the recently described un-named TM7 and SR1 phyla in addition to the 
already allocated ‘red-complex’ bacteria (Dewhirst et al. 2010, Liu et al. 2012).  This work 
also identified potential contributions from several less well studied organisms such as 
Filifactor alocis, which may now describe an expanded ‘red-complex’ (Schlafer et al. 2010; 
Griffen et al. 2012) .  However, research has yet to establish how crucial these organisms 
are in vivo, despite a proliferation of in vitro experiments (Aruni et al. 2014). 
Since these early studies describing the microbial complexes involved in periodontitis, the 
term “dysbiosis” has been coined to describe the complicated shifts in microbiota that are 
associated with disease in conditions including periodontitis (Darveau 2010; Hajishengallis 
et al. 2012) and other conditions such as inflammatory gastro-intestinal (GI) diseases 
(Matsuoka & Kanai 2015). The association of shifts in the microbiota (or dysbiosis) and the 
resulting inflammation is probably the most widely accepted cause of periodontitis, 
although other factors (section 1.2.3) do play roles in modulating inflammation and 
microbiota shifts.  
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Figure 1.2. Periodontal bacteria complexes in the subgingival plaque. 
Purple complex: Veillonella parvula and Actinomyces odontolyticus. Green complex: 
Eikenella corrodens, Capnocytophaga gingivalis, Capnocytophaga sputigena, 
Capnocytophaga ochracea, Campylobacter concisus, and Agrigatibacter 
actinomycetemcomitans. Yellow complex: Streptococcus mitis, Streptococcus oralis, 
Streptococcus sanguis, Streptococcus gordonii, and Streptococcus intermedius. Orange 
complex: Campylobacter gracilis, Campylobacter rectus, Campylobacter showae, 
Streptococcus constellatus, Eubacterium nodatum, Prevotella intermedia, Prevotella 
nigrescens, Peptostreptococcus micros, Fusobacterium nucleatum, and Fusobacterium 
periodonticum. Red complex: Porphyromonas gingivalis, Tannerella forsythia, and 
Treponema denticola. Non-clustered associated bacteria: Aggrigatibacter 
actinomycetemcomitans, Selenomonas noxia, and Actinomyces naeslundii.  (Adapted from 
Socransky et al. 1998, with permission from John Wiley and Sons, license number 
3990801197733.) 
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1.2.2 The Importance of Inflammation in Periodontitis 
 Given that the presence and levels of different bacteria cannot predict the outcome of 
periodontitis, or explain why different patients respond differently to treatment, the role of 
the host immune system has been extensively studied. Cellular and humoral effectors are 
regulated by immune signalling molecules, which are themselves modulated by the 
presence of bacteria.  
 Overview of the Response to Periodontal Pathogens and Innate Immunity 1.2.2.1
Epithelial cells, fibroblasts, and innate immune cells are all encountered by pathogens on 
colonisation of the periodontium, and all of these cells are capable of contributing to the 
inflammatory response. Epithelial cells are the first encountered during colonisation and 
secrete a number of cytokines, including interleukin-8 (IL-8, also known as CXCL8), which is 
responsible for increasing blood vessel permeability and GCF flow, neutrophil migration 
and monocyte adhesion in blood vessels (Hajishengallis & Hajishengallis 2013). 
Pathogens may penetrate the oral epithelium, making contact with gingival and 
periodontal ligament fibroblasts. Similarly to epithelial cells, fibroblasts secrete pro-
inflammatory cytokines including IL-6, IL-8, and tumour necrosis factor (TNF), and other 
cytokines. This fibroblast response has been shown to be important in maintaining 
inflammation and potentially plays a role in periodontal disease progression, even though 
this is less well understood than epithelial cell interactions (Morandini et al., 2010; Sun, 
Shu, Li, & Zhang, 2010).  
Many of the responses by the innate immune system are initiated by the interaction of 
several conserved bacterial surface components such as lipopolysaccharide (LPS) of Gram-
negative bacteria, teichoic acids of Gram positives and other repeating structures of various 
pathogen types such as flagella, pili and surface proteins.  In addition, lysed bacteria release 
genetic material that is also recognised by innate immune components.  As a whole these 
conserved molecules are known as ‘pathogen associated molecular patterns' (PAMPS).  It is 
the recognition of these PAMPs by pattern recognition receptors (or PRRs, such as Toll-like 
receptors, (TLRs, reviewed later in this introduction) that elicits the release of host 
cytokines by cells that initially encounter pathogens, such as epithelial cells.  As a result 
these signals cause the recruitment of immune cells such as neutrophils and macrophages 
which in turn then release further pro-inflammatory cytokines including tumour necrosis 
factor-α (TNF-α), IL-6, and IL-1 (Shaddox et al. 2011; Morandini et al. 2010).  It is well 
established that during periodontitis, levels of these cytokines correlate with both 
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inflammation but also increased bone resorption (reviewed in Di Benedetto, et al., 2013), 
though ultimately production of receptor activator of nuclear factor κB (RANKL) is 
responsible for the imbalance in osteoblast and osteoclast turnover that causes bone 
resorption (favoured by the increase in osteoclast number and activity). These signals, 
produced primarily by PAMP-activated neutrophils cause changes in macrophage 
phenotype, which themselves also express pro-inflammatory cytokines in the presence of 
PAMPS (Bodet & Grenier 2010).  
In addition to neutrophils and macrophages, dendritic cells (DCs) are another group of 
innate immune cells with professional phagocytic capacity. These are present in the 
epithelia of blood vessels and within mucosal surfaces, including the gingiva, and in 
addition to cytokine production these cells also act to stimulate adaptive immunity as 
antigen presenting cells: DCs migrate from the epithelia to lymph nodes, where they are 
effective in stimulating T- cells, including Cytotoxic T-lymphocytes, also called natural killer 
T-lymphocytes (NKTs). Periodontitis lesions are rich in mature DCs, distinct from DCs in the 
surrounding gingival tissue (and in non-chronic tissue infections) because DCs typically 
mature as they migrate to lymph nodes (Tew et al. 2012), a trait also seen in other chronic 
conditions (such as atherosclerosis). In addition to production of pro-inflammatory 
cytokines, mature DCs may contribute to inflammation by antigen presentation on the 
CD1d receptor, which is recognised by NKTs, and some periodontal pathogens appear to 
activate specific subclasses of NKTs through antigen processing by DCs.  For example, A. 
actinomycetemcomitans stimulates type 1 NKTs via antigen presentation by DCs in vitro, as 
does P. gingivalis in the presence of exogenous IFNγ, hinting at the importance of DCs in 
periodontal disease progression.  
 Innate Immune Components and Periodontitis 1.2.2.2
Neutrophils and macrophages are considered the most important sources of pro-
inflammatory cytokines in periodontitis, which contribute to the switching of host cell 
phenotypes to states more associated with disease. In the case of innate immunity, this 
means overactivation of neutrophils to produce a number of cytokines and increased 
migration into the periodontium (section 1.2.2.2.1), and for macrophages it means the 
majority of the population differentiate to become “M1” macrophages-associated with 
inflammation, rather than “M2”-associated with healing and inflammatory regulation 
(section 1.2.2.2.2).   
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1.2.2.2.1 Neutrophils 
Neutrophils are terminally differentiated leukocytes, which differentiate in the bone 
marrow and enter cardiovascular circulation. IL-17 is the major cytokine associated with 
activation and recruitment of neutrophils, as it causes up-regulation of granulocyte colony 
stimulating factor (GCSF). Circulating neutrophils migrate to endothelial cells of tissues 
throughout the body, following a chemokine gradient of host secreted factors. At the 
gingivae, neutrophils migrate into the gingival crevice, coordinated by the presence of 
localised gradients of CXCL8, ICAM-1, and E-selectin (Hajishengallis & Hajishengallis 2013).  
Once at the endothelium of the target tissue (gingivae) neutrophils utilise glycoprotein 
ligands-for example, the sialoglycan residue sialyl lewis X is important in mediating this 
interaction (Lowe 2003)-to bind endothelial cell surface E-selectin and initiate “crawling 
motility”, which leads ultimately to integrin dependent tight adhesion. Tight adhesion is 
mediated by integrin LFA-1 on neutrophils which binds the ICAM-1 receptor on endothelial 
cells, and the neutrophil moves via crawling motility to endothelial tight junction-a site 
suitable for transmigration-movement across the endothelium (Ley et al. 2007). Once they 
have reached their target tissue-in this case the periodontium-they are activated by 
stimulation of various receptors. These include TLRs, cytokine receptors, and perhaps most 
importantly the Fcγ receptor IIa, which binds Fcγ (heavy, conserved antibody chain)-
important for recognition of antigens, which may be present on bacterial surfaces. 
Stimulation of the neutrophil via the Fcγ receptor IIa triggers a phagocytic response by the 
neutrophils, where bacteria are engulfed in intracellular vesicles-phagosomes, which fuse 
with lysosomes, forming phagolysosomes-an important mechanism in bacterial clearance. 
These phagolysosomes contain reactive oxygen species (ROS), and neutrophil serine 
proteases, including cathepsin G and neutrophil elastase- all of which are bactericidal.  In 
addition these and other antibacterial products can also be released during degranulation, 
a poorly understood process by which neutrophils release pre-stored vesicular granules 
that act on extracellular microbes but also possibly contribute to inflammation and tissue 
damage in many conditions (Lacy 2006). Tissue damage leads to the production of host-cell 
derived damage associated molecular patterns (DAMPS) these include host DNA, chromatin 
associated proteins, heat shock proteins and intracellular metabolites such as uric acid (Shi 
et al. 2003; Kang et al. 2015). An additional, recently discovered function of activated 
neutrophils is the production of neutrophil extracellular traps (NETs). These consist of 
chromatin; DNA-and associated proteins such as histones, polysaccharides, and 
antimicrobials (White et al. 2016), which function by immobilisation and entrapment of 
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microbes-preventing further invasion of the tissue before killing with degranulation 
products.  NETs were described relatively recently, with their role in periodontitis still 
under some debate: Studies of patients have found that levels of NETs are increased during 
periodontitis compared to healthy sites (Vitkov et al. 2009), and it has been suggested that 
the inability to clear NETs results in increased concentrations of neutrophil pro-
inflammatory products, contributing to destructive inflammation. On the other hand, a 
decrease in the levels of NETs may contribute to disease progression-periodontitis is an age 
related condition, and age has been associated with decreases in NET production 
(Hazeldine et al. 2014). However, the contribution of NET production to disease is unclear 
since aging causes other effects that probably contribute to periodontitis. 
 Neutrophils have a short lifespan after differentiation, and are cleared after 6-8 hours, 
through apoptosis and phagocytosis by macrophages with phagocytic clearance playing an 
important role in downregulation of neutrophil recruitment, due to inhibition of IL-23, 
which mediates IL-17 production (Stark et al. 2005) . Evidence for the importance of 
neutrophils in periodontitis comes from observations of patients with deficiencies in 
neutrophil production- known as neutropenia, a condition that arises under a variety of 
circumstances including autoimmune disease, HIV/AIDS, or as a result of chemo- or 
radiotherapy treatments and also in a wide range of congenital genetic conditions  
(Donadieu et al. 2011) such as Fanconi anaemia that are associated with severe periodontal 
disease (Goswami et al. 2016).  Interestingly, one study noted an improvement in oral 
health with recombinant GCSF treatment as part of an attempt to restore immunological 
status (Matarasso et al. 2009). 
Excessive neutrophil activation may also contribute to periodontitis, due to their multiple 
pro-inflammatory mechanisms (ROS, and proteases can damage host cells, and stimulated 
neutrophils produce pro-inflammatory cytokines). Studies of periodontitis patients have 
linked disease severity with neutrophil hyper-reactivity, and disease severity has been 
associated with a single nucleotide polymorphism in the genes encoding Fcγ receptor IIa 
(Yamamoto et al. 2004), implying that neutrophil sensitivity to stimuli does play a role in 
periodontal disease. Several neutrophil responses may be involved in periodontitis: 
Neutrophil elastase (and other proteases) are elevated during periodontitis, and elastase  is 
thought to be predictive (with other biomarkers) for periodontitis progression (Gul et al. 
2016).  
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1.2.2.2.2 Macrophages 
Peripheral blood monocytes migrate through the endothelium and differentiate to 
macrophages, which phagocytose bacteria and produce a variety of cytokines, playing a 
role in clearance of pathogens and in regulation of inflammation. On activation by bacteria, 
bacterial products, or cytokines/chemokines, macrophages can display varying phenotypes, 
a process termed polarisation. Macrophages may polarise into one of two subtypes, M1 or 
M2, although there is no strict distinction between the two, with macrophages falling on a 
spectrum from M1 to M2, with some macrophages termed “regulatory macrophages” 
(Sima & Glogauer 2013). In essence, M1 macrophages are considered pro-inflammatory, 
secreting IL-6, Il-8, and TNF among other cytokines, while M2 macrophages are considered 
to be associated with healing, secreting IL-10 and other factors. This is reflected in 
periodontitis, with several studies indicating that the M1 subpopulation is the dominant 
subset during periodontitis (Gonzalez et al., 2015; Yu et al., 2016, and others), although a 
recent study highlighted the potential for M1 macrophages to downregulate 
osteoclastogenesis in vitro (Yamaguchi et al. 2016), suggesting a more complicated picture 
for the role of macrophage subsets in periodontitis.  
1.2.2.2.3 Toll-Like Receptors 
Toll like receptors (TLRs) are expressed by multicellular eukaryote hosts, and impact heavily 
on bacterial infections due to their function in recognising PAMPs, and activating various 
inflammatory signalling cascades. At least ten TLRs have been characterised in humans, 
associated with the plasma membrane (TLRs -1, -2, -4, -5, -6, -10) and intracellular 
endosomes (TLRs -3, -7, -8, -9). All TLRs consist of a an extracellular leucine rich repeat 
(LRR) region involved in ligand binding, a membrane spanning, and a cytosolic TLR/IL-1R 
(TIR) domain which functions in signal transduction. The TLRs and their intracellular 
signalling are summarised in figure 1.3. 
TLRs -2, -4 and -9 are thought to be those responsible for immune signalling resulting in 
inflammation during periodontitis, as these TLRs have been shown to be upregulated in 
patients with aggressive periodontitis, both localised and generalised (Sahingur et al. 2013; 
Wara-Aswapati et al. 2012; Kikkert et al. 2007). TLR-2 recognises peptidoglycan and 
bacterial lipoproteins, and has been shown to be up-regulated in periodontal ligament cell 
lines exposed to P. gingivalis, P. intermedia, F. nucleatum, or A. actinomycetemcomitans 
(Sun et al. 2010). T. forsythia has also been shown to induce pro-inflammatory cytokines 
through TLR-2 activation via Bacteroides surface protein A-discussed later (Kikkert et al. 
2007). 
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TLR-4 recognises bacterial LPS, and while the importance of TLR-2 appears clear cut, the 
role of TLR-4 for certain periodontal pathogens is less well defined. P. intermedia, F. 
nucleatum, or A.actinomycetemcomitans but not P. gingivalis have been shown to induce 
production of pro-inflammatory cytokines through TLR-4. Some studies indicate that P. 
gingivalis LPS does not readily activate TLR-4, only doing so in high concentrations (Wara-
Aswapati et al. 2012). On the other hand, comparison of pro-inflammatory cytokines in 
periodontitis-patient blood showed that periodontal therapy results in a decreased 
sensitivity to P. gingivalis LPS (Kikkert et al. 2007). These findings highlight the importance 
of different species acting synergistically to stimulate multiple TLRs and cause inflammation 
during periodontitis. 
TLR-9 is activated by non-methylated CpG DNA motifs found in bacteria and viruses. TLR-9 
has been shown to be upregulated during periodontitis, in tissues affected by periodontitis 
(Sahingur et al. 2013), and in cell lines challenged with P. gingivalis. The up-regulation of 
TLR-9 is also of interest as herpesviruses have been shown to be associated with 
periodontitis (Alexandra et al. 2008; Grande et al. 2011). It is therefore entirely possible 
that bacteria and viruses act synergistically in activation of TLR-9, and when coupled with 
additional pro-inflammatory signalling of TLRs -2 and -4 this causes more severe disease 
compared to infection with bacteria alone. 
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Figure 1.3. Summary of TLR activation and key signalling events leading to pro-
inflammatory signalling. 
TLR-4 and -5 form homodimers on binding to their ligands; TLR-5 recognises flagellin, while 
TLR-4 recognises lipid A of LPS through LPS binding protein (LBP), and activation through 
formation of a complex with myeloid differentiation factor 2 (MD2) and CD14. TLR-2 forms 
a heterodimer with TLR-1 or -6 on binding either triacetylated or diacetylated lipopeptides, 
respectively. TLR-1 appears to share ligand specificity with TLR-2, and may have other 
unique ligands. The ligands for the intracellular TLRs -7 and -8 are single stranded (ss) RNA, 
TLR-9; unmethylated CpG rich DNA, while TLR-3 recognises double stranded (ds) RNA. All of 
the intracellular TLRs form homodimers on binding their ligands. All TLRs with the 
exception of TLR-3 signal through myeloid differentiation factor 88 (MyD88), which 
requires an interaction between TIR and a MyD88 adaptor-like (MAL) Protein. MyD88 
complexes with Il-1 receptor associated kinase (IRAK) proteins, sometimes termed the 
“myddosome”, and this allows signalling through TNF receptor associated factor (TRAF) 6. 
Through further signalling molecules, this ultimately results in degradation of inhibitor of 
NFκB (IκBα), releasing p50 and p65, and formation of the NFκBp65p50 complex, a key 
promoter of pro-inflammatory gene expression.  Some intermediate signalling molecules 
are not shown, indicated by dotted lines (reviewed in Gay, Symmons, Gangloff, & Bryant, 
2014; McClure & Massari, 2014). 
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Two other pro-inflammatory promoters are also activated downstream of TRAF 6, cAMP-
responsive element-binding protein (CREB), and Activator Protein 1 (AP-1). TLR-3 does not 
act through the myddosome, instead operating through TIR domain-containing adaptor 
protein inducing IFNβ (TRIF), which may activate TRAF6 and associated downstream 
signalling, but primarily acts to stimulate an antiviral response: TRIF activates a signalling 
cascade which activates IFN-regulatory factor (IRF) promoters, resulting in expression of 
interferon (IFN) stimulated response elements (ISREs) 3 and 7, production of type I IFN, and 
ultimately, stimulation of other antiviral responses such as T-cell activation. All signal 
transduction pathways are part-regulated by cross-talk during regulation of apoptosis or 
cell survival. 
1.2.2.2.4 Complement 
 Complement is present in human serum, including GCF and functions directly in innate 
immunity through bacterial killing or opsonisation, and can stimulate cytokine production 
and activation of innate or adaptive immune cells. Complement activation occurs via a 
protein cascade (designated C1-9) and may occur through one of three pathways; classical, 
lectin binding, or alternative, as summarised in figure 1.4. Ultimately, the pathway results 
in production of membrane attack complexes (MACs) on pathogen surfaces, causing them 
to lyse. Complement also marks pathogens for phagocytosis (termed opsonisation). 
(reviewed in G. Hajishengallis, 2010). Given the involvement of complement in a variety of 
immune functions, over-stimulation or disruption of regulatory pathways can result in or 
influence disease progression. 
Multiple mechanisms involving complement upregulation have been linked with 
periodontitis. It was observed that patients with periodontal disease have increased 
complement cleavage products in their GCF (Schenkein & Genco 1977), and more severe 
periodontal disease (increased pocket depth) is associated with an increase in cleavage 
products (Niekrash & Patters, 1986). An experimental human gingivitis model also showed 
a positive correlation between inflammation (gingival indices and BOP ), and increased 
cleavage products (Patters et al. 1989). In addition, periodontitis therapy  reduces the 
amount of complement cleavage products in the GCF of patients being treated for 
periodontitis, and decreases levels of C3 gene expression (Niekrash & Patters, 1986). 
Furthermore, expression of C3 by gingival tissue is also down-regulated following non-
surgical periodontal treatment, relative both to before-treatment, and to healthy control 
patients (Beikler et al. 2008). 
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This correlation between complement cascade upregulation and periodontal disease hints 
at a possible role of complement in causation of periodontitis, but is unsurprising given the 
corresponding increase in bacterial load seen in study participants-i.e. upregulation of the 
complement system could be a product of periodontal disease rather than a contributing 
factor. However, it has been shown that C3b and C5a complement factors are required for 
alveolar bone loss during P. gingivalis infection in murine models, and that expression of 
pro-inflammatory cytokines (TNF, IL-1β, IL-6, and IL-17)  is inhibited by a C5aR antagonist  
(Liang et al. 2011, Abe et al. 2012). A C5aR antagonist was also shown to reduce expression 
of pro-inflammatory cytokines and inhibit alveolar bone loss in a murine model of 
periodontitis. These studies point to the importance of C5a in up-regulation of other 
inflammatory responses rather than other complement factors in direct cellular killing (i.e. 
autoimmunity through deposition of complement on host cells). Therefore, complement 
and C5a activation in particular is important in promoting inflammation, and together with 
TLR based signalling determines the progression of periodontitis (Hajishengallis & Lambris 
2010).   
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Figure 1.4.  The complement cascade featuring complement (C) proteins 1-9. 
The classical pathway begins at the antigen-antibody (Ag-Ab) complex, to which the C1q 
subunit of C1 binds, activating and causing C4 and C2 cleavage. The lectin pathway also 
causes C4 and C2 cleavage, but is initiated by mannose binding lectin (MBL) which 
recognises bacterial glycans. C4 and C2 cleavage results in formation of C3 convertases 
C4bC2b and C3bBb (The C2a and C4a subunits diffuse away). The alternative pathway 
results from hydrolysis of C3 to C3(H2O), a C3b analogue. The presence of factors B and D, 
results in formation C3(H2O)Bb, another C3 convertase. At this point, all three pathways 
converge, and the C3 convertases cleave C3 to C3b and C3a. C3b acts during opsonisation 
through the complement receptors (CRs) 1 and 3 present on phagocytic cells, but may also 
interact with previous products of the cascade to form C5 convertases; C4bC2bC3b, and 
C3bBbC3b. C5 is then cleaved into two subunits, with functions for both products. C5a and 
C3a both regulate the C3a receptor (C3aR) and C5a receptor (C5aR, of which there are two, 
C5a1 and C5a2) G-protein coupled receptors (GPCRs) on leukocytes, resulting in leukocyte 
activation and migration-and ultimately upregulation of inflammation. C5a also interacts 
with C5aR-like (C5aRL) GPCR, which has regulatory roles in complement-mediated 
activation of leukocytes. C5b begins the terminal pathway, binding to (microbial) cell 
membranes, and forming a complex with C6-9, which is termed the membrane attack 
complex (MAC). This results in bacterial lysis, or host signalling at sub lytic concentrations 
(Reviewed in  Hajishengallis & Lambris, 2010; Hajishengallis, 2010). 
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 Adaptive Immune Response 1.2.2.3
T- and B- cells differentiate and mature in the lymph nodes, and may migrate to host 
tissues. Both groups of lymphocytes have been found in periodontitis lesions, implying a 
role for both during periodontitis.  Several studies indicate that B-cells and a humoral 
immune response do not contribute to clearance of periodontal pathogens and resolution 
of periodontitis: Mice immunised with the pathogens P. gingivalis and F. nucleatum express 
circulating antibodies against these pathogens in their serum, but when infected with both 
P. gingivalis and F. nucleatum this does not illicit protection from colonisation and disease 
(Choi et al. 2001; Gemmell et al. 2002). More recently however, immunization of mice 
utilizing certain adjuvants or specific P. gingivalis proteins to generate specific anti-
virulence factor antibodies has shown that given appropriate stimulation, B-cells and 
antibody production can contribute to periodontal disease resolution (Wilensky et al. 2016; 
Curtis et al. 1999). 
T-cells definitely play a part in periodontitis progression, but the picture is complex. Earlier 
histological studies of periodontitis lesions seemed to show that T-cells were important in 
preventing periodontal disease, with the switch from a gingivitis to periodontitis lesion 
coinciding with decreases and increases of T- and B- cell levels, respectively (Yamazaki et al. 
1993). In addition to confirming the association of B-cells with periodontitis, CD8+ T-cells 
were later shown to be important in suppressing osteoclastogenesis (Choi et al. 2001). 
However, CD8+ T-cells are not the only T-cell type present during periodontitis. Sub-
populations of T-helper (Th, also known as CD4+) cells have also been described, beginning 
with the Th1 and Th2 subsets, the levels of Th1 being considered most important in 
periodontitis progression since this subset expresses higher levels of RANKL (reviewed in 
Hienz, Paliwal, & Ivanovski, 2015). In addition, Th17 and Treg subsets of Th cells have been 
described, with pro- and anti-inflammatory roles, and over-stimulation of either subset 
seems to be capable of progressing periodontal disease:  T. forsythia has been shown to 
stimulate the proliferation of Th17 cells in mice via its surface-layer (discussed further in 
section 1.5.2), and this coincides with increased alveolar bone loss (Settem et al. 2013). The 
final subset of Th cells-Treg- has been shown to infiltrate periodontitis lesions to a greater 
extent than gingivitis lesions, possibly implying that they are important in mediating the 
switch to periodontitis (Nakajima et al. 2005). There is also a possibility of crosstalk 
between the innate and adaptive immune responses through Th cells (the Treg and Th17 
subpopulations), and the complement system. Increased activation of the complement 
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system has been shown to increase Th17 cell proliferation in mice stimulated by mannan 
(activating the lectin binding pathway), mice deficient in the receptor for C5a (C5aR) do not 
display increased Th17 cell proliferation (Hashimoto et al. 2010).  
1.2.3 Other Factors in Periodontitis Onset and Progression 
 Age  1.2.3.1
Severe periodontitis usually occurs from ~38-40 years of age, with severity sometimes 
increasing as the patient ages, but often remaining stable (Kassebaum et al. 2014). Indeed, 
its presence in children is often referred to as juvenile –or- early onset periodontitis, 
though these classifications are supposedly redundant, in favour of the term “aggressive 
periodontitis”, since age-dependent classification has never been validated (Armitage 
2013). In any case, aging and accompanying cellular senesensce in general is marked by 
progressive modifications to the immune system as a result of anti-stress responses, which 
primarily act to control aging. However, the progressive alterations to the immune system 
results in what in has been termed “immunosenescence” or “inflamm-ageing”, where 
extensive immune-modification results in greater susceptibility to infection, neoplasia, and 
autoimmunity (reviewed in Ebersole et al., 2016). However, biomarkers associated with 
age/immunosenescence and age-related conditions occur to similar extents in both healthy 
and non-healthy individuals (Baggio, et al. 1998). Furthermore, not all adults are affected 
by periodontitis, so other factors must play roles in modulating the microbiota and 
inflammatory response.  
 Diabetes and Obesity 1.2.3.2
Periodontitis is associated with diabetes (Eke et al. 2016) and obesity (Gaio et al. 2016), and 
it has been suggested that there may be a causal or bi-directional relationship between 
either condition and periodontitis. 
The majority of research between periodontitis and diabetes has focused on type 2 
diabetes, in which patient genetics, diet, and body mass index (BMI) play central roles 
resulting in resistance to insulin. Periodontitis has been suggested to cause increased 
susceptibility to type 2 diabetes by increasing circulating levels of TNF, which acts to cause 
insulin resistance through a number of mechanisms. The onset of diabetes causes 
neutrophil dysfunction as well as increased levels of IL-1 and TNF, both of which are 
considered important in periodontitis progression (reviewed in Gurav, 2012). 
Obesity or a high BMI also appears to be a risk factor for periodontitis (Eke et al. 2016; 
Suvan et al. 2015). In vivo rat models showed that obesity alone may be sufficient to induce 
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periodontitis (Cavagni et al. 2013), or exacerbate periodontitis symptoms (Cavagni et al. 
2015), as evidenced by alveolar bone loss in rats that were overweight due to high 
fat/calorie diets. Suggested mechanisms for this include increased circulating pro-
inflammatory cytokines in obese individuals (Vincent & Taylor 2006) and  increased 
oxidative stress in the periodontal pocket/GCF of obese individuals (Atabay et al. 2016).  
 Smoking  1.2.3.3
Smoking is a well-established risk factor in many diseases, and periodontitis is no exception 
(Eke et al. 2016). Suggested mechanisms linking smoking to periodontitis (reviewed in 
Johannsen, Susin, & Gustafsson, 2014) include exposure to higher levels of ROS (in 
cigarette smoke), decreased neutrophil migration, decreased levels of osteoprotegerin (the 
antagonist of RANKL), and decreased antibody production (smokers display decreased 
levels of serum Ig, particularly IgG2). 
1.3 Periodontitis-Systemic influences 
Although periodontitis does not cause mortality directly, it does have a high prevalence and 
considerable morbidity, and a growing body of evidence hints at its contribution to other 
conditions (reviewed in Han, Houcken, Loos, Schenkein, & Tezal, 2014). This includes head 
and neck cancer, atherosclerosis/heart disease, and other morbid conditions such 
rheumatoid arthritis. 
1.3.1 Head and Neck Cancer 
Although the possible correlation between head and neck (and other) cancers with 
periodontitis is well documented (Moergel et al. 2013; Tezal et al. 2005; Wen et al. 2014), 
establishing a causal relationship between the two is difficult due to the role of smoking in 
both conditions. However, it was been shown that in men who self-report as having-never-
smoked, the incidence of smoking related cancers (including head and neck cancers) was 
increased in men with advanced periodontitis (Michaud et al. 2016). While this correlation 
does not prove causality, mechanisms by which periodontal pathogens might contribute to 
oral cancer have been described, with cell-based studies highlighting the ability of P. 
gingivalis to increase migration, invasiveness, and cancer/stem cell associated biomarkers 
in an oral squamous cell carcinoma (OSCC) cell line (Ha et al. 2015). An in vivo model also 
showed that in mice with induced oral carcinomas, infection with P. gingivalis and F. 
nucleatum caused increases in tumour growth (size) and invasion, as well as increased 
expression of certain biomarkers in the oral mucosa that are either associated with oral 
cancer or cause increased tumourigenesis, such as the proinflammatory cytokine IL-6 
(Gallimidi et al. 2015).  However, this work is still in its infancy and it will be of interest to 
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note how this story develops over the coming years.  It is notable though that the common 
oral bacterium Fusobacterium nucleatum has been strongly linked with colorectal cancer, 
via the action of its surface adhesin FadA (Rubinstein et al. 2013).  This fact alongside 
various observations regarding P. gingivalis in terms of anti-apoptotic action suggest 
several mechanisms that might lead one to believe periodontal pathogens may be cancer 
promoting, if not causing (Whitmore & Lamont 2014; Kuboniwa et al. 2008). 
1.3.2 Heart Disease and Atherosclerosis 
The association and causative link between periodontitis and heart disease (or more 
specifically atherosclerosis) is fairly well established, with an ever-growing body of 
evidence indicating that patients with increased severity of periodontitis are more likely to 
suffer from atherosclerosis and other cardiovascular disease (CVD) (Demmer & Desvarieux 
2006; Beck & Offenbacher 2005; Spahr et al. 2006), or experience additional cardiac 
problems (Reichert et al. 2016). There is also evidence indicating periodontal bacteria and 
associated inflammatory responses play a causative role in the development of heart 
disease: A high proportion of atheromatous plaques extracted from CVD patients have 
been shown to contain DNA from a variety of periodontal pathogens (Haraszthy et al. 
2000), and viable periodontal pathogens have been isolated from atheromatous plaques in 
patients with chronic periodontitis (Padilla et al. 2006).  Several mechanisms by which the 
periodontal pathogens contribute to atherosclerosis/CVD have been suggested (reviewed 
in Schenkein & Loos, 2013): Firstly, increased levels of systemic biomarkers/inflammatory 
mediators relevant or associated with both atherosclerosis/CVD and periodontitis-such as 
IL-6, C-reactive protein, and low density lipids. Secondly, through induction of self-
recognising antibodies, as seen in the case of antibodies against the heat shock protein 
(HSP) 60 of P. gingivalis. Aortic inflammation in response to periodontitis has also been 
shown in vivo using a rat model (Miyajima et al. 2014), where ligature-induced-
periodontitis increased pro-inflammatory cytokine expression in circulating monocytes 
(Tumour Necrosis Factor (TNF) and IL-6), and monocytes also displayed increased adhesion 
to vascular endothelial cells, which themselves displayed greater intracellular markers of 
inflammation (VCAM-1 and NFκB). 
1.3.3 Rheumatoid Arthritis 
Rheumatoid arthritis is perhaps the most well established extra-oral condition linked with 
periodontitis, with an early observation of their association made by Hippocrates (460-370 
BC). More recent, wider-scale studies have confirmed this association (Joseph et al. 2013; 
Chou et al. 2015). Mouse models have shown that periodontal bacteria can influence the 
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progression of Rheumatoid Arthritis, with P. gingivalis playing a central role in disease 
(Yamakawa et al. 2016). In humans, associations between the levels of P. gingivalis, 
periodontal disease, and rheumatoid arthritis severity have also been reported (Mikuls et 
al. 2014; de Smit et al. 2012). A biological mechanism has also been described, which 
implies that periodontal disease and more specifically P. gingivalis is a causative factor of 
rheumatoid arthritis: P. gingivalis possesses genes encoding a peptidyl arginine deaminase 
(PAD), which citrullinates some of its expressed proteins (Gabarrini et al. 2015). Protein 
citrullination is usually only performed in higher eukayotes including humans (indeed, P. 
gingivalis is the first bacteria shown to possess the capacity for protein citrullination). This 
results in the generation of anti-citrullinated-peptide antibodies, which possess self-
recognising properties and are highly associated with rheumatoid arthritis onset (Gabarrini 
et al. 2015). 
1.4 Treatment of Periodontitis  
Treatment of periodontitis aims primarily to prevent further attachment loss, primarily by 
removing the periodontal pathogens responsible for promoting inflammation, and in some 
cases removing severely inflamed or damaged tissue (which is also beneficial in reducing 
the periodontal pocket depth). The two approaches used here can be considered surgical 
and non-surgical. Systemic antibiotics such as azithromycin (Muniz et al. 2013) can be 
administered as an adjunct to mechanical removal of the subgingival plaque, and this 
results in improved clinical parameters compared to treatment in their absence (Guerrero 
et al. 2005), with at least one study suggesting that this is due to the complete removal of 
red complex organisms by the antibiotic-therapeutic adjunct (Jünemann et al., 2012), 
although recolonization and re-population by red complex species post-treatment is likely 
even in the case of antibiotic-treated individuals (Johnson et al. 2008). In any case, despite 
treatment a proportion of patients poorly-respond to periodontal therapy, and it appears 
that post-treatment, in these patients the levels of certain periodontal pathogens 
(including the red-complex pathogens) are higher than in patients who respond to 
treatment, or in healthy controls (Colombo et al. 2009). 
Considering the impact of periodontitis on the quality of life of patients, its apparent 
involvement in other conditions, and the occasional inability to successfully treat disease, 
research into the virulence mechanisms of the periodontal pathogens with a view to 
improving treatment is a worthwhile pursuit. 
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1.5 Virulence Factors of the Periodontal Pathogens 
As discussed above, the Gram negative, anaerobic red complex organisms T. forsythia, P. 
gingivalis, and T. denticola are the three sub-gingival species most strongly correlated with 
severity of periodontitis (Socransky et al. 1998), and of these three organisms, T. forsythia 
and P. gingivalis are the focus of this thesis. Also associated with periodontitis are species 
comprising the orange complex, of which the gram negative, anaerobic Fusobacterium spp. 
including Fusobacterium nucleatum and its various subspecies are prominent members, so 
F. nucleatum is also focused on in later chapters. These pathogens can be considered 
distinct from commensals due to their expression of virulence factors, which can be 
defined as “processes or products of pathogenic organisms which contribute to disease”. 
While technically all of the processes involved in a pathogen’s lifecycle will contribute to 
disease by simply allowing survival of the pathogen (for example, carbon metabolism or 
amino acid synthesis), virulence factors are usually taken to mean those that damage the 
host directly (for example, a secreted toxin) or indirectly (for example, lipopolysaccharide 
(LPS) over-stimulating an inflammatory response). Virulence factors may also allow 
persistence of a microbial pathogen despite an immune response or allow competition with 
other bacteria in its environment. For example, the ability to persist in the face of a lack of 
freely available nutrients, or the presence of antibiotics, may permit spread of an organism 
from the original site of colonisation to other sites within the host. Factors that allow 
attachment to surfaces (including host cell surfaces) and invasion (also termed 
internalisation) of host cells can also be considered virulence factors. 
1.5.1 Porphyromonas gingivalis 
Perhaps the most well characterised member of the red complex, P. gingivalis has been 
called the  “Keystone Pathogen” (Hajishengallis et al. 2012), being considered the most 
important organism in causing or maintaining inflammation and resulting dysbiosis 
responsible for periodontal disease progression. Some of its most important virulence 
factors are its fimbriae, capsule, and its arginine/lysine proteases-the gingipains. 
 Fimbriae 1.5.1.1
P. gingivalis expresses two different fimbriae on its surface; major and minor (also called 
long and short), which are composed of protein subunits FimA and MfaI, respectively. 
Major fimbriae are considered important for initial attachment as they have been shown to 
bind epithelial cells (Umemoto & Hamada 2003), and in the case of endothelial cells major 
fimbriae attach via the host cell integrins (Yilmaz et al. 2002). Major fimbriae are also 
involved in binding to Streptococcus oralis and Streptococcus gordonii- early/intermediate 
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colonizers of the gingiva (Park et al. 2005; Maeda et al. 2004) P. gingivalis strains possess 
multiple copies of the fimA gene, with variations coding for slightly different proteins. 
Based on variation of fimA genes, the major fimbriae have been classified into 6-types , 
types I-V and Ib (Amano, Nakagawa, Okahashi, & Hamada, 2004). Strains expressing Type II 
major fimbriae have been shown to be associated with more severe periodontitis 
compared to strains expressing the other types, and were found to have greater 
attachment and invasiveness during infection of host cells. In periodontally healthy patients 
posititive for P. gingivalis colonisation, type I fimbriae strains were the most prevalent 
(Amano et al., 2004), highlighting the relevance of different strains to periodontal infection, 
and inferring that different fimbriae can influence the outcome of periodontal infection.  
The role of minor fimbriae in virulence is less well characterised. However, mutant strains 
of P. gingivalis that did not express minor or major fimbriae have shown complete loss of 
adherence to oral epithelial cells, while strains expressing only minor fimbriae retained 
some ability to adhere to epithelial cells. Invasion of host cells was also reduced 8-fold in 
minor fimbriae deficient strains  (Umemoto & Hamada 2003). 
 Polysaccharide Capsule 1.5.1.2
Polysaccharide capsules are a common feature of Gram negative bacteria, and are thought 
to function by ‘covering’ other surface antigens which would otherwise make the organism 
vulnerable to an adaptive immune response, or complement deposition. It has been 
observed that non-encapsulated strains of P. gingivalis are more virulent than 
encapsulated strains in a mouse abscess model (Singh et al. 2011), but are unable to spread 
systemically. P. gingivalis non-encapsulated strains also induce higher cytokine secretion 
(IL-6, IL-10, TNF-α, and IFN-γ) in macrophages than wild type strains, and undergo 
phagocytosis more rapidly (Singh et al. 2011), as well as inducing cytokine  transcription 
more rapidly in human gingival fibroblasts. This highlights the importance of the capsule in 
P. gingivalis immune evasion. 
 Gingipains-Secreted Proteases of P. gingivalis 1.5.1.3
P. gingivalis expresses serine proteases, two of which cleave at lysine residues-RgpA and 
RgpB, and one which cleaves at lysine-Kgp. Termed “gingipains”, these are considered 
paramount to P. gingivalis pathogenicity, with evidence for their involvement in multiple 
pathogenic processes coming from studies of gingipain-deficient mutant strains.  
The first study of RgpA and RgpB-null mutants showed almost complete abrogation of 
proteolytic activity in culture supernatants of a strain deficient in both proteases (activity 
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was also substantially reduced in strains deficient in one of the two arginine-gingipains) 
(Nakayama et al. 1995). Functional studies of the double Rgp mutant showed decreased 
haemagglutination and decreased activation of leukocytes relative to the wild type strain, 
providing evidence for their role in immune-stimulation and attachment to host cells 
(Nakayama et al. 1995). Further work using Rgp and Kgp deficient mutants and purified 
gingipains has confirmed their role in host cell attachment , and in immune system 
interactions such as serum/complement resistance (Grenier et al. 2003), cleavage of CD4 
and CD8 proteins from T-cell surfaces (resulting in downregulation of T-cell responses) 
(Kitamura et al. 2002), and cleavage and inactivation of antibodies (Vincents et al. 2011). 
Furthermore, gingipains are important for nutrient acquisition by P. gingivalis, since it 
utilises free amino acids for catabolism, and gingipains have been shown to be required for 
growth in chemically defined media (containing only host proteins as carbon and nitrogen 
sources), since they degrade host proteins-releasing amino acids and peptides (Grenier et 
al. 2001) . Gingipains also interfere with intracellular signalling pathways in oral epithelial 
cells during invasion, specifically, by degradation of mTOR (mammalian target of 
rapamycin, Stafford et al. 2013), which may be the major mechanism by which P. gingivalis 
induces autophagy or changes to the host-cell lifecycle. 
The importance of gingipains are also highlighted by in vivo studies, where a mouse model 
of periodontitis (measuring alveolar bone loss in P. gingivalis infected mice) showed that 
infection with RgpA-deficient strains induce significantly less bone loss than the wild type 
strain (Wilensky et al. 2013). 
1.5.2 Tannerella forsythia 
Early studies of T. forsythia (initially named “Bacteroides forsythus”) were hampered by an 
inability to culture it in isolation from other organisms. It was later discovered that 
exogenous N-acetylmuramic acid (NAM, one of the two monomers in peptidoglycan) was 
required for the growth of T. forsythia in monoculture (Wyss 1989). Despite being poorly 
understood initially, the organism’s biology, virulence factors, and how they contribute to 
disease are beginning to come to light, partly as result of work described in this thesis. 
Previously characterised virulence factors include the proteinaceous, glycosylated surface 
layer (S-layer), Bacteroides surface protein (BspA), and proteases including PrtH (also called 
“forsythia detaching factor” (FDF)) and karilysin. 
 T. forsythia surface layer 1.5.2.1
The S-layer of T. forsythia is composed of two glycosylated proteins; TfsA and TfsB. It 
appears to be a multi-functional virulence factor. Firstly, it has been shown to interact with 
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the host immune system in a number of ways: It is antigenic, with periodontitis patients 
possessing elevated anti-S-layer IgG compared to healthy controls (Yoneda et al., 2003). 
However, this humoral immune response does not result in clearance of T. forsythia, 
possibly due to biofilm formation preventing antibody binding, or the fact that T. forsythia 
does not penetrate deeply into the tissues. The S-layer also functions in serum resistance 
(Shimotahira et al., 2013), and could therefore be considered important for survival due to 
the presence of GCF in the periodontal pocket. S-layer deficient mutants have been shown 
to increase the viability of macrophages resulting in more rapid expression of pro-
inflammatory cytokines (IL-1β and TNF-α) compared to wild type T. forsythia (Sekot et al., 
2011), indicating a role for the S-layer in delaying, or perhaps redirecting the innate 
immune response. The importance of S-layer glycosylation in immune modulation by T. 
forsythia has been the focus of recent studies. The gene encoding WecC, responsible for 
incorporation of a trisaccharide motif into the S-layer glycan of T. forsythia was deleted, 
resulting in increased uptake and phagocytosis by dendritic cells (DCs), followed by antigen 
presentation and increase in secretion of the Th17-activating cytokines IL-6 and IL-23. Thus, 
this glycosylation under the control of WecC is key in delaying the immune response. The 
importance of the S-layer in immune modulation is underlined by in vivo studies: Wild type 
T. forsythia was shown to inhibit Th17 T-cell responses, while a mutant with an altered 
terminal glycan moiety (lacking the pseudaminic acid branch-a sugar related to sialic acid) 
induced robust Th17 responses and phagocytosis dependent killing, resulting in reduced 
alveolar bone loss in mice infected with S-layer deficient T. forsythia compared to mice 
infected with the wild type strain (R P Settem et al., 2013).  
 In addition to immune-modulatory functions, the S-layer is also involved in mechanisms of 
attachment in the oral cavity: mutant strains lacking one or both Tfs proteins have shown 
reduced adherence or invasion of oral epithelial cells (Sakakibara et al. 2007). Furthermore, 
Tfs single or double mutants also show decreased haemagglutination compared to the wild 
type. Given that bleeding occurs during non-destructive periodontal disease where T. 
forsythia may not be present, or only in low numbers, attachment to red blood cells could 
be a useful mechanism of adherence allowing T. forsythia to colonise, or do so more 
extensively. Haemagglutination by T. forsythia (via the S-layer) appears to be sensitive to 
sialyllactose (Murakami et al. 2002), highlighting the importance of host glycoconjugates in 
T. forsythia attachment, a particularly important observation in the context of the work 
described in this thesis.  In addition to host cell binding, S-layer deficient T. forsythia 
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mutants show decreased co-aggregation with the early coloniser S. sanguinis compared to 
wild type T. forsythia (Shimotahira et al., 2013). 
 Bacteroides Surface Protein A 1.5.2.2
A second important virulence factor for T. forsythia is BspA, also expressed at the surface of 
T. forsythia. Similarly to the S-layer, BspA is considered a multifunctional virulence factor 
for T. forsythia. Roles include attachment and invasion of epithelial cells (Mishima & 
Sharma 2011), coaggregation with orange and red complex species, and immune system 
modulation (Myneni et al. 2012). BspA consists of four subunits: The N-terminal, leucine 
rich repeats (LRRs), Bacterial Ig-like domains, and the C-terminal. In the context of 
attachment, T. forsythia mutants deficient in BspA show a twofold decrease in aggregation 
with F. nucleatum compared to the wild type, but do not show a significant decrease in 
biofilm formation (Sharma et al. 2005). These findings indicate a central role for BspA in 
initial colonisation of the periodontium by T. forsythia with F. nucleatum as a bridging 
organism. Another study investigated the role of BspA in epithelial cell co-infection with T. 
forsythia and P. gingivalis: T. forsythia BspA mutants displayed decreased attachment and 
invasion of oral epithelial cells in both the presence and absence of P. gingivalis (or P. 
gingivalis outer membrane vesicles) compared to wild type T. forsythia (Inagaki et al. 
2006). However, the study did not show decreased co-aggregation of BspA mutants with P. 
gingivalis, in contrast to the co-aggregation studies with F. nucleatum. Taken together, 
these studies point to a mechanism by which T. forsythia co-aggregates with F. nucleatum, 
allowing initial colonisation, which is followed by association with epithelial cells through a 
BspA dependent pathway that acts synergistically with P. gingivalis, or P. gingivalis outer 
membrane vesicles (Inagaki et al. 2006). 
Similarly to the S-layer, BspA appears to play roles in immune-modulation, and adhesion 
and maintaining colonisation in the oral cavity: Regarding immunity, BspA has been shown 
to act through TLR-2 (Hajishengallis et al., 2002), and is antigenic; causing production of 
specific IgG and IgA in the serum in mice immunized with BspA. Again, the humoral 
response was not sufficient to clear T. forsythia. Furthermore, a mouse model of 
periodontitis comparing wild type to BspA deficient strains showed that BspA is important 
in alveolar bone resorption (Sharma, Inagaki, Honma, et al., 2005) presumably due to 
induction of cytokines through TLR-2 activation, resulting in differentiation of osteoclasts. 
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 Secreted Proteases 1.5.2.3
The T. forsythia genome encodes several putative proteases, but karilysin and PrtH (also 
called forsythia detaching factor, FDF) have been the subject of study due to their multiple 
apparent functions in virulence. The two proteases are distinct; karilysin has been termed 
metalloprotease-like, while PrtH is considered similar to caspases due to its caspase like 
fold (incidentally, the P. gingivalis gingipains also possess caspase-like folds). 
Karilysin has been shown to play roles in immunomodulation, firstly by protecting T. 
forsythia from the antimicrobial effects of human serum. Karilysin was shown to inhibit 
deposition of complement components activating the classical and alternative pathways 
(MBL and C4). Even so, T. forsythia is recognised by complement (as evidenced by C3 
deposition on the T. forsythia surface), but karilysin also interferes with the terminal 
pathway (from complement component C5 onwards) (Jusko et al. 2012). A second 
metalloprotease from T. forsythia, mirolysin, has also been shown to prevent deposition of 
complement components (in the classical, alternative, and terminal pathways), 
contributing to complement resistance of T. forsythia  (Jusko et al. 2015).  In addition to its 
functions in immune-evasion by preventing the action of complement, T. forsythia may 
upregulate inflammation by interacting with macrophages. Karilysin was shown to cleave 
membrane-associated TNF from macrophages, and as well as increasing levels of soluble 
TNF, levels of IL-6 (another pro-inflammatory cytokine), were also increased.  
Exposure of host cells to T. forsythia extracts led to the discovery of a cytopathic “forsythia 
detaching factor” (FDF), which was later cloned and expressed in E. coli, and further 
characterised, enabling its designation as PrtH (Nakajima et al. 2006). Although the cell-
killing activity of PrtH has been characterised, its mode of action and precisely how it 
contributes to disease remains unclear. However it may show some clinical relevance: A 5-
year longitudinal study showed that periodontitis patients with higher levels of PrtH 
(quantified by real-time PCR) displayed greater attachment loss over a five year period. 
1.5.3 Fusobacterium nucleatum 
F. nucleatum is currently subdivided into five subspecies; nucleatum, polymorphum, 
vincentii, fusiforme, and necrophorum (Dzink et al. 1990).  Fusobacterium nucleatum subsp. 
nucleatum (F. nucleatum) and Fusobacterium nucleatum subsp. polymorphum (F. 
polymorphum) are the most common subspecies isolated from the human oral cavity. The 
major role of Fusobacterium spp. in periodontitis pathogenesis appears to be during 
association with host cells and other bacteria, where it utilises its adhesins to aid in 
colonising the plaque, and by doing so it can facilitate other pathogens’ attachment. 
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F. nucleatum has been shown to play a role in adherence of other periodontal pathogens, 
implicating this species’ importance in the progression of periodontal disease. It has been 
well established that F. nucleatum co-aggregates with Gram positive early colonisers 
(Kolenbrander et al. 1989), and that this is important for its integration into the oral 
microbial community of the supra-gingival plaque (He et al. 2012). Furthermore, membrane 
capture approaches (where one bacterial species is immobilised to a surface, then exposed 
to suspensions containing other bacteria to observe inter-species co-aggregation) and 
analysis of 16S ribosomal-DNA have been used to highlight the ability of F. nucleatum to 
adhere to a number of different species enriched from saliva, including Gemella, 
Granulicatella, Neisseria, and Peptostreptococcus species, as well as non-culturable 
unclassified organisms (Wang et al. 2011). Therefore, perhaps its most important virulence 
factors are those that enable attachment to host and bacterial cells. 
It has also been shown that F. nucleatum subsp. nucleatum and polymorphum strains do 
adhere forming mono-species biofilms in vitro, but slowly and to varying degrees. However, 
in the presence of the early colonisers V. parvula and A. oris, F.  nucleatum polymorphum 
and nucleatum rapidly adhered and proliferated (Biyikoğlu et al. 2012), thus the presence 
of these early colonisers is likely key in allowing adherence of F. nucleatum.  As well as co-
aggregating with early coloniser organisms, F. nucleatum also forms synergistic biofilms 
with T. forsythia (Sharma et al. 2005), and together the two act synergistically in causing 
alveolar bone loss (Settem et al. 2012), highlighting the importance of co-aggregation of F. 
nucleatum with other pathogens during periodontitis. In addition to bacterial co-
aggregation, F. nucleatum has been shown to attach to host cells via the adhesin FadA (Han 
et al. 2005), a factor also associated with colon cancer as mentioned above (Rubinstein et 
al. 2013).  
The mechanisms by which inter-species and host cell attachment is achieved were 
classified into two groups based on inhibition of aggregation by D-galactose or L-arginine: 
Lactose and related sugars have been shown to prevent aggregation of F. nucleatum 
nucleatum with other periodontal bacteria (Kolenbrander et al. 1989; Kolenbrander & 
Andersen 1989). However, F. nucleatum subsp.  polymorphum appears to utilise an 
arginine sensitive mechanism for co-aggregation: Arginine binding proteins from bacterial 
lysates were purified using immobilised arginine, and mass spectrometry identified 
candidate proteins potentially responsible for F. polymorphum binding to Gram positive 
early colonisers (Edwards et al. 2007). Construction of mutants deficient in one of these 
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candidates followed by co-aggregation studies revealed that the outer membrane protein 
RadD was largely responsible for aggregation with several early-colonising Streptococci 
(Kaplan et al. 2009). Thus, RadD can be considered key to F. nucleatum polymorphum initial 
attachment. 
1.5.4 Biofilm Formation 
All three pathogens exist in the sub- and supra- gingival plaque as part of a mixed species 
biofilm, and this state contributes to disease pathogenesis. 
Initial adherence allows further bacterial proliferation at a given site. Be it an 
environmental or host-associated ecological niche, the presence of different microbial 
species results in development of a mixed-species community of micro organisms attached 
to this surface (Nobbs et al. 2011). The bacterial community is enclosed in a matrix 
composed of bacterial and host products, and environmental substrates (Branda et al. 
2005). This type of community is termed a biofilm, and is in stark contrast to the now 
redundant idea of bacteria existing in isolation with no interactions between different 
species. Biofilm formation (outlined in figure. 1.5) occurs by initial attachment and bacterial 
growth resulting in a monolayer, microcolonies form consisting of clusters of multiple 
species with adaptations for their location in the biofilm, eventually these microcolonies 
form different structures, as determined by microscopy. For instance, fluorescence 
microscopy has been used to characterise structures and architecture of polymicrobial 
biofilms in the context of oral microbiota (Zijnge et al., 2010). Expression of different 
factors is required at each stage of biofilm formation, so cell signalling including quorum 
sensing has been extensively studied in a number of bacteria (reviewed in Davey, George, 
& Toole, 2000). Different positions in the biofilm also present different ecological niches 
(e.g. anaerobic at colonised surface-aerobic externally, a higher concentration of bacterial 
metabolites at colonised surface, exposure to flow conditions at external surface, higher pH 
at colonised surface-neutral externally). Thus, biofilm formation may indirectly facilitate 
colonisation of organisms that were previously unable to do so. 
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Figure 1.5. Stages of biofilm formation. 
1) Initial attachment; bacteria attach to a surface, such as the gingival epithelium. 2) 
Proliferation; bacteria replicate at the surface 3) Formation of microcolonies; bacteria 
undergo further proliferation and coaggregation (between organisms of the same or 
multiple species), such as aggregation of fusobacteria and streptococci. 4) Biofilm 
formation; organisms form matrix enclosed structures, resulting in increased persistence 
and survival while attached to the surface. 
 
 
 Subgingival Plaque-Periodontal Biofilms 1.5.4.1
Sub- and supra- gingival plaque can be considered a perfect example of a biofilm 
(Periasamy & Kolenbrander, 2009; Rosan & Lamont, 2000; Zijnge et al., 2010): Initial 
colonisers adhere to the acquired pellicle, followed by intermediate colonisers including 
streptococci. Resulting anaerobic conditions permit colonisation by the periodontal 
pathogen F. nucleatum, which adheres to the streptococci as described above. F. 
nucleatum acts as a bridging organism allowing colonisation of the biofilm by T. forsythia 
and P. gingivalis. Bacteria are enclosed in a matrix consisting of bacterial products, host 
salivary proteins including those composing the pellicle, mucins, and DNA, as well as 
environmental substrates consumed by the host. The biofilm state confers a variety of 
advantages on composing bacteria, these are discussed below.  
 Inter-species interactions 1.5.4.2
Adhesion between species is important in oral biofilm formation. Colonisation by 
periodontal pathogens relies on mixed species biofilm formation: It has been shown that P. 
gingivalis initially colonises by adhering to receptors on S. gordonii (and other streptococci) 
via its major and minor fimbriae (Park et al. 2005; Lamont et al. 2002; Maeda et al. 2004). 
The receptor for P. gingivalis fimbriae on S. oralis has been shown to be Glyceraldehyde-3-
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Phosphate (GAPDH) (Maeda et al. 2004). Furthermore, P. gingivalis forms poor 
monospecies biofilms in vitro using saliva as a growth substrate, under static and flow 
conditions, but does form biofilms in the presence of oral streptococci and F. nucleatum 
(Periasamy & Kolenbrander 2009). In addition, F. nucleatum has been shown to be 
important in facilitating colonisation and subsequent biofilm formation of T. forsythia 
(Sharma et al. 2005). These studies point to the importance of co-aggregation by 
periodontal pathogens in biofilm formation. 
 Tolerance to Environmental Conditions 1.5.4.3
Colonisation is not the only advantage to biofilm formation: F. nucleatum has been shown 
to have increased oxygen tolerance in a biofilm state compared to planktonic cells (Gursoy 
et al. 2010), and has been shown to increase the oxygen tolerance of P. gingivalis in a 
mixed species biofilm (Diaz et al. 2002). Furthermore, proteomics studies of T. forsythia 
have also shown the upregulation of oxidative stress response genes in biofilm compared 
to planktonic state, and that biofilms resisted oxidative stress when exposed to hydrogen 
peroxide (Pham et al. 2010). 
 Antibiotic Resistance 1.5.4.4
Bacteria in a biofilm often display resistance to antibiotics that they are sensitive to in a 
planktonic state, and this has been shown to be true for periodontal pathogens (Sedlacek & 
Walker 2007; S.-M. Kim et al. 2011). Suggested mechanisms of increased antibiotic 
resistance for periodontal biofilms include the inability of antibiotics to diffuse through the 
extracellular matrix (Gilbert et al. 1997), and that antibiotic resistance genes are 
upregulated (Kim et al. 2011). ‘Persister cells’ are another proposed mechanism of 
antibiotic resistance (reviewed in Wood et al. 2013), though this mechanism has not been 
described in periodontal pathogen biofilms. This describes a subset of the bacterial 
population in a biofilm that display decreased metabolism meaning that antibiotics which 
target dividing cells do not affect them.  The implication of biofilms for treatment of 
periodontitis is that patients who receive a course of antibiotics should only do so in 
combination with debridement. This mechanical disruption of the biofilm allows antibiotics 
to inhibit growth of any remaining bacteria before a new biofilm structure can form. This 
theory is supported by studies of periodontitis patients undergoing biofilm therapy, i.e. 
improvement in clinical parameters (e.g. periodontal pocket depth) when also treated with 
systemic antibiotics is more pronounced than in patients who do not receive antibiotics  
(Guerrero et al. 2005). 
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 Changes in Metabolism 1.5.4.5
Differences in metabolism between biofilm and planktonic cells are also evident. Proteomic 
and transcriptomic studies have highlighted several metabolic pathways with proteins that 
differ between periodontal pathogens in biofilm and planktonic states. In T. forsythia, 
proteins involved in butyrate production from catabolism of glutamate and succinate were 
shown to be down regulated in biofilm cells (Pham et al. 2010), a pathway which is also 
downregulated in P. gingivalis biofilms (Lo et al. 2009) hinting at the importance of this 
pathway during colonisation by periodontal pathogens. 
Proteins associated with sialic acid metabolism in T. forsythia were also shown to be up 
regulated in a biofilm state, and T. forsythia can substitute its requirement for the bacterial 
product N-acetylmuramic acid (NAM) for sialic acid, but only in the biofilm state (Roy 
2010). Taken together, this highlights the importance of free sialic acid in proliferation of T. 
forsythia in the host, and prevention of sialic acid release from host glycoproteins could be 
a useful method in preventing T. forsythia growth.  
1.6 The Anti-Virulence Approach 
Some periodontitis patients, and people with infections more generally, are not 
successfully treated by conventional antibiotics (discussed in section 1.4). While for many 
infections this may be due to antibiotic resistance, for periodontitis the explanation may 
revolve around the polymicrobial nature of the condition: Since periodontitis appears to be 
part-mediated by the periodontal microbiota, and antibiotics will target the entire 
microbiota rather than pathogenic species specifically, their ability to re-establish a health-
associated bacterial population (i.e. pathogens in low abundance, commensals in high 
abundance) may be somewhat limited. 
This inability to treat bacterial infections has led to research and development of the so-
called “anti-virulence approach” to target the virulence factors of specific pathogens or 
groups of pathogens, including those responsible for periodontitis. This has been seen in 
the case of the gingipains of P. gingivalis, with several plant extracts (Lohr et al. 2015), 
active molecules (isolated from extracts, Kariu et al. 2016), and short peptides (Huq et al. 
2013) shown to reduce gingipain activity , with in vitro studies showing reductions in P. 
gingivalis biofilm formation (Kariu et al. 2016), and disruption of bacterial nutrient 
acquisition leading to decreased P. gingivalis  growth (Huq et al. 2013). Plant extracts that 
inhibit gingipains have also shown disruption of host-P. gingivalis interactions; attachment 
and invasion of host cells, and cytokine production (Lohr et al. 2015), though this could be 
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due to interactions between the active ingredients and host cells, rather than targeting the 
gingipains. 
Quorum sensing, which is involved in periodontal pathogen biofilm formation, has also 
been investigated as an anti-virulence target. The auto-inducer 2 (AI-2) of F. nucleatum 
enchances biofilm formation by F. nucleatum and also other periodontal pathogens (T. 
forsythia and P. gingivalis), and this increase in biofilm formation is inhibited by the 
presence of quorum sensing inhibitors (Jang et al. 2013).  
As alluded to at the beginning of section 1.5, this project aims to examine the potential to 
target periodontal pathogen sialidases as anti-virulence approach, since all three red 
complex species possess sialidases. Furthermore, they and other periodontal pathogens 
possess mechanisms for metabolising the products of sialidase activity, and the activity of 
pathogen sialidases could be important for host-pathogen interactions.  
1.7 Sialic Acid, Sialidases, and Virulence 
1.7.1 Sialic Acid 
Sialic acid describes a family of 9-carbon sugars, ubiquitous in nature. These sugars are 
typically present at the termini of glycan (polysaccharide) chains present on glycolipids or 
glycoproteins (figure 1.6), which can be cell associated or extracellular/secreted. The glycan 
chains may be termed sialoglycans, with the term sialoglycoconjugates used to describe a 
sialoglycan as part of either a glycolipid or glycoprotein. 
 
Figure 1.6. Graphic representations of A) Neu5Ac and B) a sialoglycoprotein. 
Neu5Ac contains 9 carbons (excluding the acetyl group), numbered C1-9 as indicated. 
Sialoglycans present in sialoglycoproteins are linked to the underlying protein via the amino 
acids asparagine (N-linked glycosylation) or serine or threonine (O-linked glycosylation). 
 
A) B) 
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 The most common sialic acid in humans and other eukaryotes is N-acetylneuraminic acid 
(5-N-acetylneuraminic acid, Neu5Ac, figure 1.6) and is the only core sialic acid synthesised 
by humans, though another structurally and chemically similar mammalian sialic acid (N-
glycolylneuraminic acid, Neu5Gc) may be obtained from the diet and incorporated into our 
glycans. Sialic acid may be further modified by the presence of additional chemical groups, 
substituting one of the hydroxyl groups at carbons (C) -4, -7, -8, and -9  for O-acetyl, O-
methyl, O-sulfate, O-lactyl or phosphate groups. Lactones may also be present as 
modification of the sialic acids in some human glycans. In addition to the sialic acid itself, 
the linkage to the underlying glycan chain affects the properties and interactions of the 
sialoglycan with other molecules. In humans, the sialic acid is linked through the C-2 of 
sialic acid to C-3 or C-6, or sometimes C-8 of the underlying sugar. Finally, the underlying 
(branched) glycan chain and glycan class (glycolipid or glycoprotein type) also affect the 
structure-function of the sialoglycan. This  massive potential variety of sialoglycoconjugates 
has been termed “the sialome” (Cohen & Varki 2010). 
1.7.2 Sialidases 
Given the ubiquitous expression of sialic acids on eukaryotic cell membranes and 
secretions, it is unsurprising that humans express their own sialidases to modulate 
glycoprotein sialylation and thus function. To date, four mammalian sialidases have been 
characterised, designated Neu1, Neu2, Neu3, and Neu4, with different substrate 
specificities (Reviewed in Miyagi & Yamaguchi 2012), but do share some conserved  
features (discussed further in the next paragraph). The sialidases are also largely localised 
to one specific cellular location, namely lysosomes (Neu1), cytosol (Neu2), plasma 
membrane (Neu3) and lysosomal or mitochondrial membrane (Neu4), however, the 
sialidases may mobilise elsewhere in response to certain stimuli, such as exposure to 
PAMPS causing TLR activation (Amith et al. 2010). 
As a consequence of global expression of sialic acid in higher eukaryote tissues and thus the 
abundance of a potential food source, many pathogens also possess sialidase enzymes, 
which have been shown to serve a multitude of functions in different pathogens. Despite 
the vast phylogenetic differences between humans and pathogens, there appear to be 
some similar features between bacterial and mammalian sialidases: Sequence alignment 
software can be used to align amino acid sequences that may initially appear to show no 
homology based on the crystal structure of one of the aligned proteins. Based on the 
structure of Neu2, mammalian Neu and bacterial Nan sialidases appear to show some 
conserved sequences with similar topology (Miyagi & Yamaguchi 2012), indicating these 
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structural features are important for sialidase function. These include the characteristic β-
propeller (made up of several (~5) “blades” formed by β-sheets), several “Asp-boxes” 
(conserved sequences with the residues S/T-X-D-X-G-X-X-W/F/Y) positioned between the β-
propeller blades (not necessarily between all blades), and a “RIP” domain (the residues 
arginine-isoleucine-proline, R-I-P) which is highly conserved among bacterial and 
mammalian sialidases, and thus considered essential for catalytic activity. In addition to the 
sequence catalytic region, sialidases may possess subunits that appear to serve non-
catalytic functions, such as the Carbohydrate Binding Module (CBM) seen in some 
sialidases (Park et al. 2013) including the T. forsythia sialidase (further discussed in section 
2.3.1.1, and elsewhere in chapter 2). These features are identified in figure 1.7. 
 
Figure 1.7. Conserved features of sialidases. 
β-propeller blades, Asp-boxes and the RIP domain are indicated (green trapezoids, purple 
crescents, and a red box, respectively). Neu5Ac is shown in the diagram to highlight the 
position of the β-propeller around the sialic acid binding pocket. Numbers of Asp-boxes and 
β-propellers vary between different sialidases. A single carbohydrate binding module 
(CBM) is indicated here, but some bacterial sialidases (such as NanH in Vibrio cholerae) 
possess two, one at both C- and N- terminals of the protein. 
 
 Perhaps the most extensively studied sialidase is the Neuraminidase (NA) of influenza (so 
called since the enzyme was initially shown to release N-acetylneuraminic Acid). Found in 
the viral lipid envelope, this sialidase is thought to function in virus exit from host cells, 
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since the viral adhesin Haemagglutinin (HA) binds to host cell-membrane associated sialic 
acid preventing virus release in the absence of NA. NA may also assist influenza virus in 
evasion of binding and immobilization by host mucins. 
Sialidases are also present in a wide variety of host-associated bacteria, with some 
possessing multiple sialidases. An example of sialidases as an important virulence factor for 
a bacterial pathogen can be seen in Streptococcus pneumoniae- a commensal of the 
nasopharynx and opportunistic pathogen, causing meningitis and pneumonia. The 
sialidases of S. pneumoniae, NanA and NanB, have been extensively studied, and have been 
shown to contribute to the pathogenesis of S. pneumoniae through several mechanisms; 
NanA is important in mediating attachment and invasion of human brain and laryngeal 
epithelial cells, and in biofilm formation (Brittan et al. 2012; Uchiyama et al. 2009). The role 
of NanB is less well understood, though it does show different substrate specificity (Gut et 
al. 2008), and is optimum at a lower pH. Considering that different sialidases may be 
required for cleavage of different types of sialic acid, or have different specificities due to 
structural differences in the underlying glycans, it might be the case that S. pneumoniae 
requires multiple sialidases for colonisation of different sites or host species. Certainly, the 
pathogenicity of S. pneumoniae is affected by expression of different sialidases; for 
example, NanC expressing strains (a third sialidase, not present in all strains of S. 
pneumoniae) have been shown to be more frequently associated with haemolytic uremic 
syndrome in children with necrotizing pneumonia than strains that do not encode nanC 
(Janapatla et al. 2013). 
The virulence of various GI pathogens is also partly reliant on sialidases. Examples of this 
can be seen in toxigenic Vibrio cholerae, which utilises sialidases to unmask GM1 
gangliosides-the ligand for its toxin (Galen et al. 1992) or obtain sialic acid as a nutrient 
(Almagro-Moreno & Boyd 2009). Both of these studies also show decreased virulence 
and/or colonisation of sialidase-deficient V. cholerae in mouse models. Another example of 
the importance of sialidases for GI pathogens can be seen in Salmonella and Clostridium 
infections: Similarly to cholera they use free sialic acid as a nutrient source, and this is 
important for their proliferation-mutant strains deficient in sialic acid catabolic genes 
displayed decreased ability to proliferate in mice following antibiotic treatment (Ng, et al. 
2013).  In this case sialic acid acquisition from host sugars may be heavily dependent on 
other bacteria present in the microbiota, highlighting the importance of microbial 
interactions in sialic acid acquisition from a nutritional perspective. 
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1.7.3 Sialic Acid in the Oral Cavity 
Sialic acid-initially named since it was first discovered in saliva, and named for the Greek 
“σίαλον/sialon,” meaning saliva-is abundant in the oral cavity as part of various 
sialoglycoconjugates. These can be cell membrane associated or secreted. Cell membrane-
associated sialic acids often play roles in receptor structure-function, and in some cases 
may regulate their activity. This is seen in the case of the TLRs (discussed below).  
Mucins are the most abundant proteins in saliva, composing ~26% of salivary protein 
content (Rayment et al. 2000). These proteins can be described as “bottle brush” in 
appearance (Lewis & Lewis 2012), with a large number of glycan chains capped with sialic 
acid extending from a protein backbone. Mucins function to trap and exclude particles by 
formation of net-like structures , and can also bind lectins and adhesins (host or bacterial), 
as well as growth factors, antibodies, and cytokines. Furthermore, mucin production is 
upregulated in response to the presence of PAMPs (reviewed in McGuckin et al. 2011), and 
during periodontitis (Sánchez et al. 2013) highlighting its role in innate immunity, and 
hinting that it would be advantageous for bacteria to avoid mucin binding, harness mucin 
for adhesion purposes, or degrade mucin for use as a growth substrate.  
GCF is similar in composition to serum, and in serum the most prevalent glycoproteins 
(gammaglobulins) are sialylated. Since periodontal pathogens are exposed to GCF (and 
presumably gammaglobulins), an ability to process sialic acid might prove beneficial in 
metabolism of glycoproteins for nutrient and energy acquisition. Fetuin is another 
sialylated glycoprotein present on mucosal surfaces and in serum and saliva. Fetuin 
functions to dampen inflammatory responses to infection and physical damage (Wang & 
Sama 2013), and T. forsythia has been shown to bind and degrade fetuin for the purposes 
of attachment (Roy et al. 2011). It is tempting to speculate that fetuin degradation by 
pathogens plays a role in periodontal disease progression due to fetuin’s role in immune 
modulation. 
1.7.4 Sialic Acid and the Immune System 
An important role of sialic acid is to down-regulate immunity: Classical studies have shown 
sialic acid to be a self-associated molecular pattern (SAMP), acting through a variety of 
mechanisms to downregulate immune system activity (see below). Furthermore, it has 
been shown that sialic acid regulates (at least partially) the activation of receptors 
associated with pro-inflammatory responses. Given the overall immune dampening activity 
attributed to sialic acid, the effect of sialidases on immune activation has been extensively 
studied. 
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 Sialic Acid and Toll Like Receptors 1.7.4.1
TLRs are important in pro-inflammatory immune signalling, and are thought to mediate 
inflammation during periodontitis. TLRs -2,  -4, and presumably -9 are heavily glycosylated, 
a requirement for functionality (Feng et al., 2012; J. Sun et al., 2006), but the importance of 
sialylation has only become apparent recently. It has been shown that human Neu1 
sialidase complexes with TLRs -2 and -4 present on DCs and macrophages (Stamatos et al. 
2010; Amith et al. 2010), resulting in pro-inflammatory responses including cytokine 
signalling and DC maturation.  The intracellular (endosomal) TLR-9 is also regulated by the 
activity of the human sialidase Neu1 (Abdulkhalek & Szewczuk 2013). However, no-one to 
date has studied the effect of sialidases on TLR stimulation in epithelial cells, which is likely 
to be important since these are the first cells that periodontal-and-other pathogens come 
into contact with, and are likely important in initiating immune signalling.  
 Sialic Acid and Complement 1.7.4.2
The recognition of sialic acid as a Self-Associated Molecular Pattern (SAMP) by complement 
involves factor H, which binds to sialoglycans present on host cells and prevents 
complement deposition (Meri & Pangburn 1990). Later studies have shown that the extent 
of O-acetyl modifications of the sialic acid side chain is what determines factor H binding 
(reviewed in Varki & Gagneux, 2012). T. forsythia possesses a sialate-O-acetylesterase 
capable of cleaving an acetyl- modification present on di-acetylated sialic acid (Neu5,9Ac). 
If T. forsythia does remove either the sialic acid or the di-acetylation present on some host 
sialoglycans on cell membranes, it could result in complement deposition on host cell 
membranes and subsequent destruction of host cells-further contributing to periodontal 
disease. Indeed, it has been shown that NanS is capable of converting Neu5,9Ac to Neu5Ac 
at the cell surface (Phansopa et al. 2015), so this might be a possibility. 
 Siglecs 1.7.4.3
“Sialic acid-recognizing immunoglobulin-like superfamily lectins” (Siglecs) describe a series 
of vertebrate cell-surface glycoproteins that function to bind sialic acid, resulting in positive 
or negative regulation of the immune system. Siglec-1 (sialoadhesin) was first to be 
characterized; shown to be involved in binding of erythrocytes by macrophages, and that 
this binding was abolished by a bacterial sialidase (Crocker et al. 1991). Later, a number of 
different lectins including a B-cell adhesion molecule-CD22, siglec-2 (Sgroi et al. 1993), 
myelin associated glycoprotein-MAG, siglec-4 and siglec-15 (Angata et al. 2007), and CD33 
were shown to be involved in sialic acid dependent cell-cell adhesion. Initially dubbed 
“sialoadhesins”, the term “siglecs” was eventually accepted (Varki & Angata 2006). 
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Siglecs are often described as one of two groups; conserved between mammals and even 
between vertebrates, or evolutionarily divergent-showing variation between species (Varki 
& Angata 2006). CD33-related (CD33r) siglecs are evolutionarily diverse, and are thought to 
inhibit inflammation by binding sialic acid residues on their external domains, followed by 
recruitment of intracellular phosphatases such as SHP-1 and SHP-2. This is thought to 
inhibit phosphorylation of kinases associated with other surface membrane receptors, and 
ultimately reduce expression of inflammatory molecules (Paul et al. 2000). On the other 
hand, some CD33r-siglecs appear to upregulate inflammatory responses. An example of 
this can be seen in siglec-15, which has been shown to bind adaptor proteins DAP12 and 
DAP10, which in turn recruit the tyrosine-phosphatase Syk, suggesting siglec-15 can 
upregulate pro-inflammatory signalling cascades (Angata et al. 2007). Furthermore, siglec-
15 has been shown to upregulate the differentiation of osteoclast precursors into 
osteoclasts (Hiruma et al. 2011), therefore this siglec could be important in mediating bone 
resorption, and perhaps play an important role in periodontitis. 
1.7.5 Sialidases of Periodontal Pathogens 
Given the multifarious roles of sialic acid in the immune system and its presence on the 
surface of host cells and secretions on mucosal surfaces, an ability to express sialidases 
stands to benefit any organisms attempting to colonise these areas. In addition to 
sialidases, bacteria may also possess sialic acid utilisation systems, permitting them to 
metabolise sialic acid for energy, or incorporate sialic acid into other structures. Examples 
of characterised sialic acid uptake and utilisation pathways are summarised in figure 1.8. 
Given that the oral cavity is also a rich source of sialic acids, sialidases and glycosidases 
more broadly speaking could be of potential value to a coloniser of the periodontium, not 
least for nutrient acquisition. In any case, the periodontal pathogens of the red complex all 
possess sialidases. Most research of red complex pathogen sialidases has focussed on its 
role in virulence of T. forsythia and P. gingivalis and is discussed below. T. denticola has 
also recently been shown to express a surface exposed sialidase, which functions in 
protection from complement (Kurniyati et al. 2013). 
 Tannerella forsythia Sialidase  1.7.5.1
T. forsythia was thought to possess two sialidases-SiaHI and NanH. SiaHI was initially 
characterised by cloning T. forsythia open reading frames into E. coli and screening the 
recombinant strains for sialidase activity using a fluorogenic substrate (Ishikura et al. 2003). 
Recombinant SiaHI appeared to display sialidase activity in this first study, which was 
qualitative in nature (i.e. the presence of fluorescence resulting from sialidase-fluorogenic 
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substrate was used for highthroughput screening), but in a later study SiaHI did not appear 
to display sialidase activity (Thompson et al. 2009). The availability of the T. forsythia 
genome allowed discovery of a sialidase which shared homology with an orthologue from 
the closely related organism Bacteroides fragilis (Thompson et al. 2009). Termed NanH, this 
sialidase is characterised by several features, including a secretion signal sequence, 
putative carbohydrate binding moiety (CBM) at its N-terminal, three aspartic acid-boxes 
and a “RIP” domain considered important for catalytic activity as part of its C-terminal. 
NanH was found to be in close proximity to other genes thought to be involved in sialic acid 
uptake and metabolism, and together with NanH these form a sialic acid utilisation operon 
(Stafford, Roy, Honma, & Sharma, 2012, further discussed in chapter 3, section 3.4). 
Sialidase activity is also considered an important virulence factor with functions for T. 
forsythia besides metabolism. For example, NanH deficient T. forsythia mutants show 
reduced attachment to a variety of epithelial cell lines (Honma et al. 2011), suggesting that 
sialidase is involved in unmasking epitopes present on host glycoconjugates enabling  
T. forsythia attachment. Perhaps in a scenario involving co-infection of oral epithelial cells 
with T. forsythia and other pathogens such as F. nucleatum (which shows lactose-
dependent adhesion), sialidase activity would also bolster attachment of Fusobacterium.  
NanH has also been shown to be important in biofilm formation on sialoglyconjugates; for 
in vitro growth, T. forsythia requires NAM (in vivo this is presumably generated by other 
autolysed bacteria), though NAM can be substituted for sialic acid, albeit at a higher 
concentration. It was then observed that the sialidase inhibitor oseltamivir could inhibit T. 
forsythia biofilm growth on a variety of sialoglyconconjugates (including mucin, fetuin, and 
6-sialyllactose) suggesting that host factors act as source of sialic acid, and that T. forsythia 
sialidase is important for proliferation in its niche within the host (Roy et al. 2011). 
  
60 
 
 
 
  
  
61 
 
 
 
 
 
 
Figure 1.8. Uptake and utilisation of sialic acid in gram negative bacteria. 
Sialic acid can be transported across the outer membrane by active processes, as seen in T. 
forsythia (and Bacteroides) where sialic acid is sequestered by NanU, and actively 
transported by NanO, which is energised by the TonB-ExbB-ExbD complex. Bacteria lacking 
specific transporters presumably use general porins for outer membrane sialic acid 
transport. Sialic acid can then be transported across the inner membrane via a number of 
mechanisms, including NanT (as seen in T. forsythia) or the SiaPQM Tripartite-ATP 
independent Transporter (TRAP) complex (as seen in F. nucleatum). Sialic acid is then 
metabolised, starting with an N-acetylneuraminate lysase (NanA), followed by one of two 
pathways: In E. coli this involves (NanK) and (NanE), and in Bacteroidetes this involves 
(NanE) and (RokK). At this point the two pathways converge, and the end product (N-
acetylglucosamine-6-phosphate, GlcNAc-6-P) undergoes conversion to Fructose-6-
Phosphate, which undergoes glycolysis. T. forsythia is thought to be able to utilise GlcNAc-
6-P as a substrate for NAM biosynthesis. As an alternative to metabolism, some bacteria 
are apparently capable of sialylating their surface structures or secreted proteins. This is 
seen in some capsular polysaccharides (such is in E. coli K1 strains), LPS (Group B 
streptococci, GBS), or secreted proteins (such as P. gingivalis gingipains). 
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 Porphyromonas gingivalis Sialidase 1.7.5.2
P. gingivalis possesses sialidase activity, with one sialidase-related gene; PG0352, and two 
genes annotated as O-sialoglycoproteases; PG0778, and PG1724 (Aruni et al. 2011). 
PG0352 is analogous to the NanH sialidase of T. forsythia, possessing the characteristic 
putative CBM, Asp-boxes and FRIP domain, and a similar predicted structure (sections 1.7.2 
and 2.3.1). PG0352 deficient mutants have been used to highlight multiple roles for this 
sialidase in the virulence of P. gingivalis, with mutants showing reduced adherence and 
invasion of oral epithelial cells (Aruni et al. 2011). Interestingly, biofilm formation of P. 
gingivalis in vitro is impaired in PG0352 deficient mutants, though biofilm formation is 
restored by addition of Neu5Ac (Li et al. 2012). Furthermore, PG0352 deficient mutants 
display altered morphology and reduced capsule formation compared to the parent strain. 
Perhaps P. gingivalis (or the strain used in this study) incorporates Neu5Ac into its capsule, 
or requires Neu5Ac as a precursor for synthesis of other capsular sugars. This mutant also 
displayed decreased resistance to human serum, which is perhaps unsurprising due to the 
reduction in capsule formation, though the absence of sialidase could also contribute to 
complement mediated killing. This reduced ability to survive complement, and the 
deficiencies in biofilm formation, could also be due to altered gingipain activity/structure, 
since it has been shown that Neu5Ac is a major component of RgpA glycosylation 
(Rangarajan et al. 2005). Since P. gingivalis lacks the genetic ability to synthesize sialic acid 
(at least by known pathways), sialidase activity is likely key in acquisition of exogenous 
sialic acid for reprocessing.  
In summary, sialidases are expressed by all three red complex species, and sialic acid 
utilisation pathways are present in other periodontal pathogens (Stafford et al. 2012), as 
well as other bacteria. Given that pathogen sialidases appear to have multiple 
contributions to virulence, they represent a strong candidate for inhibition as an anti-
virulence approach, with the ultimate aim to apply sialidase inhibition to treatment of 
periodontitis in patients.  
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1.8 Sialidase Inhibition 
1.8.1  Viral Sialidase-The Driving Force Behind Inhibitor Development 
Influenza neuraminidase (NA, N) is one of the two components of the current human flu 
vaccine (the other being Haemagglutinin, H) but both are prone to point mutations or 
different virus strains may recombine on co-infection of the same host, resulting in progeny 
with an alternative combination of H and N antigens. As a result, annual manufacture of 
vaccines based on the N and H antigens of the most prevalent influenza strains is required.  
The need to treat influenza infection lead to the development of sialidase (or 
neuraminidase) inhibitors. These aim to prevent the effects of aiming to prevent the virus 
from exiting host cells, thus halting viral proliferation. Sold under the names Tamiflu and 
Relenza, the sialidase inhibitors oseltamivir and zanamivir are licensed worldwide as a 
treatment for flu.  
1.8.2 Sialidase Inhibitors 
Sialidase inhibitors are structural analogues of sialic acid (figure 1.9), and act by competing 
with native ligands for the sialidase active site. Interestingly, the catalytic intermediate 2-
deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) was shown to be bind viral NA with 
greater affinity than sialic acid (Meindl et al. 1974), and further derivatives of DANA and 
Neu5Ac led to the development of different inhibitors. 
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Figure 1.9. Sialidase inhibitors are structural analogues of sialic acid. 
Neu5Ac shown with the sialidase inhibitors DANA (2-deoxy-2,3-dehydro-N-
acetylneuraminic acid), oseltamivir, and zanamivir. (Credit for Image: Chatchawal 
Phansopa, Stafford Group, University of Sheffield.) 
 
1.8.3 Sialidase Inhibition-Potential Impact on Virulence 
Conventional antibacterial chemotherapy targets ubiquitous bacterial processes. 
Unfortunately, this comes with several drawbacks, including disruption of the host normal 
flora, and selection of antibiotic resistant bacteria. An alternative to conventional 
antimicrobial chemotherapy is to target virulence factors or pathogenic processes, which 
avoids issues seen with disruption of normal flora and antibiotic resistance. Given the role 
of sialidases in biofilm and capsule formation, host cell invasion, adherence, and immune 
modulation in a number of periodontal pathogens, sialidase inhibitors are a potential anti-
virulence drug that could be used to treat periodontitis. Initial supporting evidence comes 
from studies of sialidase deficient strains of P. gingivalis, T. denticola, and T. forsythia.   
T. forsythia has been shown to form biofilms in the presence of a variety of 
sialoglycoconjugates, including saliva, sialyllactose and mucin, but the sialidase inhibitor 
oseltamivir inhibits this in a dose dependent manner (Roy et al. 2011), while biofilms 
cultured in the presence of sialic acid remain unaffected by oseltamivir. In addition, 
 
Neu5Ac 
 anamivir 
DANA 
oseltamivir 
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attachment of T. forsythia to epithelial cells is inhibited in the presence of DANA (Honma et 
al. 2011). Sialidase activity has also been shown to modulate virulence of T. denticola, since 
sialidase deficient mutants display decreased complement sensitivity and ability to cause 
tissue damage in a murine abscess model, and the sialidase activity of T. denticola has been 
shown to be decreased in the presence of the sialidase inhibitor DANA (Kurniyati et al. 
2013). These studies demonstrate the potential of sialidase inhibitors as anti virulence 
compounds against periodontal pathogens. 
1.8.4 Sialidase Inhibition-Impact on the Host Immune Response 
Given that a pro-inflammatory response is also responsible for the pathology seen in 
periodontitis, an ability to regulate this would result in decreased morbidity. TLRs -2 and -4 
are activated in response to periodontal pathogens (Sahingur et al. 2013; Wara-Aswapati et 
al. 2012; Papadopoulos et al. 2012). These TLRs have been shown to be extensively 
glycosylated, hinting at the potential for sialidases to unmask ligand binding sites (da Silva 
Correia & Ulevitch 2002). TLR-2 and -4, activated by bacterial lipoprotein and bacterial LPS, 
respectively, have been shown to form a complex with the human sialidase Neu1 (Amith et 
al. 2010), and desialylation is required for receptor activation . Furthermore, LPS induced 
expression of IL-6, IL-12p40, and TNF-α by mature DCs is reduced in the presence of 
zanamivir or DANA (Stamatos et al. 2010), and macrophages show reduced LPS-activation 
in the presence of Zanamivir, DANA, and oseltamivir (Amith et al. 2009). While this reduced 
activity is due to the inhibition of human sialidases, exogenous sialidases were shown to 
increase TLR -2 and -4 activation (Amith et al. 2010), and the ability to inhibit pro-
inflammatory signalling through sialidase-regulated TLR activation is another advantage for 
sialidase inhibitors as potential therapeutic agents in periodontitis. 
1.8.5 Aims and Hypothesis-The Prospect of Sialidase Inhibitors as a Treatment 
for Periodontitis 
Periodontal pathogens of the red complex express sialidases with multiple functions for 
themselves and other pathogenic organisms.  Given the apparent role of sialidases in 
pathogenic processes, sialidase inhibitors could be potential anti-virulence compounds. 
Thus, this project aimed to investigate the effect of sialidase inhibitors on host cell 
association and host-pathogen interactions, as well as in biofilm formation and growth of 
periodontal pathogens. This study also aimed to further characterise the periodontal 
pathogen sialidases using biochemical approaches.  It was hypothesised that zanamivir or 
other sialidase inhibitors would inhibit periodontal pathogen sialidase activity, and 
subsequently inhibit biofilm formation of periodontal pathogens on sialoglycoproteins, as 
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well as inhibiting host-pathogen interactions including host-bacteria association and 
immunomodulation. 
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2 Chapter 2: Biochemical Characterisation of Periodontal 
Pathogen Sialidases 
2.1 Introduction-The Sialidases of P. gingivalis and T. forsythia 
The ecological niche in which periodontal pathogens live is rich in glycoproteins and 
glycolipids. In the supragingival plaque these may be from the surfaces of oral epithelial 
cells, or salivary mucins and other salivary proteins. The subgingival plaque is also exposed 
to these glycoprotein sources and others including components of gingival crevicular fluid 
(GCF, more similar in composition to serum) and immune cells that infiltrate the 
periodontium, such as neutrophils and macrophages. Glycoproteins and glycolipids 
themselves are a source of sialic acid which often caps the sugar chains, or glycans (the 
ends furthest from the protein backbone in glycoproteins, or cell surface in the case of 
glycolipids), and these can be termed sialoglycans. Host secretions are rich in sialoglycans, 
for instance, 80% of the oligosaccharide chains in salivary mucins are estimated to be 
sialylated (Levine et al. 1987), and serum proteins in healthy humans contain ~1% w/w 
sialic acid (Carter & Martin 1962). Cell surfaces are also rich in sialic acid, with a single 
erythrocyte plasma membrane thought to possess more than 10 million sialic acid 
molecules (Varki A, Schauer R. Sialic Acids. In: Varki A, Cummings RD, Esko JD, et al., 
editors. Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press; 2009. Chapter 14. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1920/).  
Release of sialic acid can provide a carbon source for bacteria or expose underlying glycans 
which can then be targeted by other enzymes (Stafford et al. 2012). As well as its potential 
roles in bacterial nutrition, sialic acid has a number of functions for the host, and it has 
been suggested that sialic acid release can have consequences for disease progression in a 
number of infections (Feng et al. 2013; Chang et al. 2012; Li et al. 2012). 
Given the abundance of sialic acid in the oral cavity it is unsurprising that many pathogens 
and some commensals possess sialidase enzymes capable of cleaving sialic acid from the 
sialoglycans. T. forsythia, P. gingivalis, and T. denticola comprise the “red complex,” 
present in subgingival plaque because of their association with severe periodontitis 
(Socransky et al. 1998). All three members of the red complex possess sialidases. In T. 
forsythia, a candidate protein dubbed “SiaHI” was initially suggested to be responsible for 
this (Ishikura et al. 2003) , but an overwhelming body of evidence has shown that the 
sialidase NanH (TF0035), is primarily responsible for sialidase activity in T. forsythia (Roy et 
al. 2011; Honma et al. 2011; Thompson et al. 2009). 
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Strains of P. gingivalis also possesses a sialidase (PG0352), termed “SiaPG” for the purposes 
of this work. Although SiaPG (PG0352) is currently annotated as a “putative sialidase” in the 
NCBI protein database (http://www.ncbi.nlm.nih.gov/protein/AAQ65563.1), the function of 
PG0352 has been confirmed through construction and testing of gene-knockout strains (Li 
et al. 2012; Aruni et al. 2011). 
Previous studies have highlighted the importance of sialidases in the virulence of T. 
forsythia and P. gingivalis (Li et al. 2012; Aruni et al. 2011; Honma et al. 2011). However, 
purification and biochemical characterisation of NanH has not been described, besides its 
initial characterisation in E.coli cell lysates (Thompson et al. 2009) and preliminary 
characterisation by our group (Roy et al. 2011), and to our knowledge only one publication 
has shown preliminary characterisation of purified SiaPG (Li et al. 2012). Elucidation of 
ligand specificity and conditions under which these enzymes function would provide 
information regarding their activity and functions in vivo. Furthermore, as described above, 
a number of studies have highlighted the importance of periodontal pathogen sialidases in 
biofilm formation, attachment and invasion of host cells, and ultimately disease. Given the 
multitude of apparent functions for pathogen sialidases, they are a strong candidate for 
targeting pharmacologically, with a view to preventing these virulence mechanisms. 
However, before any in vitro virulence studies could be performed, it had to be established 
if the periodontal pathogen sialidases could be inhibited using commercially available 
sialidase inhibitor compounds.  
This chapter describes the ultimately successful attempts to clone and purify functional 
NanH and SiaPG, along with attempts to clone and purify the NanH-C Terminal (catalytic) 
Domain (CTD), SiaPG-Carbohydrate Binding Module (SiaPG-CBM) and SiaPG-C Terminal 
(catalytic) Domain (SiaPG-CTD). Production of active pathogen sialidases allowed 
determination of their activity on various substrates including host-relevant ligands. 
Furthermore, the efficacy of the sialidase inhibitor zanamivir, produced as the 
pharmaceutical preparation Relenza™ by GSK, for inhibition of the periodontal pathogen 
sialidases was investigated. 
2.2 Materials and Methods- Biochemical Characterisation of 
Periodontal Pathogen Sialidases 
2.2.1 Bacterial Strains, Growth Conditions, and Plasmids 
E. coli strains were required for cloning and protein expression work. All E. coli were 
cultured on Luria Bertani agar (LB agar) or Lysogeny broth (LB broth) (Thermo Fisher 
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Scientific). When attempting transformation, or culturing transformed strains, these were 
cultured on LB agar or LB broth supplemented with 50 μg/ml ampicillin, as the plasmids 
used confer ampicillin resistance. All cultures were incubated at 37°C, broth cultures were 
shaken at 200-250 rpm. E. coli growth for protein expression studies is described in section 
2.2.8. 
E. coli Strain Genotype Reference 
DH5α 
    2 Δ(    -   Z)U169          44 Φ80 
Δ(   Z)M15     96     1     1     1    -1 
hsdR17 
New England 
Biolabs (NEB)  
BL21 Origami B 
(DE3) 
F- ompT hsdSB(rB
- mB
-) gal dcm lacY1 ahpC 
(DE3) gor522:: Tn10 trxB (KanR, TetR) 
Novagen 
(MerckMIllipore)  
Table 2.1. E. coli strains. 
 Details of the E. coli BL21 origami B and E. coli DH5α strains are currently available at: 
http://www.merckmillipore.com/GB/en/product/Origami%E2%84%A2-B%28DE3%29-
Competent-Cells---Novagen,EMD_BIO-70837 
-and- 
https://www.neb.com/products/c2987-neb-5-alpha-competent-e-coli-high-efficiency  
__________________________________________________________________________ 
 
Plasmids for cloning and expression work were either the pET plasmids pET21a, or pET20b, 
or the pJET plasmid which was commercially available with the blunt ended ligation kit 
used in this work (see below). The plasmid features are summarised in table 2.2. 
Plasmid Description Phenotype Source 
pET21a 
Suitable as a cloning vector, also for 
protein expression with N-terminal 
His+ tag for affinity chromatography 
Ampicillin 
Resistant 
Novagen  
pET20b 
Suitable as a cloning vector, also for 
protein expression with C-terminal 
His+ tag for affinity chromatography 
Ampicillin 
Resistant 
Novagen  
pJET 
Cloning vector only. Suitable for blunt 
ended ligation.  
Ampicillin 
Resistant 
Thermo-Fisher 
Scientific 
Table 2.2. Plasmids for cloning and expression. 
__________________________________________________________________________ 
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2.2.2 Sialidase Activity of Whole Bacteria 
Bacteria were scraped from agar plates and washed by resuspension in 1ml PBS pH 7.4 
(Sigma Aldrich) and centrifuged at 13000 xg for 2 minutes. Supernatant was disposed of 
and bacteria were resuspended in PBS pH 7.4 before use in a reaction mixture containing 
PBS pH 7.4 (Sigma Aldrich) and 0.1 mM of 4-methylumbelliferyl N-acetyl-a-D-neuraminic 
acid sodium salt (MUNANA; carbosynth, UK), at an optical density at 600nm (OD600) of 0.05, 
and incubated at 37 ˚C for up to 24 hours in clear flat-bottomed 96 well polystyrene plates 
(Greiner, UK).  
Sialidase activity was quantified by observing the cleavage of MUNANA to yield Neu5Ac 
and the fluorochrome 4-Methylumbelliferone (4-MU). In early work described here, the 
periodontal pathogen sialidase activity was quantified immediately using a Polarstar Galaxy 
plate reader (BMG Labtech) where fluorescence was measured at excitation 355nm, 
emission 430-10nm. This was advantageous as it allowed reaction mixtures to be quantified 
over time, but these fluorescence parameters and the Flurostar plate reader itself were not 
sensitive to small changes in 4-MU release. Therefore, the majority of sialidase activity 
experiments were performed according to a different protocol; Reaction mixtures were set 
up, and at any given time point 50µl of reaction mixture was removed and quenched by 
addition of 75µl of 100mM sodium carbonate buffer, pH 10.5 (a mixture of sodium 
carbonate and bicarbonate made according to buffer reference table, currently available at 
http://www.sigmaaldrich.com/life-science/core-bioreagents/biological-buffers/learning-
center/buffer-reference-center.html). This quenching step stopped the reaction and 
equalised the pH (4-MU fluorescence is pH sensitive, optimum at >pH 10). Fluorescence 
was measured with excitation at 350 nm, emission 450 nm, using a Tecan Infinite M200 
microplate reader.  
The sialidase inhibitor zanamivir (GlaxoSmithKline, UK) was used in assays to test the effect 
of sialidase inhibition. Zanamivir was dissolved in water at 50mM, and diluted into reaction 
mixtures at a variety of concentrations, from 0-10mM.  
Sialidase activity of different periodontal pathogens was measured as the fluorescence at 
450 nm after excitation at 350 nm and expressed as arbitrary units. Sialidase activity of 
different bacteria in the presence of inhibitor was expressed as the percentage change in 
fluorescence at a given concentration of inhibitor, compared to fluorescence in the absence 
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of inhibitor, as determined by the formula: 
 
2.2.3 DNA Extraction 
 Genomic DNA 2.2.3.1
Periodontal pathogen genomic DNA was extracted from cultures harvested from agar 
plates, which were washed twice by resuspension in PBS and centrifugation at 13000 g. 
Extractions were performed using the Wizard Genomic DNA Purification kit (Promega), 
according to the manufacturer’s instructions. 
 Plasmid DNA 2.2.3.2
Plasmid extraction was performed on 5ml of overnight liquid cultures of E. coli, using the 
ISOLATE II Plasmid Miniprep kit (Bioline), according to manufacturer’s instructions.  
2.2.4 Polymerase Chain Reaction (PCR) 
PCRs performed in this project were attempting to amplify DNA for further cloning work: 
High-Fidelity PCR was performed using the Phusion® PCR kit (New England Biolabs), which 
has proofreading capabilities resulting in a low rate of nucleotide insertion errors during 
the amplification stage of the PCR reaction. PCRs were performed to obtain a number of 
different products, each of which required extensive optimisation, including primer design, 
adjustments of primer concentration, reaction mixture size, and Thermocycling conditions. 
Therefore, the PCR reaction conditions that were successful for each product are shown in 
appropriate results section in this chapter (sections 2.3.2 and 2.3.3). 
 Agarose Gel Electrophoresis 2.2.4.1
Agarose gels were prepared using 1-1.5% agarose (w/v) in 1x TAE (Tris Base, Acetic acid, 
EDTA), with 5 µg/ml ethidium bromide added to the gel before casting. Agarose gels were 
run in 1x TAE on a BioRad mini-sub®-cell GT system or BioRad sub-cell® GT systems (for 
small and large gels, respectively). DNA was visualised using a UV transiluminator-GBOX 
(Syngene) with associated imaging software programs GeneSnap or Genesys (Syngene). 
Various standards were used to assess DNA band sizes, described alongside the agarose 
gels in the appropriate results section in this chapter (sections 2.3.2 and 2.3.3). 
 Purification of PCR Products 2.2.4.2
PCR Products (and restriction endonuclease digestion products, below) were excised from 
agarose gels using a scalpel, and extracted using the QIAquick Gel Extraction kit (QIAGEN). 
   fluorescence at 0mM zanamivir      x 100    = Change in Fluorescence (%) 
fluorescence at 0-10mM zanamivir 
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2.2.5 Restriction Endonuclease Digestion of Plasmid DNA or PCR products 
Plasmids and PCR products underwent digestion using NdeI and XhoI restriction enzymes 
(or others as appropriate) and reagents were purchased from New England Biolabs. 
Reagents are described in table 2.3. Reactions were incubated at 37˚C for a total of 3 hours.  
Reagent Volume (μl) Per 60μl Reaction 
NdeI 2 
XhoI 2 
Plasmid/PCR Product (concentration varied) 44.4 
Buffer 4 (10x concentration) 6 
BSA 0.6 
(CIP) 2 
Table 2.3. Reagents for restriction digest of plasmids and PCR products. 
CIP; calf intestinal alkaline phosphatase, was only added to plasmid digestion reactions, 
after 2 hours of incubation. A further 1μl of each restriction en yme was also added after 1 
hour of incubation. DNA was purified by use of the same gel extraction method used for 
agarose gels, treating the gel volume as 100μl, and eluted in dH2O. The concentrations of 
digested, purified plasmids and PCR products were checked using a Nanodrop. 
__________________________________________________________________________ 
Restriction endonuclease digestion reactions underwent agarose gel electrophoresis, and 
where appropriate, extraction and purification of products from agarose gels was 
performed using the QIAquick Gel Extraction kit (QIAGEN). 
2.2.6 DNA Ligation 
Ligation of restriction digested plasmids and PCR products or GeneStringsTM was carried out 
using Instant Sticky-end Ligase Master Mix (New England Biolabs, NEB) or T4 DNA ligase 
(NEB). Plasmid vector and PCR products were mixed at a molar ratio of 1:5 (plasmid:PCR 
product), and for Instant Sticky-end Ligase, an equal volume of  Instant Sticky-end Ligase 
Master Mix was added to the vector-PCR product mix. T4 DNA ligase was added to 
reactions with volumes adjusted to make 1x enzyme and 1x ligation buffer, in accordance 
with the manufacturer’s instructions. In both cases, the ligation reaction was incubated at 
74 
 
room temperature (approximately 16˚C) overnight. Post-reaction ligation mixture was used 
directly for transformations. 
2.2.7 Bacterial Transformation 
E. coli strains were either chemically competent (DH5α) or electrocompetent (BL21 
Origami). 
 Transformation of E. coli DH5α 2.2.7.1
E. coli DH5α (NEB) were transformed according to the  manufacturer’s protocol: One vial of 
competent cells was thawed on ice for 10 minutes, 3 µl of ligation reaction mix was added, 
and gently mixed, before heat shock at 42 °C for 30 seconds. The cells were then incubated 
on ice for 5 minutes, after which 900 µl of SOC media was added. The cells were left to 
recover by incubating at 37 °C, with shaking at 200 rpm. 50 µl of recovered cell suspension 
was plated onto LB agar supplemented with 50 µg/ml ampicillin, and incubated overnight 
at 37 °C. Colonies were patched by spreading over an area approximately 5 mm in diameter 
on a fresh LB agar plate (also supplemented with 50 µg/ml ampicillin) and incubated 
overnight at 37 °C.  
 Transformation of E. coli BL21 Origami 2.2.7.2
2.2.7.2.1 Preparation of Electrocompetent BL21 Origami 
Preparation of electrocompetent E. coli largely involves removal of ionic components from 
the bacterial suspension in order to prevent arcing during electrotransformation.  
E. coli were cultured in 25 ml LB broth to an OD600 of 0.5-0.7 (mid log phase). Cultures were 
pelleted by centrifugation at 3500 g for 15 minutes, then resuspended gently in 25 ml ice-
cold 10 % glycerol, and incubated on ice for 30 minutes. E. coli were pelleted, resuspended, 
and incubated in ice cold 10 % glycerol twice more; resuspended once in 12.5 ml glycerol, 
then in 1 ml glycerol.  E. coli were aliquoted into 50 µl aliquots and stored at -80 °C until use 
in electrotransformation. 
2.2.7.2.2 Electrotransformation 
A Biorad Micropulser system was used according to manufacturer’s instructions. Briefly, 
10-100 ng of plasmid DNA was gently mixed with a 50 µl aliquot of electrocompetent E. 
coli. E. coli-plasmid mixtures were added to pre-chilled 0.1 cm electroporation cuvettes. 
The suspension was electroporated using a BioRad micropulser at the EC1 setting (1.8 kV 
potential difference, 200 Ω, time constants 1.0-4.0 milliseconds). After electroporation, 
cells in the cuvette were immediately mixed with 1 ml of room temperature LB, and 
incubated for 1 hour at 37 °C, with shaking at 200 rpm. 50 µl of recovered cell suspension 
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was plated onto LB agar supplemented with 50 µg/ml ampicillin, and incubated overnight 
at 37 °C. Colonies were patched by spreading over an area approximately 5 mm in diameter 
on a fresh LB agar plate (also supplemented with 50 µg/ml ampicillin and incubated 
overnight at 37 °C. 
2.2.8 Protein Production and Purification by Affinity Chromatography 
Expression strains could be induced to produce protein, then lysed, and lysates could 
undergo affinity chromatography to purify expressed protein.  This relies on the production 
of a 6-Histidine tag (His+ tag) conjugated to the protein of interest in the cell lysate. In this 
project this was achieved using pET plasmid vectors. The His+ tagged protein can weakly 
bind to immobilised nickel (hence the term “affinity chromatography”), while the rest of 
the cell lysate flows through or is washed off. The His+ tagged protein is eluted from the 
nickel (Ni2+) using buffer containing imidazole, which interacts more strongly with nickel 
than the His+ tag.  
In addition to His+ affinity chromatography, Glutathione-S-Transferase (GST) affinity 
chromatography was also performed. The principle remains the same, but the protein is 
tagged with a large (26kDa) GST tag, which binds immobilised reduced glutathione. The 
protein can be eluted using buffer with reduced glutathione, causing the protein to become 
disassociated from the reduced glutathione, or the GST-tag cleaved from the protein of 
interest using thrombin, releasing the protein. 
Affinity chromatography only works for purification of proteins in solution. Both readily 
soluble and initially-insoluble proteins were produced during this project. In the case of the 
latter, proteins had to undergo an initial urea-solubilisation step prior to affinity 
chromatography, and afterwards the protein had to undergo re-folding by slowly reducing 
the concentration of urea present, with the intention that it retains its solubility.   
 Protein Expression  2.2.8.1
E.coli expression strains were incubated at 37 ˚C, shaking at 200 rpm overnight in LB broth 
supplemented with 50 µg/ml ampicillin. This was used to seed 2YT broth supplemented 
with 50 µg/ml ampicillin, and incubated at 37 ˚C, shaking at 200 rpm for ~2.5 hours until 
OD600 0.5-0.7 was reached (mid log phase). At this point, E. coli were induced to express 
proteins by addition of 1 mM IPTG, and were incubated at 25 ˚C, shaking at 200 rpm for up 
to 20 hours. E. coli were pelleted by centrifugation at 7000 g for 15 minutes, and were 
frozen at -20 ˚C for storage until purification, or underwent protein purification 
immediately. 
76 
 
 
 Purification of Soluble Proteins 2.2.8.2
E.coli that had been induced to express readily-soluble protein were thawed, if required, 
and resuspended in resuspension buffer (50 mM Sodium Phosphate buffer, 0.5 mM NaCl, 
20 mM imidazole pH 7.4). E. coli were lysed by passing through a French press three times 
at 1000 bar, and the lysate was centrifuged at 15000 g for 45 minutes. Supernatant 
underwent affinity chromatography using a 1ml Ni2+ column (GEHealthcare, UK) at a flow 
rate of 1 ml/min, and washed using 10-20 ml wash buffer (50 mM sodium phosphate 
buffer, 0.5 mM NaCl, 40 mM imidazole pH 7.4) at a flow rate of 2 ml/min. Protein was 
either manually eluted from the column in 1 ml fractions using elution buffer (50 mM 
sodium phosphate buffer, 0.5 mM NaCl, 300mM imidazole pH 7.4) at a flow rate of  
1 ml/min, or eluted using an AKTA-Prime HPLC and a gradient elution of 50-500 mM 
imidazole in elution buffer at a flow rate of 1 ml/min over 10-15 1ml fractions. Cell lysates, 
flow through, wash through, and elutions were tested for the presence of over-expressed 
protein and purity using SDS-PAGE (see below) pure protein-containing fractions were 
pooled and dialysed using dialysis buffer, (50 mM sodium phosphate, 200 mM sodium 
chloride, pH 7.4) for 10-18 hours at 4 ˚C, and could be stored at 4 °C in the short term (up 
to a week) or longer-term at -20˚C. 
 Purification of Initially-Insoluble Proteins 2.2.8.3
E.coli that had been induced to express initially-insoluble proteins were thawed, if 
required, and resuspended in resuspension buffer (50mM sodium phosphate buffer, 
0.5mM NaCl, 20mM imidazole pH 7.4). E. coli were lysed by passing through a French press 
three times at 1000 bar, and the lysate was centrifuged at 15000 g for 45 minutes.  
The insoluble fraction of the cell lysate was suspended in resuspension buffer containing 8 
M urea, and incubated for 3 hours at room temperature, on lab rollers. The suspension was 
centrifuged at 15000 g for 45 minutes, then subjected to affinity chromatography using a 
1ml Ni2+ column (GEHealthcare, UK) at a flow rate of 1 ml/min, and washed using 10-20 ml 
wash buffer (8 M urea, 50mM Sodium Phosphate buffer, 0.5 mM NaCl, 40 mM imidazole 
pH 7.4) at a flow rate of 2 ml/min. Protein was manually eluted from the column in 1 ml 
fractions using elution buffer (8 M urea, 50 mM sodium phosphate buffer, 0.5 mM NaCl, 
300 mM imidazole pH 7.4) at a flow rate of 1 ml/min, cell lysates, flow through, wash 
through, and elutions were tested for the presence of over-expressed protein and purity 
using SDS-PAGE (see below). Pure protein-containing fractions were pooled and underwent 
step-down dialysis to remove urea, and attempt to refold the protein, while maintaining 
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solubility. Dialysis was performed in five stages using dialysis buffer (50 mM Sodium 
Phosphate, 200 mM Sodium Chloride, pH 7.4), which contained either  4 M, 1 M, 0.5 M, 0 
M, and 0 M urea, respectively. All stages were performed for 2 hours, except for the first 0 
M urea stage (the fourth stage), which was performed for ~20 hours (overnight).  
 Protein Purification using GST-Affinity Chromatography 2.2.8.4
E.coli that had been induced to express readily-soluble GST-tagged proteins were thawed, if 
required, and resuspended in PBS (100 mM sodium Phosphate Monobasic-Potassium  
Phosphate Dibasic buffer, with 50 mM NaCl, pH 7.4). E. coli were lysed by passing through a 
French press three times at 1000 bar, and the lysate was centrifuged at 15000 g for 45 
minutes. Supernatant underwent affinity chromatography using a 1 ml GSTrap column 
(GEHealthcare, UK) at a flow rate of 1 ml/min, and washed using 10-20 ml PBS at a flow 
rate of 2 ml/min. The GST tag was cleaved by injection of 1 ml of 1 mg/ml thrombin (Sigma 
Aldrich, in PBS) onto the column, followed by incubation at room temperature for 4 hours 
(or at 4 °C overnight). Protein was eluted from the column using PBS into 1 ml fractions. To 
remove thrombin, fractions were incubated with 50 µl Benzamidine-agarose beads (Sigma 
Aldrich) per fraction on lab rollers at 4 °C for 30 minutes. Benzamidine agarose was 
removed by centrifugation for 5 minutes at 15000 g, and purified protein was placed into 
fresh Eppendorf tubes. 
 LPS-Decontamination of Purified NanH 2.2.8.5
Purified NanH for use in experiments aiming to investigate immunomodulation of epithelial 
cells (chapter 4, sections 4.2.5 and 4.3.5.1) had to be free of residual LPS from the E. coli 
expression strain. Purified NanH underwent treatment with polymixin agarose beads 
(Sigma Aldrich) at a volume of beads considered appropriate according to the 
manufacturer’s intructions. NanH was incubated with the polymixin-agarose beads for 1 
hour at 4 °C, with agitation using lab rollers. Beads were removed by centrifugation at 
16000 g for 5 minutes. 
2.2.9 BCA Assays 
BCA assays were routinely performed to check protein concentrations, using the Pierce BCA 
assay kit (Thermo-Fisher Scientific), according to manufacturer’s instructions. Samples and 
bovine serum albumin (BSA) standards for production of standard curves were always 
diluted in the same buffer during each assay. 
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2.2.10 Sodium Dodecyl Sulphate-Poly Acrylamide Gel Electrophoresis (SDS-
PAGE) 
  SDS-PAGE Gel Preparation 2.2.10.1
Buffers and reagents to make gels were prepared in house with reagents and instructions 
shown in table 2.4, or bought from commercial suppliers. 
Buffer 
Name 
Reagents Instructions 
Upper 
Tris 
6.06 g Tris Base, 0.4 g SDS 
Reagents dissolved in dH2O,  adjusted 
to pH 6.8 with HCl, total volume 100 
ml. 
Lower 
Tris 
18.17 g Tris Base, 0.4 g SDS 
Reagents dissolved in dH2O, adjusted 
to pH 8.8 with NaOH, total volume 
100 ml 
Running 
Buffer 
12 g Tris Base, 4 g SDS, 57.5 g 
glycine 
Reagents dissolved in 1000 ml dH2O 
to make a stock solution. Prior to use, 
160 ml was added to 840 ml dH2O.  
Loading 
Buffer 
40 ml 100 mM Tris-HCl, 10 ml 
20% glycerol, 1 g SDS, 0.1 g 
Bromophenol Blue, 200mM DTT 
Reagents mixed to make a stock 
without DTT. DTT added prior to use. 
 
Table 2.4. SDS-PAGE buffers. 
DTT-Dithiothreitol, dH2O-deionised water. Reagents purchased from Thermo-Fisher 
Scientific. 
 
Polyacrylamide gels were prepared prior to SDS-PAGE using the reagents as described in 
table 2.5. The resolving gel was prepared and cast first; reagents were combined in the 
order shown in the table from top to bottom, with the volumes shown here sufficient for 
two 1 mm-depth SDS-PAGE gels cast using BioRad-supplied glass plates and gel casting 
stations. After pouring into the casting station (leaving ~1 cm room for the stacking gel), 
the gel was levelled using isopropanol (which also prevented air bubbles from disrupting 
gel formation), which was washed from the gel with water prior to adding the stacking gel, 
into which a comb was placed to form wells. After the gel was set, it was placed in a BioRad 
SDS-PAGE tank (mini PROTEAN Tetra System) and the tank filled with running buffer. 
Loading buffer was added to protein samples and heated at 95 °C for 5 minutes, before 
loading into the wells of the SDS-PAGE gel, with the inclusion of a molecular weight marker 
in at least one well (pre-stained EZ run Protein Ladder, ThermoFisher Scientific). Gels were 
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run at 100-220 V (constant amps) for up to 3 hours until the loading dye was seen to have 
left the gel or the molecular weight marker was well distributed. The gel was removed from 
the glass plates and stained using InstantBlue ™ (Expedeon) for at least 45 minutes at room 
temperature with agitation. 
 
Resolving Gel 
 
Reagent 12% Gel 15% Gel 
Stacking 
Gel 
Lower Tris 2.5 ml 2.5 ml - 
Upper Tris - - 2.1 ml 
Acrylamide 3 ml 3.75ml 4.725 ml 
dH2O 4.3 ml 3.55 ml 0.975 ml 
TEMED 5 ul 5 ul 17 ul 
APS 350 ul 350 ul 100 ul 
Table 2.5. Reagent volumes required for casting of SDS-PAGE resolving gels. 
TEMED- Tetramethylethylenediamine, APS-Ammonium Persulphate, dH2O-deionised water.  
 
2.2.11 Biochemical Studies of Sialidases and Sialidase Subunits 
Purification of the sialidases of P. gingivalis (SiaPG) and T. forsythia (NanH) enabled studies 
of the enzymes in isolation from their native organisms. 
 pH optima derivation of periodontal pathogen sialidases 2.2.11.1
The fluorogenic sialic acid substrate MUNANA (described further in section 2.3.6) was used 
to ascertain the activity of NanH and PGsia under different pH conditions.  2.5 nM NanH or 
5 nM SiaPG was incubated in the presence of 0.1mM MUNANA, in a variety of 20 mM 
buffers; Sodium Citrate-Citric Acid (pH 3-6.4) Sodium Phosphate Monobasic-Dibasic (pH 
6.8-8.8), or Sodium Carbonate-Sodium Bicarbonate (pH 9.2-10.5), at room temperature for 
up to 2 minutes. At 1 and 2 minutes, 50µl of each reaction was quenched in 75µl of 100mM 
sodium carbonate buffer, pH 10.5. Fluorescence at each time point was measured at 
excitation at 350 nm, emission 450 nm, using a Tecan Infinite M200 microplate reader. 
Sialidase activity of whole pathogens was also carried out using reaction conditions 
described in section 2.2, but PBS was replaced with the buffers described here, and 
reactions were quenched at 30 second time points. Sialidase activity of whole pathogens or 
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purified sialidases was expressed as the fluorescence at 450 nm after excitation at 350 nm 
(arbitrary units).  
 Reaction kinetics of Periodontal Pathogen Sialidases with MUNANA 2.2.11.2
MUNANA was exposed to NanH or SiaPG. Reactions contained 1 or 2.5 nM NanH or SiaPG 
and a variable concentration of MUNANA, in one of a variety of buffers: Either 50 mM 
sodium phosphate, 200 mM NaCl, pH 7.4, or 20 mM sodium phosphate buffer, pH 7.2, or 
20 mM sodium citrate buffer, pH 5.2, or 20 mM sodium citrate buffer, 20 mM NaCl, pH 5.2. 
These were incubated at room temperature for up to 3 minutes, with 50 µl of each reaction 
removed at 1 minute intervals, and the reaction was halted and pH equalised by addition of 
75 µl sodium carbonate buffer, pH 10.5. Fluorescence at each time point was measured at 
excitation at 350 nm, emission 450 nm, using a Tecan Infinite M200 microplate reader, and 
application of a 4-MU standard curve enabled quantification of the rate of 4-MU release. 
The initial rate in all conditions tested appeared to occur between the 2 and 3 minute time 
points, and Initial Rate, or Velocity (V0, 4-MU release µmol/min/mg enzyme) was plotted 
against ligand concentration (µM), and the KM, Vmax determined using the following 
equation: 
Y = Vmax × X/(KM + X) 
Where X is the substrate concentration, and Y is the enzyme velocity, Vmax is the maximum 
enzyme velocity, and KM is the Michaelis-Menten constant. 
 Inhibition of Purified Sialidases 2.2.11.3
2.5 nM NanH or 5 nM PGsia was incubated in the presence of 0.1 mM MUNANA, in 50 mM 
Sodium Phosphate 200 mM NaCl, pH 7.4 (to mimic host physiological conditions), in the 
presence of different concentrations of zanamivir. Sialidase inhibition was expressed as the 
percentage change in fluorescence at a given concentration of inhibitor, compared to 
fluorescence in the absence of inhibitor, as determined by the formula described in section 
2.2. In the case of zanamivir, sialidase inhibition (%) was plotted against log[inhibitor], and 
the variable slope model was applied to obtain the IC50 of zanamivir for SiaPG and NanH, 
using the equation: 
Y=100/(1+10 (LogIC50-X) ×HillSlope)  
Where Y=Sialidase Activity, relative to no inhibitor condition (%), X= logarithm [inhibitor], 
and Hillslope refers to the steepness of the curve. 
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 Quantification of Sialic Acid Release from host-glycans; Thiobarbituric 2.2.11.4
Acid Assay 
Release of sialic acid from the host-relevant ligands 3-sialyllactose, 6-sialyllactose, 3-sialyl 
lewis A (SLeA), 3-sialyl lewis X (SLeX), and bovine submaxillary mucin (BSM) by NanH and 
SiaPG was carried out in a number of different assays (described in sections 2.2.10.5, 2.3.6, 
and 3.2.1, and 3.3.1), and released sialic acid was quantified by the thiobarbituric acid 
(TBA) assay, using a protocol based on work by Aminoff et al. (Aminoff 1961). After 
digestion of host ligand by NanH or SiaPG, 50µl of the resulting reaction mix containing free 
sialic acid was oxidised by addition of 25 µl of 20 mM Sodium Periodate in 60 mM H2SO4, 
and incubated at 37 °C for 30 minutes. Oxidation was halted by addition of 25µl 2% (w/v) 
sodium arsenite in 250 mM H2SO4. Oxidised sialic acid was labelled with a thiol group by 
addition of 200 µl 100 mM Thiobarbituric Acid pH 9.0 and heating at 95 °C for 7.5 minutes. 
In some reactions, the resulting chromophore was extracted by vortexing with 500 µl 
acidified butanol (butanol containing 5 % (v/v) 12 M HCl) and centrifugation at 15000 g for 
2 minutes. 100 µl of reaction mix or 100 µl of butanol-extracted chromophore was added 
to the wells of a clear 96 well plate, and the absorbance at 549 nm was measured using a 
TECAN plate reader. By performing the TBA assay on a standard curve of known sialic acid 
(Neu5Ac) concentrations in the above assay, and blank conditions containing ligand but no 
sialidase, Neu5Ac release (µM) from the above ligands was determined. 
 Reaction kinetics of Periodontal Pathogen Sialidases With Host-Relevant 2.2.11.5
Ligands 
The host relevant ligands 3-sialyllactose, 6-sialyllactose, 3-sialyl lewis A (SLeA), and 3-sialyl 
lewis X (SLeX) were exposed to NanH or SiaPG before undergoing the TBA assay described 
above (section 2.2.10.4) to determine the release of Neu5Ac over time. Reactions 
contained 50 nM NanH or SiaPG and a variable concentration of ligand, in 50 mM sodium 
phosphate, 200 mM NaCl (pH 7.4). These were incubated at 37 °C for up to 15 minutes, and 
50 µl of each reaction was removed at different time points and oxidised by addition of 25 
µl of 20 mM Sodium Periodate in 60 mM H2SO4 (halting sialidase activity and starting the 
TBA assay). After determination of the initial rate, usually between 0.5-1 or 1-2, minutes for 
each ligand at all concentrations tested, release of Neu5Ac Initial Rate, or Velocity (V0, 
Neu5Ac release µmol/min/mg enzyme) was plotted against ligand concentration (µM), and 
the Km, Vmax determined using the following equation: 
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Y = Vmax*X/(KM + X) 
Where X is the substrate concentration, and Y is the enzyme velocity, Vmax is the maximum 
enzyme velocity, and KM is the Michaelis-Mentin constant. 
  Investigation of Protein-Ligand Binding 2.2.11.6
A fluorescence based tryptophan quenching assay was used to quantify binding of proteins 
to a variety of potential ligands. This relied on the presence of tryptophan residues, which 
fluoresce at ~330 nm on excitation at 295 nm. Binding of a protein to a given ligand results 
in conformational changes in the peptide, further exposing the tryptophan residues to 
excitation (leading to increased fluorescence), or enclosing the tryptophan residues and 
decreasing excitation (resulting in decreased fluorescence).  
Proteins were diluted to 0.1 µM in 50 mM sodium phosphate, 200 mM sodium chloride, 
and 195 µl was dispensed to the wells of a UV clear 96 well plate (Greiner, UK) and 5 µl of 
ligand at 20 x concentration. Conditions were incubated at 25 °C for 5 minutes and 
fluorescence was quantified using a TECAN 200M infinite series plate reader (Tecan, 
Switzerland). Fluorescence was measured at excitation 295 nm, emission scanned from 
315-380 nm, slit apertures were 5 nm each. Changes in protein fluorescence in the 
presence of a given concentration of ligand were plotted as a percentage change in 
fluorescence from the protein-only condition, and used to determine the Bmax and Kd of a 
given ligand using the following equation: 
Y = Bmax / X(Kd+X) 
Where X is the final concentration of ligand, Y is the percentage change in protein 
fluorescence in relation to the protein-only fluorescence signal, and Bmax is the extrapolated 
maximum specific binding. 
2.2.12 Structural Characterisation of NanH -Crystal Trials 
Structural characterisation of NanH CBM and its binding with ligands requires X-ray 
crystallography approaches. To this end, high throughput crystal screens were set up using 
a Hydra liquid dispensing robot (Art Robbins Instruments, USA)  to seed 96 well-sitting drop 
crystallisation plates (Greiner, UK) using the commercially available crystal trial buffer suite; 
JCSG+ (Qiagen, UK). Each sitting drop well contained a 1 µl droplet of 1.6 mg/ml NanH 
CBM. During attempts to co-crystallise with zanamivir, 25 mM zanamivir was incubated on 
ice for 30 minutes with NanH CBM before spotting on sitting drop plates as described. 
 
83 
 
2.3 Results 
2.3.1 Bioinformatic Analysis of NanH and SiaPG 
Establishing the similarity of periodontal pathogen sialidases to those from other bacteria 
was an important first-step before purification and biochemical characterisation and one 
that could potentially yield new information on these enzymes. A bioinformatics approach 
was taken, which also allowed the prediction of sialidase-protein structures based on 
similarity to other sialidases, and to establish the presence of putative functional domains. 
 NanH Possesses a Sialidase Domain and Putative Carbohydrate Binding 2.3.1.1
Module (CBM)  
NanH is the major sialidase of T. forsythia, a BLAST search was carried out on NanH from T. 
forsythia 92.A2 (http://blast.ncbi.nlm.nih.gov/Blast.cgi)- this was the original sequenced 
strain of T. forsythia that was erroneously annotated as ATCC 43037 by the Forsyth 
Institute, and this revealed two distinct domains as indicated in figure 2.1. These are the 
“BNR associated N superfamily”- a sequence of ~200 resides (in NanH this is 149 residues 
without the signal peptide, or 197 with signal peptide). The BNR associated superfamily is a 
conserved sequence located at the N-terminus among similar proteins. The second domain 
was part of the “sialidase superfamily”, and this was which was shown to contain the 
catalytic active site and predicted β-propellers which are a feature associated with the 
active site of sialidases, discussed later.  
 
 
Figure 2.1 The amino acid sequence of NanH highlights distinct domains. 
The NanH sequence from T. forsythia 92.A2 underwent a BLAST search against non-
redundant protein sequences to reveal two distinct domains; the N-terminally located 
BNR_assoc_N superfamily, and the Sialidase superfamily. The active site and β-propellers 
which are a characteristic feature of sialidases are also highlighted. 
 
Unsurprisingly, the most homologous sequences found by the BLAST came from T. 
forsythia strains, followed by other Bacteroidetes. The majority of alignments with strong 
homology came from the closely related Bacteroides spp., but there were some proteins 
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from other genera identified, including Porphyromonas. (although P. gingivalis was not 
listed). Alignments of a selection of the proteins closely related to NanH were performed 
using Clustal Omega and ESPript (figure 2.2). These sequences were obtained from four T. 
forsythia strain sequences that are present in the public databases, two Parabacteroides 
species with the greatest homology to NanH, two Bacteroides species with the greatest 
homology to NanH, and one each from Allistaphanes, Porphyromonas, and Dysgonomonas 
species, which were genera only listed once on the protein BLAST search. The precise 
sequences and strain details can be seen in appendix 7.1. Key findings from this alignment 
were that the sialidases have greater homology in the C-terminal sialidase superfamily 
domain (from residue 198 in the alignment, 197 in T. forsythia NanH), and across all the 
enzymes in this group of bacteria this sequence is quite well conserved; the lowest 
homology was 58.92% between the sialidases in B. fragilis and Allistipes spp., and all T. 
forsythia sialidases had >97% homology.  
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86 
 
 
 
 
1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11)
1) Allistippes spp. 100 68.66 68.66 68.28 68.66 63.5 65.67 65.36 60.52 58.92 59.48
2) T. forsythia_ KS16 68.66 100 97.22 97.77 97.77 74.54 73.93 73.37 63.75 65.61 64.87
3) T. forsythia_ 92.A2 68.66 97.22 100 97.96 97.96 74.16 73.74 73.18 63.38 65.8 65.61
4) T. forsythia_3313 68.28 97.77 97.96 100 98.14 74.91 74.3 73.74 63.94 66.17 65.43
5) T. forsythia_ ATCC 43037 68.66 97.77 97.96 98.14 100 75.09 74.3 73.74 63.57 65.99 65.43
6) P. gordonnii 63.5 74.54 74.16 74.91 75.09 100 85.56 85.19 66.17 66.67 65
7) P. distasonis 65.67 73.93 73.74 74.3 74.3 85.56 100 98.71 64.81 67.53 66.98
8) Porphyromonas_Sp.31_2 65.36 73.37 73.18 73.74 73.74 85.19 98.71 100 65 67.16 66.42
9) Dysgonomonas 60.52 63.75 63.38 63.94 63.57 66.17 64.81 65 100 66.73 65.43
10) B. fragilis 58.92 65.61 65.8 66.17 65.99 66.67 67.53 67.16 66.73 100 77.76
11) B. thetaiotaomicron 59.48 64.87 65.61 65.43 65.43 65 66.98 66.42 65.43 77.76 100
B) 
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Figure 2.2. Primary amino acid sequence homology in sialidases closely related to NanH 
from T. forsythia. 
BLAST revealed a number of sequences with homology to T. forsythia (strain 92.A2) NanH. 
All were annotated as “sialidase” in the NCBI database, with the exception of the entry for 
Allistipes spp., which was annotated as “bNR/Asp-box repeat protein”.  These sequences 
were aligned in Clustal Omega, followed by ESPript. A) ESPript Alignment of Sequences 
similar to T. forsythia NanH. B) Percentage Identity Matrix from Clustal Omega, the 
numbers shown represent % homology between each sialidase.  
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Protein BLAST searches (BLASTP) and sequence alignments shown above shed some light 
on the domains of T. forsythia NanH, but these alone cannot accurately predict secondary 
structural features. To do this, Multalin was used to align the T. forsythia NanH amino acid 
sequences with the sequence of a glycoside hydrolase from Parabacteroides distasonis- a 
candidate sialidase-for which the crystal structure has been determined (Protein Data 
Bank-PDB-ID: 4FJ6). The resulting alignment was analysed using ESPript to predict 
secondary structural features using the P. distasonis candidate sialidase. Percentage 
equivalence with a threshold global score of 0.7 was used to determine the similarity 
between aligned amino acid residues and the overall alignment. The resulting alignment 
shown in figure 2.3 gave an indication of the secondary structural features of T. forsythia. 
Notably, all but one of the secondary structural predictions fell completely within 
sequences with a high degree of similarity (as determined by the above parameters, 
framed in blue)-indicating, at least to some degree, that the secondary structural prediction 
is valid. The alignment appeared to display characteristic features found in sialidases; Asp-
boxes and the RIP motif, the latter of which is considered essential for sialidase activity. A 
total of five Asp-boxes were found in the aligned sialidases (starting at residues 237, 317, 
377, 422 and 484). These are short motifs with the amino acid sequence S/T-X-D-X-G-X-X-
W/F/Y. Asp-boxes were initially discovered in sialidases, and later in a number of 
carbohydrate-active enzymes, yet their precise function has yet-to-be elucidated (Copley et 
al. 2009).  
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Figure 2.3. Alignment of T. forsythia sequences and prediction of secondary structural 
features. 
The crystal structure from P. distasonis glycoside hydrolase (PDB ID: 4FJ6) was used as a 
template to predict structural features of T. forsythia NanH, and P. gingivalis SiaPG, with 
alignments between the sialidases performed using Multalin, and secondary structural 
predictions and other sequence analysis using ESPript. To establish similarity between 
aligned residues, percentage equivalence with a global score of 0.7 was used. Aligned 
sequences above the percentage equivalent threshold are framed in blue, and aligned 
residues above this threshold are shown in red. Strictly conserved residues are shown in 
white on a red background. Secondary structural features are shown above the alignment: 
The η symbol refers to a 310-helix, α-helices, 310-helices and π-helices are displayed as 
medium, small, and large squiggles, respectively. β-strands are rendered as arrows, strict β-
turns as TT letters and strict α-turns as TTT. Boxes are used to highlight the (F/Y)RIP domain 
(orange) and Asp-boxes (black). The predicted boundary between the Secretion Signal 
Sequence and N-terminal (CBM), and C-Terminal Domain (CTD, sialidase domain) are 
indicated by a pink vertical line at residue 185.  
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Based on the protein BLAST and alignment results, NanH from T. forsythia was predicted to 
be composed of two domains and a secretion signal sequence. These were dubbed the “C-
Terminal Domain (CTD)”, which was identified as the sialidase superfamily by the protein 
BLAST, and contains the catalytic active site. The function of the N-terminal domain is less 
obvious, it does not possess a sialidase active site. However, the sequence was well 
conserved between the T. forsythia strains, and appears to share structural features with 
the P. distasonis N-terminal (figure 2.4), as well as being characterised as a conserved 
feature, the “BNR_assoc_N superfamily” by the BLAST search. Considering this, we 
hypothesized that this N-terminal could have a putative carbohydrate binding function, 
similar to the Carbohydrate Binding Modules (CBMs) seen in other organisms. CBMs appear 
to function in binding of an enzyme to a given carbohydrate ligand (a polysaccharide or 
glycan), while the active site is then in a better position for catalytic activity, i.e. the CBM 
assists in ligand-enzyme interactions but does not have any activity. 
 
Although the structure of T. forsythia NanH is not currently published, the structure of a 
glycoside hydrolase-a candidate sialidase from the closely related Parabacteroides 
distasonis was used to predict the structure of T. forsythia NanH and highlight the location 
of discrete domains, in combination with amino acid sequence alignment (Figure 2.4). The 
P. distasonis glycoside hydrolase structure is available on RSCB-Protein Data Bank, 
http://www.rcsb.org/pdb/explore/explore.do?structureId=4FJ6. 
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Figure 2.4. Predicted structure and features of T. forsythia NanH modelled using the 
crystal structure of a closely related glycoside hydrolase from P. distasonis. 
BDI_2946; PDB ID: 4FJ6), with arrows, spirals, and coils representing β-sheets, α-helices and 
loop regions, respectively.  Based on bioinformatic analysis of T. forsythia NanH, the 
domains of BDI_2946 corresponding to the CBM, c-terminal catalytic domain, FRIP motif, 
and Asp boxes of T. forsythia NanH were coloured in blue, green, purple, and red, 
respectively.  The image was rendered in PyMOL (www.pymol.org). Note the position of 
the Asp-boxes surrounding the active site, and FRIP domain within the catalytic active site. 
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 SiaPG Possesses a Sialidase Domain and a Domain of Unknown Function 2.3.1.2
P. gingivalis possesses a gene annotated as encoding a “putative sialidase”-PG0352-in P. 
gingivalis strain W83. Here, and in preliminary characterisation work by Li et al. (Li et al. 
2012), PG0352 is dubbed SiaPG. SiaPG from P. gingivalis strain ATCC33277 also underwent 
the protein BLAST, but this time only the sialidase superfamily domain at the C-terminal 
end was identified, the N-terminal part of the protein was not annotated (figure 2.5).  
 
 
Figure 2.5. The amino acid sequence of SiaPG appears to only contain a sialidase domain. 
The SiaPG protein sequence from T. forsythia 92.A2 underwent a BLAST search against non-
redundant protein sequences to reveal the Sialidase Domain. The active site and β-
propellers which are a characteristic feature of sialidases are also highlighted. The BLAST 
search has also annotated SiaPG sialidase domain as similar to a NanH sialidase. 
 
The C-terminal sialidase superfamily domain was annotated, and this included the catalytic 
sites and β-propellers which are a common feature in sialidases. The BLAST found that the 
sialidase domain in PGsia appeared to contain six β-propellers, compared to the five seen in 
NanH.  
Further BLAST searches with just the N-terminal (non-annotated) SiaPG sequence were 
performed, excluding Porphyromonas spp. from the search parameters (inclusion of 
Porphyromonas spp. yielded Porphyromonas and some Bacteroides sialidases, similar hits 
to the BLAST search performed with the full SiaPG sequence). Unfortunately this approach 
failed to highlight any homologous protein sequences for the SiaPG N-terminal (only two 
protein sequences with low sequence coverage and low homology were found, discussed 
below), and did not yield any insight into a putative function for this N-terminal portion.  
The most homologous sequences found by the BLAST came from sialidases in P. gingivalis 
strains and other Porphyromonas spp. Sequences annotated as sialidases, glycosyl 
hydrolases, or uncharacterized proteins from other members of the Bacteroidetes were 
also identified in the BLAST search, including Prevotella spp. and gut-commensal organisms 
(Bacteroides spp. and Barnesiella viscericola). The annotated proteins from six of the P. 
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gingivalis strains, and some of the other Bacteroidetes were aligned using Clustal Omega 
and ESPript. Most of the protein sequences from the non-Porphyromonas genera were 
much larger than those from the Porphyromonas spp., which rendered their alignments 
difficult to interpret. The putative sialidase sequences from Porphyromonas gingivalis and a 
related organism, Porphyromonas gulae (a coloniser of the periodontium in animals) were 
aligned (figure 2.6). Sequences possessed a high degree of homology; P. gulae and P. 
gingivalis sialidases displayed ~88% homology, while the lowest observed homology 
between the P. gingivalis strains was 96.96%. The alignment also highlighted the presence 
of the characteristic, highly conserved F/YRIP domain (which is considered essential for 
sialidase activity), located at residue 193, and four Asp-boxes (a motif with the sequence 
T/S-X-D-X-G-X-X-W/F/Y, discussed above, section 2.3.1.1), located at residues 231, 293, 
363, and 413 in the consensus sequence. 
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Figure 2.6. Alignment of Porphyromonas sialidases. 
BLAST revealed a number of sequences with homology to SiaPG from P. gingivalis strain 
ATCC 33277. Those shown here were annotated as “sialidase” or “Putative Sialidase”  in the 
NCBI database.  These sequences were aligned in Clustal Omega, followed by ESPript. A) 
ESPript alignment of sequences similar to SiaPG from P. gingivalis ATCC 33277.  B) 
Percentage identity matrix from Clustal Omega, the numbers shown represent % homology 
between each sialidase. The individual input sequences and strain details can be viewed in 
appendix 7.2. Boxes are used to highlight the (F/Y)RIP domain (orange) and Asp-boxes 
(black). The predicted boundary between the secretion signal sequence and N-terminal 
(CBM), and c-terminal domain (CTD, sialidase domain) are indicated by a pink vertical line 
at residue 188. 
 
The P. distasonis glycosyl hydrolase has only 23 % homology to SiaPG, and was deemed 
unsuitable for rendering a model, so the SiaPG sequence was analysed using the Phyre 2 
Database (available at: http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index), and 
imaged using Pymol (figure 2.7). This application uses a PSI-BLAST to align the input 
sequence (SiaPG in this case) to other proteins, and then compares this list of homologues 
to crystal structures available in Protein Data Bank (PDB), and then the input sequence 
(SiaPG in this case) can be modelled. The alignment carried out by Phyre 2 revealed that 
the most homologous available crystal structure in PDB was sialidase VPI 5482 (BTSA) from 
Bacteroides thetaiotaomicron (PDB ID: 4BBW). This sialidase only shared 26% homology 
with SiaPG (The P. distasonis glycosyl hydrolase used to model T. forsythia was the second 
hit), but Phyre 2 was able to model SiaPG (figure 2.7). The first 126 residues were excluded 
from the model by Phyre 2 as they were not homolgous with the B. thetaiotaomicron 
sialidase, but the following 378 residues (127-521) were modelled with 100% confidence.  
As expected the C-terminal domain forms a predicted six-component beta-sheet domain, 
1) 2) 3) 4) 5) 6) 7) 8)
     1) P.gingivalis _W83  100 99.05 98.86 97.34 97.15 96.96 88.4 91.63
     2) P.gingivalis _F0570  99.05 100 99.43 97.15 96.96 96.77 88.78 91.83
     3) P.gingivalis _AJW4    98.86 99.43 100 96.96 96.77 96.58 88.59 91.63
     4) P.gingivalis _W4087        97.34 97.15 96.96 100 97.15 97.34 88.97 91.43
     5) P.gingivalis _ATCC_33277   97.15 96.96 96.77 97.15 100 99.81 88.4 91.83
     6) P.gingivalis _A7A1-28    96.96 96.77 96.58 97.34 99.81 100 88.59 91.83
     7) P.gulae _COT-052_OH4119 88.4 88.78 88.59 88.97 88.4 88.59 100 94.42
     8) P.gulae _COT-052_OH2179  91.63 91.83 91.63 91.43 91.83 91.83 94.42 100
B) 
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whereas the N-terminus is likely to form a novel domain that is hard to predict using these 
methods. 
 
Figure 2.7. Predicted structure and features of P. gingivalis SiaPG modelled using the 
crystal structure of a sialidase from B. thetaiotaomicron. 
 (VPI_5482; PDB ID: 4BBW). The image was rendered in PyMOL (www.pymol.org). Arrows, 
spirals, and coils represent β-sheets, α-helices and loop regions, respectively.  Based on 
bioinformatic analysis of SiaPG, the domains of VPI_5482 corresponding to part of the N-
terminal Domain, C-terminal catalytic domain, YRIP motif, and Asp boxes of SiaPG were 
coloured in blue, green, purple, and red, respectively. Orientated so that the arrangement 
of β-propellers is visible in the sialidase domain. Note the position of the Asp-boxes 
surrounding the active site, and FRIP domain within the catalytic active site. 
 
2.3.1.2.1 Attempted Functional Prediction of the SiaPG-N-terminal Domain 
The SiaPG N-terminal domain (SiaPG-NTD) function remained difficult to ascertain through 
bioinformatics analysis-this domain contains ~178 residues (including the secretion signal 
sequence), but in the above model the first 127 residues of SiaPG were excluded. The N-
terminal domain was highly conserved between the Porphyromonas spp. (figure 2.7), and 
in P. gingivalis strains the homology was very high, the lowest homology between strains 
was 93.82% (figure 2.8).  
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Figure 2.8. Alignment of P. gingivalis sialidase N-terminal domains. 
The first 198 residues of SiaPG in six P. gingivalis strains were aligned in Clustal Omega, 
followed by ESPript. A) ESPript alignment of sequences similar to SiaPG from P. gingivalis 
ATCC 33277.  B) Percentage identity matrix from Clustal Omega, the numbers shown 
represent % homology between each SiaPG N-terminal domain. The individual input 
sequences and strain details can be viewed in appendix 7.3. 
 
Since BLAST alone had not indicated the function of the SiaPG-NTD (discussed in this 
section, above) Phyre 2 was used in an attempt to predict the structure function of the 
SiaPG-NTD. Unfortunately there were no crystal structures available with a high coverage 
or homology for the SiaPG-NTD. The best alignment was a C-terminal domain of inner 
1) 2) 3) 4) 5) 6)
     1) P.gingivalis _W83  100 100 98.88 94.94 97.19 96.63
     2) P.gingivalis _F0570  100 100 98.88 94.94 97.19 96.63
     3) P.gingivalis _AJW4    98.88 98.88 100 93.82 96.07 95.51
     4) P.gingivalis _W4087        94.94 94.94 93.82 100 96.63 97.19
     5) P.gingivalis _ATCC_33277   97.19 97.19 96.07 96.63 100 99.44
     6) P.gingivalis _A7A1-28    96.63 96.63 95.51 97.19 99.44 100
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membrane protein from Salmonella enterica (PDB identified this as a membrane protein), 
but this only covered 16% of the SiaPG-NTD with 40% identity, so this was not considered 
an appropriate model.  
Ultimately, although bioinformatics failed to ascertain a function for SiaPG-NTD, the fact 
that it is highly conserved between P. gingivalis (and other Porphyromonas spp.) suggests it 
has an important function in P. gingivalis (and other Porphyromonas spp.). The partial 
similarity with an inner membrane protein (discussed in the previous paragraph) might 
suggest that this domain anchors the SiaPG to the surface of P. gingivalis. However, other 
functions for this domain could not be ruled out, so for the purposes of this project (and for 
ease of discussion in the context of T. forsythia NanH), it was tentatively dubbed the 
“SiaPG-CBM”. 
 Summary of the Bioinformatics Analysis of SiaPG and NanH 2.3.1.3
The purified whole sialidases could yield insights into their target ligands within the 
pathogens’ hosts, and studying the sialidases in isolation from pathogens could provide 
insight into their precise roles in virulence, and might highlight potential biochemical 
applications. Purification and study of the sialidase domains is perhaps an even more 
intriguing prospect, but this requires elucidation of the domain boundaries in NanH and 
SiaPG. To this end, the protein domains were modelled and predicted before the first stage 
of sialidase cloning. 
Both sialidases were analysed using the NCBI protein BLAST, and aligned to proteins from 
different strains/species. This appeared to yield two distinct domains for NanH; a sialidase 
domain with catalytic activity (containing five characteristic β-propellers and the highly 
conserved RIP domain), and a N-terminal domain which was hypothesized to be a 
carbohydrate binding module (CBM). NanH from T. forsythia was modelled onto a closely 
related enzyme from P. distasonis, revealing the predicted structures of the NanH-CBM, 
and NanH-C-Terminal Domain (NanH-CTD). 
The BLAST and sequence alignments for SiaPG highlighted the sialidase domain at the C-
terminal domain (with six characteristic β-propellers and the highly conserved RIP domain), 
but the N-terminal domain (NTD) function was not immediately obvious. Modelling of 
SiaPG based on a related sialidase structure from B. thetaiotaomicron was beneficial, 
providing a structural model for the whole catalytic domain, but did not highlight a function 
for the NTD. However, this was highly conserved between P. gingvalis strains, and was 
considered likely to have a function, so it was termed “SiaPG-CBM”.  
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Both sialidases were of a similar size (521 and 546 residues for SiaPG and NanH, 
respectively). They did not share sequence homology; aligning their sequences in Clustal 
Omega showed they only had 23 % identity. However, both sialidases could be divided into 
two domains (and a secretion signal sequence); the C-terminal domain (CTD) with sialidase 
activity, and an N-terminal domain or carbohydrate binding module (CBM). The distinct 
domains were visible in the case of both sialidase’s predicted structures. Both sialidases 
possessed four-five Asp-boxes in their CTDs, and the RIP motif was located upstream of the 
Asp-boxes in both sequences. Both sialidases were submitted to SignalP to predict the 
location of the secretion signal sequence (http://www.cbs.dtu.dk/services/SignalP/) 
(appendix 7.4). The features and domains of both enzymes are summarised in Figure 2.9. 
 
 
Figure 2.9. Linear schematic of NanH and SiaPG. 
Both periodontal pathogen sialidases were divided into two domains and the Secretion 
Signal (SS), the Carbohydrate Binding Module (CBM) and the C-Terminal domain, (CTD) 
which possesses the RIP domain and Asp-Boxes characteristic of sialidases. The domains 
and their positions in each enzyme are summarised in the table below the linear schematic. 
 
2.3.2 Production of SiaPG-CBM, SiaPG-CT, and NanH-CT  
NanH and SiaPG are both encoded by genes approximately 1500bp in size. The analysis 
described in section 2.3.1 delineated SiaPG and NanH into the secretion signal sequence 
two domains and; the CBM, and the CTD. The nucleotide sequences encoding these are ~80 
bp, ~500 bp, and ~1000 bp in size, respectively. To elucidate the function of each domain in 
isolation, attempts were made to express and purify the individual domains of NanH and 
Sialidase Gene/Protein Size Domains
Domain Location 
(Residue Numbers)
(F/Y)RIP domain  
(Residues and 
residue numbers)
Asp-Box  (location-
Residue Numbers)
NanH-SS  1-20
NanH-CBM 21-165
NanH-CTD 166-552
SiaPG-SS  1-31
PGsia-CBM 32-188
PGsia-CTD 189-525
231-238, 292-299, 
362-269, 411-418
237-244, 316-323, 
376-383, 422-429, 
483-490
57.4 kDaNanH
SiaPG 54.8 kDa
FRIP, 210-213
YRIP, 192-195
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SiaPG. The first stage in this was performed by attempting to use a polymerase chain 
reaction (PCR) approach to produce DNA fragments encoding the sialidase domains, by 
using PCR primers designed to target the domain-encoding sequences in the genomic DNA 
of T. forsythia and P. gingivalis. Ultimately this meant three PCR products could be 
produced for each sialidase, two encoding the individual domains, and one encoding the 
whole sialidase (figure 2.10). The signal sequence was excluded during primer design, with 
the intention of producing fully mature proteins in the cytoplasm of the expression strain. 
 
 
Figure 2.10. Targeting sialidase domains. 
Both P. gingivalis and T. forsythia possess sialidase-encoding genes that could be 
delineated into the CBM- and CTD-encoding regions, as well as the sequence encoding the 
whole protein. Primers were designed to produce PCR products encoding the different 
domains and a whole sialidase-encoding product. These were of the size indicated by the 
scale bars. Primer binding sites are indicated by orange lines on the scale bars. 
 
A variety of primers were designed to amplify siaPG and nanH domains from genomic DNA 
extracted from P. gingivalis and T. forsythia. These are outlined in table 2.6.  
  
104 
 
 
Designation Primer Name Primer Sequence (5’-3’) Targets 
A TF0035N-NdeI-Fwd AATACATATG_GCGGACAGTGTTTTAC nanH, 
B TF0035C-XhoI-Rev AATACTCGAG_TCGTATCAGGTCTTT nanH, nanH-CT 
C TF0035C-NdeI-Fwd AATACATATG_ATCGGGGTGCGTCAT nanH-CT 
D TF0035N-NdeI-Fwd(2) AATACATATG_GCGGACAGTGTTTACGTAC nanH,  
E TF0035C-XhoI-Rev(2) AATACTCGAG_TCGTATCAGGTCTTTGAT nanH, nanH-CT 
F TF0035C-NdeI-Fwd(2) AATACATATG_ATCGGGGTGCGTCATGCG nanH-CT 
G TF0035C-NdeI-Fwd(3) AATACATATG_GCGGACAGTGTTTACGTAC nanH-CT 
H PG0352N-NdeI-Fwd AATACATATG_GAAGTCACTATGTGGGGGG SiaPG, SiaPG-CBM 
I PG0352N-XhoI-Rev AATACTCGAG_TTGCCGGACATCGAAGAGATC SiaPG-CBM 
J PG0352C-NdeI-Fwd AATACATATG_TATAGGGGGTATGAGGCCC SiaPG, SiaPG-CT 
K TF0035C-XhoI-Rev AATACTCGAG_CAGACGACGGGAGGCAG SiaPG, SiaPG-CT 
 
Table 2.6. Design of primers for siaPG, nanH and domain amplification from genomic 
DNA. 
For ease of description, the primers are designated letters A-K. Primer name indicates the 
product produced: PG0352-siaPG, TF0035-nanH, the letters “C” or “N” indicates the primer 
position on the sialidase gene; C-C-terminal, N-N-terminal or CBM. The restriction enzyme 
used is also indicated in the primer name (XhoI or NdeI). Primers include a sequence for 
restriction digest at their 5’ ends, separated from the sialidase-gene specific sequence by 
an underscore. Combinations of different primers were designed to produce whole 
sialidase (without secretion signal sequence), sialidase-CT, or sialidase-CBM. Restriction 
sites are underlined in the primer sequence.  
 
After genomic DNA extraction from T. forsythia and P. gingivalis, various PCR conditions 
were tested in a series of experiments to amplify the PCR products discussed above. PCRs 
used primers attempting to yield nanH-CT (combinations of primers B, C, E, F, and G), 
siaPG-CBM (primers H and I), and siaPG-CT (primers J and K). Experiments focused on 
changing annealing temperatures and primer concentrations in an attempt to obtain PCR 
products. After multiple PCR failures, PCR was performed on nanH already present in a pET 
plasmid construct, and PCR products thought to represent nanH-CT, siaPG-CBM, and siaPG-
CT were produced (figure 2.11). The NanH-CBM had been produced separately (Chatchawal 
Phansopa., Stafford Research Group, University of Sheffield, manuscript in preparation). 
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Reagent 5x Kit 
Buffer 
100-
1000ng/µl 
genomic 
DNA  
10µM 
Primer H 
or J 
10µM 
Primer K 
2mM 
dNTPs 
Polymer-
ase 
Deionised 
Water 
DMSO/ 
deionised 
water 
Volume 
(µl) 
4 0.5 1 1 0.2 0.2 11 0.6 
 
 
 Cloning of PCR Products Encoding Sialidase Domains 2.3.2.1
The PCR products were excised from their agarose gels, and purified using commercially 
available kits. Purified PCR products were digested with NdeI and XhoI restriction enzymes, 
and the reaction mixes were purified a second time. These digested PCR products 
corresponding to siaPG-CT, siaPG-CBM, and nanH-CT, were purified using a commercially 
available kit, before further processing, with the aim of producing pET- plasmid constructs:  
pET plasmids were chosen as vectors due to their inclusion of these restriction sites in 
appropriate locations, and the presence of a 6-histidine (His+) tag at the 3’ end (C-terminal 
in the expressed protein) for affinity chromatography purification of the expressed protein 
(section 2.3.2.2). Undigested pET plasmids were digested using NdeI and XhoI restriction 
enzymes, with calf alkaline phosphatase present. The digested reaction mix then 
underwent agarose gel electrophoresis, and the bands corresponding to digested pET 
plasmid were extracted using commercially available kits.  
Digested PCR products underwent ligation with digested pET-20b plasmids, followed by 
transformation using heat shock into commercially available E. coli DH5α. Resulting 
bacterial colonies underwent colony PCR followed by restriction digest to confirm the 
presence of an insert at the expected size  (figure 2.12). The resulting plasmid constructs 
were transformed into E. coli Origami B (EC origami), for expression. Transformed E. coli 
DH5α were cultured and pET20b-constructs extracted. All constructs were sequenced using 
an in house sequencing service to confirm insertion of the coding sequence, and that no 
mutations had occurred during the cloning process. 
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Reagent 5x Kit 
Buffer 
100-
1000ng/ul 
Plasmid 
DNA  
Primer E Primer F dNTPs Polymer-
ase 
Deionised 
Water 
DMSO 
Volume 
(µl) 
4 0.2 1 1 0.2 0.2 12.8 0.6 
Reagent 5x Kit 
Buffer 
100-
1000ng/µl 
Genomic 
DNA  
10µM 
Primer H 
10µM 
Primer I 
2mM 
dNTPs 
Polymer-
ase 
Deionised 
Water 
Volume 
(µl) 
10 2.5 2.5 2.5 0.5 0.5 31.5 
98°C -1 min 
98°C-30 secs 
65°C-45 secs       30 cycles 
72°C-45secs 
72°C-10 min 
10°C-hold 
98°C -3 mins 
98°C-10 secs 
60°C-30 secs       30 cycles 
72°C-20 secs 
72°C-10 min 
10°C-hold 
984bp 
A) nanH-CT (gel cropped for ease of viewing) 
B) siaPG-CBM (gel cropped for ease of viewing) 
444bp 
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Reagent 5x Kit 
Buffer 
100-
1000ng/µl 
genomic 
DNA  
10µM 
Primer H 
or J 
10µM 
Primer K 
2mM 
dNTPs 
Polymer-
ase 
Deionised 
Water 
DMSO/ 
deionised 
water 
Volume 
(µl) 
4 0.5 1 1 0.2 0.2 11 0.6 
 
Figure 2.11. PCR amplification of A) nanH-CT, B) siaPG-CBM, and C) siaPG-CT from P. 
gingivalis genomic DNA. 
1.5% (w/v) Agarose gel, DNA-absent negative controls indicated by “-“. Expected PCR 
products and their sizes are indicated by arrows. Reaction mixtures, thermocycling 
conditions, primer pairs, and primer annealing temperatures (Tm) are indicated, adjacent 
to the agarose gel images. Gel B) siaPG-CT contains reactions performed on genomic DNA 
from two strains of P. gingivalis; ATCC 33277, and 381, only the PCR on genomic DNA from 
ATCC 33277 resulted in products. 
 
98°C -3 mins 
98°C-10 secs 
48°C-30 secs       30 cycles 
72°C-1 min 
72°C-10 min 
10°C-hold 
C) siaPG-CT (gel cropped for ease of viewing) 
1044bp 
108 
 
 
 
  
 
   
 
  
 
Figure 2.12. Confirmation of pET-sialidase subunit constructs. 
1.5 % (w/v) agarose gel. Restriction digestion products and their expected sizes are 
indicated by arrows. A) pET21a-nanH-CTD B) pET20b-siaPG-CBM C) pET20b-siaPG-CTD 
  
 984bp 
(nanH-CT) 
5443bp 
(pET21a 
 plasmid) 
A) pET21a-NanH-CT 
B) pET20b-siaPG-CBM 
444bp 
(SiaPG-CBM) 
3716bp 
(pET20b  
plasmid) 
1044bp 
(siaPG-CT) 
3716bp 
(digested pET 20b 
plasmid) 
4769bp pET20b-siaPG-CT 
(undigested) 
C) pET20b-siaPG-CBM 
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 Expression and Purification of Sialidase Subunits 2.3.2.2
To test expression of sialidase domains, cultures of transformed EC Origami B were grown 
to OD600 0.5 and induced with 1 mM IPTG, and harvested at different time points. All 
harvested bacterial cultures were diluted to OD600 1.0, 1 ml of this suspension was pelleted, 
and resuspended in 100 µl of SDS loading buffer. 10-30 µl of this bacterial suspension 
underwent SDS-PAGE (the volume of bacterial suspension was constant during each 
individual experiment). 
2.3.2.2.1 Expression and Initial Attempts to Purify PGsia-CBM 
 SiaPG-CBM appeared to be successfully expressed, with bands at ~15 kDa visible in SDS-
PAGE of E. coli (expression strain) cell lysates, at the size expected for the SiaPG-CBM (~15 
kDa, figure 2.13. A). Affinity chromatography on the soluble fraction of the cell lysates was 
carried out. Unfortunately, a band corresponding to the SiaPG-CBM was present in the 
insoluble fraction of the cell lysate, not the eluted fractions (figure 2.13 B). 
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Figure 2.13. Expression test and attempted purification of SiaPG-CBM. 
SDS-PAGE gel, 12 % (v/v) polyacrylamide gel. L=Mw Ladder (kDa, size approximation based 
on manufacturer’s guide) A) SiaPG-CBM from two expressions strain clones, induced and 
harvested at different time points as indicated, h=hours, Un=un-induced. The arrow 
indicates the band corresponding to SiaPG-CBM  B) Attempted purification of SiaPG-CBM 
on soluble fraction of expression strain lysates. Ins=Insoluble Fraction of cell lysate, 
Sol=soluble fraction of cell lysate F=Flow Through, W=Wash Through, 1-7= Eluted fractions. 
The arrow indicates the possible SiaPG-CBM in the insoluble fraction of the cell lysate. 
 
2.3.2.2.2 Expression and Solubility Testing of SiaPG-CT and NanH-CT 
After observing the apparent insolubility of SiaPG-CBM, NanH-CTD and SiaPG-CTD 
underwent expression testing and solubility testing. EC origami containing the pET20b-
nanH-CTD and pET20b-siaPG-CTD were induced to express NanH-CTD and SiaPG-CTD, and 
cell lysates of induced cultures were separated into insoluble and soluble fractions. The 
NanH-CT (~37 kDa) appeared to be highly overexpressed and insoluble, while the SiaPG-CT 
A) Expression test of SiaPG-CBM; whole cell lysates 
B) Affinity Chromatography of SiaPG-CBM; soluble fraction 
~15kDa 
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was less overexpressed, a band corresponding to SiaPG-CTD was present at the appropriate 
size in the insoluble fraction(~35 kDa) (figure 2.14). 
 
Figure 2.14. SDS-PAGE of cell lysates overexpressing SiaPG-CT and NanH-CT. 
12% (v/v) polyacrylamide gel. L=Mw Ladder (kDa, size approximation based on 
manufacturer’s guide), Un= non-induced fraction of cell lysate Ins=insoluble fraction of cell 
lysate, Sol=soluble fraction of cell lysate. Arrows indicate the bands suspected to 
correspond to SiaPG-CT (~37 kDa) and NanH-CT (~40 kDa). 
 
 
2.3.2.2.3 Solubilisation and Re-Purification of Sialidase Domains 
In an attempt to solubilise the overexpressed proteins, the insoluble fraction of the cell 
lysates were incubated in buffer containing 8M Urea, agitated by vortex then by lab-rollers, 
at room temperature for 3 hours. The resulting mixture was centrifuged to remove still-
insoluble proteins and cell debris, and urea-solubilised fractions could then undergo affinity 
chromatography followed by SDS-PAGE to confirm their presence or absence in the cell 
lysate-soluble fraction, urea-insoluble, urea-solublised, flow through, wash through, and 
elution stages of purification. SiaPG-CBM and NanH-CT appeared to be successfully purified 
in this way (figure 2.15 A and B), but the band corresponding to SiaPG-CT appeared to be 
present in the flow through and still-insoluble fractions during purifications, not the eluted 
fractions (figure 2.15 C). 
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Figure 2.15. SDS-PAGE of A) SiaPG-CBM, B) NanH-CT, and C) SiaPG-CT following urea 
solubilisation and affinity chromatography. 
A) 15% (v/v) polyacrylamide gel, B) & C) 12% (v/v) polyacrylamide gel. L=Mw Ladder (kDa, 
si e approximation based on manufacturer’s guide), Insol=Still-Insoluble Fraction of cell 
lysate, Sol=soluble fraction of cell lysate F=Flow Through, W=Wash Through, 1-7= Eluted 
fractions.  
 
Fractions containing purified NanH-CT or SiaPG-CBM were pooled and dialysed in 
decreasing concentrations of urea, a process termed step-down dialysis. The resulting 
dialysed solution was centrifuged to separate out precipitant before SDS-PAGE. While a 
significant proportion of the urea-solubilised proteins (NanH-CT or SiaPG-CBM) appeared to 
~15kDa 
~40kDa 
~37kDa 
C) SiaPG-CTD 
A) SiaPG-CBM 
B) NanH-CTD 
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have precipitated once all the urea had been removed by dialysis, some protein remained 
soluble in the dialysed solutions i.e. NanH-CT and SiaPG-CBM appeared to have been 
purified and were soluble (figure 2.16). 
 
Figure 2.16. SDS-PAGE of A) NanH-CT, and B) SiaPG-CBM following step down dialysis to 
remove urea. 
A) 12% (v/v) polyacrylamide gel, B) 15% (v/v) polyacrylamide gel. L=Mw Ladder (kDa, size 
approximation based on manufacturer’s guide), Sol=soluble fraction of dialysed elution 
fractions after affinity chromatography, Insol= soluble fraction of dialysed elution fractions 
after affinity chromatography. Numbers above lanes indicate which eluted fractions from 
affinity chromatography were pooled for dialysis. 
 
Ultimately, NanH-CTD, and SiaPG-CBM were purified, and after step dialysis appeared to 
remain in an apparently soluble form, but the NanH-CTD was later shown to be inactive 
(lacking sialidase activity, section 2.3.2.2.4), possibly due to incorrect re-folding during urea 
resolubilisation and step-down dialysis, resulting in a structure unlike the native NanH-CTD. 
B) SiaPG-CBM 
~15kDa 
~40kDa 
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It was intended to test the ability of SiaPG-CBM to bind different sialic-acid ligands, but 
unfortunately the timeframe of this project did not permit further optimisation of sialidase 
domain expression, and the low protein yields and low stability after step down dialysis 
made ligand binding studies impractical.  
2.3.2.2.4 Attempted Characterisation of NanH-CT domain 
NanH is predicted to possess two functional domains, the carbohydrate binding module 
(CBM), and C-terminal (CT) domain, the latter of which contains the enzyme active site. 
Studying the two domains in isolation might yield useful insights into the function of the 
CBM and its importance in enzyme-host ligand interactions, and could highlight the 
potential for inhibitors that target the CBM instead of the enzyme active site. The NanH-CT 
domain might display altered ligand-specificity, with potential applications for 
biotechnology. 
NanH-CT, which contains the NanH active site, appeared to be successfully purified. It was 
anticipated that NanH-CT would possess sialidase activity. The fluorescence based 
MUNANA assay described in was applied to test the sialidase activity of NanH-CT. 
 Unfortunately, both visualisation of activity with UV light and image capture, and the use 
of a plate reader to try and detect low levels of 4-MU fluorescence showed that the NanH-
CT purified here possesed no sialidase activity. The NanH-CT also had no activity when 
tested in the thiobarbituric acid assay with 3-sialyllactose as a substrate (Figure 2.17).  
 
Figure 2.17. Purified NanH-CT displays no activity. 
3-SL was exposed to NanH and NanH-CT for 15 minutes, followed by a TBA assay. Data 
shown represent the mean of three experimental repeats. Error bars=SD. 
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This lack of sialidase activity might infer that the protein was incorrectly folded during 
translation by the E. coli expression system. Given that whole NanH is codon optimised for 
expression in E. coli, and was readily soluble after lysis of the E. coli expression system, but 
the NanH-CT was not codon optimised (nanH-CT was obtained using PCR amplification of T. 
forsythia genomic DNA), and was insoluble after lysis of the expression system, this might 
be the case. It could also be the case that the NanH-CT is less stable or does not fold 
correctly without the presence of the NanH-CBM at the N-terminal of the protein. On the 
other hand, it was possible to obtain a low yield of soluble NanH-CT using urea 
solubilisation followed by stepdown dialysis, and it might be the case that NanH requires 
the CBM for ligand binding, so even soluble, stable NanH-CT would not possess sialidase 
activity, these are still open questions. 
Fluorescence spectroscopy (which relies on similar priniciples to the tryptophan quenching 
experiments discussed in section 2.3.6.5) could provide information on tertiary and 
quaternary structure, but this approach would rely on comparison of the resulting 
spectrum to closely related proteins, and since these subunits are unique (generated as 
part of this project) this approach was not possible. Nuclear magnetic resonance 
spectroscopy (NMR) could have been used to provide a limited amount of structural 
information, assuming the proteins would remain stable in water for a short amount of 
time, but given the low protein yields following step-down dialysis and the time consuming 
nature of NMR and subsequent analysis, this was not feasible as part of this project. 
 Structural Characterisation of NanH-CBM from T. forsythia  2.3.2.3
As mentioned previously, the NanH-CBM had been produced during previous work and 
shown to bind a variety of sialic acid containing ligands (Chatchawal Phansopa, Stafford 
Research Group, University of Sheffield, manuscript in preparation). Part of this work 
highlighted the ability of the NanH-CBM to bind sialic acid-ligands, which I have also 
confirmed in tryptophan quenching experiments (not shown). It was also desirable to 
obtain the structure of ligands in complex with the NanH-CBM. To this end, attempts were 
made to crystallise the CBM of T. forsythia NanH, and co-crystallisation with a variety of 
ligands are ongoing. The use of robotics allowed set up of large scale crystallisation trials 
using commercially available crystallisation buffers. Two conditions yielded putative 
crystals of NanH CBM co-crystallised with zanamivir, these are shown in figure 2.18. The 
shape and size of the crystals suggested that they could be protein crystals, so these 
conditions were considered to be promising candidates for further optimisation. However, 
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the crystals shown here did not undergo any X-ray diffraction, so the possibility that they 
are not protein crystals could not be ruled out. 
 
Figure 2.18 Putative NanH CBM co-crystallised with zanamivir. 
 Images captured under light microscopy using a polarised lens, 25x magnification + camera 
zoom function. Left pane- Crystal trial conditions: 1.6 mg/ml NanH CBM, 25mM zanamivir, 
0.2M Magnesium Chloride, 0.1M Tris pH 8.5. 50% (w/v), 3.4 M 1,6-Hexanediol. Right pane-
Crystal trial conditions: 1.6 mg/ml NanH CBM, 25 mM zanamivir, 1.6 M Sodium citrate pH 
6.5. 
 
Although obtaining these crystals-which may represent NanH-CBM in complex with 
zanamivir-was an exciting development, unfortunately, elucidating the crystal structure of 
NanH-CBM in complex with zanamivir was not possible in the timeframe of this project.  
2.3.3 Production of Periodontal Pathogen Sialidases: NanH and SiaPG 
Investigating whole periodontal pathogen sialidases in isolation from the organisms that 
utilise them was a key focus of this project. This required production of sialidase-encoding 
DNA fragments, and expression and purification of pathogen sialidases.  
 PCR Approach to Production and Amplification of NanH and SiaPG 2.3.3.1
Initial attempts to produce whole siaPG and nanH from genomic DNA from P. gingivalis and 
T. forsythia used various PCR conditions in a series of experiments using combinations of 
primers attempting to yield nanH (primers A, B, D, and E), and siaPG (primers H and K). 
Experiments focused on changing annealing temperatures and primer concentrations in an 
attempt to obtain PCR products. After multiple PCR failures for nanH amplification from T. 
forsythia genomic DNA, PCR was performed on nanH already present in a pET plasmid 
construct, and PCR products thought to represent nanH and siaPG were produced (figure 
2.19). It later transpired that there had been a mistake during the submission of the 
genome of T. forsythia strain 43037 (considered the type strain for T. forsythia) to the NCBI 
117 
 
and oralgen genomic databases, instead, the genome of T. forsythia strain 92.A2 had been 
submitted and labelled as T. forsythia strain 43037 by the team at the Forsyth Institute in 
Boston (see Friedrich et al. 2015). Since PCR primers had been designed based on these 
databases, using what was actually the T. forsythia 92.A2 genome, it is perhaps 
unsurprising that PCRs using T. forsythia 43037 genomic DNA templates failed so often. 
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Reagent 5x Kit 
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1000ng/µl 
Plasmid 
DNA  
Primer A Primer B 2mM 
dNTPs 
Polymer-
ase 
Deionised 
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DMSO/ 
deionised 
water 
Volume 
(µl) 
4 0.5 1 1 0.2 0.2 11 0.6 
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DNA  
10µM 
Primer H 
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10µM 
Primer K 
2mM 
dNTPs 
Polymer-
ase 
Deionised 
Water 
DMSO/ 
deionised 
water 
Volume 
(µl) 
4 0.5 1 1 0.2 0.2 11 0.6 
 
Figure 2.19 PCR amplification of A) nanH and B) nanH-CT from T. forsythia genomic DNA.. 
1.5% (w/v) Agarose gel, DNA-absent negative controls indicated by “-“. Expected PCR 
products and their sizes are indicated by arrows. Reaction mixtures, thermocycling 
conditions, primer pairs, and primer annealing temperatures (Tm) are indicated, adjacent 
to the agarose gel images.  
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98°C-10 secs 
48°C-30 secs       30 cycles 
72°C-1 min 
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98°C-10 secs 
48°C-30 secs       30 cycles 
72°C-1 min 
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1450bp 
A) nanH 
B) SiaPG (Gel Cropped for ease of viewing) 
SiaPG 
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Although the PCR to produce nanH and siaPG from genomic DNA was successful, PCRs 
were difficult to reproduce and ligation into pET-plasmids and transformation of E. coli 
storage vectors was never optimised. This, and the insolubility of the sialidase domains 
produced by native genomic DNA sequences (section 2.3.2.2) alongside the discovery by 
others in our laboratory that even full-length NanH produced from a PCR product cloning 
was insoluble prompted an alternative method of sialidase gene production-namely gene 
synthesis with codon optimisation of siaPG and nanH. 
 
 Gene Synthesis Approach to Production and Amplification of siaPG and 2.3.3.2
nanH 
Gene synthesis is an increasingly popular alternative to more traditional methods of cloning 
with the aim of protein expression, partly due to its relative inexpense (1 kb can now be 
produced for £200). This is also attractive since many of the synthesis companies offer an 
optional codon optimisation step, where the target gene’s codons are changed to encode 
the same amino acids of the original gene, but match the preferentially-used codons in a 
given organism, according to proprietary algorithms. To assess whether or not codon 
optimisation would be beneficial, the native nanH and siaPG codons were compared to the 
codon preference in E. coli, using the Graphical Codon Usage Analyser (GCUA), freely 
available at http://gcua.schoedl.de/index.html. T. forsythia nanH was shown to possess a 
mean difference of 12.53%, between nanH frequency of codon usage and frequency of E. 
coli codon usage, while for siaPG codon usage compared to E. coli codon usage, this mean 
difference was 13.27% (figure 2.20). While the mean difference between siaPG or nanH  
and E. coli codon usage may not seem high, some codons differed in frequency of usage by 
~30%, as seen for isoleucine (Ile, I) and asparagine (Asp, N). The difference in codon usage 
of these residues is noteworthy, since they are critical to the function of the sialidase 
catalytic domain (in the F/Y-R-I-P motif) and Asp-boxes, respectively.  
Ultimately, for this project, siaPG and nanH were synthesised and codon optimised for 
expression in E. coli. Both sialidase sequences were designed without the secretion signal 
sequence, and included restriction sites for NdeI and XhoI at 5’ and 3’ sites, respectively. 
The resulting codon optimised sialidase-encoding nucleotides can be viewed in appendices 
7.5 and 7.6. Synthesised DNA strands were obtained from GeneArt as linear fragments 
(GeneStrings) and ligated into pJET plasmids (ThermoFisher Scientific) via blunt-ended 
ligation, with a commercially available kit, followed by transformation into commercially 
available E. coli DH5α. Successful construction of pJET-nanH and pJET-siaPG (pJET-
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sialidases) was confirmed by restriction digestion of plasmids extracted from the 
transformed E. coli, followed by agarose gel electrophoresis (figure 2.21). 
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Figure 2.20 Comparsion of codon utilisation between A) nanH or B) siaPG and E. coli. 
Nucleotide sequences encoding nanH and siaPG were compared against the E. coli genome 
to assess the frequency each codon is used with, using the GCUA 
(http://gcua.schoedl.de/index.html). Red= frequency (%) of a given codon used in nanH or 
siaPG, black= frequency (%) of a given codon used in E. coli.  
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Figure 2.21.  nanH and siaPG pJET constructs. 
1.5% (w/v) agarose gel, restriction digestion products and their expected sizes are indicated 
by arrows. PG=pJET-siaPG, TF=pJET-nanH. 
 
The bands corresponding to siaPG or nanH were extracted from the agarose gel with a 
commercially available kit, before further processing, with the aim of producing pET- 
plasmid constructs: Undigested pET-21a plasmids were digested using NdeI and XhoI 
restriction enzymes, with calf alkaline phosphatase present. The digested reaction mix then 
underwent agarose gel electrophoresis, and the bands corresponding to digested pET 
plasmid (~5.4 kbp for pET21a and ~3.5 kbp for pET20b) were extracted using commercially 
available kits.  
Digested codon optimised-genes encoding nanH and siaPG underwent ligation with 
digested pET21a, followed by electro-transformation using heat shock into commercially 
available E. coli DH5α. Resulting bacterial colonies underwent colony PCR followed by 
restriction digest to confirm the presence of an insert at the expected size  (figure 2.22).  
  
siaPG-1490bp, nanH-1610bp 
2974bp (pJET plasmid) 
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Figure 2.22. Confirmation of pET21a -NanH construct. 
1.5% (w/v) agarose gel. Restriction digestion products and their expected sizes are 
indicated by arrows. A) pET21a-nanH B) pET1-siaPG 
 
Transformed E. coli DH5α were cultured and pET21a-constructs extracted. All constructs 
were sequenced to confirm insertion of the sialidase-encoding sequence, and that no 
mutations had occurred during the cloning process. The pET21a-nanH and pET21a-siaPG 
constructs were transformed into EC origami B), for expression. 
 Expression and Purification of Periodontal Pathogen Sialidases 2.3.3.3
Expression of NanH and SiaPG in EC origami B was tested in a similar fashion to the 
sialidase domains: cultures of transformed EC Origami B were grown to OD600 0.5 and 
induced with 1 mM IPTG, and harvested at different time points. All harvested bacterial 
cultures were diluted to OD600 1.0, 1 ml of this suspension was pelleted, and resuspended 
in 100µl of SDS loading buffer. 10-30µl of this bacterial suspension underwent SDS-PAGE, 
the volume of bacterial suspension was constant during each individual experiment (Figure 
2.23). 
  
1610bp (nanH) 
5443bp 
(pET21a 
plasmid) 
A) pET21a-NanH  
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Figure 2.23. Sialidase expression trials. 
SDS-PAGE using 15 % (v/v) SDS-PAGE gels showing cell lysates of E. coli overexpressing A) 
NanH and SiaPG. Cultures were grown at 37 °C to OD600 0.5, then induced with IPTG and 
cultures were incubated at different times and temperatures as indicated, and collected at 
different time points. Expected protein sizes and bands thought to represent proteins of 
interest are indicated by arrows. L=Mw weight marker (size approximation based on 
manufacturer’s guide). Un; un-induced expression strains (strains prior to induction with 
IPTG), h; hours.   
 
After expression trials, larger scale cultures of pET-sialidase EC Origami were cultured, and 
these underwent purification. This included lysis by French pressure cell, centrifugation to 
remove insoluble proteins and cell debris, and affinity chromatography using nickel 
columns to isolate the His+ tagged proteins.  
Soluble and insoluble fractions of the cell lysate, flow through and wash through from the 
nickel columns, and eluted fractions were collected, and underwent SDS-PAGE to 
determine the presence of NanH or SiaPG at any of these stages. NanH and SiaPG were 
found to be present in the soluble fraction of the cell lysate, and were successfully eluted 
as pure protein in the elution fractions (figure 2.24). Only soluble proteins are likely to be 
functional in biochemical tests and other in vitro work, so the fact that both sialidases were 
readily soluble and apparently stable in a low salt buffer (50 mM sodium phosphate, 200 
mM NaCl) was a major advantage. Unlike the insoluble sialidase-domains (section 2.3.2.2), 
the yield of protein from the sialidase producing cultures was quite high; a litre of EC 
Origami induced to produce NanH or SiaPG could yield up to 15 ml of ~2-5 mg/ml of either 
protein, and during some purification batches NanH or SiaPG would be present in the wash 
 
NanH (57.4kDa) 
SiaPG (54.8kDa) 
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or flow through stages during affinity chromatography, possibly due to exceeding the 
binding capacity of the Nickel column, or re-use of the column resulting in loss of Nickel. 
This large quantity of purified SiaPG and NanH made it possible to carry out biochemical 
tests and other in vitro studies of the two periodontal pathogen sialidases, described in this 
chapter and others. 
 
Figure 2.24. Affinity chromatography purification of NanH and SiaPG. 
A) NanH, B) SiaPG, C) NanH and SiaPG post-dialysis. 12% (v/v) polyacrylamide gels. L=Mw 
Ladder (kDa, si e approximation based on manufacturer’s guide), Ins=Insoluble Fraction, 
F=Flow Through, W=Wash Through, 1-6= Eluted fractions. Note: C) is NanH and SiaPG from 
two separate SDS-PAGE gels, imaged using the same parameters and shown side by side. 
 
2.3.4 Expression and Purification of Other Enzymes  
Although the focus of this project was on the sialidases NanH and SiaPG, other proteins 
were expressed and purified, creating more avenues for biochemical and other in vitro 
studies related to SiaPG and NanH. These proteins were the Sialate-O-Acetylesterase from 
T. forsythia (NanS) (section 3.3.1.1), and an active site mutant of NanH (below), where the 
conserved FRIP motif had been mutated to YMAP, with the aim of producing an inactive 
NanH (~57.4kDa) SiaPG (~54.8kDa) 
NanH (57.4kDa) 
SiaPG (54.8kDa) 
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sialidase with the same structure and ligand binding capacity as native NanH and to probe 
the importance of the FRIP motif on biochemical activity of NanH. 
 Purification of a NanH-Active Site Mutant Sialidase 2.3.4.1
The active site of NanH contains a FRIP motif in the catalytic β-propeller which is highly 
conserved between sialidases, the motif is almost always F/YRIP, although isoleucine is 
sometimes substituted for leucine (S. Kim et al. 2011). It was hypothesized that mutation of 
this conserved region would abrogate NanH sialidase activity, while probably retaining its 
native configuration. An inactive sialidase could be useful for future studies, since it would 
not have any catalytic activity, but might still retain its capacity to bind ligands: An inactive 
sialidase mutant could be used to accurately study the cellular targets of the native 
sialidase. In the future, an inactive sialidase might represent a sialidase inhibitor itself, if it 
was capable of outcompeting the native enzyme for its ligand.  
Although it might have been possible to choose any combination of amino acids with the 
result of abrogation of activity, in an attempt to preserve a tertiary structure most similar 
to the native protein, specific residues were chosen to replace three of four present in the 
FRIP motif, the resultant mutated motif being YMAP. The amino acid substitutions are 
further discussed in section 2.3.6.5. 
Previous work had changed the sequence of the codon optimised nanH through a PCR-
based approach, mutating the resulting protein motif from FRIP  YMAP (Jennifer Parker, 
Stafford Research Group, University of Sheffield, unpublished). Importantly, this quick 
change PCR had been carried out on the codon optimised NanH, i.e. encoding a mutated 
version of the active NanH described here (section 2.3.3).  
This protein was termed NanH-YMAP. The plasmid encoding NanH-YMAP had been 
transformed into EC origami for expression. NanH-YMAP was successfully purified using the 
same protocol as NanH (figure 2.25). Protein yield after purification of NanH-YMAP was 
typically lower than for NanH, 1 litre of EC origami culture could yield 10ml of ~1-2 mg/ml 
protein, though this was sufficient for the scope of this project.  Testing of the activity of 
this mutant and its functionality in ligand binding is outlined in section 2.3.6.5. 
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Figure 2.25. Purification of NanH-YMAP. 
SDS-PAGE using 12% (v/v) polyacrylamide gel. L=Mw Ladder (kDa, size approximation based 
on manufacturer’s guide), Ins=Insoluble Fraction, F=Flow Through, W=Wash Through, 1-6= 
Eluted fractions. 
 
2.3.5 Sialidase Protein Production-a Summary 
Bioinformatic approaches highlighted the presence of two domains in both sialidases-NanH 
and SiaPG, from T. forsythia and P. gingivalis, respectively-which were dubbed the 
carbohydrate binding module (CBM) and the C-terminal domain (CTD), the former thought 
to play a role in ligand binding (in T. forsythia at least), and the latter being responsible for 
sialidase activity. Before studies of the sialidases and their domains, production of NanH, 
SiaPG, and their domains NanH-CTD, PGsia-CBM, and PGsia-CTD was attempted. This 
involved production of a number of plasmid constructs, summarised in table 2.7.  
These plasmid constructs were transformed into E. coli BL21 Origami for expression. 
Ultimately, the sialidase subunits were only purified producing a low yield, but the whole 
sialidases NanH and SiaPG were successfully purified with high yields, ideal for further 
studies. It is important to note that these were codon optimised for expression by E. coli, 
rather than the native T. forsythia or P. gingivalis sialidase genes. This could explain the 
high yield of soluble protein during expression by E. coli, compared to the mostly insoluble 
sialidase domain sequences which were obtained by PCR using T. forsythia or P. gingivalis 
genomic DNA as a template. Furthermore the codon optimised T. forsythia nanH was 
designed based on the nanH gene from T. forsythia strain 92.A2-an accident due to the 
incorrect submission of 92.A2 genome in place of the T. forsythia 43037 genome on the 
NCBI and oralgen databases. However, considering that the two NanH protein sequences 
share 98% homology with each other-11 amino acid substitutions out of 539 residues, and 
NanH-YMAP (57.4kDa) 
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none of these occur within Asp-Boxes or the FRIP domain, it is likely that the two sialidases 
possess almost identical activity.  An alignment of the two sialidases can be viewed in 
appendix 7.8 
 
Table 2.7. Plasmids constructed for storage or expression of sialidases and 
sialidase domains. .  
pJET plasmids were used as secondary storage vectors and to ensure continued 
amplification of codon optimised nanH and siaPG, while pET plasmids were used for 
storage and ultimately for protein expression. “Native” and “codon optimised, gene 
synthesised” refers to the source of the inserted sequence present in the plasmid, either a 
PCR construct from pathogen DNA, or synthetically produced and optimised for expression 
in E. coli. 
  
Transformed into
E. coli Stra in(s )
pJET-NanH pJET plasmid containing codon optimised, gene synthes ised nanH DH5α
pJET-s iaPG pJET plasmid containing codon optimised, gene synthes ised s iaPG DH5α
pET21a-NanH pET21a plasmid containing codon optimised, gene synthes ised nanH DH5α, EC Origami
pET21a-s iaPG pET21a plasmid containing codon optimised, gene synthes ised s iaPG DH5α, EC Origami
pET20b-NanH-CT pET20b plasmid containing native nanH-CT DH5α, EC Origami
pET20b-s iaPG-CBM pET20b plasmid containing native s iaPG-CBM DH5α, EC Origami
pET20b-s iaPG-CT pET20b plasmid containing native s iaPG-CT DH5α, EC Origami
Name of Construct Detai ls  of Construct
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2.3.6 Biochemical Characterisation of Purified Periodontal Pathogen Sialidases 
Elucidating the conditions and under which NanH and SiaPG can function is an important 
first step in characterising the activity of these enzymes. The initial studies of purified NanH 
and SiaPG shown here were performed using the model sialic acid-substrate MUNANA, 
which allows quantification of sialidase activity through detection of 4-MU release from 
MUNANA (Neu5Ac is also produced when MUNANA is cleaved). Although this ligand is not 
present in the pathogens’ hosts, it is a widely used substrate for high throughput testing of 
sialidases (Cabezas et al. 1989; Han et al. 2000; Tailford et al. 2015).  
A simple MUNANA-based activity test to confirm activity of purified NanH and SiaPG was 
frequently used to confirm that a given batch of protein, or diluted protein, possessed 
sialidase activity before use in further studies (figure 2.26). MUNANA based assays were 
also used to quantify sialidase activity under variable pH conditions.  
 
Figure 2.26 Visualisation of MUNANA cleavage to rapidly confirm sialidase activity. . 
MUNANA was exposed to no enzyme (-), or NanH, or SiaPG as indicated. In the case of 
sialidase activity resulting in release of 4-MU, fluorescence under UV light can be seen. 
 
Further work utilised thiol- labelling of free (non-conjugated) sialic acid to study sialidase 
cleavage of Neu5Ac from 3- and 6-sialyllactose (3- and 6-SL) to determine any preference 
or specificity for two types of sialic acid linkages- i.e using the thiobarbiturate based assay 
for sialic acid. The activity of NanH on the host relevant ligands 3-sialyl lewis A and 3-sialyl 
lewis X (SleA and SleX) using the thiol- labelling method is also reported and discussed 
below. Furthermore, the MUNANA based assay was used to elucidate the efficacy of 
zanamivir for the purified sialidases and live pathogens, providing a backdrop for in vitro 
studies on the effect of sialidase inhibitors on periodontal pathogen virulence.  
 Periodontal Pathogen Sialidases Display Broad pH Optima 2.3.6.1
Understanding the pH under which sialidases function is important for further biochemical 
and other in vitro experiments, and may yield information on where and when the sialidase 
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act during infection; for instance, different sites within the host are likely to possess 
different pH conditions, and in the case of periodontitis, the periodontium may show 
variable pH as periodontal disease progresses (Bickel & Cimasoni 1985; Eggert et al. 1991; 
Galgut 2001).  
MUNANA was exposed to SiaPG and NanH under different pH conditions, and the sialidase 
activity quantified by release of 4-MU (and Neu5Ac), resulting in an increased fluorescence. 
Optimum 4-MU fluorescence occurs on excitation at ~345-380nm, with fluorescence 
emission at ~445-454 nm. However, 4-MU fluorescence is also pH dependent, with optimal 
fluorescence under these wavelengths occurring at pH 10.5 (Mead et al. 1955).  
It is possible to measure the fluorescence of 4-MU at lower pH in a given experiment, 
provided all conditions are under the same pH, although this will result in decreased 
sensitivity as the fluorescence of 4-MU is decreased. An alternative is to use a lower 
excitation wavelength of 331 nm, and record fluorescence emission at 368nm-this almost 
completely abrogates the effect of pH on fluorescence of 4-MU under the higher 
wavelength measurements, although this also decreases assay sensitivity (Strachan et al. 
1961). 
 To negate the impact of pH on fluorescence while retaining assay sensitivity, a 
quenching/equilibrating step was performed; an excess amount of pH 10.5 buffer was 
added to stop the reaction (the enzymes lose their activity at high pH) and equilibrate the 
reaction to above pH 10. 
 Both sialidases appeared to display optimum activity under moderately acidic conditions: 
SiaPG at pH 5.6, and NanH at ~pH 5.2 (figure 2.27). Notably, activity is present across a 
wide pH range; activity of NanH is above 50 % between pH4-6.8, only dropping below 10 % 
above pH 8.4, or below pH 4.4. Similarly for SiaPG, activity remains above 50 % between 
pH4.4-6.4, only dropping below 10 % above pH 8.0, or below pH 4.4.  
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Figure 2.27. pH optima of A) NanH and B) SiaPG. 
MUNANA was exposed to NanH or SiaPG for 1 minute under a variety of pH conditions. 
Reactions were performed in clear microtitre plates for 1 minute, before being quenched 
with an excess of pH 10.5 buffer to ensure fluorescence reading of 4-MU was obtained at 
the same pH for each condition, and to stop the reaction. Data shown represent the mean 
of two experiments, where each condition was repeated three times per experiment. Error 
bars=SEM. 
 
MUNANA was also exposed to live pathogens-T. forsythia and P. gingivalis whole cells-
under different pH conditions in an assay similar to the one described above, and sialidase 
activity quantified.  It was important to establish the sialidase activity of whole pathogens 
under similar conditions to their purified enzymes, both for practical purposes and to 
confirm the activity of the whole, live pathogens could take place under the same broad-pH 
conditions as the purified enzymes. In contrast to the purified sialidases, P. gingivalis and T. 
forsythia whole cell sialidase activity was optimum under nearly neutral conditions (figure 
2.28), with T. forsythia highest at pH 6.8, and P. gingivalis also at pH 6.8.  In addition, the 
live pathogens appear to display higher relative sialidase activity over a broader pH range 
than their purified sialidases. This might be expected, since cell membranes, surrounding 
proteins and glycans can stabilise cell-associated proteins, it follows that cell-associated 
sialidases might display increased pH-stability compared to proteins free in solution (i.e. 
the purified sialidases). An alternative explanation is that the live pathogens might continue 
to secrete sialidases into the reaction, replacing any that have become unstable and 
inactive over time. The data from these experiments are from reactions stopped after 
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longer time points, the T. forsythia reaction was quenched/pH equalised after 30 minutes. 
Live P. gingivalis displayed lower sialidase activity, reactions were quenched/pH equalised 
after 4 hours. Unfortunately this longer time point produced larger error between 
experimental repeats, though the trend remained the same between experiments. Using a 
greater concentration of P. gingivalis to counter this was also problematic, perhaps 
because the absorbance of the resulting bacterial suspension interfered with fluorescence. 
  
Figure 2.28. pH Optima of A) T. forsythia and B) P. gingivalis. 
MUNANA was exposed to T. forsythia or P. gingivalis for 30 minutes and 3 hours, 
respectively, under a variety of pH conditions. Reactions were performed in clear microtitre 
plates for 1 minute, before being quenched with an excess of pH 10.5 buffer to ensure 
fluorescence reading of 4-MU was obtained at the same pH for each condition, and to stop 
the reaction. Data represent the mean of two experimental repeats, where each condition 
was repeated three times per experiment. Error bars=SD. 
 
Bacterial, viral, and eukaryotic sialidases often display acidic-neutral pH optima (Kurniyati 
et al. 2013; Cabezas et al. 1989; Park et al. 2013; Manzoni et al. 2007), so it is perhaps 
unsurprising that both SiaPG and NanH also follow this trend.  
 Reaction Kinetics of Pathogen Sialidases and MUNANA  2.3.6.2
The model sialic acid-ligand MUNANA is widely used for high throughput testing of sialidase 
activity, and characterisation of the reaction kinetics of NanH and SiaPG with MUNANA 
would allow comparison of these with previously characterised sialidases from other 
pathogens, and to assess the efficacy of sialidase inhibitors. 
Given the pH variations in the pathogens’ ecological niche, i.e. the conditions the sialidases 
would encounter in the host it was necessary to evaluate sialidase activity at different pH 
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conditions. There were also practical implications for this, as in vitro work discussed in later 
chapters was performed under neutral conditions (which are also the normal conditions in 
the host). 
Reaction kinetics for NanH and SiaPG were obtained by quantifying 4-MU release from a 
variable concentration of MUNANA by the two sialidases, and applying a standard curve of 
known 4-MU concentrations. Initial rate of 4-MU release (µmol/min/mg sialidase) by NanH 
and SiaPG under the different pH conditions was plotted against MUNANA (the enzyme 
substrate) concentration to obtain a Michaelis-Menten plot, and subsequently the ligand-
enzyme affinity (KM) and maximum reaction rate (Vmax) (figure 2.29).  
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Figure 2.29. Reaction kinetics of MUNANA with A) NanH and B) SiaPG.  
 Variable concentrations of MUNANA were exposed to NanH or SiaPG, under different pH 
and salinity conditions. Reactions were quenched by addition of pH 10.5 buffer at 1, 2, and 
3 minutes, and the rate of 4-MU release (V0) determined by application of a 4-MU standard 
curve. This was plotted against [MUNANA] to obtain the Michaelis-Menten plots. The Vmax, 
KM and associated error (SD) of MUNANA cleavage by NanH and SiaPG are displayed. 
 
The Vmax of NanH and SiaPG are both higher at their acidic (optimum) pH conditions 
compared to neutral conditions: At pH 5.2 NanH Vmax was 11.1 µmol/mg/min NanH, 
compared to 11.1 µmol/mg/min NanH at pH 7.2. For SiaPG, at pH 5.6 Vmax was 9.7 
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µmol/mg/min SiaPG, compared to 3.2 µmol/mg/min SiaPG at pH 7.2. After this first finding, 
a buffer with physiological pH 7.4, and with higher salinity (200mM NaCl)-used in work 
described here in other chapters as it more closely mimics physiological conditions-was 
also tested. It was expected that this physiological buffer would display very similar kinetics 
to the pH 7.2 buffer (with a small difference in pH of 0.2 between the two conditions), but 
in the NanH condition both KM and Vmax were increased relative to the pH 7.2 (no salt) 
condition (table 2.8). SiaPG also displayed an increase in Vmax (table 2.8). The pH 5.2 and 5.6 
conditions were repeated for NanH and SiaPG, with the higher salinity (200mM NaCl) to 
observe if the reaction kinetics were also shifted at this pH. Again, for NanH, both the KM 
and Vmax were increased relative to the pH 5.2 (no salt) condition (table 2.8), and SiaPG 
displayed an increased Vmax in the presence of NaCl. In the case of NanH, the presence of 
200mM NaCl shifted the Vmax by a factor of ~1.2 in both acidic and neutral conditions, while 
KM was shifted by similar factors of 2.8 and 3.7 at acidic or neutral pH, respectively. For 
SiaPG, the presence of 200mM NaCl shifted the Vmax by a factors of 1.1 and 0.8 in acidic and 
neutral conditions, respectively, while KM was shifted by similar factors of 1.3 and 3.7 at 
acidic or neutral pH, respectively. Interestingly, the reaction between NanH and MUNANA 
in the pH 5.2, no salt condition appears to display product or substrate inhibition (indicated 
by the decrease in reaction rate when [MUNANA] >100µM), but in the presence of 200mM 
NaCl, substrate/product inhibition is not visible (figure 2.29 A). 
 
 
Table 2.8. The effect of salt on sialidase kinetics under different pH conditions.  
Vmax and Km data shown in Figure 2.29 were tabled to allow easy comparison of the change 
in  Km and Vmax between different pH conditions in the presence and absence of NaCl. The 
salt-induced fold change was obtained by dividing the Vmax or Km of the 200mM NaCl 
condition from the no-salt condition for both pH conditions. Error=SD.  
Enzyme pH Conditions
No Salt
200mM 
NaCl
No Salt
200mM 
NaCl
Acidic-Enzyme 
Optimum
11.1±0.3 13.8±0.8 1.2 5.7±0.9 15.8±3.7 2.8
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pH  
4.1±0.1 4.8±0.1 1.2 1.8±0.3 6.6±0.5 3.7
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Optimum
9.7±0.2 13.2±0.5 1.3 10.9±1.1 11.6±1.9 1.1
Neutral-Host 
pH  
3.2±0.3 5.3±0.3 1.7 18.8±7.4 14.2±3.2 0.8
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The apparent increase in maximum reaction speed  (increased Vmax), but decreased affinity 
(increased KM) necessitated an alternative plot; in this case the rate of MU release against 
concentration of sialidase active sites (MU release /min –at a given concentration of 
enzyme active sites, as opposed to µM/min/mg enzyme seen in the above plots).  This 
establishes the Kcat, which can be divided by KM to obtain catalytic efficiency under acidic 
(enzyme optimum) and neutral (host-environment) pH conditions (figure 2.30). A separate 
curve to obtain Kcat was required as the reaction velocity (V0) used in calculating Kcat uses 
different units to that of Vmax.  
Interestingly, salt appeared to decrease the catalytic efficiency of NanH; Kcat/Km changed by 
a factor of 0.5 and 0.3 for acidic and neutral conditions, respectively. Conversely, for SiaPG 
the catalytic efficiency was increased in the presence of salt, i.e. Kcat/Km changed by a factor 
of 1.3 and 1.5 for acidic and neutral conditions, respectively (table 2.9). 
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Figure 2.30. Catalytic efficiency of A) NanH and B) SiaPG. 
Variable concentrations of MUNANA were exposed to NanH or SiaPG, under different pH 
and salinity conditions. Reactions were quenched by addition of pH 10.5 buffer at 1, 2, and 
3 minutes, and the rate of 4-MU release determined by application of a 4-MU standard 
curve. This was plotted against [MUNANA] to obtain the Michaelis-Mentin plots. The Kcat, 
Km and associated error (SD) of MUNANA cleavage by NanH and SiaPG are displayed.  
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Table 2.9. The effect of salt on sialidase kinetics under different pH conditions. 
Kcat and Km data shown in figure 2.30 were tabled to allow easy comparison of the change 
in Km and Kcat between different pH conditions in the presence and absence of NaCl. The 
salt-induced fold change was obtained by dividing the Kcat/Km of the 200mM NaCl condition 
from the no-salt condition for both pH conditions. Error=SD. 
 
 Preference of NanH for Different Sialic Acid Linkages 2.3.6.3
In humans, sialic acid is typically found at the terminating end of N- or O-glycans, linked to 
the underlying sugar-usually a galactose (Gal) or N-Acetyl Galactosamine (GalNAc)-via its 
second carbon, and either the third, sixth, and sometimes eighth carbon in the underlying 
sugar (reviewed in (Cohen & Varki 2010) and (Varki & Gagneux 2012)). This is termed α2-3, 
α2-6, or α2-8 linked sialic acid. Bacteria, such as E. coli K12, may possess polymeric sialic 
acid within glycans, linked through the second carbon and eighth carbon on the sialic acid 
(poly α2-8 linked sialic acid). Some human cells also possess poly α2-8 Neu5Ac, but in the 
periodontium the most commonly encountered sialic acids are α2-3 and α2-6 linked sialic 
acid, and therefore the ability of periodontal pathogen sialidases to act on these was 
examined.  
In a series of experiments, the sialoconjugates α2-3, and α2-6 sialyllactose (3- and 6-SL, 
depicted in figure 2.31) were exposed to NanH to release sialic acid. These short glycans 
are commonly used in studies assessing linkage specificity of sialidases (Tailford et al. 2015; 
Thompson et al. 2009; Li & McClane 2013), but unlike the MUNANA based assay, which 
quantifies sialidase activity by measuring the release and fluorescence of 4-MU, the 
products of sialic acid release from sialyllactose are not readily quantifiable using 
fluorometric methods.  
pH Conditions
No Salt 200mM NaCl No Salt
200mM 
NaCl
No Salt
200mM 
NaCl
Acidic-Enzyme 
Optimum
0.03±0.001 0.04±0.002 5.7±0.9 15.8±3.7 0.005263 0.00253 0.5
Neutral-Host 
pH  
0.011±0.0003 0.013±0.0001 1.8±0.3 6.6±0.5 0.006111 0.00197 0.3
Acidic-Enzyme 
Optimum
0.03±0.001 0.04±0.002 10.9±1.1 11.6±1.9 0.002752 0.00345 1.3
Neutral-Host 
pH  
0.03±0.001 0.034±0.002 18.8±7.4 14.2±3.2 0.001596 0.00239 1.5
K cat /Km (min-1 
µM-1)
Salt-induced 
Fold Change 
in K cat /K m
K m (µM MUNANA)K cat (min)
NanH
SiaPG
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Figure 2.31. 3- and 6- sialyllactose. 
Trisaccharides of glucose-galactose-Neu5Ac used to probe sialidase specificity, due to the 
only difference being the linkage between Neu5Ac and Galactose. Image rendered in Glyco 
Workbench (Ceroni et al. 2008). 
 
 
Quantification of free sialic acid required adaptation of the Thiobarbituric Acid (TBA) assay 
described by Aminoff (Aminoff 1961). This assay results in labelling of free sialic acid in a 
given sample with a thiol group, allowing sialic acid to be arbitrarily quantified by 
spectrophotometry: A standard curve of known sialic acid concentrations can also undergo 
the TBA assay and spectrophotometry, and applied to obtain the actual concentration of 
sialic acid in the sample. In this work, a high throughput version of the TBA assay was 
optimised-the key difference being smaller reaction volumes, and absence of a 
chromophore solubilisation/enhancement step at the end of the assay, which was included 
in other TBA assays shown in section 3.3.1. 
Variable concentrations of 3- and 6-SL were exposed to NanH, in a 50mM sodium 
phosphate, 200mM NaCl, pH 7.4 buffer to imitate physiological conditions in the host. 
Reactions were halted at given time points by oxidation with sodium periodate-the first 
step of the TBA assay, which was immediately carried out to completion. The TBA assay 
was always performed with a Neu5Ac standard curve alongside the sialidase treated 
ligands. 
Digestion of variable concentrations of the sialyllactose ligands enabled plotting of the 
Michaelis-Mentin curve, and subsequently to obtain the ligand-enzyme affinity (KM) and 
maximum reaction rate (Vmax) of NanH for 3- and 6-SL (Figure 2.32 A). A separate curve to 
obtain Kcat was also plotted (Figure 2.32 B), as the initial velocity (V0) used in calculating Kcat 
uses different units to that of Vmax. 
β1-3 α2-6 β1-3 α2-3 
Neu5Ac Galactose Glucose 
3-Sialyllactose 6-Sialyllactose 
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Figure 2.32. Kinetics of NanH on α2-3 and α2-6 linked sialic acid under physiological 
conditions. 
Variable concentrations of 3- and 6-SL were digested with NanH, reactions were stopped at 
different time points and immediately subjected to the TBA assay. Application of a 
standard curve enabled determination of the rate of Neu5Ac release. The reaction was 
performed in buffer intended to mimic physiological conditions; 50mM Sodium Phosphate, 
200mM NaCl, pH 7.4. A) KM and Vmax of NanH for 3- and 6-SL B) KM and Kcat of NanH for 3- 
and 6-SL. The KM, Kcat and Kcat/KM of NanH for 3- and 6-SL are displayed beneath the plots. 
Data shown represent the mean of three experimental repeats. Error bars=SD. 
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NanH displayed a much higher affinity for 3-SL than 6-SL; with a KM, of 0.36 and 2.027mM, 
respectively-a fivefold difference. However the maximum reaction rate was lower for 3-SL 
than 6-SL; with a Vmax of 141.6 and 239.2µmol/min/mg, respectively. The Kcat of NanH for 3-
SL and 6-SL was obtained and the catalytic efficiency determined. NanH was shown to be a 
much more efficient catalyst for 3-SL (Kcat / KM =1.122 min
-1mM-1) than 6-SL (Kcat / KM = 
0.339min-1mM-1).  
 Activity of NanH on the Sialic acid Ligands Sialyl Lewis A and  2.3.6.4
Sialyl Lewis X 
Sialyl lewis A (SLeA) and sialyl lewis X (SLeX) are important sialic acid-containing human 
antigens. These short glycans are isomers, consisting of the same sugar chains, differing in 
only the fucose-N-acetylglucosamine linkage, which is α4 in the case of SLeA and α3 in the 
case of SLeX, and the terminal galactose-N-acetylglucosamine linkage which is β3 in the 
case of SLeA and β4 in the case of SLeX (Figure 2.33). SLeA/X are involved in a number of 
cancers including oral cancer (Renkonen et al. 1999), they play roles in neutrophil tissue 
migration (Lowe 2003),  and are involved in bacterial attachment to host cells. SLeA/X may 
also be expressed on salivary glycoproteins such as salivary mucins, which are glycoproteins 
that comprise 16-26% of salivary total protein content. In the context of the periodontium, 
SLeX is highly expressed on neutrophils, where it has been extensively studied for its role in 
binding endothelial selectins enabling tissue migration (discussed further in chapter 5) and 
endothelial cells can also express SLeX. SLeA is an isomer of SLeX, is also expressed on a 
variety of cells, and is also capable of binding selectins (Melorose et al. 1991). Given the 
apparent multi-functionality of SLeA/X for the host, the ability to cleave sialic acid from one 
or both of these could influence a number of processes and contribute to virulence. The 
kinetics of NanH activity on SLeA and SleX were obtained by exposure of SLeA and SLeX to 
NanH, followed by a TBA assay (experiments were similar to the kinetics studies of NanH 
desialylation of 3- and 6- SL in section 2.3.6.4).  
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Figure 2.33. Graphic representation of sialyl lewis A/X. 
Sialyl lewis A and X are isomers of the same polysaccharide sequence. Image rendered in 
Glyco Workbench (Ceroni et al. 2008). 
 
NanH displayed greater efficacy in cleavage of SleA than SleX: The maximum rate of 
reaction was apparently not too dissimilar; Vmax for NanH SleA desialylation was 41.45 
µmol/min/mg NanH, compared to 35.15 µmol/min/mg NanH for SLeX desialylation. 
However, the affinity of NanH for SleA was tenfold greater; the KM of NanH for the two 
sialyl lewis ligands was 0.20mM SleA, compared to 2.05mM SleX (figure 2.34). Discussing 
the efficacy of NanH in desialylation of SleA/X in the context of other enzymes is difficult, 
since to our knowledge there have been no studies (besides work presented here) which 
establish Michaelis-Menten kinetics of any sialidases with either SleA or SleX. However, 
apparently not all sialidases possess greater catalytic efficiency for SLeA, with all human 
sialidases (Neu1-4) showing greater efficacy  in desialylation of SLeX than SLeA (Shiozaki et 
al. 2011). 
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Figure 2.34. Kinetics of Neu5Ac release from SleA and SLeX by NanH 
Variable concentrations of SLeA/X were digested with NanH, reactions were stopped at 
different time points and immediately subjected to the TBA assay. Application of a 
standard curve enabled determination of the rate of Neu5Ac release. The Km and Vmax of 
NanH for SLeA and SLeX are displayed beneath the plots. Data shown represent the mean 
of three experimental repeats. Error bars=SD. 
 
 Sialidase Active Site Mutation Abrogates Sialidase Activity, but not Ligand-2.3.6.5
Binding Capacity 
The NanH active site contains a highly conserved FRIP motif, thought to be important for 
catalyitic activity. This was mutated in previous work to YMAP in an attempt to abrogate 
activity (Jennifer Parker, Stafford Research Group, The University of Sheffield). FY is 
actually a conservative mutation, likely to preserve function since this residue is used in 
other sialidases (e.g. SiaPG). RM was chosen since the amino acids are similar in mass 
(Mw=156 and 131, respectively). Perhaps lysine (K) could have been substituted for R 
instead of substitution with M, but retaining the positive charge by mutating RK might 
not have resulted in loss of sialidase activity. I A mutations were chosen since they are 
both hydrophobic amino acids, and it was considered possible that use of leucine (L) 
instead of alanine for the substitution would not result in loss of sialidase activity. For 
reference, the structures of the native amino acids alongside the residues chosen for 
substitution are shown in figure 2.35.  
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Figure 2.35. Structures of the substituted amino acids in NanH and NanH-YMAP. 
The FRIP motif was mutated to YMAP, the native and substituted amino acids are shown 
adjacent to each other. Arrows = substituted amino acid. Molar mass (Mw) is also shown. 
 
In addition to showing that this motif is required for catalytic activity, an inactivated 
sialidase is potentially a useful for probing sialidase-host ligand interactions if the sialidase 
is still capable of ligand binding following inactivation, since the ligand will not be turned 
over, the inactive sialidase could perhaps be used in a variety of ligand binding studies. The 
mutation of FRIPYMAP was performed with this in mind, it was hoped that the replaced 
residues would not disrupt the protein structure, and that NanH-YMAP would retain its 
capacity to bind host ligands, or to see if ligand affinity is altered by a (small) modification 
of the active site.  
The NanH active site mutant (NanH-YMAP) was successfully purified and was shown to be 
inactive (figure 2.36). 
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Figure 2.36.  NanH-YMAP displays no Sialidase Activity. 
 NanH or NanH-YMAP were exposed to MUNANA for 1 minute or 10 minutes before 
imaging under UV-light. The low-level fluorescence of YMAP in these images is likely due to 
UV-light fluorescence of protein. Negative control was MUNANA without enzyme. 
 
NanH-YMAP underwent ligand-enzyme interaction studies with 3- and 6-SL. These assays 
relied on the intrinsic fluorescence of tryptophan to assess conformational change of the 
enzyme on binding the two ligands. NanH-YMAP was shown to be capable of binding both 
3- and 6- sialyllactose (figure 2.37). 
 
Figure 2.37. Affinity of 3- and 6-Sialyllactose for NanH-YMAP. 
NanH-YMAP was exposed to variable concentrations of 3- and 6-SL, and the resulting 
change in protein fluorescence (%) used to ascertain the affinity (KD) of the two ligands for 
NanH-YMAP. Data represent the mean of three experimental repeats, error bars=SEM. 
Statistical difference between the two data sets was assessed using an extra sum of 
squares F-test (p=0.002). 
 
The affinity (KD) of NanH-YMAP for 3- and 6-SL were determined here as 0.143 mM and 
0.290 mM, respectively. An extra sum of squares F-test was used to assess whether or not 
a single curve could be adequately fitted to both data sets, but this revealed that the 
datasets were significantly different from each other (p=0.002). This result follows the 
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trend shown in the studies of active, whole NanH,reflected by the KM values (figure 2.32) 
i.e. that NanH-YMAP shows higher affinity for 3-SL than 6-SL. The data imply that NanH-
YMAP is capable of binding sialic acid-ligands without catalysing sialic acid release, with 
similar ligand preferences to active (wild type, non-mutant) NanH and that the conserved 
FRIP site is indeed key for catalytic activity in NanH. Future work using NanH-YMAP could 
yield insights into which host sialoglycans are preferentially targeted by NanH. 
 Summary-Biochemical Characterisation of Purified Periodontal Pathogen 2.3.6.6
Sialidases 
The key results shown in this section were that both sialidases from T. forsythia (NanH) and 
P. gingivalis (SiaPG) display broad pH optima, which is likely to be an adaptation to their 
ecological niche, where pH is variable. NanH was shown to be capable of cleaving both 3- 
and 6- linked sialic acid, although it is a more efficient catalyst for 3- linked sialic acid. 
Furthermore, NanH was capable of desialating the important host sialoglycans SLeA and 
SLeX, though NanH displayed a tenfold greater affinity for SLeA than SLeX.  In addition, the 
importance of the FRIP residues to NanH sialidase function was also established. Overall, it 
was implied that the enzymes are broad-specificity sialidases, capable of functioning under 
a variety of conditions likely to be found in the oral cavity.  
2.3.7 Inhibition of Periodontal Pathogen Sialidases by Zanamivir 
A key aim of this project is to ascertain the potential of sialidase inhibitors to abrogate or 
inhibit virulence processes mediated by pathogen sialidases. The main focus of the project 
is on the inhibitor zanamivir, chosen partly because it is licensed worldwide for the 
treatment of influenza and might more-easily transition to other therapeutic areas than 
novel or unlicensed inhibitors. Therefore, ascertaining the ability of zanamivir to inhibit 
periodontal pathogen sialidase activity, and that of the purified sialidases, was of 
paramount importance.  
 T. forsythia and P. gingivalis Possess Sialidase Activity, Which is Inhibited 2.3.7.1
by Zanamivir 
Before studying the effects of zanamivir on inhibition of whole pathogens, the sialidase 
activity of the periodontal pathogens used in this work had to be assessed. A variety of 
strains underwent characterisation of sialidase activity. The various wild type strains of T. 
forsythia and P. gingivalis possessed sialidase activity, while F. nucleatum strains did not 
(figure 2.38). 
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Figure 2.38. Sialidase activity profiles of periodontal pathogens. 
Pathogens were resuspended in Phosphate Buffer Saline and Exposed to MUNANA. The 
fluorescence of the reactions (excitation 380nm emission 420nm) was measured after 30 
minutes. Nuc= subspecies nucleatum, poly= subspecies polymorphum. Data shown 
represent the mean of three experimental repeats. Error bars=SD. 
 
The absence of sialidase activity in F. nucleatum strains was expected, as F. nucleatum 
(polymorphum and nucleatum) do not possess any predicted sialidase genes in its 
published genome sequence, though F. nucleatum does possess a sialic acid utilisation 
operon (Stafford et al. 2012). P. gingivalis possessed some sialidase activity, and T. 
forsythia possessed the most. Further testing of other strains of P. gingivalis strain 
ATCC33277 and strain 381 (for which we had a sialidase deficient mutant courtesy of Prof A 
Sharma, SUNY, Buffalo, USA) and T. forsythia 43037 and 92A.2 revealed sialidase activity to 
be a conserved feature, and the sialidases NanH and SiaPG were shown to be the sialidases 
responsible for sialidase activity by testing the sialidase mutant strains T. forsythia ΔnanH 
and P. gingivalis ΔsiaPG, where sialidase activity was completely abrogated compared to 
their parent strains (figure 2.39). 
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Figure 2.39. Sialidase activity profiles of P. gingivalis and T. forsythia strains. 
Bacteria were resuspended in PBS and Exposed to MUNANA. The fluorescence of the 
reactions (excitation 350nm emission 450nm) was measured after 30 minutes for T. 
forsythia, and 4 hours for P. gingivalis. Reactions were stopped at each time point by 
addition of an excess of pH 10.5 Sodium Carbonate Buffer. Data shown represent the mean 
of three experimental repeats. Error bars=SD. 
 
Whole P. gingivalis and T. forsythia underwent the MUNANA based assay to determine 
sialidase activity in the presence of variable concentrations of zanamivir. Both pathogens 
displayed decreased sialidase activity as zanamivir concentration was increased (figure 
2.40). The decrease in activity was far more drastic for P. gingivalis, with a decrease in 
activity of ~70% in the presence of 10 mM zanamivir, compared to T. forsythia which only 
showed a decrease of ~25%.  
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Figure 2.40. Inhibition of A) T. forsythia and B) P. gingivalis by Zanamivir. 
MUNANA was exposed to T. forsythia or P. gingivalis in the presence of zanamivir for 1 
hour and 4 hours, respectively, and sialidase activity expressed as the difference in 4-MU 
fluorescence relative to conditions with no inhibitor. Experiments were repeated twice, 
each condition performed in triplicate per experiment. Data shown represent the mean of 
one representative experiment. Error bars=SD. Significant reductions in sialidase activity 
between the no inhibitor condition and the conditions containing zanamivir at different 
concentrations were determined by one-way ANOVA with repeated measures, with 
Dunnet’s correction for multiple comparisons (*p=<0.05, **p=<0.01, ***p=<0.001). 
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 Efficacy of Zanamivir for Pathogen Sialidases 2.3.7.2
The Inhibitory Constant (IC50) of a given inhibitor for an enzyme represents the 
concentration at which the inhibitor has abrogated half of the en yme’s activity on a given 
ligand, and represents the efficacy of the inhibitor. The efficacy of zanamivir for inhibition 
of MUNANA desialylation by NanH and SiaPG was obtained. Both NanH and SiaPG were 
inhibited by zanamivir, although zanamivir was far more efficacious during inhibition of 
SiaPG than inhibition of NanH (figure 2.41): The IC50 of zanamivir was found to be 369µM 
for SiaPG and 6.16mM (6156µM) for NanH. These IC50 values are comparable to those 
seen for zanamivir inhibiting sialidases from other human-dwelling bacteria, such as in the 
case of V. cholerae (0.1 mM), S. pneumoniae (5 mM), Arthrobacter ureafaciens (5 mM) 
(Nishikawa et al. 2012), and Ruminococcus gnavus (11.89mM) (Tailford et al. 2015). 
Knowledge of the IC50 of zanamivir for SiaPG and NanH had implications for work 
described in later chapters, investigating the impact of zanamivir on virulence processes 
mediated by the pathogen sialidases. 
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Figure 2.41.  Inhibition of NanH and SiaPG by Zanamivir. 
A) Inhibition of NanH and B) Inhibition of SiaPG by zanamivir, expressed as a percentage of 
sialidase activity relative to a condition with no inhibitor. C) Plot of the LOG [zanamivir] 
against % of sialidase activity relative to no inhibitor allows determination of the IC50 of 
zanamivir for inhibition of MUNANA cleavage by NanH and SiaPG. Data represent the mean 
of three experimental repeats, where each condition was repeated three times. Error 
bars=SEM.   
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2.4 Discussion 
Bioinformatics work delineated the sialidases of T. forsythia (NanH) and P. gingivalis 
(SiaPG) into the CBM and CTD domains; the CBMs were proposed to assist in ligand 
binding, and the CTD were suggested to have catalytic activity, respectively. Therefore, 
attempts were made to clone, express and purify both the whole sialidases-NanH and 
SiaPG-and their CBM and CTD domains separately from each other. The cloning process 
using genomic DNA from T. forsythia to amplify sialidase-encoding DNA was plagued with 
difficulties. This may have been due to the incorrect annotation of the T. forsythia 92.A2 
genome as T. forsythia 43037 in the NCBI and oralgen databases (i.e. the primers for PCR 
amplification of sialidase  were designed to target the T. forsythia 92.A2 genomic DNA, but 
T. forsythia 43037 genomic DNA was present in PCR reactions). Ultimately, a codon 
optimisation approach where the nanH sequence was altered to contain the preferred 
codons of E. coli, meant that NanH from strain 92.A2 was successfully expressed in E. coli, 
which was successfully purified. Importantly, the amino acid sequences of NanH from T. 
forsythia 43037 and 92.A2 have ~98% homology, and the substituted amino acids occur 
away from key regions of the enzyme (The FRIP motif and Asp Boxes), meaning it is unlikely 
there would be any differences in ligand specificity in NanH from both strains. siaPG was 
successfully amplified by PCR from genomic DNA, but a codon optimisation approach was 
also taken, and SiaPG was successfully expressed and purified. 
After purification of the sialidases, some of the most important objectives of this part of 
the project could be addressed: Characterisation of NanH and SiaPG-under what conditions 
do they function? Do the sialidases show a preference for different sialic acid linkages? Do 
the sialidases preferentially target specific host sialoglycans, such as sialyl Lewis A and X? 
And perhaps most importantly, are the pathogen sialidases inhibitable using commercially 
available compounds? 
2.4.1 pH, Pathogen Sialidases, and Periodontitis 
Supragingival oral biofilms are well studied, and are known to result in acidic pH due to 
sugar fermentation by various bacterial species. Particularly well described is the 
contribution of Streptococcus mutans and various Lactobacilli –which produce lactic acid, 
damaging enamel, and ultimately leading to caries (tooth decay). pH in the supragingival 
environment is usually physiological (approximately neutral), but has been shown to vary 
widely in short spaces of time, as highlighted by pH measurements of plaque after food 
consumption (Edgar 1982). In vitro studies of individual organisms (Takahashi & Yamada 
1999) and mixed species oral biofilms (Vroom et al. 1999; Edlund et al. 2013) have also 
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highlighted the potential for variable pH in these biofilms. The data shown here indicate a 
broad range of activity under variable pH conditions for the sialidases of T. forsythia and P. 
gingivalis, and given that T. forsythia and P. gingivalis do colonise the supragingival biofilm, 
this might explain why their sialidases are capable of activity over the broad pH range 
shown here.  
However, the subgingival biofilm is the most important ecological niche for T. forsythia and 
P. gingivalis. It is isolated from salivary flow, and is therefore likely to be less prone to rapid 
changes in pH. The pH of the periodontium during disease progression has been the focus 
of some debate. Early patient studies have indicated a link between increasing periodontal 
inflammation and pH of the GCF, i.e. a basic pH was associated with periodontitis 
progression (Bickel & Cimasoni 1985). However, others have failed to find this association, 
and cite the use of metallic electrodes during the previous studies as a factor affecting the 
pH of the GCF being measured (Eggert et al. 1991), or that there are wide variations in pH 
even within a single periodontal pocket (Galgut 2001). In vitro studies of mixed periodontal 
biofilms have also shown pH gradients within their biofilms (Vroom et al. 1999). Taking all 
this into account, it is likely that the ability to function under a wide variety of pH 
conditions would enable periodontal pathogens to more effectively colonise and survive in 
the supra- and sub-gingival biofilms. Therefore, the broad pH optimum of the periodontal 
pathogen sialidases may enable them to function under these variable pH conditions, and 
contribute to the proliferation and survival of T. forsythia and, perhaps to a lesser extent, P. 
gingivalis, since sialidases may enhance protein degradation, assisting with nutrient 
acquisition (discussed further in the next chapter). 
Reaction kinetics of MUNANA cleavage by NanH and SiaPG were performed, to observe the 
effect of pH on reaction kinetics. NanH and SiaPG were more efficient catalysts under 
mildly acidic conditions compared to neutral conditions, unsurprising given their apparent 
pH optima (5.2 and 5.6, respectively). A kinetics experiment was also performed where salt 
(200 mM NaCl) was included in the neutral pH condition with the intention of mimicking 
physiological conditions, which would be used in experiments involving host-relevant sialic 
acid ligands, and later studies of human cells. Interestingly, the presence of salt shifted the 
enzyme-MUNANA affinity (KM) and maximum reaction rate (Vmax) for both NanH and SiaPG. 
Addition of salt to acidic conditions also shifted these parameters. In the case of NanH at 
either pH condition, affinity was decreased but maximum reaction rate increased. Overall 
though, NanH was a more efficient catalyst in the absence of salt. SiaPG displayed 
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decreased affinity and maximum rate of reaction in the presence of salt, under acidic and 
neutral conditions. Furthermore, in the case of NanH under acidic conditions, product-or-
substrate inhibition does not appear to occur in the presence of salt, but it does in its 
absence, which could be beneficial if there is a high concentration of sialoglycans at a 
specific location, such as at the cell surface, or in certain glycoproteins such as salivary 
mucin.  It should also be noted that regadless of the NaCl dependent changes in activity, 
the enzymes show high affinity (KM in the low M range in either presence or absence of 
salt) and rapid reaction rate (high Vmax). 
The finding that the presence of NaCl can affect enzyme catalysis is not entirely surprising. 
Salt ions can interact directly with proteins through their charged amino acid side chains-
potentially affecting enzyme stability (and ability to change conformation on ligand 
binding). Furthermore, if salt ions interact with charged side chains at the enzyme active 
site or binding pocket, this might inhibit catalysis, and this is termed “electrostatic 
shielding”. This type of salt inhibition has been shown to affect en ymes that interact with 
charged or polarised ligands, while this inhibitory effect of salt is minimal for enzymes with 
non-polar ligands, the salt ions only affecting protein structural stability by interaction with 
charged amino acids away from the ligand binding site (Warren & Cheatum 1966). 
Discussion of the periodontal pathogen sialidases relative to those from other organisms is 
difficult, though many studies do use MUNANA as a substrate. Discussion is further 
complicated due to the use of different units for reporting maximum reaction rates (Vmax) in 
different studies. Comparisons of ligand affinity are easier to discuss, and can be compared 
directly. Sialidases from a variety of organisms, including the ones shown in this study, and 
their kinetic parameters-KM and Vmax-with respect to MUNANA are shown in table 2.10. The 
table highlights that NanH and SiaPG, produced and analysed as part of this project actually 
have a very high affinity (low KM) for the model ligand MUNANA, relative to the other (non-
periodontal pathogen) sialidases characterised by others, indicating that NanH and SiaPG 
are highly active compared to other sialidases (see references in table 2.10). The same is 
true of the sialidase from the third red complex pathogen, T. denticola, which has been 
reported to have the highest affinity (lowest KM) for MUNANA of all enzymes presented in 
the table.   
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Organism 
Sialidase 
Designation 
Km  Vmax Source 
Tannerella 
forsythia 
NanH 
15.6µM 13.8µmol/min/mg enzyme This study 
33µM 
Enzyme not purified-Vmax 
not comparable 
(Thompson et al. 
2009) 
Porphyromonas 
gingivalis 
SiaPG 11.6µM 13.2µmol/min/mg enzyme This study 
Treponema 
denticola 
TDE0471  0.019µM 0.6nmol/min/nM enzyme 
(Kurniyati et al. 
2013) 
Bacteroides 
thetaiotaomicron 
VPI-5482 110µM Not reported (Park et al. 2013) 
Salmonella 
typhimurium 
NanH 
250µM 
Enzyme not purified-Vmax 
not comparable 
(Hoyer et al. 
1991) 
370µM Not reported 
(Minami et al. 
2013) 
Ruminococcus 
gnavus 
NanH 590µM 
1.37µM/min (enzyme 
concentration not reported) 
(Tailford et al. 
2015) 
 
 
Table 2.10. A Comparison of Bacterial Sialidase Reaction Kinetics (Km and Vmax) with 
MUNANA. 
 
2.4.2 The Importance of Sialic Acid Linkage preference for T. forsythia 
The oral cavity is rich in sialogycans, and this presents many possible benefits for pathogens 
capable of harnessing the sialic acid, the underlying glycoprotein, or otherwise 
manipulating host processes that are regulated by sialic acid. Therefore, discovering the 
sialoglycans preferentially targeted by pathogen sialidases is an important milestone in 
understanding, and possibly treating, periodontal pathogen virulence.  
Periodontal pathogens might encounter sialoglycans from saliva, serum and GCF, or those 
on cell surfaces. Previous studies have looked at sialic acid linkages in these sources as 
means to diagnose or prognose oral cancer. Briefly, these found that α2-6 linkages are 
more prevalent in human saliva than α2-3 linkages (Vajaria et al. 2014), but α2-3 linkages 
are more prevalent in oral tissues and serum (Shah et al. 2008). The studies also found the 
prevalence of both types of linkage, or the activity of α2-3 and α2-6 sialyltransferases 
(enzymes that sialate the glycans), were greater in oral cancer patients compared to 
healthy controls. 
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T. forsythia’s ecological niche is in close proximity to the tissue, both in the supragingival 
biofilm where it colonises the most anaerobic location (i.e. closest to the host tissue) and in 
the periodontal pocket. T. forsythia is thought to be exposed to low salivary flow in this 
location (compared to the supragingival environment), but a large amount of GCF, which is 
similar in composition to serum. The data shown here indicate that NanH has a preference 
for α2-3 linkages, and this appears to fit the narrative that these linkages are more 
prevalent in the described ecological niche of T. forsythia: i.e. T. forsythia is more likely to 
encounter α2-3 linked sialic acids than α2-6 linked sialic acids, and it follows that its 
sialidase-NanH-is adapted accordingly. This apparent linkage preference is in agreement 
with the preliminary work on NanH by Thompson et al., who showed that NanH released 
more sialic acid from α2-3 than α2-6 linked sialic acids over time (Thompson et al. 2009). 
Many bacterial sialidases do appear to be capable of targeting both types of sialic acid 
linkage, but often display greater efficacy in cleavage of one of the two linkages, as 
indicated in table 2.11. 
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Organism Sialidase 
Linkages 
Targeted 
Linkage 
Preference  
Reference 
Streptococcus pneumoniae 
NanA α2-3, α2-6 α2-6 (Gut et al. 2008) 
NanB α2-3 α2-3 (Gut et al. 2008) 
NanC α2-3 α2-3 (Xu et al. 2011) 
Pseudomonas aeruginosa 
PAO1 
neuraminidase 
α2-3, α2-6 unknown (Cacalano et al. 
1992) 
Pasturella multocida  
NanB α2-3, α2-6 α2-6 (Mizan et al. 2000) 
NanH α2-3, α2-6 α2-3 (Mizan et al. 2000) 
Clostridium perfringens 
NanI α2-3, α2-6 α2-3 (Li & McClane 
2013) 
NanJ α2-3, α2-6 α2-6 (Li & McClane 
2013) 
NanH α2-3, α2-6 α2-3 (Li & McClane 
2013) 
Salmonella typhimurium NanH α2-3, α2-6 α2-3 (Hoyer et al. 1991) 
Corynebacterium diptheriae NanH α2-3, α2-6 α2-6 (Kim et al. 2010) 
Bacteroides thetaiotaomicron VPI-5482 α2-3, α2-6 α2-6 (Park et al. 2013) 
Vibrio cholerae NanH α2-3, α2-6 α2-3 (Eneva et al. 2015) 
Porphyromonas gingivalis SiaPG α2-3, α2-6 unknown (Li et al. 2012) 
Treponema denticola 
TDE0471 α2-3, α2-6 unknown (Kurniyati et al. 
2013a) 
Tannerella forsythia 
NanH α2-3, α2-6 α2-3 This study, 
(Thompson et al. 
2009) 
Actinomyces viscosus 
NanH α2-3, α2-6 α2-3 (Yeung & 
Fernandez 1991) 
Streptococcus oralis NanA α2-3, α2-6 α2-3 (Byers et al. 2000) 
Streptococcus mitis* 
NanA* Unknown* Unknown (Johnston et al. 
2010) 
 
Table 2.11 Sialic acid-linkage preferences of sialidases from bacteria associated with 
different mucosal sites. 
Blue=Respiratory Tract, Green=GI tract, Pink=Oral Cavity. P. multocida is a respiratory 
pathogen of cattle, and can cause wound infections in humans. *Not all S. mitis isolates 
possess sialidase activity, and the ability to target both sialic acid linkages is unknown, but 
presumably both α2-3 and α2-6 linkages can be targeted, as inferred by its homology with 
NanA from other streptococci.  
 
It is interesting to note that although the gut and respiratory tract bacteria seem to possess 
a mixture of sialidases with a higher efficacy for either α2-3 or α2-6 linked sialic acid, so far 
no oral bacteria sialidases have shown this, instead they display higher efficacy for α2-3 
linked sialic acid. In fact this seems to generally be the case for most bacterial sialidases of 
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human-dwelling organisms, and could reflect biochemical/biophysical properties that 
inherently make this linkage more labile to enzymatic cleavage. 
2.4.3 The Importance of Sialyl Lewis Ligands for T. forsythia 
The secreted salivary mucins are an important source of SLeA/X, and many different cell 
types are capable of expressing SLeA and SLeX on their surfaces, including endothelial and 
epithelial cells, and leukocytes. Given the ubiquitous presence of SLeA/X in the oral cavity 
or peridontium, it follows that T. forsythia sialidase would be capable of cleaving sialic acid 
from these ligands.  
NanH appears to display almost tenfold greater efficacy for SLeA than SLeX, despite the 
only difference between the two ligands being the fucose-GalNAc linkage. As well as its 
possible presence on mucin (though SLeX is perhaps the more prevalent isoform), SLeA is 
present on oral/laryngeal epithelial cells (where its expression is upregulated in head and 
neck cancers (Renkonen et al. 1999; Wiest et al. 2010)), and erythrocytes. Therefore, the 
preference of NanH for SLeA might reflect its ecological niche of the periodontal pocket or 
gingival crevice, where it is most likely to encounter SLeA due to infliltration of blood cells 
and inflammatory exudate. Targeting of cellular sialyl lewis is discussed further in chapter 
5. 
2.4.4 T. forsythia NanH- the RIP Motif of the Catalytic Domain is Essential for 
Catalysis, and the N-terminal CBM is involved in Ligand Binding 
Bioinformatics highlighted two domains of T. forsythia NanH, the CTD with catalytic 
activity, containing the Asp Boxes and highly conserved RIP motif-and the carbohyrdate 
binding module or CBM which was considered likely to have ligand binding properties. The 
NanH FRIP motif was mutated to YMAP, expressed (the resulting enzyme was named 
NanH-YMAP), and was shown not to possess catalytic activity. Despite this, NanH-YMAP 
retained the ability to bind 3- and 6-SL with high (Kd in the micro molar range) affinity. Since 
NanH appears to retain binding capacity in the absence of substrate turnover it might be 
useful for structural or other enzyme-ligand studies, where the absence of substrate 
turnover would allow studies of the enzyme in complex with its ligand. This might include 
pull down assays with host-cell or secreted glycoprotein sources (such as saliva) to establish 
preferential targets of NanH in the host. However, at least one study of RIP motif mutation 
in a bacterial sialidase (NanH from C. perfringens) has also been performed previously 
(Chien et al. 1996), where arginine was mutated to isoleucine. In this case the enzyme 
activity on 3-SL was reduced tenfold, but it did result in changes to the whole enzyme 
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structure (indicated by decreased antibody-binding during western blotting). If the 
FRIPYMAP mutation in this work did result in significant conformational change to NanH 
(particularly the NanH CTD) and abrogation of ligand binding capacity it might be the case 
that the ligand binding is due to the NanH CBM.  
The NanH CBM was shown to have ligand binding properties (and no catalytic activity) in 
work occurring alongside this project (Stafford Research Group, University of Sheffield): 
The CBM was successfully expressed and purified, then tested in tryptophan quenching 
experiments in a manner similar to the NanH-YMAP ligand binding assays shown in section 
2.3.6.5. This showed that the CBM was capable of binding both 3- and 6-SL (figure 2.42) 
with high affinity (Kd= 528 and 334 µM, respectively), confirming that this domain was a 
novel CBM. This represents a potentially new subfamily of CBMs, distinct from that of the 
Vibrio cholerae sialidase, which is the founding member of the CBM40 subfamily.  
 
Figure 2.42. NanH-CBM Binds 3- and 6- sialyllactose. . 
NanH-CBM was exposed to variable concentrations of 3- and 6-SL, and the resulting change 
in protein fluorescence (%) used to ascertain the affinity (KD) of the two ligands for NanH-
YMAP. Data represent the mean of three repeats, error bars=SEM. (Data collected, 
processed, and plotted by Chatchawal Phansopa, Stafford Research Group, University of 
Sheffield). 
 
 
2.4.5 Zanamivir Inhibits Periodontal Pathogen Sialidases 
Zanamivir was shown to possess a greater inhibitory efficacy (a lower IC50) for SiaPG than 
NanH. The discrepancy in IC50 between the two sialidases is in line with the finding for the 
whole pathogen sialidase inhibition assay-that zanamivir is more effective at inhibiting P. 
gingivalis than T. forsythia sialidase activity. Nonetheless, both T. forsythia and P. gingivalis 
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sialidase activity appeared to be significantly inhibited by zanamivir. This finding was crucial 
for the rest of this project, which aims to evaluate the potential for sialidase inhibitors 
(using zanamivir as a case study) in preventing periodontal pathogen virulence. 
Assuming periodontal pathogen virulence is inhibited by zanamivir (or other inhibitors), the 
ultimate aim would be to create formulations to apply sialidase inhibitors to treat or 
prevent periodontitis. While zanamivir appears to be reasonably efficacious in its inhibition 
of P. gingivalis sialidase activity (IC50 ~300µM), the relatively high (~6mM) IC50 of 
zanamivir for NanH is mirrored in studies of other bacterial sialidases, which report a high 
IC50 of zanamivir for a purified bacterial sialidase, or that live pathogen sialidase activity is 
more readily abrogated by other inhibitors (Tailford et al. 2015; Nishikawa et al. 2012). This 
might have consequences for developing zanamivir (or another inhibitor with millimolar 
efficacy) as a therapeutic; an efficacy in the millimolar range may not justify taking an 
antimicrobial agent forward for further development. On the other hand, given that a 
therapeutic for periodontitis would probably be a topical treatment applied to the site of 
infection, rather than a systemic treatment, a therapeutic designed to obtain localised 
millimolar concentrations of an active ingredient could be possible. 
Chlorhexidine (Molar mass 506.47 g/mol) is one example of a frequently used active 
ingredient for control of oral biofilms or oral bacteria. Perhaps its most frequent use is in 
over-the-counter mouthwashes, where it can be present at 0.2%, or ~4mM (Corsodyl 
Mouthwash, GlaxoSmithKline). In dental gels, which are also over-the-counter, the 
concentration of chlorhexidine is higher; at 1 % or ~20 mM (Corsodyl dental gel, 
GlaxosmithKline). Chlorhexidine has also been used in dental gels in clinical settings at 2% 
(~40mM), as an adjunct to apical periodontitis therapy to disinfect the root canal (Wang et 
al. 2007). Considering that at least some active ingredients, such as chlorhexidine, are 
present at millimolar concentrations in both clinical and consumer products designed to 
treat or prevent gingivitis/periodontitis, it is not unreasonable to suggest that zanamivir, or 
other sialidase inhibitors, could be included at these concentrations in formulations 
designed to treat or prevent periodontitis. 
2.5 Summary 
The sialidases from T. forsythia-NanH, and P. gingivalis-SiaPG were codon optimised for 
expression by E. coli. Purification of these sialidases was successful, and they underwent 
biochemical characterisation: This highlighted their pH optima, which has practical 
implications but also highlights their ability to function under a wide range of conditions; a 
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useful ability in the oral environment. Secondly, NanH was shown to be a broad host-range 
sialidase but act preferentially on α2-3 linked sialic acid, possibly providing insights into its 
functions in vivo. The highly conserved NanH FRIP motif was also shown to be essential to 
enzyme function, but its mutation to YMAP did not prevent NanH binding to sialic acid-
ligands. Furthermore, both SiaPG and NanH were inhibited by zanamivir, though zanamivir 
displayed much greater efficacy for SiaPG (IC50=235µM) than for NanH (IC50=6309µM). 
The biochemistry of periodontal pathogen sialidases provides useful insights into their 
ligand preferences and the potential to inhibit these interactions. However, more 
experiments were required to ascertain the contribution of pathogen sialidases to disease. 
With this in mind the next two chapters of this thesis focus on how the sialidases 
contribute to pathogen growth and biofilm formation on host sialoglycoproteins, and how 
sialidases contribute to host-pathogen interactions. The effect of the sialidase inhibitor 
zanamivir on pathogen growth and biofilm formation, and host-pathogen interactions is 
also examined. 
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3 Chapter 3: Investigating the Targeting of Host Sialoglycans 
by Periodontal Pathogens- the Effects on Growth and 
Biofilm Formation, and the Impact of Zanamivir 
3.1 Introduction 
In the host, secretions and all cell surfaces are rich in glycoproteins and glycolipids, 
glycoproteins possess one or more polysaccharide chains (glycans), which are covalently 
attached to serine or threonine residues (O-linked glycans, O-glycosylation), or asparagine 
(N-linked glycans, N-glycosylation). Glycolipids are fatty acids present in cell membranes 
with glycans extending away from the cell. As described elsewhere in this thesis, Sialic acids 
often cap these glycans, the most common of which in humans is Neu5Ac (5-N-acetyl 
neuraminic acid).  However, Neu5Ac can have additional chemical modifications, such as 
possession of additional chemical groups at its 9th carbon: O-acetylation, -methylation, -
sulphylation and others (Cohen & Varki 2010). Sialic acid affects structure-function of 
glycoproteins; one of the most important properties is its negative charge, leading to high 
hydrophilicity and interactions with other molecules. In the context of the oral cavity and 
the periodontium, two secretory fluids represent rich sources of sialoglycans: Gingival 
Crevicular Fluid (GCF) is similar to serum in composition, and is therefore rich in 
glycoproteins such as fetuin, immune components (such as complement, IgA antibodies, 
and cytokines), and numerous others, all of which can be sialic acid capped. In periodontal 
disease, bleeding may also occur, introducing further serum/blood plasma glycans into the 
periodontium. Saliva is another secretion present orally and an important source of mucins, 
which are secretory glycoproteins. Salivary mucins are predominantly composed of mucins 
MUC7, MUC5B, and to a lesser extent MUC4 and other salivary proteins. 
Given the prevalence of sialic acid in the oral cavity and periodontium, it is unsurprising 
that periodontal pathogens and human dwelling bacteria more broadly have adapted to 
interact with sialic acid and sialoglycoproteins.  
The previous chapter highlighted the ability of sialidases from T. forsythia and P. gingivalis 
to cleave sialic acid from a variety of sources; the two most common sialic acid linkages in 
humans were cleaved (α2-3 and α2-6 linked sialic acid), and the host-relevant sialyl-lewis A 
and X sialoglycans were also desialyated by pathogen sialidases in in vitro biochemical 
assays. Free sialic acid is a particularly important nutrient for T. forsythia and potentially 
other oral organisms (e.g. F. nucleatum nucleatum). T. forsythia usually requires an 
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exogenous source of N-acetylmuramic acid (NAM) for growth because it lacks two gene 
homologues required for intermediate stages of NAM synthesis; UDP-N-acetylglucosamine-
enolpuruvate transferase and UDP-enolpyruvate reductase (Wyss 1989; Sharma 2011). 
However, T. forsythia growing in a biofilm is capable of bypassing this NAM requirement in 
the presence of Neu5Ac  (Roy et al. 2010), highlighting the importance of sialic acid for T. 
forsythia. 
The importance of sialic acid release for the other red complex periodontal pathogens P. 
gingivalis and T. denticola is less clear. Both of these organisms possess sialidase enzymes, 
but lack the uptake and catabolic genes seen in other periodontal pathogens. It may be the 
case that sialic acid removal is a means to “soften up” glycoproteins for further digestion by 
proteases. It has been shown that salivary mucins treated with sialidases are more rapidly 
degraded by proteolytic activity than intact mucins (Takehara et al. 2013). P. gingivalis 
possesses the gingipains-arginine and lysine proteases (RgpA, RgpB, and Kgp) and these are 
considered key virulence factors of P. gingivalis (Curtis et al. 1999). Gingipains are 
considered important for nutrient acquisition by P. gingivalis. Furthermore, their inhibition 
can reduce the growth of P. gingivalis in culture and during biofilm formation (Eick et al. 
2003; Kariu et al. 2016), implying that inhibiting the gingipains decreases amino 
acid/peptide release, and P. gingivalis growth is slowed as it cannot rapidly acquire amino 
acid nutrients. Since sialic acid acts to protect glycoproteins from proteolytic degradation-a 
factor important for growth in this pathogen, then sialidase activity could be an important 
virulence factor with a role in nutrient acquisition for P. gingivalis. T. denticola also 
possesses a serine protease, “dentilisin” (Ishihara et al. 1996), which is considered an 
important virulence factor, and since T. denticola also catabolises free peptides or amino-
acids for nutritional purposes (Hook et al. 1971), the expression of sialidase may be 
important in their release from sialoglycoproteins for nutritional purposes in T. denticola.  
As mentioned above, host glycoproteins represent a nutrient source for periodontal 
pathogens, and they can also present epitopes for pathogen adhesion. Both of these 
factors could contribute to biofilm formation by a given pathogen, and since a high 
proportion of glycoproteins are sialylated, sialidases are considered to be important 
contributors to biofilm formation. The gut pathogen V. cholerae is one example where 
sialidase acquisition and utilisation is clearly involved in growth, since it possesses 
appropriate genes, annotated as nan-nag (Jermyn & Boyd 2002), and can grow using sialic 
acid as a sole carbon source. Some of the Nan proteins downstream of NanH in the sialic 
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acid acquisition and catabolism pathway were essential for this-mutants deficient in nanA 
(neuraminate lyase) or nanE (N-acetylmannosamine-6P epimerase) were unable to grow on 
sialic acid alone (Almagro-Moreno & Boyd 2009). 
Perhaps the best studied in terms of biofilm formation are the commensal but frequently 
opportunistic pathogens of the nasopharynx Streptococcus pneumoniae and Pseudomonas 
aeruginosa. S. pneumoniae expresses three sialidases, NanA, NanB, and NanC, of which 
NanA is considered the most important for virulence (Brittan et al. 2012). Mutant strains 
deficient in NanA show reduced ability to adhere to airway epithelial cells, and reduced 
biofilm formation in microtitre plates compared to their parent strains (Parker et al. 2009). 
NanA deficiency also abrogated the ability of S. pneumoniae to colonise the nasopharynx in 
a mouse model (Brittan et al. 2012). P. aeruginosa also possesses a sialidase-PA2794 
(dubbed “pseudaminidase” in the NCBI protein database)-and mutant strains deficient in 
PA2794 display reduced biofilm formation, as well as a decreased ability to colonise the 
nasopharynx in a mouse model (Soong et al. 2006). Both of these organisms appear to use 
their sialidases to facilitate attachment to desialylated GM1 ganglioside, a glycan of four 
sugars; galactose-N-Acetylglucosamine-Galactose-Glucose (Galβ1,2GalNAcβ1,4Galβ1,4Glc) 
attached to the cell membrane via ceramide (a fatty acid). Interestingly, particularly with 
regards to the aims of this project, sialidase inhibitors were also able to reduce biofilm 
formation of the wild type (sialidase-expressing) strains of S. pneumoniae and P. 
aeruginosa (Brittan et al. 2012; Soong et al. 2006). However, these biofilm studies were not 
performed on glycoprotein-coated surfaces, so the importance of sialidases in attachment 
and biofilm formation of these respiratory pathogens to glycoproteins is not entirely clear.  
Regarding periodontal pathogens, P. gingivalis and T. forsythia sialidases have been shown 
to be important for biofilm formation: A sialidase deficient P. gingivalis  mutant strain was 
found to display abrogated biofilm formation relative to its parent strain (Li et al. 2012), 
although the capsule of the strain (W83) used in the study was also disrupted when its 
sialidase was knocked out, which could also account for the changes in biofilm formation. 
Furthermore, biofilm formation was only characterised on plastic surfaces, so the role of 
sialidases in biofilm formation of P. gingivalis on host glycoproteins from this work is also 
unclear.  
Given the above, pathogen sialidases can be said to be an important virulence factor, 
boosting periodontal pathogen growth through nutrient acquisition pathways, aiding in 
colonisation by increasing attachment to surface-associated glycans, and aiding biofilm 
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formation. The previous chapter showed the ability of zanamivir to inhibit P. gingivalis and, 
to a lesser extent, T. forsythia sialidase activity. Therefore, the work described in this 
chapter aimed to study the growth and biofilm formation of periodontal pathogens on 
sialoglycoproteins, and if growth and biofilm formation could be inhibited by zanamivir. 
This also involved testing the ability of the sialidases to cleave sialic acid from bovine 
submaxillary mucin (BSM)-a common model of human salivary mucins, and salivary mucin 
represents a glycoprotein source rich in sialic acid that periodontal pathogens would be 
exposed to. Furthermore, an accessory enzyme-NanS- which is co-expressed with NanH as 
part of the nan operon of T. forsythia (described below), was tested for its impact on the 
activity of these sialidases on mucin. 
3.2 Materials and Methods- Investigating the Targeting of Host 
Sialoglycans by Periodontal Pathogens- the Effects on Growth 
and Biofilm Formation, and the Impact of Zanamivir 
3.2.1  Enzyme synergy in Sialic Acid Release from Salivary Mucin 
Bovine submaxillary mucin (6 µM) was incubated for 30 minutes at 37 °C in the presence of 
NanS, NanH, PGsia, NanS + NanH, and NanS + PGsia. Reactions with NanH + NanS or SiaPG 
+ NanS were performed in the presence or absence of 0.5 mM zanamivir. All reactions were 
carried out in 50 mM sodium phosphate buffer, 200 mM NaCl, and all enzymes were 
included at 100 nM. In reactions containing two enzymes, both were included at 100 nM 
per enzyme. After incubation, reactions immediately underwent the TBA assay as described 
in section 2.2.10.4. 
3.2.2 Bacterial Strains and Growth Conditions 
Strains of the periodontal pathogens Fusobacterium nucleatum, Tannerella forsythia, and 
Porphyromonas gingivalis used in this work are summarised in table 3.1. All periodontal 
pathogens were cultured at 37˚C under anaerobic conditions (10% CO2, 10% H2, 80% N2) in 
a Don-Whitley mini-macs anaerobic cabinet. P. gingivalis and F. nucleatum strains were 
cultured on Fastidious Anaerobe Agar (Lab M, Lancashire, UK) supplemented with 5% (v/v) 
oxalated horse blood (Thermo Fisher Scientific, UK), for 2-3 days before harvesting for use 
in experiments or cultured on fresh media. T. forsythia strains were cultured on Fastidious 
Anaerobe Agar (Lab M, UK) supplemented with 5 % (v/v) Oxalated Horse Blood (Thermo 
Fisher Scientific), 10 g/ml N-acetylneuraminic acid (NAM) (Sigma Aldrich, UK), and 25 
µg/ml Gentamicin (Sigma-Aldrich) for 3-7 days before harvesting for use in experiments or 
culture on fresh media. In addition, a strain of T. forsythia deficient in the gene encoding 
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NanH (T. forsythia ∆nanH) was intermittently subcultured in the presence of 10 µg/ml 
erythromycin to ensure maintenance of the antibiotic resistance cassette marker 
responsible for sialidase inactivation. 
Species Strain Notes 
Tannerella 
forsythia 
ATCC 43037 
T. forsythia type strain, supplied by 
William Wade, QMUL, UK 
92.A2 
Genome sequenced strain- supplied by 
Floyd Dewhirst, Forsyth Institute, 
Boston, MA, USA 
TFM0035(Δ   H) 
Derived from T. forsythia ATCC 43037, 
gift from Prof A Sharma, University at 
Buffalo, USA 
Porphyromonas 
gingivalis 
ATCC 33277  Sheffield strain collection  
381 
Supplied by A Sharma, University at 
Buffalo, USA 
Fusobacterium 
nucleatum 
NCTC 25586 
F. nucleatum subspecies nucleatum, 
supplied by William Wade, QMUL, UK 
NCTC 10953 
F. nucleatum subspecies polymorphum, 
from ATCC (directly purchased) 
 
Table 3.1. Periodontal pathogen strains. 
The mutant strain T. forsythia ΔnanH was a gift from Professor Ashu Sharma (University of 
Buffalo, New York, USA).  Note that the genome of the T. forsythia strain 92.A2 had been 
previously submitted to NCBI and Oralgen databases annotated as that of T. forsythia ATCC 
43037-an error only rectified in 2015. This had repercussions for work described in chapter 
2, which involved attempts to amplify genomic DNA of T. forsythia ATCC 43037.  
 
3.2.3 Collection and preparation of Human Saliva 
Human saliva was collected from healthy adult volunteers who had not consumed food or 
drink for 1 hour prior to collection. Saliva was pooled (4-5 volunteers per pool, each 
contributing 5-10ml of saliva), centrifuged at 3500xg for 30 minutes, and sterile filtered 
using 0.45 µm sterile filters. Sterile saliva was stored at -20°C until ready for use. Ethical 
approval to collect adult human saliva from healthy people was held by the University of 
Sheffield, School of Clinical Dentistry, ethics permission number 31. 
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3.2.4 Culture of Periodontal Pathogens on Defined Media Supplemented with 
Host Sialic Acid Sources 
A carbon and nitrogen deficient media (defined media) was formulated based on previous 
studies (Milner et al. 1996; Oda et al. 2007), containing the following compounds: 10 mM 
monosodium phosphate, 10mM potassium chloride, 2mM citric acid, 1.25 mM magnesium 
chloride, 0.1mM iron (III) chloride,  20 µM calcium chloride, 0.1µM sodium molybdate, 25 
µM zinc chloride, 50 µM manganese chloride, 5 µM copper (II) chloride, 10 µM cobalt (II) 
chloride, and 5 µM boric acid. After formulation, media was sterile filtered using 0.45 µm 
filters. Defined media was supplemented with 5 µg/ml  hemin, 50 µg/ml gentamicin, 1 
µg/ml menadione (vitamin K), various sialoglycoproteins: Including either 6 µM bovine 
submaxillary mucin (BSM), 1, 5 or 10 % (v/v) pooled human saliva, or 1, 5, or 10 % (v/v) 
foetal bovine serum (FBS). FBS and saliva were also used as co-supplements. Conditions 
were also supplemented with 10 mM zanamivir. In some experiments, hemin and 
menadione were omitted. After supplementation, media was sterile filtered using 0.45 µm 
filters. Media was equilibrated overnight at 37°C, anaerobically. Bacteria were harvested 
from agar plates and resuspended in defined media, centrifuged at 10000 g for 2 minutes 
and resuspended in defined media, twice, to wash the bacteria. Bacteria were resuspended 
to an OD600 of 2.5 in defined media, before dilution to OD600 0.05 in 1-5 ml defined media 
with various supplement conditions as above. Cultures were incubated at 37 °C 
anaerobically for up to 7 days. At various time points (usually 24 hour intervals), 100 µl 
samples of cultures were transferred to transparent, flat 96 well plates (Greiner) and their 
(absorbance) OD600 was measured using a TECAN M200 infinite plate reader. 
3.2.5 Biofilm Assays 
T. forsythia, F. nucleatum, and P. gingivalis were cultured in the wells of a 96-well tissue 
culture plate (poly-lysine coated, Greiner): Bacteria were resuspended to an OD600 of 0.05 
in Tryptic Soy Broth (TSB; Sigma-Aldrich) supplemented with 2 % (w/v) yeast extract, 1 
µg/ml vitamin K, 5 µg/ml  hemin, 50 μg/ml gentamicin, and either no additional 
supplements, 0.17 mM NAM, or 6 mM N-acetylneuraminic acid. In conditions testing host 
glycoproteins, 100 µl of 6 µM bovine submaxillary mucin (BSM), 100 % (v/v) pooled human 
saliva as collected above, or fetal bovine serum (FBS) was added to plate wells and left to 
coat the wells by incubation at 4 °C overnight. In conditions testing the effect of sialidase 
inhibition, the supplemented TSB was further supplemented with 10 mM zanamivir. All 
media was equilibrated overnight in anaerobic conditions at 37 °C. Cultures were incubated 
for 5 days at 37 ˚C under anaerobic conditions (10% CO2, 10% H2, 80% N2) in an anaerobic 
cabinet. To quantify planktonic or total growth, all conditions underwent OD600 
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measurement using a Tecan Infinite M200 Plate Reader. Conditions were set up in triplicate 
during each assay. 
Crystal violet staining was tested as a means of quantifying biofilm formation, and was used 
to visualise biofilm formation: 100 µl of 0.1 % crystal violet solution was added to each well 
and incubated at room temperature for 30 minutes. After incubation, crystal violet was 
removed and wells were gently washed 3-4 times with PBS pH 7.4, before visualisation 
using light microscopy or extraction with 100 µl 80:20 Ethanol: Acetone. Direct counting 
techniques were also used for biofilm quantification: Biofilms were gently washed twice 
using 100 µl PBS to remove planktonic cells, and biofilms were vigorously resuspended in 
PBS and serial diluted where appropriate. Bacteria were enumerated by counting using a 
Helber chamber (Hawksley) under phase contrast microscopy, 400 x magnification. 
3.3 Results 
3.3.1  Release of Sialic Acid from Mucin glycoproteins by Periodontal Pathogen 
Sialidases is enhanced by T. forsythia Sialate-O-Acetylesterase 
Secretory mucins are a group of glycoproteins likely to be encountered by periodontal 
pathogens as they represent a major component of salivary-mucins account for 
approximately 16-26 % of the total salivary protein content (Zalewska et al. 2000; Rayment 
et al. 2000). Furthermore, their concentration in saliva is correlated with severity of 
periodontal disease, and mucins have been called a non-immunological response to 
periodontitis (Sánchez et al. 2013). Mucins have been grouped into the high and low 
molecular weight MG1 and MG2 mucins, which are products of the MUC5b (and to a lesser 
extent MUC4) and MUC7 genes, respectively. Mucins, including these salivary mucins are 
heavily glycosylated (table 3.1) and of their O-glycosylated sugar chains, which make up 40-
80% of their mass (Levine et al. 1987; Zalewska et al. 2000), a high proportion are sialylated 
(Zalewska et al. 2000). Sialic acids possess a number of functions in mucin including 
contributing to an overall negative charge and structure-function (Zalewska et al. 2000). As 
well as its contribution to mucin structure function, sialic acids have been shown to protect 
mucin from proteolytic degradation (Takehara et al. 2013).  
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Mucin Gene Protein Domains 
Domain 
Features Glycosylation Sialylation Review  
MG1 
MUC5b 
(MUC4 
to a 
lesser 
extent) 
N-terminal Region 
(1321 Residues) 
Cys- rich 
GalNAc-
Thr/Ser 
118 Sialic 
Acid-
containing 
units 
  (Zalewska 
et al. 
2000; 
Levine et 
al. 1987) 
Tandem Repeat Region 
(3750 residues) 
29-residue 
Ser/Thr-rich 
tandem repeats, 
short Cys- rich 
regions 
C-Terminal Region (879 
Residues) 
Cys- rich 
MG2 MUC7 
N-terminal Region (144 
Residues) 
"Histatin-like" -
Histidine Rich 
Primarily 
GalNAc-
Thr/Ser, also 
GlcNAc-Asn 
67 sialic 
acid-
containing 
units 
  (Zalewska 
et al. 
2000; 
Levine et 
al. 1987) 
Tandem Repeat Region 
(115-138 residues) 
23-Residue 
Ser/Thr-rich 
Tandem Repeats 
C-Terminal Region (75 
Residues) 
No Cys- 
 
Table 3.2. Salivary mucins-a summary of glycosylation features. 
MG1 is the high Mw salivary mucin, MG2 is the low Mw salivary mucin. Glycosylation refers 
to the sugar-amino acid linkage between the numerous branched glycans present on the 
mucin. “sialic acid-containing units” refers to the number of oligosaccharide chains with 
Neu5Ac at their non-reducing ends (furthest from the protein backbone of the mucin). 
 
In humans, the native sialic acid Neu5Ac may be further modified by additional chemical 
groups (Cohen & Varki 2010). A common modification in humans is the presence of an 
additional O-acetyl group at Carbon 9 (C-9) to become Neu5,9Ac (5,N-acetyl-9,O-
acteylneuraminic acid). As part of a sialoglycan, Neu5,9Ac has been shown to resist the 
activity of bacterial sialidases that would cleave the mono-acetylated Neu5Ac (Corfield 
1992). Recent work including data generated as part of this project has shown that T. 
forsythia produces a sialate-O-acetylesterase (NanS) that catalyses removal of the 
additional acetylation, converting Neu5,9Ac to Neu5Ac (Phansopa et al. 2015, includes 
work performed as part of this project-appendix 7.10).  Before investigating how NanS 
impacted sialic acid cleavage from salivary mucin by the periodontal pathogen sialidases, 
NanS had to be purified.  
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 Purification of the Sialate-O-Acetylesterase, NanS, from T. forsythia 3.3.1.1
T. forsythia possesses a nan operon (Roy et al. 2010), dedicated to harvesting and uptake of 
sialic acid. One of the nan genes encodes a sialate-O-acetylesterase, NanS. This enzyme is 
capable of removing the second (O-)acetyl- group from Neu5,9Ac-a prevalent human sialic 
acid-which is otherwise resistant to NanH de-sialylation of sialoglycans (Phansopa et al. 
2015). NanS was successfully purified using a method developed by Dr Chatchawal 
Phansopa in our laboratory (Figure 3.1) by Glutathione-S-Transferase (GST) affinity 
chromatography followed by thrombin cleavage of the fusion protein, as described 
previously (Phansopa et al. 2015). Protein yield after purification of 1 litre of expression 
strain-culture was typically 10ml of ~1mg/ml of this 76.3 kDa protein, this was sufficient for 
the scope of this project. Activity of NanS was confirmed using p-nitrophenol acetate (pNP-
Ac), which was incubated with NanS, which de-acetylated pNP-Ac, producing pNP; a yellow 
chromophore which could be visualised (Phansopa et al. 2015). 
 
Figure 3.1. Purification of NanS. 
SDS-PAGE using 12% (v/v) polyacrylamide gel. L=Mw Ladder (kDa, size approximation based 
on manufacturer’s guide), Ins. =Insoluble Fraction of cell lysate, sol=soluble fraction of cell 
lysate, F=Flow Through, W=Wash Through, 1-5= Eluted fractions. This purification was 
performed as part of this project-i.e. by Andrew Frey. 
 
 NanS Boosts The Activity of SiaPG and NanH to Release Sialic Acid From 3.3.1.2
Mucin 
Mucins have been shown to contain high levels of di-acetylated Neu5,9Ac, which is often 
resistant to the activity of bacterial sialidases, and NanS was shown to be a sialate-O-
acetylesterase, which acts to removes the second acetylation, forming Neu5Ac, which was 
then susceptible  to sialidase activity (Phansopa et al. 2015, appendix 7.10).  
NanS (~76.3 kDa) 
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The impact of NanS and zanamivir on sialic acid release from mucin by the periodontal 
pathogen sialidases NanH and SiaPG was assessed, and the ability of zanamivir to inhibit 
cleavage of sialic acid from this host-relevant sialoglycan was also tested. Experiments 
utilised bovine submaxillary mucin (BSM), since it is relatively cheap, commonly used in 
studies involving salivary mucins and is a rich and often used source of (diacetylated) sialic 
acid (Varki & Diaz 1983). BSM was digested for half an hour with various enzyme and 
zanamivir combinations before undergoing the TBA assay to quantify sialic acid release, 
with significant differences assessed using repeated measures one-way ANOVA, with 
Bonferroni correction for multiple comparisons (figure 3.2). 
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Figure 3.2. Enzyme synergy in sialic acid release from BSM, and inhibition by zanamivir.  
BSM was incubated with either NanS, NanH, or SiaPG alone, or NanS+NanH or NanS+SiaPG, 
in the presence or absence of 0.5mM zanamivir, before undergoing the TBA assay to assess 
sialic acid release. Data based on the mean of three experiments, each condition was 
tested in triplicate during each experiment. Error Bars=SEM. Significance determined by 
one-way ANOVA with repeated measures, with Bonferroni correction for multiple 
comparisons (*p=<0.05, **p=<0.01). 
 
As expected, NanS alone did not release any sialic acid from salivary mucin, but it did 
double sialic acid release by NanH (from 113 to 228 pmol/min, p=0.033) and the relative 
increase in sialic release in the presence of NanS was even greater for SiaPG (from 302 
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pmol/min to 746 pmol/min). It was also noteworthy that SiaPG released more sialic acid 
than NanH, although these changes were not deemed statistically significant (302 and 113 
pmol/min, respectively in the absence of NanS, p=0.136, or 746 and 228 pmol/min, 
respectively in the presence of NanS, p=0.091). 0.5 mM zanamivir could significantly inhibit 
the sialic acid release from mucin treated with SiaPG and NanS, reducing sialic acid release 
to a level lower than SiaPG alone (SiaPG; 302 pmol/min, SiaPG + NanS; 746 pmol/min, 
SiaPG + NanS + Zan; 164 pmol/min). NanH sialidase activity was not inhibited at this 
concentration of zanamivir. The finding that SiaPG, but not NanH, was significantly 
inhibited by 0.5 mM zanamivir is in accordance with the NanH and SiaPG inhibitory curves 
used to obtain the IC50 (shown in section 2.4.5), which revealed that zanamivir had an IC50 
of 0.36 mM for SiaPG (lower than 0.5mM used in this assay), but zanamivir had an IC50 of 
6.15 mM for NanH (greater than the 0.5mM used in this assay). Concentrations of 
zanamivir higher than 0.5 mM were found to produce high levels of precipitate and 
interfere with the production of the chromophore during the TBA assay, rendering free-
sialic acid quantification impossible or difficult, so only sialidase inhibition by 0.5mM 
zanamivir was tested during this experiment. This might be overcome in future 
experiments using High Performance Liquid Chromatography (HPLC) based approaches to 
assess sialic acid cleavage from mucin, or indeed other substrates. 
NanS was incapable of sialic acid release by itself, but it improved sialic acid release from 
salivary mucin by both NanH and SiaPG sialidases, more-than doubling sialic acid release by 
both sialidases. SiaPG was capable of releasing more sialic acid than NanH, both in the 
presence and absence of NanS. However, commenting on how the release of sialic acid 
from salivary mucin contributes to periodontal pathogen proliferation cannot be 
ascertained from this experiment alone. It could be the case that NanS-improved sialic acid 
release assists in nutrient acquisition by periodontal pathogens (discussed below), and this 
increases their ability to proliferate. To investigate this, experiments involving the growth 
of periodontal pathogens in the presence of salivary mucin, whole saliva, and serum were 
performed. 
3.3.2 P. gingivalis is Capable of Growth Utilising Host Glycoproteins as Sole 
Carbon and Nitrogen Sources, and this is Enhanced by NanS  
Sialic acid has been shown to protect salivary proteins from degradation (Takehara et al. 
2013). It was suspected that sialic acid release from host glycoproteins would enable more 
rapid proteolysis for nutrient acquisition by P. gingivalis (and perhaps other periodontal 
pathogens), meaning sialidases could contribute to increased growth of P. gingivalis, and 
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that sialidase inhibition (using zanamivir) could limit growth of P. gingivalis. Furthermore, 
given that NanS was capable of enhancing the release of sialic acid from heavily di/tri 
acetylated sialic acid glycoproteins of by the P. gingivalis sialidase, NanS might enhance P. 
gingivalis growth on host glycoproteins. 
This idea was tested using a culture based approach, using media supplemented with host 
glycoproteins. However, using conventional growth media (brain heart infusion or tryptic 
soy based media) could interfere with the experiment, since these are rich in sialoglycans 
from sources besides the ones desired for testing, and these media contain other nutrients 
that might compensate for the effects of experimental conditions, masking any meaningful 
result. Therefore, optimisation of a chemically defined media capable of growing P. 
gingivalis was performed.  
 Optimisation of Chemically Defined Media 3.3.2.1
This defined media was based on formulations in previous studies (Milner et al. 1996; Oda 
et al. 2007), followed by studies of the effect of NanS and zanamivir on P. gingivalis growth 
on host glycoproteins as sole carbon and nitrogen sources. It consisted of a number of 
metal salts (10 mM monosodium phosphate, 10 mM potassium chloride, 2mM citric acid, 
1.25 mM magnesium chloride, 0.1 mM Iron (III) chloride,  20µM calcium chloride, 0.1 µM 
sodium molybdate, 25 µM zinc chloride, 50 µM manganese chloride, 5 µM copper (II) 
chloride, 10 µM cobalt (II) chloride, and 5 µM boric acid), which are considered to be an 
important basal media capable of supporting the growth of a variety of micro organisms 
(Milner et al. 1996). During initial optimisation this was supplemented with either 10 % 
(v/v) fetal bovine serum (FBS), 10 % (v/v) pooled human saliva, or 6 µM bovine submaxillary 
mucin (BSM) as sole carbon and nitrogen sources (Figure 3.3). Gentamicin (50 g/ml) was 
always present in the media (to suppress contamination, but all organisms were resistant 
at levels up to 500 g/ml), and the effect of hemin on P. gingivalis cultures was also tested 
during growth (figure 3.4). P. gingivalis, T. forsythia and F. nucleatum were tested for their 
ability to grow in this defined media (figure 3.3). 
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Figure 3.3. Initial testing of defined media for culture of periodontal pathogens.   
 Defined media cultures of T. forsythia, P. gingivalis, and F. nucleatum were grown 
anaerobically for 5 days, with different host-glycoprotein susbtrates as indicated, 
Saliva=pooled human saliva, SerumFBS=fetal bovine serum, BSM=bovine submaxillary 
mucin,    ̅= no-glycoprotein supplement/negative control.  
 
  P. gingivalis was the species most capable of growth in this defined media, as indicated by 
visible growth (aggregates or possibly biofilm) localised at the bottom of culture containers. 
Growth was not observed in the no-bacteria control for any glycoprotein, and allowed a 
qualitative estimation of turbidity which indicates bacterial growth. P. gingivalis growth (as 
indicated by visible differences between cultures containing either P. gingivalis or no-
bacteria) appeared to be dependent on the type of glycoprotein supplement, with mucin 
resulting in no visible (or very little) growth, followed by saliva, and the most prolific P. 
gingivalis growth was seen in serum-supplemented media. T. forsythia and F. nucleatum 
may have been capable of limited growth in all three conditions, as indicated by the slight 
turbidity of the three suspensions compared to the negative control, and this appears to be 
particularly localised at the bottom of the cultures. There also appears to be some 
formation of aggregates in conditions containing bacteria but no glycoprotein source, 
possibly due to sequestration of hemin by bacteria. 
P. gingivalis was most capable of growth in this defined media, so growth of P. gingivalis 
was taken forward for a further optimisation step; testing the effect of dual 
supplementation of the defined media with saliva and FBS. This experiment was also 
Saliva 
T.forsythia 
No  
bacteria 
P. gingivalis 
_ 
FBS BSM 
F.nucleatum 
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performed in the absence of hemin, since the dark pigmentation of P. gingivalis seen in the 
above culture might mask differences in absorbance between culture conditions, and it was 
previously shown that defined media-cultures of P. gingivalis could grow in the absence of 
hemin, without black pigmentation occuring (Oda et al. 2009), this was shown to be the 
case here (figure 3.4). Cultures were grown for 5 days and Optical Density at 600nm (OD600) 
readings were taken every 24 hours to assess growth. P. gingivalis cultures were unable to 
grow in 1 or 5 % (v/v) serum (at least in the absence of exogenous hemin), and it appeared 
that saliva was capable of boosting the growth of P. gingivalis in the presence of 10 % (v/v) 
FBS (heat-inactivated) in a dose dependent manner; at 72 hours (the timepoint with the 
highest optical density for all conditions) cultures with 10% FBS and 0, 1, or 5% (v/v) saliva 
had OD600 values of  0.33, 0.37, and 0.45, respectively. However, each condition was only 
repeated once, so this cannot be definitively reported based on this experiment.  
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Figure 3.4. Optimisation of P. gingivalis culture in defined media; the effect of saliva and 
serum (FBS) 
Defined media was supplemented with different quantities of FBS and human saliva as 
indicated (% values are v/v), and used to grow P. gingivalis for 5 days, with growth 
measurements taken every 24 hours. A) Growth Curve of P. gingivalis in Defined Media. 
Unsupplemented=media Containing no additional supplements, No bacteria=Saliva and 
serum only without P. gingivalis inoculation. Data shown represent the readings taken from 
a single repeat of each condition. B) Comparison of P. gingivalis cultures grown in defined 
media without hemin, in the presence or absence of 10 % v/v serum.  
 
The defined media optimisation experiments highlighted the ability of P. gingivalis to grow 
in the presence of 10 % FBS as a nutrient source (figures 3.4 and 3.5). Human saliva 
appeared to enhance growth, as seen by the increased density of cultures, with 5 % saliva 
increasing the OD600 of cultures by a factor of ~1.5 at 72 hours, relative to the 0 % saliva, 10 
% FBS condition. It was then possible to carry out further experiments testing the effect of 
B) 
Serum No Glycoprotein 
A) 
Serum No Glycoprotein 
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NanS and zanamivir on the ability of P. gingivalis to utilise these host glycoproteins for 
growth. 
Initial experiments were performed to test the effects of both NanS and zanamivir on the 
growth of P. gingivalis in defined media supplemented with FBS (figure 3.5). In NanS-
containing conditions, supplemented media was exposed to NanS for 12 hours prior to 
addition of P. gingivalis, the intention being to negate the effects of any degradation of 
NanS after exposure to P. gingivalis proteases. P. gingivalis was then inoculated into the 
supplemented, defined media and incubated for 6 days at 37°C, anaerobically. Growth was 
recorded every 24 hours by measuring the optical density of the cultures at 600nm (figure 
3.5). Statistical differences between conditions at each time point were assessed by one-
way ANOVA with repeated measures, with Tukey’s correction for multiple comparisons. 
It is important to note that the presence of NanS as a source of amino acids itself should 
have little impact on P. gingivalis growth in this experiment-FBS has been shown to contain 
approximately 3900 µg/ml total protein content (Zheng et al. 2006), and was present at 10 
% in cultures, meaning cultures contained 390 µg/ml of protein from FBS. NanS was 
present at 50 nM, or 0.382 µg/ml, meaning that in conditions containing NanS, the increase 
in protein content would be negligible compared to the level of FBS protein.   
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Figure 3.5. Growth of P. gingivalis on serum, in the presence of NanS and zanamivir. 
Conditions containing NanS were pre-treated with 50nM NanS for 12 hours prior to 
inoculation with P. gingivalis, and zanamivir conditions supplemented with 10mM 
zanamivir. A) Growth curve of P. gingivalis in defined conditions. Serum=10% FBS. 
Zanamivir=10mM zanamivir. NanS=50nM NanS. Data represent the mean of three 
experiments, where each condition was repeated once per experiment. Error Bars= SEM. B) 
Descriptive statistics of P. gingivalis growth in defined conditions. Significant differences 
between all of the conditions were assessed by one-way ANOVA with repeated measures, 
with Tukey’s correction for multiple comparisons, at each time point. The unsupplemented 
condition was almost always significantly different from the other conditions at all time 
points from 48 hours onwards, where the adjusted p-value=<0.05, shaded in blue. 
 
Condition 24 48 72 96 120 144
serum vs. unsupplemented 0.6006 0.2315 0.0213 0.0565 0.0194 0.006
serum+zan vs. unsupplemented 0.2598 0.0287 <0.0001 0.0416 <0.0001 0.0046
serum+NanS vs. unsupplemented 0.2065 0.0616 <0.0001 0.019 0.0003 <0.0001
Serum+NanS+zan vs. unsupplemented 0.1208 0.0115 0.0091 0.0065 0.0064 0.0065
serum+zan vs. serum 0.8833 0.5221 0.5494 0.9914 0.9306 >0.9999
serum+NanS vs. serum+zan 0.8906 0.9979 0.4595 0.7474 0.3355 0.2563
serum+NanS vs. serum 0.8812 0.4364 0.3407 0.5426 0.2034 0.361
Serum+NanS+zan vs. serum 0.2976 0.384 0.9333 >0.9999 0.9861 0.8899
Serum+NanS+zan vs. serum+NanS 0.9829 >0.9999 0.6171 0.6594 0.0858 0.1513
Serum+NanS+zan vs. serum+zan >0.9999 >0.9999 0.9512 0.9949 0.9084 0.5382
Time (hours)
A) 
B) 
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The lag, exponential, stationary and death phases of these cultures of P. gingivalis can be 
seen (figure 3.5 A). In all conditions, the boundary between each phase occurs (roughly) at 
the 24, 48-72, and 96-148 hour time points, although the onset of the lag and exponential 
phases may be delayed in the serum only condition, compared to the other conditions. 
Conditions containing NanS had greater optical density compared to conditions without 
NanS at each time point i.e. NanS appeared to increase the total growth of P. gingivalis in 
both the presence and absence of zanamivir, but the increase in growth was not 
statistically significant, at any time point. However, the experiments above were performed 
with just one repeat per condition, per experiment; perhaps more experimental repeats 
per condition would yield data with decreased error and greater significance.  
The effect of zanamivir on P. gingivalis growth in this series of experiments was less clear: 
Conditions containing serum without NanS actually displayed more P. gingivalis growth in 
the presence of zanamivir at all time points. However, conditions containing serum and 
NanS displayed lower P. gingivalis growth in the presence of zanamivir. Regardless, there 
were almost no statistically significant effects of zanamivir on the cultures, with the 
exception of the unsupplemented condition (figure 3.5 B), where the unsupplemented 
cultures displayed significantly lower levels of P. gingivalis. This experiment using serum as 
a nutrient source for P. gingivalis did not definitively answer whether or not P. gingivalis 
growth on serum (FBS) and saliva is enhanced by NanS.  Perhaps if conditions had 
undergone more repeats during each experiment, or if they had been altered further 
(through increasing serum, or the inclusion of hemin) a significant trend would become 
apparent.  
 NanS Enhances P. gingivalis Growth in the Presence of Human Saliva 3.3.2.2
In addition to the importance of serum as a nutrient source, the data in section 3.2.1 show 
increased sialic acid release from salivary mucin by P. gingivalis sialidase (SiaPG) in the 
presence of NanS. Therefore, another set of defined media experiments was performed to 
study the effects of both saliva (which contains high levels of mucins) and NanS on P. 
gingivalis growth (serum was also present in all conditions, figure 3.6). Statistical 
significance was determined by repeated measures 2-way ANOVA at each time point, 
which also enabled assessment of a possible interaction between the presence of both 
NanS and saliva on P. gingivalis growth. 
In accordance with the previous saliva-containing experiment (Section 3.2.2.1, figure 3.5), 
P. gingivalis growth was enhanced by the presence of saliva. However, the increased 
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growth in the presence of saliva was only statistically significant in the condition that 
contained NanS, The addition of NanS in the presence of serum alone caused no significant 
increase in P. gingivalis growth (figure 3.6). The differences in growth were greatest at the 
96 hour time point, when the serum, serum + NanS, serum + saliva, and serum + saliva + 
NanS conditions had optical densities of 0.084, 0.897, 0.124, and 0.1784, respectively 
(Serum + Saliva + NanS condtion was significantly different from both of the condtions 
without saliva, p=<0.05, but not from the condition containing saliva without NanS). 
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Figure 3.6. The effect of NanS on P. gingivalis growth on serum and saliva. 
Conditions containing NanS were pre-treated with 50nM NanS for 12 hours prior to 
inoculation with P. gingivalis. Serum=10% FBS, Saliva=5% Pooled Human Saliva, 
NanS=50nM NanS. Data represent the mean of three experiments, where each condition 
was repeated three times per experiment. A) Growth curve of P. gingivalis in the presence 
of combinations of Serum, Saliva, and NanS. Error Bars=SEM. B) P. gingivalis growth over 
time, displayed to highlight differences between conditions. Error bars=SEM. Significant 
differences caused by the presence of NanS and/or saliva were established by two-way 
ANOVA with repeated measures, and Tukey’s correction for multiple comparisons 
(multivariance analysis), at each time point. NanS was found to have a significant effect on 
P. gingivalis growth from the 24 hour condition onwards (p=<0.05). Significant differences 
at each time point, revealed by the multivariance analysis with Tukey’s correction for 
multiple comparisons, are indicated (*p=<0.05). 
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Ultimately, these experiments show that P. gingivalis can utilise host glycoproteins as sole 
carbon and nitrogen sources, specifically serum and saliva. These are particularly relevant 
since P. gingivalis is exposed to GCF (similar in composition to serum) and saliva during 
periodontal colonisation and subsequent periodontal disease. Furthermore, the T. forsythia 
sialate-O-acetylesterase, NanS, seems to be capable of enhancing the growth of P. 
gingivalis in the presence of these nutrient sources, particularly saliva. This could be due to 
the increased rate of sialic acid release by SiaPG from salivary mucins (figure 3.3) and 
perhaps other salivary proteins, resulting in increased proteolysis and free amino acids 
which can be readily utilised by P. gingivalis. In addition, zanamivir appeared to inhibit the 
release of sialic acid from mucin (figure 3.3) and is an exciting finding in the context of the 
oral microbiota.  In addition, the potential of the sialidase inhibitor zanamivir to prevent P. 
gingivalis growth on serum and saliva as a sole carbon and nitrogen source could also be 
evaluated. That said, the effect of zanamivir on P. gingivalis cultures with serum (FBS) as a 
sole nutrient source was minimal, possibly due to lower levels of glycoprotein sialylation 
compared to saliva, decreasing the importance of sialidases to cultures with only FBS as a 
nutrient source- however in the case of saliva these data may differ. Ideally, more 
experiments with different culture conditions (such as the presence of hemin, or different 
concentrations of saliva, or cultures with mixtures of mucin and serum) could be performed 
to test if this is truly the case.  
It was also hoped that T. forsythia could also be cultured using a form of the defined media, 
perhaps with additional supplements such as NAM, or Neu5Ac, and attempting to quantify 
biofilm formation if there is no observable planktonic growth. Unfortunately, optimisation 
of T. forsythia growth in a defined media was not possible during the timeframe of this 
project, despite several attempts. It might be more feasible to co-culture T. forsythia with 
P. gingivalis in these minimal media experiments, which would also serve the purpose of 
testing interspecies co-operation in nutrient acquisition from host glycoproteins.  
3.3.3 Biofilm Formation of Periodontal Pathogens on Host Glycoproteins, and 
the Potential for Zanamivir to Inhibit Periodontal Pathogen Biofilm 
Formation 
Although the ability to utilise host glycoproteins as sole carbon sources for growth is a 
useful ability for pathogens, their ability to form biofilms is considered key during 
periodontal disease. Indeed, treatment focuses on mechanical removal of the subgingival 
biofilm and any calcified plaque, followed by oral hygiene measures to maintain low levels 
of plaque. Even so, some patients are either unable to comply, or do not comply with oral 
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hygiene measures, and in some patients periodontitis continues to progress despite initial 
removal of the sub-gingival biofilm. Given this, inhibition of periodontal pathogen biofilm 
formation could be extremely beneficial for treatment or prevention of periodontitis.  
Gene-knockout studies of periodontal pathogens have highlighted the importance of 
sialidases in biofilm formation by P. gingivalis and T. forsythia (Roy et al. 2011; Li et al. 
2012). Since host surfaces are coated in glycoproteins, the decrease in biofilm formation 
seen in these sialidase-deficient strains may be due to the function of pathogen sialidases 
in nutrient acquisition, or by exposure of underlying glycans for pathogen attachment. 
Given this, sialidase inhibitors might be applied to prevent biofilm formation by periodontal 
pathogens, with the ultimate aim being the application of sialidase inhibitors as 
therapeutics or preventatives for periodontitis, since biofilm formation is important for 
disease progression.  In fact the sialidase inhihbitor oseltamivir was successful in in vitro 
experiments testing this question for T. forsythia (Roy et al. 2011), but zanamavir has not 
been tested to date, and neither has the effect of sialidase inhibitors on P. gingivalis biofilm 
formation. 
 Establishing Growth Conditions for P. gingivalis Biofilms on Glycoprotein 3.3.3.1
Coated Surfaces 
Conditions selected for optimisation of biofilm formation contained either Neu5Ac (human 
sialic acid), NAM (N-Acetylmuramic acid; peptidoglycan monomeric unit, normally required 
for T. forsythia mono-culture), or the glycoprotein sources foetal bovine serum (FBS), 
bovine submaxillary mucin (BSM), or pooled human saliva. 
Tryptic Soy Broth (TSB) supplemented with 2% Yeast Extract, 1mg/ml hemin, 1mg/ml 
menadione, and 50µg/ml gentamicin was used for all cultures. Bacteria were taken from 
agar plates, washed twice in TSB, and seeded into 96-well tissue culture (poly-lysine 
coated) plates at OD600 0.05.  Cultures were further supplemented by NAM or Neu5Ac, 
which were included in bacterial media during biofilm culture, or by glycoproteins, which 
had been pre-coated onto the biofilm assay plate by adding mucin, serum, or saliva to the 
plate and incubating at 4 °C for 18 hours. After inoculation of media, biofilm plates were 
incubated for 5 days at 37 °C anaerobically. Total bacterial growth (planktonic and biofilm 
growth) was quantified by measuring the OD600 of cultures. After removing the planktonic 
culture and gently washing the biofilm twice with PBS, two approaches were tested to 
assess biofilm formation; crystal violet staining, and bacterial counting using a Helber 
chamber with phase contrast microscopy. A condition containing no bacteria, but either 
NAM, Neu5Ac, or the glycoprotein coatings was used as a control for microbial 
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contamination of media or supplements, and underwent absorbance testing (for total 
growth) and crystal violet staining (for biofilm formation), these also acted as blank 
controls; the absorbance values of these “no bacteria” conditions were subtracted from the 
other conditions. Signficant differences between the unsupplemented condition and the 
other conditions were assessed by one-way ANOVA with Dunnet’s correction for multiple 
comparisons. 
The resulting experiments showed that P. gingivalis was capable of varying degrees of 
growth and biofilm formation in media supplemented with NAM or Neu5Ac, and on 
glycoprotein pre-coated surfaces, and that bacterial counting using a Helber Chamber and 
microscopy was a more accurate method for biofilm quantification than crystal violet 
staining (figure 3.7). NAM and Neu5Ac were selected since these are utilised by T. forsythia 
during biofilm formation, and it was initially hoped that mixed species biofilm assays could 
be performed, and a comparison of mixed-culture and mono-culture growth on NAM and 
Neu5Ac would be required. Unfortunately it was not possible to perform mixed-species 
experiments within the timeframe of this project. 
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Figure 3.7. P. gingivalis growth on NAM, Neu5Ac, serum, and saliva, and a comparison of 
biofilm quantification methods. 
Bacteria were cultured for 5 days at 37 °C, anaerobically, in the presence of NAM or 
Neu5Ac, or on surfaces coated with the glycoproteins mucin, saliva, or serum. A) Total 
Growth; OD600 of the culture was used to quantify bacteria in both biofilm and planktonic 
states. B) Biofilm formation; quantified by crystal violet staining. C) Biofilm formation, 
quantified by resuspension of biofilms and counting the number of bacteria under phase 
contrast microscopy. D) Biofilm formation normalised to total growth (biofilm formation 
(Bacteria/ml) x Total Growth (OD600). Error bars =SEM. Statistical differences determined by 
repeted measures one-way ANOVA, with Dunnet correction for multiple comparisons 
*p=>0.05, **p=>0.01. 
 
  
A)  B)  
C)  D)  
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P. gingivalis was capable of similar levels of total growth (biofilm and planktonic) in all 
conditions tested, except for in the mucin-coated conditions, where total growth on mucin 
coated wells was decreased compared to those of the non-supplemented condition (OD600 
0.03 in mucin coated conditions, compared to OD600 0.25 in unsupplemented conditions, 
almost an eightfold difference, p=0.0001). Experiments using pre-coated surfaces-with 
serum and/or saliva appeared to slightly enhance total growth, but the changes were not 
significant. 
The two methods of quantifying biofilm formation seem to show different results (figure 
3.7 B and C): The crystal violet staining method implied that none of the conditions resulted 
in any changes in biofilm formation. The actual bacterial count (obtained through 
microscopy) showed that P. gingivalis biofilm formation on mucin, and to a lesser extent 
saliva, was significantly lower than the unsupplemented condition (unsupplemented, 
saliva-coated, and mucin-coated conditions had biofilms of 3.45x109, 7.46x108, and 
1.16x108 bacteria/ml, but only the mucin coated condition was significantly different from 
the unsupplemented condition, p=0.027). NAM, Neu5Ac, and serum-coated conditions 
appeared to show some decreased biofilm formation compared to the unsupplemented 
condition, but these changes were not statistically significant. These results were also 
reflected in the normalised data (adjusted for total growth), where only P. gingivalis biofilm 
formation on mucin, and to a lesser extent saliva, was significantly lower than the 
unsupplemented condition (unsupplemented, saliva-coated, and mucin-coated conditions 
had normalised biofilms of 1.4x1010, 2.7x109, and 3.2x1010 bacteria/ml, p=0.0186 and 
0.0046, respectively). 
Ultimately, it was decided to use the direct counting (by resuspension of biofilms and 
microscopy) of bacteria during assessment of biofilm formation: Crystal violet staining 
tended to show larger variation between experimental repeats (compared to counting). 
Additionally, in the case of at least one of the conditions (P. gingivalis cultured on mucin-
coated plates) the moderate level of crystal violet staining indicating a level of biofilm 
formation similar to other conditions did not correspond with the low level of total growth 
seen in the measurement (OD600) of the planktonic and biofilm culture. There was also a 
concern that crystal violet could partially stain the glycoprotein coated surfaces, which 
would lead to an erroneous finding that biofilms had formed. Also, the crystal violet 
staining procedure required multiple washes to remove excess crystal violet after staining, 
which was often observed to result in partial detachment and loss of the biofilm from the 
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surface of the wells. Biofilm detachment was still something of a problem during the wash 
steps preceding the counting method, but detachment due to wash steps was more severe 
in using the crystal violet method. Expressing biofilm formation (biofilm count) relative to 
the total bacterial growth (OD600 of cultures prior to crytal violet staining) proved to be 
somewhat useful, providing confirmation that decreases in biofilm formation (rather than 
simply reflecting any decrease in total growth) was occurring. This method of normalising 
biofilm formation to total growth as a means to ensure quantification of reduced biofilm 
formation, rather than simply reduced overall-growth, has been utilised previously by 
others (Honma et al. 2007; Frank et al. 2007; Chen et al. 2002). Therefore, in this work, 
biofilm formation (following resuspension of biofilms and microscopic counting) and 
biofilm formation relative to total bacterial growth is displayed. 
 The Ability of Zanamivir to Inhibit P. gingivalis and T. forsythia 3.3.3.2
Glycoprotein-Dependent Biofilm Formation. 
The results above (4.2.3.2) showed that it was possible to grow P. gingivalis biofilms on 
host glycoprotein-coated surfaces, while this was already established for T. forsythia (Roy 
et al. 2011; Roy et al. 2010). The next step was to establish whether or not biofilm 
formation on these surfaces could be inhibited by zanamivir. The rationale being that 
mucin, serum, and saliva are rich in sialic acid, and sialic acid is a potential nutrient itself, 
but also caps other sugars in the underlying glycan chains which bacteria could metabolise 
or adhere to, which would be exposed by action of pathogen sialidases. So it might be the 
case that a sialidase inhibitor such as zanamivir could prevent or inhibit pathogen adhesion 
to or metabolism of host glycoproteins, resulting in decreased biofilm formation. Indeed, T. 
forsythia biofilm formation on sialoglycoproteins is inhibited by the sialidase inhibitor 
oseltamivir (Roy et al. 2010; Roy et al. 2011), so it was hoped this effect could be replicated 
with zanamivir, for both P. gingivalis and T. forsythia. 
T. forsythia and P. gingivalis were cultured in media supplemented with NAM or Neu5Ac, 
or in the presence of surfaces coated with mucin (BSM), saliva (pooled human saliva), or 
serum (FCS). Cultures were also performed in the presence or absence of 10 mM zanamivir 
to test the effect of sialidase inhibition on biofilm formation. After inoculation at OD600 
0.05, and incubation for 5 days at 37 °C anaerobically, the total growth of cultures (bacteria 
in planktonic and biofilm states) was assessed  by measuring the OD600 of cultures, and 
biofilm formation was assessed by bacterial counting using a Helber chamber and 
microscopy. Since only the effect of zanamivir on growth in the presence of a given nutrient 
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was under investigation, individual T-tests were used assess statistical significance in each 
nutrient condition in the presence and absence of zanamivir. 
T. forsythia (figure 3.8) total growth in the glycoprotein-coated conditions appeared to be 
slightly elevated in the presence of zanamivir, and in the mucin- and serum-coated 
conditions the increase was shown to be significant by T-test (OD600 of 0.044 against 0.061 
in mucin, and OD600 of 0.056 against 0.076 in serum). In the Neu5Ac supplemented 
condition, there was almost no change; a slight, non-significant decrease in total growth 
was observed.  
In terms of biofilm formation, zanamivir produced no significant changes in any of the 
conditions. The only possible difference (which was determined to be non-significant by T-
test) was a ~1.5 fold increase in biofilm formation in the saliva-coated condition in the 
presence of zanamivir (from 1.52x107 bacteria/ml to 2.39x107 bacteria/ml). In the Neu5Ac 
supplemented condition, there was almost no change; similarly to the total growth, a slight 
non-significant decrease in total growth was observed which was also shown in biofilm 
imaging. The inability of zanamivir to reduce biofilm formation appears to correlate with 
the information shown in chapter 2 (section 2.3.7), where zanamivir was shown to have 
low efficacy for sialidase inhibition of live T. forsythia. 
Representative images showing the crystal violet staining and subsequent quantification of 
the T. forsythia biofilms appears to correlate with the bacterial counting method of biofilm 
quantification -i.e. Biofilms contained only low numbers of organisms, and that Neu5Ac had 
the greatest amount of biofilm formation.  
Regarding P. gingivalis, figure 3.9 A shows that the total growth (biofilm and planktonic 
growth) of P. gingivalis in the mucin-coated condition was significantly reduced in the 
presence of zanamivir-from OD600 0.21 to 0.11 (p=<0.05, i.e. zanamivir reduced total 
growth of P. gingivalis in mucin-coated conditions by approximately half). The other 
glycoprotein-coated conditions (saliva and serum) also showed very small, non-significant 
reductions in total growth in the presence of zanamivir (saliva; OD600 0.35 and 0.33 in the 
absence and presence of zanamivir, serum; OD600 0.37 and 0.35 in the absence and 
presence of zanamivir). P. gingivalis grown in Neu5Ac-supplemented media showed almost 
identical total growth in the presence and absence of zanamivir. 
Figure 3.9 B shows that the biofilm formation of P. gingivalis appeared to be reduced in all 
conditions in response to zanamivir: In the case of mucin- and saliva-coated conditions, the 
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reduction was approximately one third (mucin; from 2.32x109 to 1.69x109 bacteria/ml, 
saliva; from 2.78x109 to 1.88x109 bacteria/ml). However, only in the case of saliva was the 
reduction found to be significant due to variation between repeats. P. gingivalis grown in 
serum-coated conditions showed a smaller reduction in biofilm formation, with zanamivir 
reducing biofilm formation by approximately one sixth (from 3.57x109 to 3.01x109 
bacteria/ml), but the reduction was not found to be significant. For the Neu5Ac-
supplemented condition, biofilm formation was reduced by approximately one quarter in 
the presence of zanamivir (from 4.22x109 to 3.25x109 bacteria/ml). Normalisation of the 
biofilm data relative to total growth resulted in almost the same trend (that zanamivir 
reduced biofilm formation), but the effect on saliva appeared to be negated by 
normalisation, while the effect of zanamivir in reducing biofilm formation of P. gingivalis on 
mucin became a signficant reduction (from 7.65x109 to 5.22x10
9
 bacteria/ml). 
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Figure 3.8. Zanamivir has no effect on T. forsythia biofilm formation on sialoglycoprotein 
sources. 
Bacteria were cultured for 5 days at 37 °C anaerobically, in the presence of Neu5Ac, or on 
surfaces coated with the glycoproteins mucin, saliva, or serum. All conditions were 
performed in the presence or absence of zanamivir A) Total growth, OD600 of the culture 
was used to quantify bacteria in both biofilm and planktonic states. B) Biofilm formation, 
quantified by resuspension of biofilms and counting the number of bacteria under 
microscopy. C) Normalisation of Biofilm Formation to Total Growth. All data shown 
represent the mean of three biological repeats, where conditions were tested three times 
per experiment. Error bars =SEM. Significance determined by T-test, *p=>0.05. D) Crystal 
violet stained T. forsythia biofilms in the presence or absence of zanamivir. The negative 
control (-) contains no bacteria or glycoprotein coating, but underwent the crystal violet 
staining procedure before imaging, which was converted to greyscale and colours inverted 
to allow quantification of biofilm formation using image processing software (ImageJ). Data 
shown represent the mean of the two conditions in the image shown. Error bars =SD. 
 
  
198 
 
 
M
u
c
in
S
a
li
v
a
S
e
ru
m
N
e
u
5
A
c
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
T
o
ta
l 
G
r
o
w
th
 (
O
D
6
0
0
)
U n tre a ted
1 0 m M  z a n a m iv ir
***
* * *p = < 0 .0 0 5
M
u
c
in
S
a
li
v
a
S
e
ru
m
N
e
u
5
A
c
0
21 0 0 9
41 0 0 9
61 0 0 9
B
io
fi
lm
 F
o
r
m
a
ti
o
n
(b
a
c
te
r
ia
/m
l)
U n tre a ted
1 0 m M  z a n a m iv ir
***
* * *p = < 0 .0 0 5
 
M
u
c
in
S
a
li
v
a
S
e
ru
m
N
e
u
5
A
c
0
51 0 0 9
11 0 1 0
21 0 1 0
21 0 1 0
B
io
fi
lm
 F
o
r
m
a
ti
o
n
(b
a
c
te
r
ia
/m
l)
 N
o
r
m
a
li
s
e
d
to
 T
o
ta
l 
G
r
o
w
th
 (
O
D
6
0
0
)
U n tre a ted
1 0 m M  z a n a m iv ir
* *
 
Figure 3.9. Zanamivir inhibits P. gingivalis growth and biofilm formation on 
sialoglycoproteins. 
 Bacteria were cultured for 5 days at 37 °C anaerobically, in the presence of Neu5Ac, or on 
surfaces coated with the glycoproteins mucin, saliva, or serum. All conditions were 
performed in the presence or absence of zanamivir. A) Total growth; OD600 of the culture 
was used to quantify bacteria in both biofilm and planktonic states. B) Biofilm formation, 
quantified by resuspension of biofilms and counting the number of bacteria under 
microscopy. All data shown represent the mean of three biological repeats, where 
conditions were tested three times per experiment. Error bars =SEM. Significance 
determined by T-test, **p=>0.01, ***p=>0.005.  
 
A)  B)  
C)  
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Figure 3.10. Crystal violet staining of P. gingivalis biofilms. 
P. gingivalis biofilms were cultured on Neu5Ac, serum, saliva, or mucin in the presence or 
absence of zanamivir, before undergoing the crystal violet staining procedure. The negative 
control (-) contains no bacteria or glycoprotein coating, but underwent the crystal violet 
staining procedure. 
 
The crystal violet-stained images of the P. gingivalis biofilms in figure 3.10 appeared to 
confirm the data shown in figure 3.9; that zanamivir reduced the biofilm formation of P. 
gingivalis in all conditions. However, it was not considered appropriate to quantify biofilm 
formation with image processing, which was done in the case of T. forsythia, since 
aggregates of the P. gingivalis biofilm appeared to have become detached and removed 
during the wash steps involved in crystal violet staining, which would interfere with the 
results. Qualitatively speaking, biofilms show much more dense purple staining, indicating 
thick biofilms with high numbers of P. gingivalis, compared to those seen for T. forsythia 
(figure 3.8 D). P. gingivalis biofilms cultured in the presence of zanamivir appeared to 
become more readily detached than in the absence of zanamivir, most drastically in the 
mucin-coated condition. This perhaps indicates that sialidase activity acts to improve P. 
gingivalis attachment to host glycans rather than assisting in nutrient acquisition for P. 
gingivalis, at least in culture conditions used here. Future work might test this in adhesion 
assays, where P. gingivalis would be incubated on surfaces coated with host glycoproteins 
for a short period of time (~3 hours), followed by bacterial enumeration. Inhibition of 
attachment would provide some support for the use of sialidase inhibitors as periodontitis 
therapeutic, since a decrease in the ability of P. gingivalis to attach to surfaces could be 
beneficial to periodontal disease treatment. Furthermore, perhaps after a two day culture 
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(as seen more frequently during in vivo biofilm studies of P. gingivalis) the differences in 
biofilm formation in the presence and absence of zanamivir would be greater. Five-day 
incubations were used in this work because T. forsythia requires that period of time to 
reach levels suitable for biofilm assessment, so using the same culture time for both 
species might have allowed a more direct comparison of biofilm formation, and it was the 
intention to perform mixed-species biofilm cultures-which is more representative of the 
situation in vivo. 
In summary, T. forsythia was shown to be capable of forming biofilms on mucins, serum, 
and saliva coated surfaces, though Neu5Ac or NAM supplements appeared to promote 
biofilm formation more so than glycoprotein-coated surfaces (mucin, saliva, or serum), but 
this might be expected given the need to release the sugars from glycans with glycoprotein 
sources over freely included sugars.  Furthermore, zanamivir had no effect on T. forsythia 
biofilm formation on host glycoprotein coated surfaces or biofilm formation in the 
presence of Neu5Ac. 
P. gingivalis was also shown to be capable of forming biofilms on mucin, serum, or saliva 
coated surfaces (and in the presence of Neu5Ac or NAM). The number of bacteria in the P. 
gingivalis biofilms was much greater than that of T. forsythia. Interestingly, salivary mucin 
appeared to inhibit P. gingivalis biofilm formation and planktonic growth. Furthermore, 
unlike the T. forsythia condition, P. gingivalis appeared to reduce biofilm formation on all 
glycoprotein coated surfaces and biofilm formation in the presence of Neu5Ac (though only 
significantly in the case of saliva and possibly mucin coated surfaces).  
As well as optimising experimental conditions for P. gingivalis it would be interesting to test 
the effect of NanS on P. gingivalis biofilm formation, which could have several effects: NanS 
may boost biofilm formation on host substrates due to its influence on nutrient acquisition, 
which was seen in the defined media experiments. NanS may also decrease the inhibitory 
effects of mucin (BSM) seen in these assays, since it was shown to enhance sialic acid 
release from mucin, and cleavage of sialic acid increases the rate of mucin proteolysis 
(Takehara et al. 2013).  
3.4 Discussion 
Since sialoglycoproteins represent an important source of nutrients for periodontal 
pathogens, and sialic acid that caps their glycans represents a barrier to further 
metabolism, periodontal pathogen sialidases may be an important virulence factor aiding in 
nutrient acquisition from the host. Sialidases may also contribute to bacterial attachment 
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to underlying glycans or proteins, an important factor in colonisation and biofilm 
formation. Investigating these sialidase-mediated processes, and the ability to inhibit them 
using zanamivir was the initial motivation for work described in this chapter. 
For some of the periodontal pathogens, sialic acid itself appears to be a potential nutrient: 
T. forsythia possesses a dedicated sialic acid utilisation (nan) operon, of which nanH is one 
of nine genes (figure 3.11 A) thought to be involved in sialic acid release (nanH, nanS), 
uptake (nanO, nanU, nanT), and initial stages of catabolism (nanA, nanE, nahA, nanM) 
(Stafford et al. 2012). The release of sialic acid has been shown to be particularly important 
as a nutrient for T. forsythia, since it is able to substitute its requirement for exogenous N-
acetylmuramic acid (NAM) for sialic acid (Neu5Ac) when growing in a biofilm (Roy et al. 
2010; Pham et al. 2010). 
Interestingly, some periodontal pathogens appear to possess partial analogues of the nan 
operon, such as F. nucleatum subsp. nucleatum, where genes for sialic acid uptake (siaP, 
siaQ, SiaM) and catabolism (nanA, nanK, nanE), but no genes encoding enzymes for sialic 
acid release are present (figure 3.11 B). In the case of these periodontal pathogens that do 
not possess sialidases it is assumed that in vivo they rely on sialidases from other bacteria 
in the sub-gingival biofilm to release sialic acid, which they can then uptake and 
metabolise. 
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Figure 3.11. Sialic Acid Utilisation Operons in A) T. forsythia and B) F. nucleatum 
nanA (peach)- neuraminate lyase, nanR (pink)-transcriptional regulator, nanE (light green), 
N-acetylmannosamine-6P epimerase, nanK (blue), ManNAc kinase, nanT and siaPQM 
(yellow)-the (inner) membrane transporters, respectively; major facilitator superfamily 
permease, Neu5Ac TRAP (tripartite ATP-independent periplasmic) transporter, nanOU 
(dark green)-TonB-dependent sialic acid outer membrane transport system, nanS, nahA, 
nanM (grey)-the accessory genes, respectively; sialate 9-O-acetylesterase, beta 
hexosaminidase, sialic acid mutarotase. Adapted from Stafford et al. 2012, permitted under 
the Creative Commons Attribution-NonCommercial 4.0 Unported license (CCNC), or the 
Creative Commons Attribution license 4.0 (CCBY). 
 
There are also periodontal pathogens that possess sialidases but no other nan homologues, 
such as P. gingivalis. However, the P. gingivalis sialidase may play a role in nutrient 
acquisition: P. gingivalis relies on free amino acids, in particular, serine, threonine, arginine, 
asparagine, aspartic acid and glutamic acid are rapidly consumed in culture (Dashper et al. 
2001). P. gingivalis is also able to utilise amino acids in the form of short peptides. This 
requirement for amino acids is met due to the action of P. gingivalis-secreted proteases, or 
gingipains, the most important of which are the lysine and arginine gingipains Kgp and Rgp 
(Grenier et al. 2003). Sialic acid has been shown to protect the salivary mucins MUC5b and 
MUC7 from proteolysis (Takehara et al. 2013). Therefore, it might be the case that P. 
gingivalis sialidase aids the gingipains in proteolytic cleavage of salivary components (and 
possibly other secreted and host-cell associated glycoproteins). Furthermore, since 
bacterial sialidases can upregulate inflammation (discussed in chapter 5), and in the 
context of periodontal disease inflammation leads to increased GCF flow and bleeding, 
sialidase activity could increase amino acid sources available to P. gingivalis. 
A) Tannerella forsythia ATCC 43037 
B) Fusobacterium nucleatum NCTC 25586 
203 
 
In addition to its glycoprotein-protective functions, sialic acid itself can be chemically 
modified, resulting in protection from the effect of sialidase; Neu5Ac (5-N-
Acetylneuraminic Acid) on human glycans can be further modified to possess an additional 
Acetyl group at its 9th carbon, at which point it is called Neu5,9Ac (9-O-Acetyl, 5-N-
Acetylneuraminic Acid). This di-acetylated sialic acid has shown the ability to resist cleavage 
from its underlying glycan chain by several sialidases, which do have activity on mono-
acetylated Neu5Ac-glycans (Corfield 1992). The data presented here show that P. gingivalis 
SiaPG is better able to de-sialylate mucin than T. forsythia NanH, but its activity is doubled 
by the presence of the T. forsythia NanS. (A BLAST search confirmed that P. gingivalis does 
not encode any homologues of NanS.) This might shed some light on the situation in vivo, 
when the pathogens form part of a community that interacts with the host and with each 
other within biofilms. In this case, the above data suggest the periodontal pathogens T. 
forsythia and P. gingivalis act in tandem to release sialic from mucin: NanS from T. forsythia 
converts Neu5,9Ac to Neu5Ac, and SiaPG (and to a lesser extent, NanH) is then able to 
extensively desialylate mucin, which has been shown to enhance mucin degradation 
(Takehara et al. 2013). The degradation of mucin could have several benefits for T. 
forsythia and P. gingivalis, so this dual-enzyme synergy might contribute directly to 
periodontal disease, but it might be countered by sialidase inhibition- which was not 
directly tested here given the difficulty in establishing this defined media. Given the 
potential of mucin as a nutrient source for pathogens, and that evasion of mucin prevents 
entrapment of pathogens, the ability to degrade mucin represents a potential boon for 
pathogen proliferation. Since sialic acid is a major component of mucin protecting it from 
degradation, and may itself represent a nutrient source, the ability to desialylate mucin 
represents an important virulence mechanism for pathogens. 
Given this enzymatic synergy observed, it was essential to test whether the sialate esterase 
activity might boost growth of P. gingivalis on diacetylated sialic acid glycoprotein sources.  
Although amino acids or carbohydrates released from host glycoproteins could bolster 
periodontal pathogen growth, this is difficult to study using monoculture-based approaches 
due to the presence of other nutrients in the growth media. In this work, P. gingivalis alone 
appeared to be capable of growth in defined media containing only serum glycoproteins as 
carbon sources, even in iron limited conditions (where no exogenous hemin was added to 
culture). Furthermore, P. gingivalis growth was bolstered by the presence of human saliva, 
implying that saliva does provide additional nutrients for P. gingivalis. The heavily 
glycosylated salivary mucins compose a significant proportion of the salivary 
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glycoproteome, so these could be an important nutrient source for P. gingivalis,  and are 
thought to be rich in diacetylated sialic acid (Phansopa et al. 2015; Varki & Diaz 1983), 
which could hinder the ability of P. gingivalis sialidase to act on sialylated mucins. In turn, 
failure to remove sialic acid could render mucins less susceptible to proteolysis by the 
gingipains, denying P. gingivalis a source of amino acids for metabolism, or at least slowing 
amino acid/peptide release. Since T. forsythia NanS can remove the second acetyl group, it 
might make salivary mucins more susceptible to proteolysis-thus boosting the growth of P. 
gingivalis. Indeed, this was shown to be the case in this chapter: NanS increased the growth 
of P. gingivalis with serum and saliva as sole carbon and nitrogen sources, and perhaps in 
vivo NanS also aids P. gingivalis in nutrient acquisition at the periodontium. Further 
evidence for increased proteolysis of host sialoglycoproteins due to NanS de-acetylation 
could be obtained by treating saliva, serum or mucin with gingipains or P. gingivalis culture 
supernatant, in the presence or absence of NanS, followed by SDS-PAGE and staining for 
(glyco)protein. 
Further work using defined media could use mixed species cultures of P. gingivalis and T. 
forsythia (and F. nucleatum) to find if the pathogens support each other during nutrient 
acquisition from host sialoglycans and subsequent growth. In addition to the possibility of 
testing the importance of sialidase for single species (T. forsythia or P. gingivalis) or mixed 
species pathogen cultures using T. forsythia or P. gingivalis mutants deficient in NanH or 
SiaPG, our lab group has also recently generated a T. forsythia mutant strain deficient in 
NanS, so the contribution of NanS to T. forsythia or mixed-periodontal pathogen nutrient 
acquisition from host sialoglycoproteins could also be examined. In addition to these more 
conventional growth studies, these effects of sialidase or NanS deficiency could be tested in 
biofilm assays using defined media instead of TSB. This might also result in more 
pronounced differences in biofilm formation in the presence of zanamivir, since the sole 
nutrient source in these assays would be the sialoglycoproteins. 
P. gingivalis biofilm formation on surfaces coated with serum, saliva, and mucin was shown 
to be decreased in the presence of zanamivir. Although the decrease in biofilm formation 
was only up to ~one third (in the cases of biofilm formation on mucin and saliva), relative 
to the absence of zanamivir, the assay did take place over five days-a shorter incubation 
time might have yielded a more striking difference between zanamivir and no-zanamivir 
conditions. In any case, zanamivir did decrease P. gingivalis biofilm formation significantly 
on human saliva, and to varying degrees on mucin, serum and slightly in Neu5Ac 
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supplemented media. Furthermore, total (planktonic and biofilm) growth of P. gingivalis 
was only significantly inhibited by zanamivir in mucin-coated conditions (though it was 
slightly inhibited in the other conditions). Considering this, it could be the case that the P. 
gingivalis sialidase is important for attachment to host glycoproteins, and this aids in 
biofilm formation, while the importance of sialidases for P. gingivalis nutrient acquisition 
was less important. However, this experiment did take place in Tryptic Soy Broth (TSB) with 
2% Yeast Extract, conditions which are rich in amino acids for P. gingivalis to metabolise, 
possibly rendering the glycoprotein coated surfaces less important from a nutritional 
perspective; i.e. in less nutrient rich conditions, the host glycoproteins might have been an 
important source of nutrients, and the presence of zanamivir might have made a more 
striking difference to P. gingivalis biofilm formation.  
It was also observed that mucin decreased both the biofilm formation and total growth of 
P. gingivalis compared to the other conditions, and that the presence of zanamivir resulted 
in further decreases in biofilm formation. Salivary mucins have been shown to display 
growth- or- biofilm inhibitory activity against oral bacteria, particularly against streptococci 
(Frenkel & Ribbeck 2015; Wei et al. 2006). Against P. gingivalis, peptides derived from the 
N-terminal of MUC7 have been shown to inhibit growth, although this does require high 
peptide concentrations (the MIC reported in the study is >100µM) (Wei et al. 2006). In this 
assay, 6µM mucin was sufficient to inhibit P. gingivalis biofilm formation and planktonic 
growth, and zanamivir further decreased biofilm formation. The difference might be due to 
the strains used: In the above study (Wei et al. 2006), the encapsulated strains W50 and 
381 were used, but in the biofilm assays described here the non-encapsulated ATCC 33277 
was used; perhaps the absence of a capsule renders P. gingivalis more susceptible to the 
inhibitory effects of salivary mucin, and P. gingivalis growth is further inhibited by the 
presence of zanamivir, possibly because mucin glycoproteins are less susceptible to 
proteolysis if they retain their sialic acid, meaning the mucin-derived peptides retain their 
inhibitory properties. Therefore, the biofilm experiments described here could be repeated 
with encapsulated strains and with clinical isolates (obtained from patients attending the 
University of Sheffield Dental Hospital). 
Regarding T. forsythia, Neu5Ac has been shown to substitute the requirement for 
exogenous NAM in T. forsythia biofilm formation, and a sialidase deficient T. forsythia 
mutant strain has been shown to display reduced biofilm formation on host glycoproteins 
relative to its parent strain. Furthermore, inhibition of biofilm formation on host 
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glycoproteins in wild type T. forsythia is also seen in in the presence of the sialidase 
inhibitor oseltamivir (Roy et al. 2010; Roy et al. 2011). Given this, it was hoped that 
zanamivir could also inhibit biofilm formation. Unfortunately, the above results indicated 
that zanamivir does not significantly inhibit biofilm formation under the current 
experimental conditions. This might be expected given the results shown in chapter 2  
(section 2.3.7), which appear to indicate that zanamivir is not an efficacious inhibitor of T. 
forsythia sialidase activity-10mM zanamivir only inhibits T. forsythia sialidase activity on the 
model sialic acid ligand MUNANA by 25%, whereas for P. gingivalis this figure was ~80%.  
3.5 Summary 
Sialic acid, its underlying glycan chain, and the proteinaceous components of human 
sialoglycoproteins represent potential nutrient sources for bacteria, and the ecological 
niche in which periodontal pathogens exist is an environment rich in sialoglycoproteins. 
From a nutritional perspective, release of sialic acid could directly benefit pathogens with 
appropriate uptake and catabolic pathways, as in the case of T. forsythia and F. nucleatum, 
or render proteins more susceptible to proteolytic digestion in organisms lacking these 
pathways, as in the case of P. gingivalis. In addition, sialyl groups on host glycoproteins 
might represent a barrier to pathogens attempting to attach to underlying glycans, and 
their desialylation could boost pathogen attachment. Therefore, sialidases could play 
important roles in periodontal pathogen nutrition and attachment to host surfaces, both of 
which could contribute to biofilm formation, with consequences for periodontal disease. 
Furthermore, T. forsythia secretes an accessory enzyme, NanS, which removes a second, 
protective acetyl- group from sialic acids present on oral glycoproteins and this may boost 
sialic acid release by sialidases from other periodontal pathogens. 
Experiments presented in this chapter showed that T. forsythia NanS doubled sialic acid 
release from salivary mucin (which is rich in diacetylated sialic acid) by the T. forsythia and 
P. gingivalis sialidases NanH and SiaPG, with SiaPG & NanS displaying the greatest amount 
of sialic acid release, and this sialic acid release was inhibited by zanamivir. This perhaps 
suggests interspecies co-operation in sialic acid release from oral host-glycoproteins. This 
prompted further work investigating the impact of NanS on P. gingivalis growth on host 
sialoglycoproteins as sole carbon and nitrogen sources: P. gingivalis was capable of growing 
on serum alone, and growth was increased in the presence of human saliva. Growth of P. 
gingivalis on saliva and serum, but not serum alone, was increased in the presence of T. 
forsythia NanS, providing support for the theory that sialic acid release from saliva (which 
contains glycoproteins rich in diacetylated sialic acid) is important for P. gingivalis 
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nutritional purposes, possibly by rendering glycoproteins more susceptible to proteolytic 
cleavage, releasing amino acids or peptides which can be catabolised by P. gingivalis. 
Finally, the ability of T. forsythia and P. gingivalis to form biofilms on surfaces coated with 
host glycoproteins, and the potential to inhibit them with zanamivir was investigated. Only 
P. gingivalis biofilm formation was significantly inhibited by zanamivir, and the lack of 
inhibition for total growth (planktonic and biofilm growth) of P. gingivalis might suggest 
that biofilm formation was inhibited because P. gingivalis was unable to attach to the 
glycoprotein coated surfaces in the presence of zanamivir, rather than zanamivir causing 
inhibiting nutrient acquisition. Future biofilm studies might test the formation of P. 
gingivalis biofilms on host glycoproteins in defined media, or quantify the impact of 
sialidase inhibition on mixed-species biofilms. 
As well as mediating bacterial growth and biofilm formation, it was considered likely that 
periodontal pathogen sialidases play roles pathogen interactions with host cells, including 
attachment and invasion of host cells by bacteria, and modulation of the host innate 
immune response. The latter is particularly important for periodontitis since host 
inflammation is responsible for the tissue destruction seen in periodontal disease. With this 
in mind, work described in the next chapter aimed to investigate the role of T. forsythia and 
P. gingivalis sialidases in host-pathogen interactions, and the potential for sialidase 
inhibitors to disrupt these interactions. 
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4  Chapter 4: The Role of Sialidases in Host-Pathogen 
Interactions, and Disruption by Sialidase Inhibition 
4.1 Introduction 
Pathogen sialidases have been implicated in a variety of host-pathogen interactions by 
studies of sialidase-gene knockout bacteria: One of the most well studied pathogens in this 
regard is the nasopharyngeal commensal and pathogen Streptococcus pneumoniae, which 
possess three sialidases; NanA, B, and C. S. pneumoniae mutants deficient in NanA or NanB 
show decreased attachment to host cells in vitro (Brittan et al. 2012). Mouse models of 
respiratory tract infection also highlight the importance of sialidases during infection with 
S. pneumoniae; NanA and B mutants lack the ability to colonise the lungs and nasopharynx 
in a respiratory infection model, and are unable to cause sepsis if intravenously 
administered (Manco et al. 2006). 
Sialidase is also important for virulence of the gut pathogen Vibrio cholerae, with the most 
virulent serotypes (the toxigenic O1 and at least one strain of O139) possessesing a 
sialidase (NanH) and sialic acid utilisation genes (Jermyn & Boyd 2002). NanH (and sialic 
acid utilisation) is a multifunctional virulence factor for V. cholera:  It has been shown to act 
in synergy with the cholera toxin during virulence, unmasking the cholera toxin receptor, 
the GM1 ganglioside on intestinal epithelial cells (Venerando et al. 1982; Galen et al. 1992). 
Most importantly, V. cholerae mutant strains deficient in nanH show decreased virulence in 
mouse models of cholera (Galen et al. 1992). V. cholerae also possesses sialic acid 
utilisation genes (nan-nag genes) (Jermyn & Boyd 2002). This is likely to confer a growth 
advantage in vivo, and indeed V. cholera is able to grow using sialic acid as a sole carbon 
source (in vivo this is presumably obtained by release from host sialoglycans by NanH), and 
nanH-deficient mutants possess a decreased ability to colonise the mouse intestine 
(Almagro-Moreno & Boyd 2009), although this may also be due to decreased attachment of 
V. cholerae rather than decreased growth. 
Periodontal pathogens have also been subjected to sialidase knockout. T. forsythia nanH 
sialidase mutants (Δ   H) displayed decreased attachment to oral epithelial cells 
compared to wild type T. forsythia (Honma et al. 2011). Different strains of P. gingivalis 
have also been made deficient in SiaPG (PG0352, Δ    G) (Li et al. 2012; Aruni et al. 2011), 
although the exact implications for virulence are less clear because the sialidase mutants 
display defects in capsule formation, although ΔsiaPG strains do show decreased 
association with oral epithelial cells (Aruni et al. 2011; Li et al. 2012). The virulence of 
211 
 
ΔsiaPG mutants in a mouse abscess model is also decreased relative to the parent strain, 
where subcutaneous injections of wild type P. gingivalis  (strain W83) resulted in the 
formation of abscesses and ultimately lethal infection (the mice died within 6 days), and 
both abscess formation and lethality were not seen in mutant P. gingivalis W83 ΔsiaPG (Li 
et al. 2012). Finally, sialidase deficient mutants of Treponema denticola have also been 
studied, and these display reduced complement evasion and decreased virulence in a 
mouse abscess model, where sialidase deficient T. denticola induced smaller lesions 
relative to their parent strain (Kurniyati et al. 2013). 
Given the apparent importance of sialidase expression for periodontal pathogen-host 
interactions, and subsequent virulence, abrogation of sialidase activity using sialidase 
inhibitors might have anti-virulence effects. This chapter discusses the ability of purified 
SiaPG and NanH to desialylate host cells, and the influence of zanamivir in disruption of 
host-pathogen interactions of T. forsythia, P. gingivalis, and the sialidase negative 
bacterium Fusobacterium nucleatum. Specifically, the ability of zanamivir to disrupt 
attachment and invasion of periodontal pathogens to oral epithelial cells, and the influence 
of pathogen sialidases and zanamivir on oral epithelial cell pro-inflammatory responses 
were investigated. Despite the seemingly-limited ability of zanamivir to inhibit T. forsythia 
sialidase activity, and no effect of T. forsythia biofilm formation, zanamivir was capable of 
inhibiting SiaPG and NanH to a lesser extent extent, as well as having some inhibitory effect 
on P. gingivalis biofilm formation. Furthermore, zanamivir is a well characterised active 
ingredient licensed globally for use in human medicines with a wealth of pharmacology and 
toxicology profiling-meaning that it might transition more easily into a novel periodontitis 
therapeutic than a completely new active ingredient.  
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4.2 Materials and Methods-The Role of Sialidases in Host-Pathogen 
Interactions, and Disruption by Sialidase Inhibition 
4.2.1 Culture of Human Cell Lines 
Immortalized human oral keratinocytes (OKF6/Tert2) (Dickson et al. 2000) were kindly 
provided by Dr J. Rheinwald (Harvard Medical School, Cambridge, MA) and were grown in 
keratinocyte-serum free media supplemented with deﬁned growth supplements (DKSFM, 
Fisher Scientiﬁc, Loughborough, UK). Cells were grown to 70–90% conﬂuence and media 
was changed every 2–4 days. The Oral Squamous Cell Carcinoma (OSCC) cell line H357 
(Thomas et al. 2001; Sugiyama et al. 1993)-a generous gift from Professor S. Prime, 
University of Bristol, UK-was grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% (v/v) foetal bovine serum (FBS), 2mM L-glutamine, and 
100units/ml Penicillin-Streptomycin (Sigma Aldrich). Cells were incubated at 37˚C, 5% CO2 
when not undergoing media changes or passaging. 
4.2.2 Antibiotic Protection Assays 
OKF6 or H357 cells were cultured as described, and resuspended at a density of either 
1.2x105-2x105 cells ml-1 in DKSFM or DMEM, and seeded into the wells of a 24-well tissue 
culture plate (Greiner, UK), 1 ml of suspension per well. Each experiment required a control 
condition (no sialidase inhibitors) and a sialidase inhibition condition (media for assay 
supplemented with10 mM zanamivir), both repeated in triplicate, and in duplicate on two 
plates; one plate for “total associated” bacteria, and one for “invaded” bacteria. To allow 
adherence to the plates, cells were incubated as above for approximately 18 hours if 
seeded at 2x105, or 48 hours if seeded at 1.2x105 cells/ml. After incubation, media was 
removed and the cells in one well were detached by trypsinisation and counted by 
haemocytometry, to determine the number of cells per well.  
The remaining cells were incubated for 1 hour in DKSFM or DMEM supplemented with 2% 
BSA, then washed twice with PBS pH 7.4 (Sigma Aldrich). Bacteria for use in the antibiotic 
protection assay were resuspended in DKSFM, and quantified using a Helber chamber 
(Hawksley) under phase contrast microscopy, 400 x magnification. Bacterial suspensions 
were diluted to a ratio of 1:100 host cells: bacteria in DKSFM or DMEM, either 
unsupplemented (for negative controls) or supplemented with 10mM zanamivir (for testing 
the effect of sialidase inhibition). Additionally, bacterial suspension (conditions with and 
without zanamivir) were added to empty wells of the “invasion” plate. These bacteria form 
the bacterial “viability” control. 
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These suspensions were incubated with the host cells at 37 °C, 5 % CO2 for 1.5 hours, or in 
empty wells containing no host cells. After incubation, the wells were washed twice with 
PBS, and DKSFM or DMEM supplemented with 200 µg/ml metronidazole (and for the 
sialidase inhibition condition, with 10 mM zanamivir) was added to wells of the designated 
“invasion” plate, then incubated at 37 °C, 5 % CO2 for 1 hour. Media from wells containing 
bacteria and host cells for “total associated” and “invaded” conditions was removed, and 
cells were washed twice with PBS before lysis using 200 μl of deionised water (dH2O) and 
scraping with a pipette tip for one minute. The “viability” control bacteria were 
resuspended by pipette mixing.  
Bacteria obtained from the suspension of the “viability” wells, and cell lysates of the “total 
associated” and “invasion” wells then underwent four tenfold serial dilutions, and the 
undiluted suspensions and serial dilutions were plated onto agar by Miles-Misra 
methodology; each serial dilution and bacterial suspension was given three 10μl spots onto 
agar appropriate for the organism, and incubated under the previously described 
conditions. Incubation times for bacteria were 1.5-2 times longer than those listed above. 
After incubation and colony counting, the following formula was used to determine the 
number of bacteria/ml in each well of the “total associated” “invasion” or “viability” plates: 
 
After ascertaining the mean number of viable bacteria/ml from the “viability” controls for 
no sialidase inhibitor and 10mM zanamivir conditions, it was possible to calculate the 
percentage of viable bacteria that were associated with and had invaded the OKF6 cells 
using the following formula, and by subtracting percentage invaded from the percentage 
associated, the number of attached bacteria was obtained: 
  
4.2.3 Cell Viability Assays 
 MTT Assays 4.2.3.1
MTT assays were only used to test the effect of zanamivir on cellular metabolism in OKF6 
cells. 100µl of OKF6 cells in DKSFM were seeded at a density of 2x105 cells/ml into the wells 
of a 96 well tissue culture plate (Greiner), and incubated for 24 hours at 37°C, 5% CO2. Cells 
were then washed twice with PBS, and media supplemented with 1000 µg/ml MTT, and 0, 
2.5, 5, 7.5, or 10 mM zanamivir was added. Cells were incubated for 2.5 hours at 37 °C, 5 % 
         Number of bacteria/ml         x 100 = % Viable bacteria  
mean viable number of bacteria 
number of colonies x dilution factor x 20 = number of bacteria/ml 
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CO2. MTT-supplemented DKSFM was removed, and cells were washed twice using PBS. 
Next, formazan crystals (formed by metabolism of MTT by viable OKF6 cells) were 
solubilised using acidified isopropanol (Isopropanol supplemented with 0.125 % HCl). Levels 
of formazan were quantified by measuring absorbance at 540 nm with a reference at 630 
nm using a Tecan Infinite M200 plate reader. 
 LDH Assays 4.2.3.2
LDH assays rely on detection of lactate dehydrogenase, released from lysed or porous cells 
into culture supernatant. Quantification of LDH in supernatants from H357 cells (during 
cytokine secretion experiments, section 4.2.5) and OKF6 cells (during zanamivir cytotoxicity 
testing) in various experiments was performed using the cytotox 96 LDH assay kit 
(Promega), according to manufacturer’s instructions. Briefly, the assay detects the 
presence of LDH in culture supernatant by formation of a red formazan salt by components 
of a proprietary assay buffer and LDH, by mixing 50 µl of assay buffer with 50 µl of culture 
supernatant, incubating at 37 °C for 30 minutes, and quenching the reaction with a 25 µl of 
a proprietary stop solution. Reaction optical density is then measured at OD490 to quantify 
LDH. A negative control consisting of media alone was used in all assays. 
 In the case of H357 cells in cytokine secretion experiments, cell culture supernatants were 
harvested at different time points, having been exposed to a number of conditions (see 
section 4.3.5 for conditions and time points). 50 µl of culture supernatant immediately 
underwent the LDH assay prior to storage at -20 °C. In the case of OKF6 cells, an 
experiment was designed to replicate the exposure to zanamivir seen in the antibiotic 
protection assay. A 96-well tissue culture plate (Greiner) was seeded with 25000 OKF6 
cells/well in 100 µl of DK-SFM and incubated overnight at 37 °C, 5 % CO2. Supernatant was 
removed, cells washed twice with PBS, and replaced with 100µl of either DKSFM or DKSFM 
with 10 mM zanamivir, and incubated for 2.5 hours at 37 °C, 5 % CO2. 50 µl of this culture 
supernatant immediately underwent the LDH assay. 
4.2.4 Immuno-Fluorescence Microscopy; Visualisation of Cell-Surface Sialic 
Acid 
 Lectin Staining for Host Cell Surface Sialic Acid 4.2.4.1
H357 cells were passaged as described (section 4.2.1) and seeded at a density of 1.5x105 
cells/ml in DMEM into the wells of a 24-well tissue culture plate which contained sterile 
glass coverslips (BDH). These were incubated at 37 °C anaerobically for 18 hours before 
undergoing sialic acid staining (or enzyme treatment before staining). 
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Cells underwent sialic acid staining using lectins from Sambucus nigra (SNA), Maackia 
amuriensis (MAA), or Cancer antennarius agglutinin (CAA) (Vector Labs). These lectins are 
specific for α2-6, α2-3 linked Neu5Ac, and diacetylated sialic acids (including Neu5,9Ac), 
respectively. After treatment, cells were washed twice with 500µl PBS followed by 
application of lectins: 4 µg/ml SNA- fluorescein isothiocyanate conjugate (SNA-FITC, Vector 
labs) or 8 µg/ml biotinylated-MAA (Vector labs), for 30 minutes at 37 °C, 5 % CO2. Cells 
were washed twice with 500 µl PBS and in conditions containing Biotinylated lectin, 
underwent a second incubation with 2 µg/ml Texas Red-Streptavidin, for 30 minutes at 37 
°C. Lectin stained cells were washed three times with 500 µl PBS and fixed with 500 µl 2 % 
(w/v) Paraformaldehyde for 15 minutes at 37 °C. Coverslips with fixed cells were removed 
from wells and mounted onto glass slides with ProLong Gold Antifade Mountant 
(containing DAPI, ThermoFisher Scientific). Mounted cells were incubated for at least 18 
hours and visualised within one week. 
 Antibody Staining for Host Cell Surface Sialyl Lewis A and X 4.2.4.2
H357 cells were passaged as described (section 4.2.1) and seeded at a density of either 
1.5x105 cells/ml in DKSFM or DMEM into the wells of a 24-well tissue culture plate which 
contained sterile glass coverslips (BDH). These were incubated at 37 °C anaerobically for 18 
hours before undergoing staining for sialyl lewis A (SLeA) or sialyl lewis X (SLeX) (or enzyme 
treatment before staining). 
Cell monolayers were washed twice with PBS. Murine Anti-SLeA IgG1 (Invitrogen), or 
murine Anti-SLeA IgM (Sigma-Aldrich) was diluted 1 in 500 in PBS, and incubated with 
washed epithelial cell monolayers for 30 minutes, at 37 °C. In isotype control conditions, 
non-specific rabbit IgG1 (Invitrogen) or murine IgM (Sigma-Aldrich) was diluted 1 in 500 in 
PBS, and incubated with cell monolayers in place of anti-SLeA/X antibodies.  
Anti-SLeA/X Antibodies were removed, and cells were washed three times in PBS. A 
secondary antibody-Goat anti-Mouse IgG1-FITC conjugated-was diluted 1 in 500 in PBS and 
applied to the cells, and incubated for 30 minutes at 37 °C.  Stained cells were washed 
three times with PBS, and fixed using 2 % (w/v) paraformaldehyde for 15 minutes at 37 °C. 
The use of FITC conjugated secondary antibodies enabled visualisation of Sialyl Lewis A/X 
with fluorescence microscopy. 
Coverslips with fixed cells were removed from wells and mounted onto glass slides with 
ProLong Gold Antifade Mountant (containing DAPI, ThermoFisher Scientific). Mounted cells 
were incubated for at least 18 hours and visualised within one week. 
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 Enzymatic Treatment of Host Cell Surfaces 4.2.4.3
Prior to the staining described above, H357 cell monolayers were treated with the purified 
periodontal pathogen sialidases NanH and SiaPG. Sialidases were diluted to 100 nM in PBS, 
added to the oral epithelial cell monolayers, and incubated at 37 °C for 2 hours. Enzymes 
were removed and monolayers washed twice before undergoing lectin or antibody 
staining. For sialidase inhibition conditions, 10 mM zanamivir was included during enzyme 
treatment of oral epithelial cells. 
  Fluorescence Microscopy, Image Processing, and Sialic Acid 4.2.4.4
Quantification 
Slides were visualised using an Axiovert 200M fluorescence microscope (Zeiss) and 
associated Axiovert software (Zeiss). Slides were imaged at 100 x, 400 x, or 1000 x 
magnification. To allow comparison of sialic acid staining, images of different conditions in 
the same experiment were captured using the same parameters for fluorescence intensity 
and weighting, and exposure time for a given fluorescence colour channel.  
All images were processed using Fiji-imageJ, Software (Schindelin et al. 2012 freely 
available at https://fiji.sc/). Fluorescence background subtraction was performed for all 
images using the same parameters for each fluorescence colour channel in a given 
experiment. 
For surface staining quantification, three fields of view were imaged at 400 x magnification, 
processed as described, and the mean pixel brightness of each image was obtained. Cell 
nuclei were manually counted to obtain the number of cells in each image, and the level of 
staining expressed as Mean Fluorescence Intensity (MFI) per cell.  
4.2.5 Immune-Signalling in Oral Epithelial Cells 
 Cell Treatments and Harvesting of Conditioned Media 4.2.5.1
H357 cells were cultured as described, resuspended at a density of 2x105 cells/ml in DMEM 
(10 % serum, 2 mM L-glutamine), and seeded into the wells of a 6-well tissue culture plate 
(Greiner, UK), 2ml of suspension per well. Cells were incubated for 18-24 hours at 37 °C, 5 
% CO2, and exposed to a variety of different conditions (table 4.3), each condition was 
performed in duplicate during each experiment. Prior to treatment, one well underwent 
trypsinisation and haemocytometry to obtain the number of cells per well at the start of 
the experiment. In conditions with live bacteria, cells were seeded at a given multiplicity of 
infection (MOI). Treated cells were incubated for 4 or 24 hours at 37 °C, 5 % CO2. 
Supernatants were collected, and cells were either detached from wells by trypsinisation 
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and counted by haemocytometry as described, or were lysed using lysis buffer; RIPA buffer, 
Sigma, with DNAse (Sigma-Aldrich), and Protease Inhibitor Cocktail (Roche), with cell 
lysates stored at -20°C. Collected supernatants immediately underwent an LDH assay 
(section 4.2.3.1), before storage at -20 °C before ELISA. 
 
Table 4.1. Cell treatment conditions for IL-8 cytokine analysis. 
Cells in 6-well tissue culture plates were treated with the above conditions, 2 ml of each 
treatment condition per well, and processed as described. Some conditions were tested at 
different concentrations, and different serum concentrations were tested in some 
conditions as indicated. LPS: Lipolysaccharide extracted from P. gingivalis, NanH: purified 
NanH treated with polymixin agarose. Seeding density: Multiplicity of infection (MOI), the 
ratio of host: bacterial cells. 
__________________________________________________________________________ 
 P. gingivalis Lipopolysaccharide Extraction 4.2.5.2
P. gingivalis ATCC33277 LPS was extracted using a commercially available LPS extraction kit 
(IntronBio). Briefly, P. gingivalis was cultured in liquid media as described, to an OD600 of 3-
5. Culture was transferred to microfuge tubes and centrifuged at 13000 g to pellet bacteria. 
Supernatant was removed, lysis buffer added and mixed thoroughly by vortex. 200 µl 
chloroform was added, mixed, and incubated at room temperature for 5 minutes. 
Reactions were centrifuged at 13000 g for 20 minutes, and the upper fraction of the 
reaction (easily distinguished due to its appearance (clear and colourless compared to the 
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dark and turbid lower fraction) was transferred to a pre-weighed microfuge tube. 800 µl of 
purification buffer was added, and the reaction incubated at -20 °C for 10 minutes before 
centrifugation at 13000 g for 20 minutes. Supernatant was removed, and 1 ml 70 % ethanol 
added and mixed by inversion. The reaction was centrifuged at 13000 g for 3 minutes and 
the supernatant removed, the pellet was air dried for 5 minutes and dried using an 
Eppendorf SpeedVac leaving purified LPS. LPS was dissolved in Tris HCl, pH 8.0 and 
incubated at 95 °C for 5 minutes. 
 Quantification of the Pro-Inflammatory Cytokine IL-8 by ELISA 4.2.5.3
Cell supernatants were thawed and processed using commercially available CXCL8 ELISA 
kits (Biolegend or BD Biosciences).  
Buffers for both kits are described in table 4.4. Capture antibody was diluted in capture 
buffer according to kit-specific recommendations and incubated in 96-well Nunc Maxisorp 
ELISA plates (Sigma-Aldrich) overnight at 4 °C. Wells were aspirated and washed three 
times with 300 µl wash buffer, and blotted with absorbent paper to remove residual buffer. 
200 µl blocking buffer was added to wells and incubated for two hours at room 
temperature (~20 °C), and washed as above. A standard curve of CXCL8 concentrations 
were prepared by dilution of CXCL8 in assay diluent, and cell supernatants were diluted 3-4 
fold in assay diluent, added to wells, and incubated for 2 hours at room temperature. Wells 
were washed five times as above, and 100 µl of working detector (or detection antibody 
alone in the case of the biolegend kit) was added to the wells. Plates were sealed and 
incubated for 1 hour at room temperature, and washed seven (or five) times as described. 
The Biolegend kit required an extra step at this point, where working detector was added 
to wells and washed seven times. Substrate solution was added to each well. Reactions 
were incubated for 30 minutes at room temperature in the dark, and 50 µl of stop solution 
was added. The absorbance at 450 nm and 570 nm was obtained using a TECAN M200 
plate reader, the absorbance at 570 nm subtracted from absorbance at 450 nm, and the 
CXCL8 standard curve was applied to quanitfy CXCL8 (pg/ml) for cell supernatant. This 
could be standardised to cell counts (haemocytometry) or cell lysate protein content 
(obtained using BCA) to provide CXCL8 pg/ml/cell, or CXCL8 relative to cellular protein (% 
w/w), although results shown here are not standardised, in accordance with the bulk of the 
literature.  
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Table 4.2. ELISA kit buffers. 
PBS-Phosphate Buffered Saline, HRP-Avidin-Horseradish Peroxidase-streptavidin conjugate, 
capture antibody-biotinylated anti CXCL8 antibody, FBS-foetal bovine serum. 
 Multiplex Cytokine Bead Array 4.2.5.4
The University of Sheffield offers an in house service for detection of multiple cytokines in 
cell culture supernatants. This makes use of a Bead-based array supplied by BDbiosciences, 
the “BD Cytometric Bead Array (CBA)”. Briefly, antibodies against the protein of interest are 
immobilised onto fluorescent beads, which is incubated with a given sample. A fluorescent 
antibody against the protein of interest is then applied, and the bead’s fluorescence 
increases relative to the concentration of the protein of interest. Reactions containing 
known concentrations of the protein of interest are also performed, to produce a standard 
curve of known protein concentration. This is applied to quantify the protein of interest.   In 
this project, this involved detection of cytokines that were suspected to be secreted by oral 
epithelial cells and might be influenced during infection with T. forsythia, and treatment 
with 10mM zanamivir. The cytokines quantified were Granulocyte Colony Stimulating 
Factor (GCSF), Interleukin -6, -8 (IL-6, IL-8), Monocyte Chemoattractant Protein (MCP-1), 
Macrophage Inflammatory Protein (MIP1α), and Tumour Necrosis Factor (TNF), further 
details are shown in table 5.3. 
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Name Abbreviation  Also Known As Functional Notes 
Reference 
(Relevance to 
Oral Epithelium 
or Periodontitis) 
Granulocyte 
Colony 
Stimulating 
Factor 
GCSF 
Colony Stimulating 
Factor 3 (CSF 3) 
Stimulates activity and 
replication of 
Granulocytes of 
Neutrophil lineage. 
Particularly mature 
neutrophils. 
(Sugiyama et al. 
2002; Shaddox et 
al. 2011; Ramage 
et al. 2016)  
Interleukin-6 IL-6 
Interferon-β-2 (IFN-
β2)B cell stimulating 
factor (BSF-2), 
hepatocyte stimulating 
factor (HSF), others. 
Many functions in 
stimulation of innate 
and adaptive immunity, 
hence its numerous 
aliases. 
(Shaddox et al. 
2011; Morandini 
et al. 2010b; Ara 
et al. 2009; 
Ramage et al. 
2016) 
Interleukin-8 IL-8 
Chemokine (C-X-C 
motif) Ligand 8, 
Neutrophil Attractant 
Factor 
Chemoattractant for 
Leukocytes, primarily 
neutrophils. Other pro-
inflammatory effects on 
other cell types in high 
concentrations. 
 (Shaddox et al. 
2011; Sugiyama 
et al. 2002; 
Ramage et al. 
2016) 
Monocyte 
Chemoattractant 
Protein-1 
MCP-1 
Chemokine (C-C motif) 
Ligand 2 (CCL2) 
Chemoattractant for 
monocytes. 
 (Shaddox et al. 
2011; Pradeep et 
al. 2009) 
Macrophage 
Inflammatory 
Protein 1α 
MIP1α 
Chemokine (C-C motif) 
Ligand 3 (CCL3) 
Chemoattractant of 
granulocytes and innate 
immune cells including 
T-lymphocytes. 
 (Morandini et al. 
2010b; Shaddox 
et al. 2011) 
Tumour Necrosis 
Factor 
TNF 
TNFα, TNF superfamily 
member 2 
Activates pro-
inflammatory 
responses in all cell 
types through NFκB and 
JNK (MAPK) pahways. 
 (Shaddox et al. 
2011; Ramage et 
al. 2016; 
Davanian et al. 
2012) 
Table 4.3. Cytokines produced by oral epithelial cells. 
The cytokines outlined were considered likely to be produced by oral epithelial cells, 
important in periodontitis, and could be assayed for using the CBA produced by 
BDbiosciences. 
The above cytokines were deteted using a Cytometric Bead Array (CBA) Human 
Inflammatory Cytokines Kit (BD Biosciences, USA), following the manufacturers instructions 
for quantification of cytokines from cell culture supernatant (full instructions available at 
http://www.bdbiosciences.com/external_file s/Doc_Recon_2.0/pm/others/23-11112.pdf). 
Acquisition was performed with a BDFACSarray flow cytometer (BD Biosceinces, Belgium), 
and initial data processing was performed using FCAP Array™ V3.0 software. Cytokine bead 
arrays were performed as part of a service offered by the Flow Cytometry Core Facility in 
the School of Medicine and Biomedical Sciences, University of Sheffield. Further data 
processing and application of cytokine standard curves was performed using Graphpad 
Prism V 7.0 software.  
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4.3 Results 
4.3.1 Zanamivir has no Detrimental Effects on Oral Epithelial Cell or 
Periodontal Pathogen Viability 
Experiments described in this and the previous chapter involved exposure to zanamivir in 
an attempt to inhibit the sialidase activity of pathogens or purified sialidases, and observe 
the effect of pathogen sialidase inhibition in models of disease processes. The apparent 
ability of zanamivir to inhibit host-pathogen association, or to inhibit cytokine secretion 
could be explained by a detrimental effect of zanamivir on host cell viability or metabolism: 
i.e. If the host cells were killed by zanamivir (and subsequently lysed), the number of 
bacteria able to attach and invade during the antibiotic protection assays would appear 
reduced, or fewer cytokines would be produced since cell numbers are lower. These results 
could also occur due to bacterial killing, since dead pathogens might be less likely to illicit 
an immune response, or would not form colonies on agar plates during the antibiotic 
protection assay. Bacterial killing could also explain some of the detrimental effects of 
zanamivir on P. gingivalis biofilm formation and growth in sialoglycan-supplemented 
minimal media seen in the previous chapter (sections 3.3.2). 
Considering the above, it was important to assess the effects of zanamivir on the viability of 
oral epithelial cells bacteria. 
 Zanamivir has no Effect on Oral Epithelial Cell Viability 4.3.1.1
Data obtained during experiments described in section 4.3.5, as well as some additional 
experiments showed that zanamivir did not influence epithelial cell-line viability: Firstly, 
during the cytokine secretion experiments (section 4.3.5) culture supernatant was 
harvested and underwent an assay to detect the usually-cytosolic enzyme lactate 
dehydrogenase (LDH), a commonly used indicator of cell lysis. This assay relies on the 
production of a red formazan salt by LDH, which can be quantified by spectrophotometry. 
No significant differences in LDH levels were observed in culture supernatants from any of 
the conditions, as determined by one-way ANOVA with Tukey’s correction for multiple 
comparisons (figure 4.1 A), with untreated, zanamivir, T. forsythia, and T. forsythia + 
zanamivir conditions presenting no significant changes in LDH levels compared to the 
untreated condition. Furthermore, cells were counted to allow normalisation of cytokine 
secretion to the number of cells in each condition, and cell counting could also be used to 
determine viability and metabolic activity (inferred by cell growth over the 24 hours of 
treatment). Counting showed that there were no significant changes in cell numbers 
between each condition, when expressed as a total count of cells after 24 hours of 
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treatment or as the fold change of cells relative to the number of cells at the start of the 
experiment i.e. cell growth (figure 4.1 B), with untreated, zanamivir, T. forsythia, and T. 
forsythia + zanamivir conditions containing ~464000, ~485000, ~430000, and ~469000 cells, 
respectively. 
The effect of zanamivir on OKF6 cells was tested in cytokine-quantification experiments, so 
these were tested in a separate set of experiments, where cells were cultured in tissue 
culture plates, and exposed to different concentrations of zanamivir for 2.5 hours (the 
duration of the antibiotic protection assay). Culture supernatants underwent either an LDH 
assay to detect cell lysis/permeability, or an MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to test viability (figure 4.2). The latter assay relies on 
production of a purple formazan salt from MTT by metabolically active cells (specifically via 
the activity of oxidoreductases on MTT, and these enzymes require NAD(P)H), and the level 
of formazan can be quantified by spectrophotometry. The assays showed that zanamivir 
does not affect LDH release into culture supernatant, or formazan formation from MTT, in 
OKF6 cells exposed to zanamivir under conditions used in the antibiotic protection assay 
(significance determined by repeated measures one-way ANOVA, with all conditions 
compared to the untreated cells, with Tukey’s correction for multiple comparisons). 
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Figure 4.1. Viability testing of H357 OSCC cells exposed to T. forsythia and/or zanamivir. 
The oral epithelial cell line H357 was exposed to T. forsythia in the presence and absence of 
10mM zanamivir for 24 hours, followed by A) an LDH assay on culture supernatant, 
quantified as the absorbance following detection of formazan formed during the LDH 
assay, and B) cell counting, where data is described as cell numbers, or as the fold change 
in number of cells between 0 and 24 hours. Data shown represent the mean of three 
experiments, where each condition was repeated twice per experiment. Error bars=SD. No 
significant differences were found (where p=<0.05), as determined by one way ANOVA, 
with repeated measures and Tukey’s correction for multiple comparisons. 
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Figure 4.2. Viability testing of OKF6 oral epithelial cells exposed to zanamivir. 
The oral epithelial cell line OKF6 was exposed to T. forsythia in the presence and absence of 
10 mM zanamivir for 2.5 hours, followed by A) an MTT assay on cells or B) an LDH assay on 
culture supernatant, with the absorbance at 490 and 540 nm for LDH and MTT, 
respectively, used to relatively quantify levels of MTT and LDH. Data shown represent the 
mean of two experiments, where each condition was repeated three times per experiment. 
Error bars=SEM. No significant differences were found (where p=<0.05), as determined by 
one way ANOVA, with repeated measures and Tukey’s correction for multiple comparisons. 
 
 Zanamivir is not Directly Detrimental to Periodontal Pathogen Viability 4.3.1.2
Data obtained during experiments described in sections 4.3.3-4 showed that periodontal 
pathogen viability was not affected by zanamivir: During antibiotic protection assays, as 
well as enumerating the number of bacteria that had attached or invaded host cells, a 
viability condition was also enumerated, for the purposes of the experiment this allowed 
the level of bacteria-host cell association to be expressed as the percentage of viable 
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bacteria that had attached to or invaded host cells. It also served as evidence for any effect 
of zanamivir on bacterial viability: T. forsythia, P. gingivalis, and F. nucleatum were 
enumerated following the single species antibiotic protection assays described in section 
4.3.3, with the “viability” condition containing the suspension used to infect host cells, 
consisting of live bacteria which had been incubated for 2.5 hours in the presence or 
absence of 10 mM zanamivir (figure 4.3). The effect of zanamivir on each individual species 
was of interest, and required independent assessment, therefore, T-tests for each species 
comparing zanamivir-treated to untreated were performed to assess statistical significance. 
T-test was deemed the most appropriate statistical test to use in this instance, as the 
viability of each species is independent from the others, so three separate T-tests were 
performed to compare the viability of each species in the presence and absence of 
zanamivir. Zanamivir had almost no effect on the viability of all T. forsythia, P. gingivalis, 
and F. nucleatum with fold-changes in the number of viable bacteria of 1.12 (p= 0.141), 
1.13 (p=0.024), and 0.92 (p=0.509) in the presence of zanamivir (relative to the untreated 
condition), respectively. P. gingivalis did apparently display a significant increase in viability 
in the presence of zanamivir, but even if zanamivir does increase its viability by ~1.1 fold 
while the number of host-cell associating organisms remains the same, this would not 
account for the large decrease seen in the percentage of viable P. gingivalis associating 
with oral epithelial cells in the presence of zanamivir (figure 4.10).  
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Figure 4.3. Viability testing of periodontal pathogens exposed to zanamivir. 
T. forsythia, P. gingivalis, and F. nucleatum were incubated in the presence and absence of 
10mM zanamivir for 2.5 hours, followed by enumeration of viable organisms by agar plate 
counts, and data were expressed as the change in cell numbers relative to the untreated 
condition. Data shown represent the mean of three experiments, where each condition 
was repeated three times per experiment. Error bars=SD. Significance determined by T-test 
(*p=<0.05). 
 
Ultimately, these data show that under assay conditions the sialidase inhibitor zanamivir 
does not have any effect on oral epithelial cell viability, and no directly-detrimental effect 
on periodontal pathogen viability (i.e. although zanamivir does not kill pathogens directly, it 
may deprive them of nutrient sources, which would not be determined by these 
experiments). The absence of bacterial killing-while still interfering with virulence processes 
such as host cell association and cytokine induction-does in fact strengthen the case for the 
use of zanamivir as a therapeutic: Unlike conventional antimicrobials which target all 
bacteria in the microbiota, targeting processes that are beneficial to pathogens (and not as 
important for commensals) might reduce the proportion of pathogenic organisms in the 
microbiota, aiding in resolution of periodontal disease.  
4.3.2 Periodontal Pathogen Sialidases Cleave Sialic Acid from Host Cell Surfaces 
and this can be Inhibited by Zanamivir 
As shown in chapter 3, the sialidase inhibitor zanamivir can inhibit sialidase activity in P. 
gingivalis and to a lesser extent T. forsythia, and that this trend is also seen with their 
purified recombinant sialidases (section 2.3.7). Taken together with evidence that 
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periodontal pathogen-host cell interactions appear to be at least partially mediated by 
pathogen sialidases, this chapter aims to investigate if the sialidase inhibitor zanamivir can 
influence the interactions of T. forsythia and P. gingivalis with host cells. Considering this, it 
was first necessary to examine if the periodontal pathogen sialidases have the ability to 
cleave sialic acid from oral epithelial cells. 
 Cleavage of α2-3 and α2-6 linked sialic acid by Periodontal Pathogen 4.3.2.1
Sialidases 
Oral epithelial cells (oral squamous cell carcinoma, OSCC, cell line H357) were cultured on 
glass coverslips to ~70% confluence in a monolayer. Cells were exposed to T. forsythia and 
P. gingivalis, or treated with their purified sialidases (NanH and SiaPG), in the presence and 
absence of zanamivir, as described below. Treated cells were stained with lectins from 
Maakia amuriensis (MAA) and Sambucus nigra (SNA), which are specific for α2-3 and α2-6 
linked sialic acid, respectively. To allow visualisation, lectins were either purchased as 
Fluorescein Isothiocyanate (FITC) conjugated versions, or as biotinylated lectins, which 
enabled labelling with Texas Red (TR)-Streptavidin (which binds to the biotin moiety of the 
lectin). Cells were then fixed with paraformaldehyde, before the coverlips were mounted 
onto glass microscope slides with a light-resistant antifade mount that containied a nuclear 
stain (DAPI, within ProLong Antifade-Gold), and visualised using immunofluorescence 
microscopy.  
T. forsythia and P. gingivalis were washed twice and resuspended in PBS at OD600 0.5, 
applied to H357 monolayers, and incubated for 2 hours at 37°C to test the ability of live 
pathogens to desialylate epithelial cell membranes, in the presence or absence of 
zanamivir to test its potential to inhibit cleavage of cell surface sialic acids by the 
pathogens. A high concentration (10 mM) was chosen to ensure sialidase inhibition, since a 
lower concentration may not inhibit live T. forsythia effectively. The relatively high IC50 
(~6.3 mM) of zanamivir for purified NanH activity on MUNANA also suggests that the use of 
a high concentration of zanamivir (10 mM) in these assays would be required in order to 
obtain some measure of T. forsythia sialidase inhibition. After treatment with live P. 
gingivalis or T. forsythia in the presence or absence of zanamivir, cells then underwent 
lectin staining as described, followed by paraformaldehyde fixation, and they were 
mounted and visualised as described above (figure 4.4). After visualisation and image 
processing, the level of α2-3 and α2-6 linked sialic acid was quantified as the mean 
fluorescence intensity (MFI) per image (figure 4.5 A). A more appropriate way to express 
staining would be as the MFI/cell, but the P. gingivalis condition displayed a significantly 
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lower cell count (figure 4.5 B) compared to the untreated control, which could skew the 
result if expressed as MFI/Cell. In any case, both MFI/Cell and MFI are presented. 
Significant differences between each condition and the untreated control were tested 
using one way ANOVA, with Dunnet’s correction for multiple comparisons. 
Exposure of oral epithelial cells to T. forsythia resulted in a twofold reduction in α2-6 linked 
sialic acid relative to the untreated control, however this was not considered statisitcially 
significant under the one way ANOVA described above (MFIs of 147 and 75, respectively, 
p=0.14, using T-test in this comparison yields a p-value of 0.02) and this reduction was not 
inhibited in the presence of zanamivir (MFI of 87). α2-3 linked cell surface sialic acid was 
apparently not reduced by the presence T. forsythia, relative to the control (MFIs of 256 
and 302, respectively, p=0.67). This was surprising, since data shown in section 2.3.6.3 
highlights the higher catalytic efficiency T. forsythia NanH for α2-3 linked sialic acid rather 
than α2-6 linked sialic acid (Kcat / KM  of 1.122 min
-1mM-1 and 0.339min-1mM-1, respectively). 
However, linkage type is not the only factor in sialidase-ligand interactions-the underlying 
glycan can also play a role, as seen in the case of the ligands sialyl lewis A and X (section 
2.3.6.4), which both contain α2-3 linked sialic acid, but displayed great differences in their 
affinity for NanH. Another explanation could be that since this experiment was conducted 
with staining on live, unfixed cells that host surface sialic acid cycling is more rapid for α2-3 
linked sialic acid (i.e. host cells may have higher 3-sialyltransferase activity to replenish 
surface sialic acids). In addition these experiments were conducted on live unfixed bacteria  
and since T. forsythia is more sensitive to oxygen than P. gingivalis (Graham Stafford, 
unpublished observation) this could explain why T. forsythia appeared to have only a small 
effect on surface sialic acid, while the P. gingivalis effect was more pronounced.   
Discussing the significant reduction in α2-3 and α2-6 linked staining caused by P. gingivalis 
is more difficult, partly due to the significant reduction in cell numbers seen in P. gingivalis-
containing conditions (the mean number of cells/field of view in untreated, P. gingivalis, 
and P. gingivalis + zanamivir conditions were 25, 7, and 4, respectively). The reduction in 
levels of surface sialic acid could also be due to the action of P. gingivalis gingipains, which 
could cleave sialoglycoproteins from the surface of the cell: While this would not affect 
sialic acid directly, loss of the sialoglycoprotein from the cell surface would result in an 
apparent reduction of surface sialic acid. 
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Figure 4.4. Exposure to periodontal pathogens removes sialic acid from epithelial cell 
surfaces. 
Cells were stained with lectins for α2-3 (red) and α2-6 (green) linked sialic acid. Prior to 
staining, cells were exposed to T. forsythia and P. gingivalis suspended in PBS, in the 
presence or absence of 10mM zanamivir, as indicated. All images were visualised using the 
same microscopy and image processing parameters (fluorescence intensity, exposure time 
and background subtraction). Images were captured in three fields of view, images shown 
are representative of each condition.  
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Figure 4.5. Quantification of cell surface sialic acid from oral epithelial cells exposed to A) 
live pathogens B) the effect of pathogen exposure on cell numbers. 
A) Cells were stained with lectins for α2-3 and α2-6 linked sialic acid. Prior to staining, cells 
were exposed to T. forsythia and P. gingivalis suspended in PBS, in the presence or absence 
of 10mM zanamivir, as indicated. All images were visualised using the same microscopy 
and image processing parameters (fluorescence intensity, exposure time and background 
subtraction). After processing, images could undergo A) staining quantification, to obtain 
the mean fluorescence intensity (MFI) per field of view, and this could be standardised to 
cell count (MFI/Cell). B) Cells were counted and expressed as-the number of cells per field 
of view. Data show the mean of three fields of view per condition, from one experiment. 
Error Bars =SD, significant deviation from the untreated condition only was determined by 
repeated measures one way ANOVA with Dunnet’s correction for multiple comparisons 
(*p=<0.05, **p=<0.01,  ***p=<0.001). 
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Exposure to pathogens resulted in loss of α2-3 and α2-6 linked sialic acid from host cells, 
and this could be due to the action of pathogen sialidases, or from pathogen proteases 
removing the sialoglycoproteins. It is also possible that this happens due to host-cell 
mediated processes, such as the mobilisation of human sialidases to the membrane, seen 
during host cell responses to pathogens (Amith et al. 2009; Stamatos et al. 2010), or 
perhaps desialylation is caused by apoptotic processes (Meesmann et al. 2010). Certainly, 
in these experiments P. gingivalis reduced the numbers of cells present at the end of the 
assay, and this was evident during image capture and subsequent cell-number 
quantification (Figure 4.5 B). 
 
Since these data were difficult to interpret due to the variation in cell numbers, the 
apparent possible interference by P. gingivalis, and the possible response of host cells to 
live periodontal pathogens, assays with the purified pathogen sialidases were performed. 
NanH and SiaPG were diluted in PBS at a concentration of 100 nM, applied to H357 
monolayers, and incubated for 2 hours at 37 °C. Cells then underwent lectin staining, 
imaging, and processing as described above (figure 4.6). Purified enzymes did not cause 
significant changes to cell numbers, as determined by repeated measures one-way ANOVA, 
with Dunnet’s correction for multiple comparisons. 
 
NanH caused reductions in α2-3 and α2-6 linked sialic acid from oral epithelial cell surfaces 
(Figures 5.6), however these were not deemed statistically significant by the one-way 
ANOVA described here. In the untreated and NanH conditions, α2-3 linked sialic acid 
staining (MFI/Cell) was 3.6 and 0.9, respectively (p=0.07), and α2-6 linked sialic acid 
staining (MFI/Cell) was 2.6 and 0.9, respectively (p=0.09). The presence of zanamivir did not 
prevent the decreases in cell surface sialic acid of either linkage type. Qualitatively, images 
appeared to confirm this assessment-that NanH desialylated both types of linkage, and was 
not inhibited by zanamivir (figure 4.6). 
 
Quantatively, SiaPG reduced staining to a lesser extent, though reductions were not 
considered significant by one-way ANOVA. Zanamivir slightly, though not significantly, 
inhibited loss of α2-3 linked sialic acid caused by SiaPG (figure 4.7). Qualitatively however, 
the change in surface sialic acid appeared to be more drastic, particularly for α2-6 linked 
sialic acid. This may be due to the presence of nuclear staining in the green channel (DAPI 
can emit green fluorescence), as evidenced by the green present in the SiaPG-FITC panel in 
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figure 4.6, but not seen in the overlay. Adjustments to parameters during image acquisition 
or processing might have removed the apparent nuclear staining, but would have rendered 
SiaPG incomparable to the other conditions. Flow cytometry would have been an 
alternative approach to assessing sialic acid staining following treatment with enzymes, and 
this was attempted during this project, but proved difficult to optimise. 
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Figure 4.6. Purified sialidases desialylate oral epithelial cell surfaces. 
Cells were stained with lectins for α2-3 and α2-6 linked sialic acid in red and green, 
respectively. Prior to staining, cells were treated with NanH and SiaPG in PBS, in the 
presence or absence of 10mM zanamivir, as indicated. All images were visualised using the 
same microscopy and image processing parameters (fluorescence intensity, exposure time 
and background subtraction). Images were captured in three fields of view, and this was 
repeated in three separate experiments. Images shown are representative of each 
condition. 
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Figure 4.7. A) Quantification of cell surface sialic acid on oral epithelial cells exposed to 
NanH and SiaPG. B) Exposure to sialidases or zanamivir has no effect on cell numbers. 
Cells were stained with lectins for α2-3 and α2-6 linked sialic acid. Prior to staining, cells 
were exposed to PBS-diluted NanH, SiaPG, or PBS alone, in the presence or absence of  
10 mM zanamivir, as indicated. All images were visualised using the same microscopy and 
image processing parameters (fluorescence intensity, exposure time and background 
subtraction. Images were captured in three fields of view, and after processing could 
undergo A) Quantification of the effect of NanH and SiaPG on α2-3 and α2-6 linked sialic 
acid, expressed as MFI/cell. Error Bars =SD, Significance determined by repeated measures 
one-way ANOVA, with Dunnet’s correction for multiple comparisons (where p=<0.15, the 
p-value is indicated). B) Cells were counted to obtain the number of cells per field of view 
and the effect of zanamivir in enzyme treated and untreated conditions was compared, 
error bars=SEM, significant deviation from the untreated condition only was determined by 
repeated measures one way ANOVA with Dunnet’s correction for multiple comparisons 
(none discovered). 
  
A) 
B) 
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 NanH acts on cell surface Sialyl-Lewis A and X 4.3.2.2
Here, in chapter 3, the T. forsythia sialidase NanH was shown to release sialic acid from 
SLeA and SLeX, with greater affinity for SLeA (Km of 0.2 and 2.0, respectively). This 
experiment was in the context of soluble SLeA/X, non-glycoprotein conjugated. To 
investigate the ability of NanH to cleave sialic acid from cell surface membrane associated 
SLeA/X, the (OSCC) cell line H357 was cultured on glass coverslips, treated under a number 
of conditions (described below), followed by staining with FITC-conjugated anti-SLeA or 
anti-SLeX antibodies. This enabled visualisation of cell surface SLeA/SLeX using fluorescence 
microscopy, and staining was quantified by image processing software using the level of 
green fluorescence in a given image, expressed as mean fluorescence intensity (MFI). MFI 
was normalised to the number of cells in a given image (MFI/cell), and by imaging three 
fields of view per condition in three separate experiments, the levels of SLeA/X staining 
between the conditions could be compared. Significant differences between the conditions 
were determined using repeated measures one-way ANOVA with Tukey’s correction for 
multiple comparisons. 
 Prior to staining, cells were incubated with or without NanH to determine whether or not 
it could target cell surface SleA/X. Conditions were also tested in the presence or absence 
of zanamivir to determine the potential to inhibit cell surface SleA/X desialylation by NanH. 
NanH was shown to be capable of cleaving sialic acid from both SLeA and SLeX on oral 
epithelial cells, and zanamivir was partially capable of inhibiting SLeA desialytion (figure 
4.8-9). Staining quantification showed that NanH decreased the levels of epithelial cell 
membrane SLeA and SLeX by approximately two thirds; from 3.5 to 1.2 MFI/Cell in the case 
of SLeA, and 3.26 to 1.03 MFI/Cell in the case of SLeX (p=<0.01 in both cases). Zanamivir 
was only capable of slightly inhibiting sialic acid release from cell surface SLeA/X by NanH 
under experimental conditions, from 1.2 to 1.5 MFI/Cell in the case of SLeA, and from 1.0 
to 1.1 MFI/cell in the case of SLeX, and in both cases this inhibition was not statistically 
significant compared to the NanH only condition. 
237 
 
  
238 
 
 
 
 
U
n
tr
e
a
te
d
N
a
n
H
N
a
n
H
 +
 1
0
m
M
 Z
a
n
0
1
2
3
4
5
6
C
e
ll
u
la
r
 S
le
A
(
M
F
I/
C
e
ll
)
**
**
  
Cell Nuclei SLeA 
Isotype 
Control 
Untreated 
NanH 
Overlay 
(SLeA+Nuclei) 
NanH+Zan 
A) 
B) 
239 
 
 
 
 
 
 
Figure 4.8. NanH desialyates sialyl-lewis A on epithelial cell surfaces. 
A) Fluorescence Microscopy. Cells were stained with rabbit anti-SLeA antibodies, followed 
by secondary staining with FITC-conjugated goat anti rabbit antibodies. Stained cells were 
mounted onto microscope slides with a DAPI stain to visualise nuclei. Prior to staining, cells 
were treated with NanH in PBS, in the presence or absence of 10 mM zanamivir (zan), as 
indicated. All images were visualised using the same microscopy and image processing 
parameters (fluorescence intensity, exposure time and background subtraction). Images 
were captured in three fields of view, in three separate experiments. Images shown are 
representative of each condition. Isotype control=non-specific primary antibody raised in 
rabbit. B) Quantification of SLeA staining. The mean level of FITC fluorescence in the green 
channel of each image corresponds to the level of SLeA staining, or Mean Fluorescence 
Intensity (MFI). MFI was normalised to the number of cells in a given image (MFI/Cell). The 
MFI/cell of the isotype control condition was subtracted from the MFI/cell in each 
condition and plotted. Data shown represent the mean from three fields of view, repeated 
in three separate experiments. Error Bars=SD. Significance determined by repeated 
measures one-way ANOVA with Tukey’s correction for multiple comparisons ( **p=<0.01). 
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Figure 4.9. NanH desialylates sialyl-lewis X on epithelial cell surfaces. 
A) Fluorescence Microscopy. Cells were primary-stained with murine anti-SLeX antibodies, 
followed by secondary staining with FITC-conjugated goat anti mouse antibodies. Stained 
cells were mounted onto microscope slides with a DAPI stain to visualise nuclei. Prior to 
staining, cells were treated with NanH in PBS, in the presence or absence of 10mM 
zanamivir (zan), as indicated. All images were visualised using the same microscopy and 
image processing parameters (fluorescence intensity, exposure time and background 
subtraction). Images were captured in three fields of view, in three separate experiments. 
Images shown are representative of each condition. Isotype control=non-specific primary 
antibody raised in rabbit. B) Quantification of SLeX staining. The mean level of FITC 
fluorescence in the green channel of each image corresponds to the level of SLeX staining, 
or Mean Fluorescence Intensity (MFI). MFI was normalised to the number of cells in a given 
image (MFI/Cell). The MFI/cell of the isotype control condition was subtracted from the 
MFI/cell in each condition and plotted. Data shown represent the mean from three fields of 
view, repeated in three separate experiments. Error Bars=SD. Significance determined by 
repeated measures one-way ANOVA with Tukey’s correction for multiple comparisons 
(**p=<0.01). 
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4.3.3 Zanamivir inhibits Attachment and Invasion of Oral Epithelial Cells by T. 
forsythia, P. gingivalis, and the sialidase-negative F. nucleatum 
Bacterial attachment and invasion was tested in a series of antibiotic protection assays: Cell 
lines (described below) were cultured as a monolayer, and infected in the presence or 
absence of zanamivir with P. gingivalis, T. forsythia, or F. nucleatum, which was included as 
a control pathogen to see if zanamivir had any effect on attachment and invasion of host 
cells by sialidase-negative organisms and since it is an important bridging organism in 
periodontal sub-gingival biofilms and is also known to synergise with T. forsythia and P. 
gingivalis in cell-interactions assays (Metzger et al. 2009;  A. Sharma et al. 2005). All 
infections were carried out at a multiplicity of infection (MOI) of 1:100 host cells: bacteria. 
After infection, cells were incubated at 37 °C, 5 % CO2, for 1.5 hours, then washed to 
remove non-cell-associated bacteria.  Infected cells were lysed, and lysates spotted onto 
agar. This enabled enumeration of the total number of bacteria associated with host cells 
(bacteria that had attached to external surface of, or invaded host cells). A second infected 
host cell monolayer undergoes an additional step, where infected cells are treated with 
metronidazole prior to lysis; this kills bacteria attached to their external surface, leaving 
only bacteria which have invaded host cells, which are enumerated after plating of cell 
lysates onto agar. Subtraction of the invaded bacteria from the total number of associated 
bacteria provides the number of bacteria attached to the host cells. Bacterial suspension 
used to initially infect the host cells is retained and the number of bacteria in this 
suspension that survive the duration of the assay is used to obtain the number of host cell-
associated bacteria between experiments (where different MOIs are used). The percentage 
of viable bacteria that associate with host cells was determined. Significant differences in 
attachment, invasion, and total association were assessed by a series of paired T-tests. This 
test was considered appropriate since the only objective was to compare the effect of 
zanamivir on bacterial attachment, invasion, and total association, independently of each 
other. Testing for statistically significant differences in bacterial attachment, invasion, and 
total association for each species was not the objective of this study. 
The OSCC cell line H357 was used in the antibiotic protection assay, since it is a well 
characterised, frequently used model for oral epithelium-bacteria interactions (Suwannakul 
et al. 2010; Al-Taweel et al. 2016), and for practical purposes since it proliferates rapidly. 
H357 cells were infected with either T. forsythia, P. gingivalis, or F. nucleatum subsp. 
nucleatum (MOI 1:100), in the presence or absence of zanamivir. For all three pathogens, 
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zanamivir significantly reduced one or more aspects of host cell association (figure 4.10). 
The percentage of viable T. forsythia attachment, invasion, and total association with H357 
cells were all significantly reduced in the presence of zanamivir; attachment from 4.6 to 1.2 
%, invasion from 3.4 to 1.6 %, and total association from 8.0 to 2.8 % (with p-values of 
<0.0001, <0.01, and <0.00001, respectively, according to paired T-test), i.e. a 3-4-fold 
reduction. The percentage of viable P. gingivalis also showed significantly reduced invasion 
n the presence of zanamivir; from to 4.5 to 1.8% (p= <0.01), i.e. over 2-fold reduction. The 
total associated P. gingivalis was also decreased in the presence of zanamivir, although the 
change was not significant. For the sialidase negative F. nucleatum, invasion was slightly, 
though not significantly inhibited by zanamivir, but the attached and total associated 
number of bacteria was significantly reduced by zanamivir, from 21 .8 to 7.2 % (p=<0.05) 
and 36.6 to 18.2 % (p=<0.05), respectively.  
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Figure 4.10. The Effect of Zanamivir on Attachment and Invasion of OSCC Epithelial Cells. 
Antibiotic protection assays were performed in the presence or absence of zanamivir with 
either T. forsythia, P. gingivalis, or F. nucleatum. Bacterial attachment, invasion, and total 
association with host cells was normalised to the number of bacteria that were used to 
infect each condition that had survived the duration of the assay (the percentage of viable 
bacteria). Zanamivir=10mM zanamivir present during host cell exposure to bacteria.  Data 
represent the mean from three independent experimental repeats, and each condition was 
repeated in triplicate during each experiment. Error bars=SEM, Significance determined by 
paired T-test, *p=<0.05, **p=<0.01.  
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Antibiotic protection assays were also performed using the same procedures as described 
above but using  the immortalised oral keratinocyte cell line, OKF6 (Dickson et al. 2000). 
Since these cells are considered more closely related to oral epithelial cells in the host, 
assays done using these cells might be considered a better model for host-pathogen 
interactions.  Again, for all three pathogens, zanamivir reduced one or more aspects of host 
cell association for T. forsythia and P. gingivalis (figure 4.11).  
The percentage of viable T. forsythia attachment, invasion, and total association with OKF6 
cells were all significantly reduced in the presence of zanamivir; attachment from 3.2 to 1.0 
%, invasion from 2.5 to 0.3 %, and total association from 5.8 to 1.4 % (p- values were <0.05, 
<0.01, and <0.05, respectively). The percentage of viable P. gingivalis also showed 
significant reductions in attachment, invasion, and total association; attachment from 0.9 
to 0.1%, invasion from 0.7 to 0.1%, and total association from 1.7 to 0.2% (p- values were 
<0.05, <0.05, and <0.01, respectively). For the sialidase negative F. nucleatum, attachment 
was not affected by zanamivir, but the number of invaded and total associated number of 
bacteria were signficantly reduced by zanamivir; invasion from 4.6 to 1.3 %, (3-fold 
reduction, p=<0.001) and total association 5.6 to 2.6 % (2-fold reduction, p=<0.01). 
Interestingly, in this cell line, most of the F. nucleatum that were associated with host cells 
appeared to have invaded the host cells, rather than simply remaining attached to the 
external surface, and this trend was consistent in all experimental repeats.  
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Figure 4.11. The effect of zanamivir on attachment and invasion of immortalised OKF6 
epithelial cells. 
Antibiotic protection assays were performed in the presence or absence of zanamivir with 
either A) T. forsythia, B) P. gingivalis, or C) F. nucleatum. Bacterial attachment, invasion, 
and total association with host cells was normalised to the number of bacteria that were 
used to infect each condition that had survived the duration of the assay (the percentage of 
viable bacteria). Zanamivir=10mM zanamivir present during host cell exposure to bacteria. 
Data represent the mean from three experimental repeats, and each condition was 
repeated in triplicate during each experiment. Error bars=SEM, Significance determined by 
T-test, *p=<0.05, **p=<0.01. 
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Zanamivir was consistently capable of reducing bacterial association with host cells; 
significant reductions in the total number of associated bacteria (the sum of attached and 
invaded bacteria) were seen for all three periodontal pathogens. T. forsythia was the most 
drastically affected by zanamivir, with association reduced by a factor of approximately 
threefold and fivefold in H357 and OKF6 cell lines, respectively. This was surprising given 
the apparently limited inhibition of T. forsythia by zanamivir (section 2.3.7.1) but maybe 
only a small reduction in activity is enough to abrogate interactions at a host-pathogen 
interface.  There are many potential reasons for these differences, but it is of note that 
zanamavir does affect interactions with both OSCC (H357) and immortalised (OKF6) oral 
epithelial cell lines in these assays. 
4.3.4 Zanamivir inhibits Attachment and Invasion of Oral Epithelial Cells 
During Infection with Multiple Periodontal Pathogens 
In addition to single species antibiotic protection assays, experiments were also performed 
where multiple periodontal pathogens were used to infect cells; this is more representative 
of the situation in vivo, where host cells encounter multiple species at once. This is 
particularly relevant during host cell association, since periodontal pathogens have been 
shown to act in synergy during attachment and invasion (Saito et al. 2012; Inagaki et al. 
2006; Kirschbaum et al. 2010).  
Antibiotic protection assays were carried out in the manner described above, using H357 
oral epithelial cells. MOI was maintained at 1:100 host cells: bacteria, so for infections using 
two species, the ratio was 1:50:50 (host cells: species 1: species 2), and for infections with 
all three species, the ratio was 1:33:33:33 (host cells: species 1: species 2: species 3). T. 
forsythia, P. gingivalis, and F. nucleatum were used in a variety of combinations to infect 
epithelial cell monolayers. In addition to quantifying the numbers of all bacteria-not 
distinguishing between species during an assay-the levels of each individual species in a 
given assay could be enumerated by colony counting on agar plates, since the colony 
morphologies of T. forsythia, F. nucleatum, and P. gingivalis are distinct from each other 
(figure 4.12). All possible combinations were tested in this way, with data described below. 
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Figure 4.12. Colony morphology of P. gingivalis, F. nucleatum, and T. forsythia during 
mixed-Species enumeration. 
Images of mixed-species agar cultures to highlight differences in colony morphology. One 
colony representative of each species is labelled on the images. P. gingivalis (PG) forms 
opaque black pigmented colonies, T. forsythia (TF) forms translucent grey colonies, and F. 
nucleatum (FN) forms large beige colonies, translucent at the edges with a raised, opaque 
centre.  
 
 T. forsythia and F. nucleatum Co-Infection 4.3.4.1
Host cells were infected, in the presence or absence of zanamivir. The attachment, 
invasion, and total association of both species were reduced in the presence of zanamivir, 
though due to variation between repeats this reduction was not always significant.  
T. forsythia had a significant reduction in bacterial invasion, from 3.8 to 1.5 % (p=<0.05), 
and a near-signficant reduction in total association, from 9.3 to 4.5% (p=0.053). T. forsythia 
attachement was also reduced, though not significantly, from 5.5 to 2.9% (p=0.17). In the 
case of F. nucleatum, invasion was signicantly reduced, in the presence zanamivir, from 
11.4 to 2.2 % (p=<0.05), while attachment and total association were both reduced, neither 
were shown to be significant, from 24.7 to 12.4 % (p=0.094), and 11.4 to 2.2 % (p=0.053), 
respectively (figure 4.13 A and B). 
Quantification of the total number of bacteria (both T. forsythia and F. nucleatum) shows 
that zanamivir significantly reduced both invasion and total association of bacteria with 
host cells, from 7.4 to 1.8 %, and 19.6 to 7.6 % (p=<0.01 and p=<0.05), respectively (figure 
4.13 C).  
Un-assisted View  Colony Counter Microscope  
PG  
TF  
FN 
FN 
PG 
TF 
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Overall, these data indicate that Zanamavir has an effect on co-infection levels of  
T. forsythia and F. nucleatum in a co-infection situation. 
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Figure 4.13. The effect of zanamivir on attachment and invasion of epithelial cells co-
infected with T. forsythia and F. nucleatum. 
Antibiotic protection assays were performed in the presence or absence of zanamivir with 
T. forsythia and F. nucleatum. A) Level of T. forsythia-host cell association, B) Level of F. 
nucleatum-host cell association, or C) Level of both T. forsythia and F. nucleatum-host cell 
association. Bacterial attachment, invasion, and total association with host cells was 
normalised to the number of bacteria that were used to infect each condition that had 
survived the duration of the assay (the percentage of viable bacteria). Zanamivir=10mM 
zanamivir present during host cell exposure to bacteria. Data represent the mean from 
three experimental repeats, and each condition was repeated in triplicate during each 
experiment. Error bars=SEM, Significance determined by paired T-test, *p=<0.05, 
**p=<0.01. 
B) A) 
C) 
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 T. forsythia and P. gingivalis co-infection  4.3.4.2
Host cells were infected, in the presence or absence of zanamivir. The attachment and total 
association of both species appeared to be reduced in the presence of zanamivir, however, 
due to variation between experimental repeats, almost no significant differences were 
found: T. forsythia displayed reductions in bacterial attachment, invasion, and total 
association in the presence of zanamivir (Figure 4.14 A), from 11.6  to 2.0 %, 2.9 to 1.4 %, 
and 14.5 to 3.6 %, respectively, though only invasion was deemed significant by T-test (with 
p-values of 0.14, 0.03, and 0.10, respectively). P. gingivalis attachment and total 
association were also reduced by zanamivir, although the decrease was not statistically 
significant in either case (where p=0.05), from 12.7 to 0.25 % (p=0.068), and from 14.6 to 
2.5 % (p=0.064), respectively (figure 4.14 B). 
 Quantification of both P. gingivalis and T. forsythia together showed that attachment, total 
association, and perhaps invasion were reduced in the presence of zanamivir, although 
again the variation between experiments meant that none of the reductions were 
statistically significant (figure 4.14 C). Attachment was reduced from 12.1 to 0.8 % 
(p=0.076), invasion from 2.7 to 53% (p=0.25), and total association from 14.4 to 2.5 % 
(p=0.062). 
Overall, these data indicate that zanamavir has an effect on co-infection levels of  
T. forsythia and P.gingivalis in a co-infection situation, although this is perhaps not as 
striking as in the case of T. forsythia and F. nucleatum. Given more time, experiments could 
be repeated, perhaps reducing experimental variation. 
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Figure 4.14. The effect of zanamivir on attachment and invasion of epithelial cells co-
infected with T. forsythia and P. gingivalis.  
Antibiotic protection assays were performed in the presence or absence of zanamivir with 
T. forsythia and P. gingivalis A) Level of T. forsythia-host cell association, B) Level of P. 
gingivalis-host cell association, or C) Level of both T. forsythia and P. gingivalis-host cell 
association. Bacterial attachment, invasion, and total association with host cells was 
normalised to the number of bacteria that were used to infect each condition that had 
survived the duration of the assay (the percentage of viable bacteria). Zanamivir=10mM 
zanamivir present during host cell exposure to bacteria. Data represent the mean from 
three experimental repeats, and each condition was repeated in triplicate during each 
experiment. Error bars=SEM. Significance determined by paired T-test, *p=<0.05.  
B) A) 
C) 
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 P. gingivalis and F. nucleatum co-infection 4.3.4.3
Host cells were infected in the presence or absence of zanamivir. The attachment, invasion, 
and total association P. gingivalis was reduced in the presence of zanamivir to varying 
extents (Figure 4.15 A): P. gingivalis bacterial attachment, invasion, and total association 
were significantly reduced by zanamivir, from 3.9 to 1.15 % (p=<0.05), 1.7 to 0.5 % 
(p=<0.01), and 5.5 to 1.7 % (p=<0.05). In the case of F. nucleatum, invasion and total 
association appeared to be reduced in the presence of zanamivir, although the decreases 
were not statistically significant (figure 4.15 B), from 4.0 to 1.6 % (p=0.23), and 7.9 to 6.0 
(p=0.12), respectively. 
Quantification of the total number of bacteria (both P. gingivalis and F. nucleatum) shows 
that zanamivir significantly reduced attachment, invasion, and total association of bacteria 
with host cells, from 1.9 to 0.8 % (p=<0.05), 4.0 to 1.56 % (p=<0.05), and 5.9 to 2.4 % 
(p=<0.01), respectively (figure 4.15 C).  
Overall, these data indicate that zanamavir has an effect on levels of P. gingivalis and F. 
nucleatum in a co-infection situation.  
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Figure 4.15. The Effect of Zanamivir on Attachment and Invasion of Epithelial Cells Co-
infected with P. gingivalis and F. nucleatum. 
Antibiotic protection assays were performed in the presence or absence of zanamivir with 
T. forsythia and F. nucleatum A) Level of T. forsythia-host cell association, B) Level of F. 
nucleatum-host cell association, or C) Level of both P. gingivalis and F. nucleatum-host cell 
association. Bacterial attachment, invasion, and total association with host cells was 
normalised to the number of bacteria that were used to infect each condition that had 
survived the duration of the assay (the percentage of viable bacteria). Zanamivir=10mM 
zanamivir present during host cell exposure to bacteria. Data represent the mean from 
three experimental repeats, and each condition was repeated in triplicate during each 
experiment. Error bars=SEM, Significance determined by paired T-test, *p=<0.05, 
**p=<0.01. 
 
B) A) 
C) 
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 T. forsythia, F. nucleatum, and P. gingivalis co-infections 4.3.4.4
 FInally, host cells were infected with all three organisms, in the presence or absence of 
zanamivir. Enumeration of the individual species revealed that the invasion and total 
association of all three was reduced in the presence of zanamivir, to varying extents. In the 
case of T. forsythia, these reductions were not significant, though invasion showed the 
greatest change (figure 4.13 A), from 28.6 to 17.7% in the presence of zanamivir (p=0.18). 
F. nucleatum invasion and total association was significantly reduced by zanamivir, from 
27.1 to 7.1% and 46.1 to 24.1%, respectively (Figure 4.13 B). In the case of P. gingivalis, 
zanamivir caused a significant reduction in invasion, from 6.5 to 3.0% (Figure 4.13 C).  
Quantification of the total number of bacteria (T. forsythia, F. nucleatum, and P .gingivalis 
enumerated together rather than individually) showed that zanamivir significantly reduced 
attachment, invasion, and total association of bacteria with host cells, from 17.7 to 7.7%, 
9.6 to 7.15%, and 26.14 to 14.6%, respectively (Figure 4.13 D).  
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Figure 4.16. The effect of zanamivir on attachment and invasion of epithelial cells co-
infected with T. forsythia, F. nucleatum, and P. gingivalis. 
Antibiotic protection assays were performed in the presence or absence of zanamivir with 
T. forsythia, F. nucleatum, and P. gingivalis. A) T. forsythia-host cell association, B) F. 
nucleatum-host cell association, C) P. gingivalis-host cell association D) T. forsythia, F. 
nucleatum, and P. gingivalis-host cell association. Bacterial attachment, invasion, and total 
association with host cells was normalised to the number of bacteria that were used to 
infect each condition that had survived the duration of the assay (the percentage of viable 
bacteria). Zanamivir=10mM zanamivir present during host cell exposure to bacteria. Data 
represent the mean from three experimental repeats, and each condition was repeated in 
triplicate during each experiment. Error bars=SEM, Significance determined by paired T-
test, *p=<0.05, **p=<0.01. ***p=<0.001.  
 
B) A) 
C) D) 
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Taken as a whole, these data show that zanamivir interfered with bacteria-host cell 
interactions during single-species antibiotic protection assays, where host cells were 
infected with either T. forsythia, P. gingivalis, or F. nucleatum. Zanamivir reduced bacterial 
attachment, invasion, and the total association (sum of attached and invaded bacteria) to 
varying degrees for each pathogenic species. The most drastically affected by zanamivir 
was T. forsythia, which displayed significant reductions in attachment, invasion, and total 
association in the presence of zanamivir, in both OSCC (H357) and normal-immortalised 
(OKF6) oral epithelial cell lines. Zanamivir also inhibited P. gingivalis association with host 
cells, with significant differences seen in invasion or total association in OSCC and 
normalised oral epithelial cell lines, respectively. The most surprising result was that 
zanamivir inhibited host cell association by the sialidase negative F. nucleatum. 
Within the mixed species antibiotic protection assays cells were co-infected with 
combinations of two or three of the periodontal pathogens (T. forsythia, F. nucleatum, or P. 
gingivalis). It is clear from these that the experiments assessing dual-infections revealed a 
role for sialidase and zanamavir in reducing co-infection levels, with the most-striking data 
obtained for the T.forsythia/F. nucleatum combination.  
However, the triple-infection situation was more difficult to reproduce in separate 
experiments, at least in terms of enumerating individual species within these assays, and it 
would be pertinent to consider increasing n-numbers for this experimental set. On the 
other hand, the combined totals of the two or three species present in each experiment 
were more consistent: This is evident in the dataset summarising the mixed species 
experiments, where significant differences between untreated and zanamivir-treated 
conditions are seen more frequently in the combined totals of the two or three species 
present in a given experiment, rather than enumeration of individual species. This implies 
that zanamivir is able to prevent some aspects of host-pathogen association, even in a 
three-species infection model-which was the most difficult to reproduce in terms of the 
association levels of individual species. 
When enumerating individual levels of the pathogens in the three-species infection 
experiment, zanamivir was capable of significantly reducing host-bacteria association, but 
only the total association of F. nucleatum was significantly inhibited (according to T-test, 
where p=0.05). However, quantifying levels of all three species together showed that 
zanamivir significantly reduced attachment and total association of host cells by the three 
species; attachment was reduced by ~66 %, and total association by ~50 %. Overall 
260 
 
indicating that sialidase inhibition did influence the host-cell interactions of this mini-
community experiment. 
Although host cell association is important for bacterial colonisation and persistence, 
ultimately it is the host immune response to pathogens that causes the tissue destruction 
seen during periodontitis. Therefore, another set of experiments was performed to study 
the effect of periodontal pathogen sialidases in pro-inflammatory signalling by oral 
epithelial cells. The ability of the sialidase inhibitor zanamivir to inhibit sialidase mediated-
pro-inflammatory signalling was also tested. 
4.3.5 T. forsythia Sialidase Influences Pro-Inflammatory Signalling in Epithelial 
Cells, and this is Affected by Zanamivir 
A key aspect of disease progression in periodontitis is overstimulation of innate immunity, 
resulting in destructive inflammation that damages host tissue. Oral epithelial (and 
endothelial) cells can express some pro-inflammatory signalling molecules in response to 
pathogens or pathogen components, or as a result of cell damage. Periodontal pathogen 
sialidases may mediate these processes in a number of ways, possibly directly through 
desialylation of host cell surfaces leading to complement deposition and cell death, or 
indirectly by influencing the attachment and invasion of pathogens to host cells.  
An important pathway leading to stimulation of the innate immune response is mediated 
by the Toll Like Receptors (TLRs), with  TLRs -2, -4, and -9  (Kikkert et al. 2007; Wara-
Aswapati et al. 2012) considered to be important during responses to periodontal 
pathogens, although there is still some debate regarding which TLRs are most important for 
recognising specific pathogens, and the relevance of each TLR to periodontitis. TLRs -2 and -
4 are present on the plasma membrane, where they recognise extracellular bacterial 
components, specifically lipoproteins and lipopolysaccharide, respectively. Specifically, the 
T. forsythia BspA protein is also capable of stimulating TLR-2 (Myneni et al. 2012). TLR-9 is 
an intracellular receptor, present on lysosomal membranes where they recognise bacterial 
DNA. TLRs -2, -4, and -9 are regulated by the activity of human sialidases Neu1 and/or 
Neu3, which are mobilised to the plasma membrane (or in the latter case lysosomal 
membranes) and desialate the TLRs, which are then able to induce gene expression 
changes through the MyD88 signalling pathway, including production of pro-inflammatory 
cytokines (Amith et al. 2010; Stamatos et al. 2010; Abdulkhalek & Szewczuk 2013). Given 
that human sialidases are required for TLR activation, it is possible that pathogen sialidases 
could mimic this function, causing an increase in TLR activation, resulting in an upregulation 
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of pro-inflammatory responses. Indeed, it has been shown that recombinant sialidase from 
Trypanosoma cruzi or S. pneumoniae is capable of upregulating TLRs -2 and -4 in 
macrophages and transfected Human Embryonic Kidney (HEK) cells, and that sialidase TLR 
activation leading to pro-inflammatory signalling could be inhibited using the sialidase 
inhibitor oseltamivir (Amith et al. 2010). Intracellular TLR-9 signalling is also inhibited by 
osteltamivir (Abdulkhalek & Szewczuk 2013). 
Given that these TLRs are important during periodontitis, are regulated by sialidase, and 
that sialidase inhibitors can prevent activation of TLR-2 and -4, resulting in decreased pro-
inflammatory signalling, investigation of the sialidase inhibitor zanamivir in preventing 
inflammatory signalling in oral epithelial cells was an exciting prospect. These experiments 
focused on stimulating the OSCC cell line H357 with the TLR-4 ligand LPS, or live pathogens 
in the presence and absence of zanamivir, then determining expression of the pro-
inflammatory cytokine Interleukin-8 (IL-8, also called CXCL8) by epithelial cells.  
 The IL-8 Response of Oral Epithelial Cells to P. gingivalis LPS may be 4.3.5.1
Upregulated by the T. forsythia Sialidase NanH, and this is Inhibitable by 
Zanamivir 
Although the over-abundance and/or over-activation of neutrophils is considered key in 
mediation of periodontal inflammation (Hajishengallis & Hajishengallis 2013), epithelial 
cells can also be stimulated by bacteria to produce proinflammatory cytokines, which act to 
recruit immune cells. Indeed, the initial production of cytokines that mediates neutrophil 
recruitment to the gingival tissue probably originates from epithelial and endothelial cells 
exposed to pathogens or bacterial components.  
Bacterial LPS is the ligand for TLR-4 activation, which stimulates production of IL-8 via the 
Myd88-NFΚB signalling pathway. TLR-4 can be expressed in epithelial cells, and its 
activation is known to be important during immune stimulation by periodontal pathogens. 
Furthermore, TLR-4 has been shown to require human sialidase for activation, and it was 
considered likely that periodontal pathogen sialidases would cause increased TLR-4 
activation, and that sialidase inhibition would decrease TLR-4 activation and subsequent IL-
8 secretion in response to LPS. The OSCC epithelial cell line H357 was chosen for cytokine 
studies due to its rapid proliferation and ease of culture, and previous work described in 
this chapter showing some degree of involvement of sialidases in host-pathogen 
interactions had been performed using this cell line. Cells were exposed to LPS purified 
from P. gingivalis ATCC 33277 for 24 hours, in the presence or absence of NanH and/or 
zanamivir LPS from P. gingivalis was chosen due to its relevance to oral disease. NanH had 
262 
 
undergone LPS decontamination (potential contamination from the E.coli expression strain) 
using polymixin-agarose beads to remove LPS remaining after purification. The secretion of 
IL-8 into epithelial cell culture media was measured by ELISA, and significant differences 
determined by one way ANOVA. A high level of day-to-day variation in cytokine secretion 
was observed between experimental repeats, so ANOVA was performed with no correction 
for multiple comparisons in order to obtain greater statistical power (Figure 4.14 A), and 
with Tukey’s correction for multiple comparisons to establish the most significant 
differences (Figure 4.14 B). The p-values discussed in the text below describe the ANOVA 
without a correction for multiple comparisons  
Interestingly, IL-8 secretion by oral epithelial cells was reduced slightly in the presence of 
zanamivir, from 218 pg/ml in the untreated condition to 185 pg/ml (p= 0.02). Surprisingly, 
LPS exposure caused no changes in IL-8 secretion by H357 cells (212 pg/ml).  More 
expectedly, NanH treatment alone also caused no change in IL-8 secretion levels (231 
pg/ml) compared to the untreated condition.  In contrast, when NanH and LPS were 
incubated with the same cells simultaneously, an increase in the average levels of secreted 
IL-8 was observed-270 pg/ml, although this change was not deemed significant by ANOVA 
(p=0.2). However, in the presence of zanamivir, IL-8 secretion by oral epithelial cells in 
response to LPS & NanH was significantly reduced compared to LPS+NanH, from 270 pg/ml 
to 164.7 pg/ml (p=0.007), which was also significantly lower level than IL-8 secretion in the 
untreated condition (p=0.02). 
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Figure 4.17. IL-8 secretion of oral epithelial cells exposed to zanamivir, LPS, and NanH. 
Oral epithelial cells were cultured as monolayers in 6-well tissue culture plates, and 
exposed to combinations of 50nM NanH (NanH), 10mM zanamivir (zan), and/or 10µg P. 
gingivalis LPS (LPS) for 24 hours, before harvesting of cell culture supernatants for IL-8 
ELISA to obtain IL-8 secreted by cells in each condition (pg/ml). Data shown represent the 
mean of four experimental repeats, where each condition was repeated twice per 
experiment. Error bars =SEM. Significance determined by one way ANOVA A) without and 
B) with Tukey’s correction for multiple comparisons *p=<0.05, **p=<0.01. 
 
Ultimately, while cells exposed to LPS alone did not display any increased IL-8 secretion, in 
the presence of NanH plus LPS the IL-8 secretion displayed an increase relative to the LPS 
only condition, although variation between repeats did mean that with Tukey’s correction 
for multiple comparisons this difference appered to be non-significant. However, this trend 
appears to be confirmed since in the presence of zanamivir, IL-8 secretion was reduced in 
cells exposed to LPS and NanH, to levels lower-than IL-8 secretion in the untreated 
condition. These results lend support to the idea that periodontal pathogen sialidases 
upregulate pro-inflammatory signalling in epithelial cells in response to bacterial LPS, 
possibly by pathways involving TLRs. It also highlights the ability of zanamivir to reduce 
inflammatory signalling even in the absence of stimulation with bacterial components (at 
least in this cell line).  
  
B) A) 
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 IL-8 Secretion by Oral Epithelial Cells Infected with T. forsythia is Reduced 4.3.5.2
in the Presence of Zanamivir. 
Although LPS stimulation of TLR-4 (or other TLRs) is one pathway which may be important 
during upregulation of inflammatory signalling in periodontitis, live periodontal pathogens 
are believed to stimulate epithelial cell inflammatory responses in a number of different 
mechanisms and represent a better model of infection than a single ligand. Therefore, the 
OSCC oral epithelial cell line H357 was infected with live T. forsythia (at a MOI of 1: 100 
bacteria: host cells) for 24 hours, in the presence and absence of zanamivir to test the 
effect of sialidase inhibition on IL-8 secretion as a measurement of pro-inflammatory 
signalling in response to periodontal pathogen infection. The secretion of IL-8 into 
epithelial cell culture media was measured again by ELISA. Given the results of the previous 
experiment, the ability of both zanamivir and T. forsythia to influence IL-8 secretion was 
tested. Therefore, repeated measures 2-way ANOVA with Tukey’s correction for multiple 
comparisons was utilised to test for significant differences between uninfected and T. 
forsythia infected cells, in the presence and absence of zanamivir (Figure 4.15). 
 Similarly to the LPS experiments described in the previous section, IL-8 secretion was 
detectable in the untreated condition at 1270 pg/ml. Zanamivir caused no change in IL-8 
secretion (1183 pg/ml). T. forsythia caused an increase in IL-8 secretion to 1739 pg/ml, 
however, under this statistical test the increase was apparently not significant (p=0.10). In 
the presence of zanamivir the IL-8 secretion caused by T. forsythia infection was reduced to 
almost the same level as the untreated condition-1269 pg/ml, although this reduction was 
also apparently not significant (p=0.10).  
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Figure 4.18. Secretion of IL-8 by oral epithelial cells infected with T. forsythia, in the 
presence and absence of zanamivir. 
Oral epithelial cells were cultured as monolayers in 6-well tissue culture plates, and 
exposed to T. forsythia, 10mM zanamivir, T. forsythia and 10mM zanamivir for 24 hours, 
before harvesting of cell culture supernatants for IL-8 ELISA. Across all conditions, both T. 
forsythia and zanamivir significantly influenced IL-8 secretion (p=<0.05 and <0.01, 
respectively, determined using 2-way ANOVA with repeated measures). Data shown 
represents IL-8 secretion (pg/ml) in each condition, from the mean of three experimental 
repeats, where each condition was repeated twice per experiment. Error bars =SEM. 
Significance between conditions was determined by 2-way ANOVA with repeated 
measures, with Tukey’s correction for multiple comparisons. P-values of 0.1 or less are 
indicated. 
 
Although the differences in Il-8 secretion between the untreated, and T-forsythia and T. 
forsythia + zanamivir conditions could be considered non-significant (with P-values 
between 0.06 and 0.1), the levels of IL-8 in the T. forsythia + zanamivir condition returned 
to a level almost exactly that of the untreated control. Furthermore, the 2-way ANOVA 
established that both zanamivir and T. forsythia caused significant changes to IL-8 
secretion, even if there were no significant differences between conditions. Therefore, it 
could be the case that zanamavir influences cytokine responses in response to bacterial 
challenge with T. forsythia. These data would be even more convincing if performed with a 
sialidase negative T. forsythia strain, but time did not allow this during my project.  
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 Broad Cytokine Production induced by T. forsythia Infection of Oral 4.3.5.3
Epithelial Cells is Altered by the Presence of Zanamivir 
IL-8 is only one of a multitude of pro-inflammatory cytokines that could be produced by 
oral epithelial cells in response to periodontal pathogens. Therefore, a panel of pro-
inflammatory cytokines was selected for multiplex analysis using a cytokine bead array 
(CBA), based on previous studies of inflammatory signalling in oral epithelial cells (table 
4.5.). The cytokines were also selected for operational reasons; the manufacturer of the 
CBA, BD biosciences, only produces kits for a limited number of cytokines. 
The same cell culture supernatants from section 4.3.5.3 were analysed using the CBA. H357 
Cells had been incubated for 24 hours in the presence of either zanamivir, T. forsythia, T. 
forsythia & zanamivir, or left untreated as a control, and the cell culture supernatant 
removed form cells and stored at -20°C prior to the IL-8 ELISA described in the previous 
section, then stored again at -20°C until undergoing cytokine quantification using the CBA 
described here. Secretion (pg/ml) of six pro-inflammatory cytokines (table 4.5) under the 
described conditions are shown in figure 4.16. Repeated measures 2-way ANOVA with 
Tukey’s correction for multiple comparisons was utilised to test for significant differences 
between uninfected and T. forsythia infected cells, in the presence and absence of 
zanamivir  
Interestingly, cells treated with zanamivir alone showed reduced levels of all six cytokines 
relative to the untreated condition. This was only deemed significant for IL-8 and MIP1α, 
which were reduced from 616 and 1.7 pg/ml to 458 and 0.94 pg/ml (p=0.02 and 0.02), 
respectively.  
 Cells treated with T. forsythia displayed increased levels of five out of the six cytokines, 
with significant increases in IL-8 and MCP-1 secretion, from 616 and 153.4 pg/ml, to 808 
and 232 pg/ml (p=0.01 and 0.03), respectively. The presence of zanamivir abrogated these 
effects; cells treated with T. forsythia and zanamivir displayed similar levels of cytokine 
secretion to the untreated condition, and there were no significant differences in cytokines 
between untreated and T. forsythia + zanamivir-treated conditions (with the exception of 
MIP1α, see below). There were also a significant differences in IL-8 secretion in the T. 
forsythia and T. forsythia + zanamivir conditions, where zanamivir reduced secretion from 
808 pg/ml to 580 pg/ml (p=0.003). 
The exception to the trend that T. forsythia increases cytokine secretion, and zanamivir 
prevents the change in cytokine secretion was MIP1α, which was decreased from 1.712 to 
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0.94 pg/ml (p=0.025), and this was further reduced  in T. forsythia + zanamivir-treated 
conditions, to 0.45 pg/ml (p=0.0023, compared to the untreated condition). 
Overall, despite the variability in the data in these experiments, there is a clear trend that 
T. forsythia/LPS challenge alters the cytokine response of oral epithelial cells.  These data, 
though interesting, do however come with the caveat that further repeats are needed to 
improve statistical power, alongside the need to introduce some element of a dose-
response of either immune ligand and introduction of sialidase negative mutant bacteria or 
sialidase negative enzymes to dissect any role for bacterial sialidase over zanamavir 
dependent effects on host sialidases.   
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Figure 4.19. Cytokine secretion by oral epithelial cells infected with T. forsythia, in the 
presence and absence of zanamivir. A) GCSF B) IL-6 C) IL-8 D) MCP-1 E) MIP1α F) TNF. 
Oral epithelial cells were cultured as monolayers in 6-well tissue culture plates, and 
exposed to T. forsythia (TF), 10mM zanamivir (zan), or T. forsythia and zanamivir (TF+Zan) 
for 24 hours, before harvesting of cell culture supernatants for CBA multiplex analysis for 
multiple cytokines. Across all treatment conditions, zanamivir was found to significantly 
influence secretion of IL-8, MIP1α, and TNF, determined by 2-way ANOVA with repeated 
measures (p=<0.01, <0.05, and <0.01, respectively), while T. forsythia infection was found 
to significantly influence secretion of only MIP1α (p=<0.05). Data shown represent the 
mean of three experimental repeats, where each condition was repeated twice per 
experiment. Error bars =SEM. Significance determined by 2-way ANOVA with repeated 
measures, with Tukey’s correction for multiple comparisons *p=<0.05, **p=<0.01, 
***p=<0.005. 
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4.4 Discussion 
4.4.1 Host Cells Are Desialylated by Purified sialidases and Live Periodontal 
Pathogens 
The previous results chapters highlighted the ability of T. forsythia and P. gingivalis 
sialidases to act on both α2-3 and α2-6 linked sialic acid-containing oligosaccharide 
substrates (3- and 6-sialyllactose), and the sialidases could act on BSM; a host relevant, 
secreted glycoprotein. However, it was a key part of this thesis to examine their ability to 
act on these and other glycans in their natural glycoprotein-conjugated cellular context. 
It was therefore reassuring that T. forsythia was able to desialylate host sialyl-glycans in the 
context of live human cells, although in this case only the SNA-lectin reactive antigens 
(containing alpha-6- linked sialic acid ligands) was significantly reduced with the MAA-
linked staining indicating a reduction by eye which was not borne out during quantification.  
One would have effected this to be more of a striking reduction given the enzymatic data 
but also since a similar experiment, with another oral cell ine by Honma et al., (Honma et 
al. 2011), who also incubated human cells with T. forsythia, and observed a reduction in 
SNA and MAA staining but was performed on cells where fixing was performed before 
staining, which was not the case in my experiments-a step that may have enhanced this 
observation.    
In the case of P. gingivalis it seemed that the human cells suffered damage and death, 
possibly via the action of gingipains. This made interpreting these data very difficult. Oral 
epithelial cell numbers appeared to be greatly reduced, compared to the un-infected and T. 
forsythia-infected conditions, as seen in the fluorescence microscopy images in figure 4.4. 
Indeed, the fields of view shown in figure 4.4 were chosen since other fields of view had 
fewer epithelial cells. This reduction in oral epithelial cells is likely due to the high 
concentration of live P. gingivalis (cells were exposed to OD600 0.5 bacteria, for both T. 
forsythia and P. gingivalis), and subsequent host cell death. The reduction in sialic acid 
staining of epithelial cell surfaces could also be due to the action of gingipains, which may 
cleave whole sialoglycoproteins from the cell surface (rather than just the sialic acid). 
Unfortunately, a lower concentration of bacteria might not possess enough sialidase 
activity to visibly reduce cell surface desialylation, so further experiments with lower 
concentrations of bacteria were not performed but may be worthwhile. An alternative 
possibility for future work would be to test desialylation by P. gingivalis gingipain mutants.  
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As a result of the difficulties in using whole bacteria, experiments were performed with 
purified sialidases to examine their action on siallyl-glycan ligands in their natural human 
context.  Therefore,  unsurprisingly, treatment of oral epithelial cells with purified NanH or 
SiaPG was capable of desialylating host cell surfaces, reducing both alpha-3- and 6- linked 
sialic acid (in accordance with the data in section 2.3.6.3) showing that NanH could cleave 
sialic acid from 3- and 6- sialyllactose). Zanamivir appeared to inhibit this activity 
(qualitatively) in the case of SiaPG but not NanH-possibly an unsurprising result given that 
zanamivir appears to be a more efficacious inhibitor of SiaPG than NanH.  
In addition to general staining for surface sialic acid, the sialoglycans sialyl lewis A and sialyl 
lewis X (SLeA and SLeX) were also stained with a view to testing the effect of NanH on 
these. SLeA and SleX are short glycan structures present at the termini of various secreted 
and membrane associated glycoproteins. They are structural isomers, consisting of an N-
acetylglucosamine (GlcNAc) and galactose backbone, with Neu5Ac (sialic acid) linked to the 
galactose via an α2-3 linkage, and fucose to the GlcNAc, through either an α3 or α4 linkage, 
giving rise to the two isomers-SLeX and SLeA (SLeX/A), respectively. SLeX/A are present in 
secreted glycoproteins such as mucins, but are also associated with cell surface 
membranes. SLeX is most highly expressed on leukocytes (and erythrocytes), where it 
functions as a ligand for E-selectin present on endothelial cells, enabling neutrophil 
attachment and crawling motility on the endothelial surface (reviewed in Bevilacqua & 
Nelson 1989). SLeA/X are also expressed on many cell types; endothelial cells for one, but 
also epithelial cells at mucosal surfaces, including the oral cavity. SLeA/X have been the 
focus of study due to changes in their levels of expression during various cancers including 
oral cancer (Renkonen et al. 1999). More recently, the involvement of host cell surface 
SLeA/X (and that of their selectin receptors) in pathogen association with host cells has 
come under scrutiny (Komatsu et al. 2012; Magalhaes et al. 2015; Colomb et al. 2013). 
Therefore it was considered important to study the effect of the purified sialidases on cell-
surface SLeA and SLeX. Unfortunately, the timeframe of the project did not permit testing 
with SiaPG as well as NanH. 
SLeX is the most well studied for its role in neutrophil migration-where it is expressed on 
the surface of neutrophils and binds E-selectin present on endothelial cells, enabling 
crawling motility and migration across the endothelium into the target tissue (Lowe 2003). 
SLeA is also capable of binding selectins (Melorose et al. 1991). It was shown in chapter 2 
(section 2.3.6.4) that NanH appears to display almost tenfold greater efficacy for SLeA than 
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SLeX during in vitro assay using isolated Sialyl-Lewis oligosaccharides, despite the only 
difference between the two ligands being the type of fucose-GalNAc and Glc-GalNAc 
linkages. As well as its presence on mucin (where SLeX is perhaps the more prevalent 
isoform), SLeA is present on oral/laryngeal epithelial cells, where its expression is 
upregulated in head and neck cancers and erythrocytes (Renkonen et al. 1999; Wiest et al. 
2010). 
In the experiments described in this chapter, NanH was capable of desialylating both SLeA 
and SLeX present on oral epithelial cell surfaces. The exposure to NanH took place over two 
hours, with a high concentration of NanH, which could explain why no variation in 
desialylation is apparent between cell surface SLeA and SLeX; i.e sialic acid was cleaved 
from both to similar extents, as indicated by similar decreases in the level of surface 
staining for SLeA/X, despite the apparent ~tenfold greater affinity of NanH for free (non-
membrane/glycoprotein associated) SLeA compared to free SLeX. The finding that 
zanamivir did not prevent host desialylation of SLeA/X (SLeA desialylation was only partially 
inhibited) by NanH was not surprising, given that zanamivir does not appear to display high 
efficacy for NanH, and any inhibition might have been overcome by the high concentration 
of enzyme used in these experiments. Another variable to consider is the rate of SLeA/X 
turnover by oral epithelial cells, and if there is any SLeA/X cleavage, any inhibition by 
zanamivir might be more evident in a cell line with a higher SLeA/X turnover rate.  
How cell surface desialylation, or more specifically cell surface SLeA/X desialylation of oral 
epithelial cell surfaces (or other cell types) contributes to the pathogenicity of T. forsythia 
(or possibly other periodontal pathogens) is not entirely clear. A number of pathogens have 
been shown to use SLeA/X antigens, or their selectin receptors for attachment to cell 
surfaces. In these cases SLeA/X is retained at the cell surface where it acts as a receptor for 
pathogen attachment, as seen in cells infected with the gastric pathogen Helicobacter 
pylori (Magalhaes et al. 2015), or the respiratory pathogen P. aeruginosa (Colomb et al. 
2013), and in both of these cases the increase in cell-surface SLeA/X expression was 
mediated by TNF.  However, desialylation of SLeA/X has not been shown to be a feature 
during host-cell attachment by H. pylori or P. aeruginosa. However, this might be the case 
for T. forsythia, since sialidase deficient T. forsythia (a nanH knockout mutant) deficient in 
sialidase activity displays decreased attachment to oral epithelial cells (Honma et al. 2011). 
Even if desialylation of cell surface SLeA/X does not enhance T. forsythia attachment to 
host-cells, decreases in cell surface Neu5Ac may increase inflammation, since Neu5Ac is an 
273 
 
important host recognition molecule, involved in preventing complement deposition on 
cell surfaces, and SLeA/X are ligands for Siglecs; self-recognition receptors present on 
innate and adaptive immune cells (but not epithelial layers), which bind sialoglycans 
present on surfaces of other cell types and dampen signalling pathways which regulate the 
pro-inflammatory responses of the Siglec-expressing immune cell (Varki & Angata 2006).   
4.4.2 The Sialidase Inhibitor Zanamivir Inhibits Periodontal Pathogen 
Association with Host Cells 
It was previously shown that mutant strains of P. gingivalis and T. forsythia have decreased 
association (attachment and invasion) with host cells compared to their parent strains (Li et 
al. 2012; Honma et al. 2011), so the experiments described in this chapter aimed to 
observe whether or not a reduction in host-bacteria association could also be achieved 
using the sialidase inhibitor zanamivir. This is the first step in assessing whether zanamivir 
(and sialidase inhibitors more broadly) might be a useful active compound in reducing 
levels of these bacteria or their effects in patients. 
At first, individual periodontal pathogen species- T. forsythia, P. gingivalis and  
F. nucleatum-were used to infect oral epithelial cells (both the OSCC cell line H357 and 
normalised cell line OKF6) in the presence and absence of zanamivir. The trend for all three 
pathogens was that attachment and invasion was reduced in the presence of zanamivir, 
with the greatest decreases occurring in attachment and invasion of T. forsythia.  
The finding that T. forsythia and P. gingivalis displayed decreased attachment and invasion  
in the presence of zanamivir was partially expected, given that their sialidases have been 
shown to be important for attachment and invasion (Li et al. 2012; Honma et al. 2011), and 
since this chapter shows inhibition of purified P. gingivalis sialidase.  However, in the case 
of T. forsythia this was not entirely expected given its complete inability to inhibit removal 
of sialic acid containing ligands from the surface of human cells by either whole cells (this 
chapter) or enzymes and given that it inhibited whole cell and T.forsythia NanH enzyme 
activity with the model ligand MUNANA only to a limited degree in in vitro biochemical 
assays (section 2.3.7).   
Nevertheless, In the presence of zanamavir a significant inhibition of host-cell interaction 
was observed.  There are several explanations for why this may be the case.  Firstly, in the 
case of the human cell experiments the bacterial-cell associated enzymes were presented 
with native human cell associated complex glycans where both the efficacy of the enzyme 
might be reduced but also where even a small abrogation of activity causes a larger effect 
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on human cell interactions.   Another explanation is that Zanamavir is also known to act 
upon host sialidases, in particular Neu1 and 3 which are known to contribute to human cell 
responses to bacteria (Stamatos et al. 2010; Hata et al. 2008), but zanamivir may also 
influence bacterial internalisation- as evidenced by these data. Another possibility is that 
the presence of live T. forsythia (but not purified NanH) caused increased mobilisation –or- 
activation of human Neu1 and/or Neu3 sialidase at the host cell membrane, which might 
be the case since increased Neu1 activity is seen in cells exposed to bacterial TLR ligands 
(Amith et al. 2009), which live T. forsythia bacteria clearly represent.  The other issue to 
consider is that currently we have no information on the larger glycan context of which 
glycans are most important for sialidase interactions, or which precisely which 
glycoproteins mediate pathogen association, and it may be that zanamavir has an influence 
on both of these in terms of invasion/TLR activation.  The other implication here is that in 
vivo even small reductions in activity might be relevant in terms of infection, and hence 
raise the possibility that these molecules could have clinical benefits. 
In addition, the effect of zanamavir on P. gingivalis is intriguing given the known 
association of P. gingivalis with integrins during its cellular internalisation process (Yilmaz 
et al. 2002).  In particular the fimbriae of P. gingivalis is known to interact with integrin-β1 
(Yilmaz et al. 2002), whose activation status is known to be affected by sialylation levels 
(Lee et al. 2012), suggesting a potential, but unproven explanation for this observation. 
The finding that F. nucleatum displayed reduced association in the presence of zanamivir 
was also somewhat surprising, since F. nucleatum does not possess sialidase activity. It 
could be the case that sialic acid ligands or their receptors partially mediate F. nucleatum 
adhesion to host cells, and a sialic acid analogue like zanamivir could interfere with 
attachment and subsequent invasion of host cells. The adhesin FadA is highly conserved 
among oral fusobacteria, and considered important for association with oral epithelial cells 
(Han et al. 2005), despite the fact that FadA has been shown to bind E-selectin, which is 
present on endothelial cells (Fardini et al. 2011) but not epithelial cells. However, the 
native ligand for E-selectin is a sialoglycan (sialyl lewis A/X), so perhaps a sialic acid 
analogue could interfere with FadA-host cell surface interactions. If this is the case, then 
this would explain why zanamivir inhibited F. nucleatum-host cell association as shown 
here. The issue with this theory is that epithelial cells are not considered to express 
selectins, but FadA has been shown to be important for oral epithelial cell association (Han 
et al. 2005), so perhaps FadA adheres to an alternative sialoglycan receptor on oral 
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epithelial cells, and this adhesion could be disrupted by using a sialic acid analogue, such as 
zanamivir.  
Although attachment and invasion of epithelial cells by individual pathogen species was 
reduced by the presence of zanamivir, this is not representative of the situation in vivo, 
where cells are exposed to numerous bacterial species at once. This is important for 
periodontal pathogens, which appear to act synergistically during host cell infection in 
vitro, enhancing their ability to attach to and invade host cells  (Saito et al. 2012; Inagaki et 
al. 2006; Kirschbaum et al. 2010).  
In antibiotic protection assays shown here, mixtures of two or three of the periodontal 
pathogen species F. nucleatum, T. forsythia, and P. gingivalis were used to infect oral 
epithelial cells. Generally speaking, the levels of host cell association by pathogens in all 
multi-species assays were equal to or higher than when individual pathogen species were 
used to infect cells by themselves. Furthermore, while experimental variation sometimes 
caused difficulties in establishing significant effects of zanamivir on attachment and 
invasion of individual species in the assays, the levels of attachment, invasion, and/or total 
association of all bacterial species in most mixed species assays were significantly reduced 
in the presence of zanamivir.  
The data on co-infections of T. forsythia and F. nucleatum were particularly intriguing given 
data in the literature showing that co-cultured F. nucleatum and T. forsythia interact with 
each other, having been shown to co-operate during biofilm formation (Sharma et al. 
2005).  In addition, in a murine infection model of periodontitis they act synergistically and 
elicit greater alveolar bone loss in co-infections than in mice infected with just one 
organism (Settem et al. 2012). Rather than simply inhibiting both pathogens in isolation (as 
seen in the single species assays) the zanamivir-inhibition of invasion could be due to 
disruption of interactions between T. forsythia and F. nucleatum which boost their host cell 
association in the absence of zanamivir. Although T. forsythia BspA is primarily responsible 
for co-aggregation of T. forsythia and F. nucleatum, BspA  is not solely responsible for 
interactions during biofilm formation, since a BspA deficicent mutant strain does not show 
decreased biofilm formation during co-culture with F. nucleatum ( a Sharma et al. 2005), 
perhaps other interactions which are zanamivir-inhibitable are involved in the virulence of 
T. forsythia and F. nucleatum.  
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Several experiments could be performed to expand on these findings. Future work with 
oral bacteria species might aim to study the effect of sialidase inhibition on host cell 
association by commensal organisms, with the hope that sialidase inhibitors would more 
drastically reduce pathogen association with host cells than host cell association by 
commensal organisms.  Assessment of host cell association with more complex bacterial 
communities could be performed using real time PCR to quantify attachment and invasion 
of multiple species. More immediate future work might also focus on T. denticola, the third 
red complex pathogen, which also possesses a sialidase-in this case an alternative means of 
enumeration (such as real time PCR) would be required since it cannot be cultured on agar. 
present.  It would be useful to repeat some of these experiments to obtain the effect of 
zanamivir concentration on attachment and invasion (dose-response), to see if the same 
effect could be achieved with a lower concentration of zanamivir. Further studies using 
sialidase deficient mutant strains of P. gingivalis and T. forsythia could also be performed 
to test if zanamivir is acting through inhibition of the pathogen sialidase or another 
mechanism. Conversely experiments where the influence of host sialidases is suppressed 
(e.g. NEU1 or NEU3) would allow a dissection of the role of different human sialidases in 
host-pathogen association. Pathogen infection could also be studied in 3D-models of oral 
mucosa (Pinnock et al. 2014) could also be performed in the presence and absence of 
zanamivir, which are more representative of in vivo oral mucosa infections. Finally, a 
zebrafish model of P. gingivalis infection has recently been developed at the University of 
Sheffield School of Clinical Dentistry (manuscript in preparation), and this would probably 
be a relatively straightforward model to test the effect of sialidase inhibition on P. 
gingivalis infection in vivo.  
Ultimately, zanamivir reduced both attachment and invasion of oral epithelial cells by 
periodontal pathogens, and this provides support for its potential application to 
periodontitis therapy: Attachment is important for bacterial colonisation, and subsequent 
host cell invasion also aids in bacterial persistence at a site because once internalised the 
bacteria avoid immune system components, are presented with a possible nutrient supply, 
and can possibly evade antimicrobial therapy. Attachment and invasion of bacteria to host 
cells can also stimulate the immune system. Sialidase inhibition might also represent a 
therapeutic for other bacterial infections where host cell association mediated by sialidases 
is important during pathogenesis, such as during pulmonary infection with S. pneumoniae, 
or gastrointestinal Vibrio cholerae and Clostridium infections.  
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4.4.3 The Influence of Periodontal Pathogen Sialidases on Pro-Inflammatory 
Signalling 
Arguably, the most important factor in periodontal disease progression is the host immune 
system, which causes tissue destruction in a number of ways. This includes increased 
complement deposition on host cell surfaces (Schoengraf et al. 2013), or cell damage due 
to autophagy and Reactive Oxygen Species (Bullon et al. 2012). In the case of alveolar bone 
loss, the production of cytokines leads to differentiation of osteoclasts-of the cytokines, 
receptor activator of nuclear factor kappa B ligand (RANKL) is ultimately responsible for 
osteoclast differentiation (Sima & Glogauer 2013), which cause bone resorption. 
Central to over-stimulation of the inflammatory response is the production of pro-
inflammatory cytokines. Although immune cells, primarily neutrophils and macrophages, 
are probably considered the most important source of pro-inflammatory cytokines, oral 
epithelial cells are also capable of pro-inflammatory  cytokine production, and are the host 
cells first (and perhaps most frequently) encountered by periodontal pathogens in the 
subgingival plaque.  
TLRs -2, -4, and -9 are receptors with bacterial component ligands, and are considered to 
be important during up-regulation of inflammatory cytokine production in periodontitis, 
and all three of these have been shown to be regulated by the human sialidase Neu1 
(Abdulkhalek & Szewczuk 2013; Amith et al. 2009; Amith et al. 2010). Furthermore, 
exogenous sialidase has been shown to upregulate the NFκB signalling pathway, 
downstream of TLR- activation and would ultimately enable cytokine production. 
Therefore, it was thought that periodontal pathogen sialidases might upregulate pro-
inflammatory responses to periodontal bacteria, and this might be inhibited by zanamivir.  
Firstly, the role of TLR-4 activation in pro-inflammatory cytokine production was studied by 
exposing epithelial cells to LPS from P. gingivalis (the TLR-2/4 ligand), in the presence and 
absence of the T. forsythia sialidase NanH, and/or zanamivir, and monitoring IL-8 secretion 
into culture supernatant. In these experiments, NanH appeared to upregulate IL-8 
secretion in response to LPS, an effect which was abrogated by zanamivir. This did appear 
to confirm that pathogen sialidases could upregulate TLR activation and subsequent 
inflammatory cytokine production. However, experimental variation meant that the change 
in IL-8 secretion induced by NanH and LPS was slightly outside the threshold for significance 
determined by T-test, compared to LPS alone (p=0.055). Given more time to perform 
experiments, perhaps with protocol adjustments such as reduced ligand/effector-
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incubation times, these results could be confirmed. In addition, at least one study has 
shown that P. gingivalis LPS activates TLR-2 (it may act primarily through TLR-2) (Ara et al. 
2009), so perhaps these LPS-based experiments should be repeated using LPS from E. coli, 
which activates only TLR-4.  
The ability of zanamivir to inhibit cytokine production by oral epithelial cells in response to 
live T. forsythia was also studied. ELISA experiments indicated that IL-8 production by oral 
epithelial cells was increased in the presence of T. forsythia, and this affect was abrogated 
by zanamivir. The CBA multiplex assays were also used to test for the production of 
multiple pro-inflammatory cytokines in these cultures; GCSF, IL-6, IL-8, MCP-1, MIP1α, and 
TNF. Results from this assay displayed more variation between repeats than the IL-8 ELISA 
data, but did appear to show similar trends for all six cytokines (except MIP1α): Relative to 
the untreated control, cells exposed to zanamivir alone displayed slightly decreased 
cytokine production, while cells infected with T. forsythia displayed approximately 1.5 fold 
greater cytokine production, and zanamivir abrogated this T. forsythia-induced increase.  
However, MIP1α production appeared to be decreased by similar levels in cells exposed to 
either zanamivir or T. forsythia, and was further reduced in cells exposed to both. This was 
unexpected, since it is also a pro-inflammatory cytokine which has been shown to be 
upregulated in various cells/tissues in response to periodontal pathogens (Morandini et al. 
2010a; Shaddox et al. 2013), and yet in this experiment it was downregulated by T. 
forsythia. This is difficult to explain. However, it might be the case that the level of 
expression of MIP1α was quite low-approaching the minimum detection thresholds for the 
CBA. (MIP1α expression was <1.5 pg/ml in the untreated condition). Therefore other 
methods to quantify expression of MIP1α might be more appropriate (such as real time 
PCR or Western Blotting.  If MIP1α expression is proven to be reduced in cells treated with 
zanamivir and/or T. forsythia, one possible explanation might be due to inhibition of TLR-4 
activation by zanamivir: An in vivo murine model of wound healing showed that mice 
deficient in TLR-4, or incapable of TLR-4 activation, had three-fold lower levels of MIP1α in 
wound fluids (Brancato et al. 2013). Importantly, in this study no bacteria were introduced 
into the wound, and the absence of LPS or bacteria in the wound was confirmed. This effect 
of decreased MIP1α production by interference or complete abrogation of TLR-4 does 
provide some explanation for why cells in the zanamivir or T. forsythia and zanamivir 
conditions produced lower levels of MIP1α- since in work presented in section 4.3.5.1 
(figure 4.14), cells treated with zanamivir may display decreased TLR-4 activation (as 
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indicated by decreased IL-8 production in the presence of zanamivir) in response to LPS and 
NanH (and relative to the untreated control). However, results shown here do not account 
for the decreased MIP1α production by epithelial cells exposed to T. forsythia, unless 
MIP1α production is also regulated through another mechanism that T. forsythia can 
disrupt.  
In summary, the precise effects of periodontal-pathogen (or other bacterial components) 
and periodontal pathogen sialidases on cytokine production in epithelial cells (and other 
cell types) requires further experiments to confirm the effects of sialidases on cytokine 
secretion shown here. Use of E. coli, Salmonella LPS, or BspA from T. forsythia might be a 
more appropriate TLR-4 ligand than LPS from P. gingivalis. Future work might also include 
analysis of other cytokines or pro-inflammatory pathway activation affected by NanH in 
combination with LPS or other PAMPs such as bacterial flagella. (Other mechanisms that 
might be studied include caspase activation, or the formation of NFΚBp65, which regulates 
several pro-inflammatory responses.) Sialylation of specific surface proteins, such as TLRs 
following exposure to PAMPs and/or sialidases could also be probed using using lectin-
based western blotting (with the lectins SNA, MMA, and Wheat Germ Agglutinin, WGA-
binds N-acetylglucosamine and Sialic Acid) to assess terminal sialoglycans in TLR4 and other 
associated sialoglycoproteins (such as MD2 and CD14).  The role of specific signalling 
pathways such as the NFΚB signalling pathway might also be studied using gene-
knockdown approaches. Gene knockdown could also be used to assess the importance of 
host sialidase (e.g. NEU1 or 3) and sialyltransferases in periodontal pathogen- host cell 
immune interactions. 
Evidence that zanamivir does reduce pro-inflammatory cytokines in response to T. forsythia 
is more robust, since IL-8 ELISA confirmed a significant reduction in oral epithelial cells 
exposed to T. forsythia, and during exposure to LPS and NanH. Furthermore, the levels of 
five out of the six pro-inflammatory cytokines tested were increased in the presence of T. 
forsythia, with significant increases in IL-8 and MCP-1, which were abrogated in the 
presence of the sialidase inhibitor zanamivir. This latter finding provides support for the use 
of zanamivir (or other sialidase inhibitors) in periodontitis therapy, since upregulation of 
inflammation is important for disease progression. As well as characterising the impact of 
inhibitors on infection of other cell types, future work here might involve mixed species 
infections, which are more representative of the situation during disease. 
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4.5 Summary 
Fluorescence microscopy revealed that the live periodontal pathogens T. forsythia and 
possibly P. gingivalis, as well as their purified sialidases NanH and SiaPG could desialylate 
host cell membranes, and in the case of purified  SiaPG this was inhibited by zanamivir. The 
sialyl lewis A and X glycans present on host cell surfaces were also desialylated by NanH. An 
in vitro model of T. forsythia, P. gingivalis, and F. nucleatum association with host cells also 
highlighted the potential of zanamivir to prevent attachment and invasion of oral epithelial 
cells by periodontal pathogens. Although bacterial colonisation and persistence is 
important during periodontal disease, ultimately the host inflammatory response causes 
the tissue destruction seen in periodontitis. Therefore, the effect of sialidase inhibition on 
cytokine production by oral epithelial cells in response to live T. forsythia, or LPS, was 
examined. Zanamivir appears to decrease the production of multiple cytokines in response 
to T. forsythia to levels seen in untreated cells, most significantly for the important pro-
inflammatory cytokine IL-8.  
Ultimately, the work described in this chapter showed the inhibitory effects of zanamivir on 
several pathogenic processes with relevance to three periodontal pathogens, without any 
observable effect on host cell or pathogen viability. This provides evidence supporting the 
application of sialidase inhibitors as “anti-virulence” therapeutics in treatment of 
periodontitis, and the issues this raises from commercial and regulatory standpoints are 
raised in the concluding chapter. 
  
281 
 
 
 
 
  
Chapter 5 
 
Summary and Concluding 
Discussion 
282 
 
5 Summary and Concluding Discussion 
The ultimate aims of this project were to further characterise periodontal pathogen 
sialidases and their role in virulence, with a view to the testing the potential application of 
sialidase inhibitors in the treatment of periodontitis. Previous chapters contain the results 
of experiments designed with this aim in mind, with detailed discussion. Therefore, this 
chapter is intended to summarise the findings, and discuss how sialidases and their 
inhibitors might undergo further study. In addition, their potential commercial application 
in the context of oral healthcare is discussed. 
5.1 Summary of Findings by Chapter 
5.1.1 Chapter 2- Purification and Characterisation of Periodontal Pathogen 
Sialidases 
 The sialidases of T. forsythia and P. gingivalis (NanH and SiaPG, respectively) 
underwent bioinformatics analysis. For NanH this revealed the presence of two 
functional domains (and the secretion signal sequence); the catalytic C-terminal 
domain (CTD) and an N-terminal carbohydrate binding module (CBM). For SiaPG, 
only the catalytic CTD was revealed by bioinformatics approaches, but the N-
terminal domain was annotated as a CBM for the purposes of this project. 
 The genes encoding the CBM and CTD of SiaPG and the CTD of NanH were 
amplified by PCR and transformed into E. coli expression strains with the aim of 
establishing the functionality of each domain in isolation. Unfortunately expression 
of soluble, functional protein was not possible for these sialidase subunits. 
 After initial difficulty using conventional PCR approaches, the genes encoding the 
periodontal pathogen sialidases NanH and SiaPG underwent gene synthesis with 
codons altered for optimum expression by E. coli. Following expression in E. coli, 
soluble, active NanH and SiaPG was successfully purified by affinity 
chromatography. 
 A NanH-active site mutant where the highly conserved FRIP motif (located in the 
sialic acid binding pocket) was mutated to YMAP was also successfully purified and 
shown to be inactive This inactive sialidase still retained binding capacity with sialic 
acid ligands, and could be useful for future studies of sialidase- host ligand 
interactions.  
 NanH and SiaPG were characterised: The pH optimum of both enzymes was 
determined to be mildly acidic. The kinetics of enzyme activity on the fluorogenic 
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substrate MUNANA (a commonly used model sialic acid-containing ligand) were 
determined under enzyme-optimum and physiological-mimicking conditions. In 
either case, the sialidases were highly efficacious in cleavage of MUNANA, 
displaying higher affinity and greater maximum reaction rates for MUNANA than 
most other bacterial sialidases characterised elsewhere.  
 The reaction kinetics of NanH on 3- and 6- sialyllactose under physiological-
mimicking conditions were determined, highlighting the ability of NanH to cleave 
both α2-3 and α2-6 sialic acid linkages, but with a much greater catalytic efficiency 
for α-2-3 linkages. This might hint at the function or targets of NanH in vivo. 
 NanH was capable of activity on the host relevant sialoglycans sialyl lewis A (SLeA) 
and sialyl lewis X (SLeX), and although maximum rate of sialic acid release was 
calculated as similar for both ligands, NanH affinity for SleA was tenfold greater 
than SLeX. 
 The sialidase inhibitor zanamivir was capable of inhibiting the sialidase activity of P. 
gingivalis and T. forsythia, as well as the purified periodontal pathogen sialidases. 
However the efficacy was much higher (by roughly twentyfold) for SiaPG than 
NanH, with IC50 of ~300µM and ~6mM, respectively. This has implications for 
studies of sialidase inhibition on pathogen virulence. 
 
5.1.2 Chapter 3- Investigating the Targeting of Host Sialoglycans by Periodontal 
Pathogens- the Effects on Growth and Biofilm Formation, and the Impact 
of Zanamivir 
 The sialate 9-O-Acetylesterase, NanS, from T. forsythia was purified. This enzyme 
catalyses the hydrolysis of an acetyl chemical group from the 9th carbon of 
diacetylated sialic acid. Diacetylated sialic acid on sialoglycans is protected from the 
activity of many bacterial sialidases. NanS was shown to double sialic acid release 
from bovine submaxillary mucin (BSM) by both NanH and SiaPG. In the absence of 
NanS, SiaPG was capable of greater sialic acid release from mucin than NanH. In 
addition, zanamivir inhibited sialic acid release from mucin by SiaPG, but not NanH. 
This highlighted the likely importance of inter-species cooperation in sialic acid 
metabolism in the oral environment and the potential of zanamivir to inhibit sialic 
acid release from a host-relevant sialoglycoprotein. 
 P. gingivalis was cultured in defined media using sialoglycans as sole nutrient 
sources. FBS, pooled human saliva (saliva), and BSM were tested, but only FBS 
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proved capable of enabling P. gingivalis growth.  However, saliva was capable of 
enhancing P. gingivalis growth in FBS, and when NanS from T. forsythia was added, 
P. gingivalis growth was enhanced further. This sheds some light on bacterial-
community interactions in sialic release and its role in nutrient acquisition and 
subsequent pathogen proliferation. 
 Biofilm formation was quantitatively assessed. T. forsythia and P. gingivalis were 
capable of biofilm formation on sialoglycoproteins; BSM, FBS, and saliva, as well as 
in media containing free sialic acid (Neu5Ac) and N-acetylmuramic acid (NAM). In 
these experiments, zanamivir did not appear to affect T. forsythia biofilm 
formation, but this was difficult to confirm since biofilm formation was lower than 
that seen in other studies. 
  P. gingivalis biofilm formation and overall growth seemed to be inhibited by BSM, 
and this effect was compounded in the presence of zanamivir. Zanamivir also 
inhibited biofilm formation in the other sialoglycoprotein conditions (and there 
were also slight decreases in overall growth), with significant effects for saliva and 
mucin. Crystal violet staining of the P. gingivalis biofilms may infer that sialidase 
inhibition/zanamivir had inhibited P. gingivalis adherence to the sialoglycoprotein-
coated surface, rather than growth of the organism.  
5.1.3 Chapter 4-The Role of Sialidases in Host-Pathogen Interactions, and 
Disruption by Sialidase Inhibition 
 T. forsythia and P. gingivalis may have been capable of cleaving α2-3 and α2-6 
linked sialic acid from the surfaces of oral epithelial cells as determined by lectin-
staining of sialic acid and fluorescence microscopy. In the case of T. forsythia, loss 
of epithelial cell surface sialic acid may be partially inhibited by zanamivir. P. 
gingivalis also appeared to reduce cell surface sialic acid, and this was not inhibited 
by zanamivir, but this may have been due to the loss of whole sialoglycoproteins 
from the cell surface caused by the action of P. gingivalis gingipains, or by 
processes involved in cell death. 
 Lectin staining and fluorescence microscopy also showed that NanH and SiaPG 
enzymes were capable of cleaving both α2-3 and α2-6 linked sialic acid from the 
oral epithelial cell surface. In the case of SiaPG, sialic acid release from oral 
epithelial cell surfaces was qualitatively inhibited by zanamivir. 
 Visualisation and quantification of the sialoglycans SLeA and SLeX on epithelial cell 
membranes was also achieved by immunofluorescence microscopy, and NanH was 
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capable of desialylating both SleA and SLeX on the epithelial cell surfaces. 
Zanamivir was capable of partially inhibiting desialation of SLeA. The ability of 
NanH to cleave sialic acid from these specific glycans may shed further light on the 
targets and function of NanH in vivo. 
 Antibiotic protection assays were used to assess the ability of P. gingivalis, T. 
forsythia, and F. nucleatum to attach to and invade oral epithelial cells. In assays 
where cells were infected with one of the above species, zanamivir was shown to 
significantly inhibit attachment, invasion, and total association in almost all cases, 
and the reduction was most significant for T. forsythia. 
 Multi-species antibiotic protection assays using all possible combinations of the 
above pathogens (P. gingivalis, T. forsythia, and F. nucleatum) to infect oral 
epithelial cells in the presence and absence of zanamivir were carried out. 
Zanamivir was shown to be capable of inhibiting attachment and invasion of host 
cells to varying degrees in all cases, including in assays where all three pathogens 
were used to infect host cells.  
 Experiments were designed to test the impact of sialidases and their inhibition on 
pro-inflammatory signalling in oral epithelial cells. The first experiments aimed to 
test the effect of NanH sialidase on TLR activation (specifically the TLRs -2 and -4, 
known to at least partially rely on human sialidase for activity). Cells were treated 
with combinations of zanamivir, P. gingivalis LPS (known to activate TLR -2 and 
possibly -4), and NanH, followed by harvesting of culture supernatant and IL-8 
ELISA. While LPS or NanH in isolation had no effect on IL-8 secretion, cells treated 
with LPS and NanH at the same time did show greater secretion of IL-8 than the 
untreated condition, and zanamivir abrogated this effect. 
 The effect of zanamivir on pro-inflammatory signalling by oral epithelial cells 
infected with live T. forsythia was also assessed. T. forsythia was shown to 
upregulate secretion of the pro-inflammatory cytokines GCSF, IL-6, IL-8, and MCP-
1, though only significantly in the case of IL-8 and MCP-1. Zanamivir was shown to 
abrogate or limit the increased secretion of IL-8 and MCP-1 (a trend also shared in 
the other non-significantly increased cytokines) in response to T. forsythia cytokine 
secretion. 
 Crucially, zanamivir was shown to have no effect on oral epithelial cell viability or 
metabolism, in both an immortalised epithelial cell line (OKF6) and an OSCC 
epithelial cell line (H357). Toxicity is an important consideration in development of 
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therapeutics, so this was an important finding. Bacterial viability was also 
unaffected by zanamivir, which is an important requirement for an anti-virulence 
compound. 
5.2 Periodontal Pathogen Sialidase Biochemistry and Future 
Directions 
In chapter 3 the sialidases of T. forsythia (NanH) and P. gingivalis (siaPG) were purified. 
NanH underwent more extensive biochemical characterisation, and given just a little bit 
more time, the same would have been done for SiaPG. NanH was shown to target the 
sialoglycan SLeA in preference to SLeX. A next step would be to determine precisely which 
sialoglycans are targeted by T. forsythia in a cellular (or secretory) glycoprotein context. 
This might utilise a glycomics based approach and mass spectrometry to observe 
desialylation of specific glycoproteins on cell surfaces (or in secretions such as salivary 
proteins).  
Further characterisation of the NanH CTD and CBM domains (and SiaPG) would also be 
beneficial: The CBM of NanH has been confirmed to have the capacity to bind sialoglycans, 
but displays no activity. It is likely that it bolsters the catalytic capacity of the CTD by 
binding to sialic acid ligand and orientating the ligand in a position appropriate for the 
active site to function, thus increasing enzyme-ligand affinity. Unfortunately this has not 
been confirmed in the case of NanH, since the CTD was not purified in isolation. Since 
human sialidases do not possess CBMs, the potential to inhibit the CBM (possibly even with 
an irreversible inhibitor, providing it was specific for the bacterial sialidase CBM and not 
human lectins) is an extremely exciting prospect, since it would specifically target the 
bacterial sialidase-albeit independently of the active site.  
5.3 Ripe for Targeting: Bacterial Sialidases and their Associated 
Pathways are Multifunctional Virulence Factors in Periodontitis 
Work described in this thesis builds on previous work highlighting the importance of 
sialidases for the pathogenesis of periodontal pathogens, and crucially here for the first 
time, the potential to inhibit their virulence mechanisms with pharmaceutically available 
sialidase inhibitors. Key to the idea that sialidase inhibitors could treat periodontitis is their 
potential to shift the dysbiotic microbiota back to a more commensal (or health)-
dominated bacterial community (reviewed in figure 5.1). The potential clinical importance 
of sialidase inhibitors as an adjunct to periodontitis therapy is underlined by a recent study 
of periodontitis patients showing increased sialidase activity in sites affected  by 
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periodontitis, and that after treatment sites with more severe disease (deep bleeding as 
opposed to non-bleeding) retained higher sialidase activity (Gul et al. 2016). 
Periodontal pathogens possess mechanisms involved in release, uptake, and utilisation of 
sialic acid: T. forsythia  makes use of the products of its nan operon to release sialic acid 
(NanS, NanH), followed by uptake (NanO, NanU, NanT), and catabolism (NanA, NanE), and 
this utilisation pathway is directly relevant for T. forsythia proliferation since this enables it 
to form biofilms on host sialoglycoproteins, and Neu5Ac can substitute T. forsythia’s 
requirement for exogenous NAM (Roy et al. 2010; Pham et al. 2010). 
P. gingivalis lacks any homologues for the synthesis of Neu5Ac, and yet Neu5Ac represents 
an important component of its gingipain RgpA (Rangarajan et al. 2005). SiaPG or other 
sialidases expressed by the microbiota would probably provide ample free sialic acid for 
uptake by P. gingivalis: While the precise mechanisms of sialic acid uptake in P. gingivalis 
are unknown thus far, this demand could be met by a general porin, and free sialic acid 
may be sequestered by the P. gingivalis secreted protein RagB, which has been shown to 
bear structural similarity to the sialic acid sequestration protein NanU in T. forsythia 
(Goulas et al. 2015). While it is unclear if P. gingivalis can metabolise sialic acid, 
desialylation of host sialoglycoproteins likely makes them more amenable to the activity of 
gingipains, since desialylation of salivary mucin makes it more amenable to proteolysis 
(Takehara et al. 2013), thus, sialidases may enhance P. gingivalis nutrient uptake. 
Furthermore, the activity of enzymes produced by other members of the microbiota could 
enhance the growth of P. gingivalis, as was shown in Chapter 4 of this thesis, where T. 
forsythia NanS enhanced P. gingivalis growth on serum (FBS) and human saliva, implying 
that in vivo this may also help other members of the microbial community, including P. 
gingivalis.  In fact the lab now has a T. forsythia nanS mutant (G.Stafford, personal 
communication), which it would be exciting to test in growth experiments and in 
community experiments to assess the role of this gene in microbial communities. 
While F. nucleatum does not possess sialidases, it does possess other components of the 
nan operon enabling uptake (unknown outer membrane transporter/porin, and inner 
membrane transporter system SiaPQM) and catabolism (NanA, NanE, NanK), implying that 
sialic acid represents a nutrient source for F. nucleatum. Furthermore, many  F. nucleatum 
strains have been shown to sialylate their outer membrane proteins (Yoneda et al. 2014), 
which is likely to play roles in immune evasion: Thus, sialic acid utilisation has a direct 
impact on metabolism and surface phenotype of F. nucleatum-which will affect 
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proliferation- and it must rely on release of sialic acid by other members of the microbiota.  
It is also of note that the original T. forsythia isolation method involved the cross-streaking 
of F.nucleatum with T.forsythia (Tanner et al. 1986), which has always been assumed to be 
due to the cross-feeding of N-acetylmuramic acid, but could equally be sialic acid given 
these recent reports. 
Finally, T. denticola also possesses a sialidase (TDE0471), although characterisation and its 
roles in virulence are only just beginning to come to light (Kurniyati et al. 2013). TDE0471 is 
expressed on the outer membrane of T. denticola, and was shown to prevent complement 
deposition on its surface. This is likely due to desialylation of complement proteins, which 
may either inactivate them or increase the activity of the T. denticola protease dentilisin, 
which is also important for complement resistance (McDowell et al. 2009). Furthermore, 
TDE0471 appears to be important for nutrient acquisition, with T. denticola mutants 
deficient in the sialidase unable to grow with serum as a nutrient source (Kurniyati et al. 
2013). 
In addition to direct effects on pathogen proliferation, the sialidases are also important for 
interactions at the mucosal surface and subsequent inflammation: Previous work has 
highlighted the importance of the sialidases of P. gingivalis and T. forsythia in host cell 
attachment and invasion (Honma et al. 2011; Li et al. 2012). In this project, the sialidase 
inhibitor zanamivir was also capable of inhibiting host cell association by these pathogens 
and the sialidase negative F. nucleatum, even during mixed species infections.  
As well as association, pathogen sialidases can modulate or enhance pro-inflammatory 
signalling (Amith et al. 2009; Amith et al. 2010), and therefore they are likely to be 
important for onset and progression of periodontal disease. In this project, zanamivir was 
capable of reducing the pro-inflammatory signalling response to live T. forsythia, and the 
enhanced response to P. gingivalis LPS in the presence of NanH. Importantly, the 
experiments shown in this thesis describing the contribution of pathogen sialidases to pro-
inflammatory signalling, and the potential to inhibit this, was performed on oral epithelial 
cells (previous work focuses on macrophages) and highlights the potential to limit 
destructive inflammation by dampening signals initiating from oral epithelial cells. Together 
with the host cell association data (chapter 5) and the capacity of inhibitors to prevent 
pathogen biofilm formation (shown here in chapter 4 and elsewhere (Roy et al. 2011)),  this 
provides strong support for further investigation of sialidase inhibitors as novel 
therapeutics. 
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Ultimately, experiments here did show the ability to inhibit multiple periodontal pathogen 
virulence processes (host cell association, immunomodulation, and biofilm formation), and 
shed light on the role of NanS (Phansopa et al. 2015). Further work should focus on the 
precise targets of sialidase inhibitors, and the ability of different inhibitors to target the 
periodontal pathogen sialidases. Work elsewhere has highlighted greater efficacy of other 
sialic acid analogues) and other apparently non-analogous compounds) for bacterial 
sialidases (Hoon et al. 2014; Walther et al. 2015; Tailford et al. 2015), in some cases with 
accompanying decreases during in vitro models of virulence. Since some of these are used 
or considered suitable for antiviral therapies, there could be a greater likelihood of their 
application to periodontitis therapy.  
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Figure 5.1. Sialidases and sialic acid-mediated interactions enhance periodontal pathogen 
proliferation and host inflammatory processes through a number of mechanisms. 
A) Periodontal pathogens uptake sialic acid through a number of mechanisms, all of which 
require sialidase activity first to enable sialic acid release (which may be bolstered by 
accessory enzymes such as NanS). B) Pathogen sialidases at the oral mucosal surface. In 
addition to increasing nutrient availability (sialic acid or enhanced proteolysis of host 
sialoglycoproteins), sialidases can interact with sialoglycans on host cell surfaces. This 
includes immune-stimulatory receptors such as TLRs -2 and -4, which signal through the 
NFΚB pathway to produce pro-inflammatory cytokines such as IL-6 and IL-8. Desialylation of 
host cell surfaces may also lead to increased complement deposition, and may expose 
glycoprotein epitopes that can be recognised by pathogens for attachment, so sialidases 
can increase attachment and invasion of host cells by pathogens. C) Dysbiosis and 
destructive inflammation at the periodontal mucosal surface. The processes discussed in B) 
and C) cause pathogen (and to a lesser extent commensal) proliferation due to increased 
nutrient availability, and increased ability to attach and persist at the mucosal surface. 
Increased pathogen proliferation and pro-inflammatory signalling leads to differentiation, 
recruitment, and activation of immune cells including neutrophils and macrophages, which 
do not successfully clear pathogens. Ultimately sialidase inhibitors have the potential to 
disrupt these virulence mechanisms, not only at the sialidase level but possibly at other 
sialic acid utilisation proteins, since the inhibitors are structural analogues of sialic acid and 
could also show affinity for enzymes and transporters besides sialidase.  
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Overall, my work continues to highlight the importance of glycans in interactions of oral 
bacteria with the host, an understudied area historically. While my focus has been sialic 
acid and sialidases, other glycans and glycosidases may also play key roles, for example the 
T.forsythia nanH is in an operon with a beta-hexosaminidase that almost certainly acts to 
cleave underlying galactose or glucose moieties during infections.  In addition, I was 
involved in work with a team from Vienna (University of Natural Lifesciences-Universität für 
Bodenkultur-BOKU) examining the role of a fucosidase with unusual properties in T. 
forsythia (Megson et al. 2015).  It may well prove that the role of glycans is crucial in the 
oral environment and the fact that periodontal pathogens seem to dedicate a proportion of 
resource in that direction indicate this might be true. It is certainly  the case that 
periodontal pathogens and other oral bacteria seem to dedicate a significant proportion of 
their genomes (much like gut bacteria) to genes that potentially have a role in glycan 
foraging, meaning that this idea of making the most of your niche is extremely pertinent 
(Martens et al. 2008; Stafford et al. 2012). 
While my work has focussed on interactions with glycoproteins, glycoprotein coated 
surfaces and human cell surfaces, I have also discussed the possible role it has in 
interbacterial interactions in the section above.  However, one other common type of 
organism present in the oral cavity in particular are fungi.  The most prominent of these is 
arguably Candida albicans.  Of note there is evidence that C. albicans contains N-glycans on 
its surface that are capped with sialic acid (2,6-linked and lectin reactive) (Soares et al. 
2000), this raises the interesting possibility that sialic acid and by extension sialidases may 
be involved in cross-kingdom inter-pathogen interactions, and represents yet more areas of 
study. 
While my work has focussed on oral micro-organisms and their sialidases, there is a 
plethora of micro-organisms that contain sialidases, many of which are human pathogens 
of import, e.g. S. pneumoniae, Vibrio cholera, Salmonella typhimurium, Gardnerella 
vaginalis amoung others (see chapter 1).  Therefore the findings of this thesis, and future 
work, may have much wider implications on the mechanisms of how bacterial pathogens 
interact with the host glycome and its implications on immunity and infection.  Of 
particular note are infections at mucosal layers, such as the respiratory or genital tracts, 
but there are also growng data that sialic acid metabolism is a key trait of gut-dwelling 
organisms such as B.thetaitomicron, Ruminococcus gnavus and other Bacteroides spp. 
(Martens et al. 2008; Phansopa et al. 2014; Tailford et al. 2015), and has even been shown 
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to be key during pathogen proliferation, including during V. cholerae, Salmonella, and 
Clostridium infections (Almagro-Moreno & Boyd 2009; Ng, J. a Ferreyra, et al. 2013). It is 
therefore clear that the implications of work shown here and elsewhere that focus on the 
oral cavity may have larger implications in human microbiology. 
5.4 Discussing the Potential for a Sialidase Inhibitor-Based Product 
for Treatment or Prevention of Periodontal Disease 
Given that zanamivir appears to show efficacy in preventing virulence of periodontal 
pathogens, it could be possible to develop sialidase inhibitors as novel therapeutics for 
treatment of periodontitis, where the sialidase inhibitor becomes an active ingredient in a 
given product, or “active” that treats or prevents periodontitis. The simplicity of this 
statement hides the multitude of options and challenges during product development, 
which include handling the regulatory issues, efficacy testing, patient or consumer trials 
and focus groups, and claims that can be made about a given product. An additional layer 
of complexity is in navigating these issues at a global level. All of these factors feedback to 
each other during development of a given product. 
Perhaps the most fundamental question in product development of sialidase inhibitors is; 
are they sold to directly to consumers as an over-the-counter treatment or preventative of 
periodontitis, or are they sold for clinical use, available for use by dental or medical 
professionals only? I explored some of these issues during a short placement at GSK 
(Weybridge, UK), so this short section shall attempt to discuss these issues and the 
potential for sialidase inhibitor-product development in oral healthcare settings.  
5.4.1 Sialidase Inhibitors in Products for Periodontitis Treatment-Future 
Directions 
This study does provide evidence for the potential of zanamivir (and perhaps other 
sialidase inhibitors) as novel active ingredients for products that treat periodontitis. 
Previous chapters have discussed possible further in vitro work that might be performed to 
continue to characterise the functions of pathogen sialidases and the potential for sialidase 
inhibition in preventing virulence. A further possibility might be to test the potential of 
zanamivir or other sialidase inhibitors to prevent virulence or pathogen proliferation and 
the onset or progression of periodontitis. 
 This might be achieved through mouse models of periodontitis, where periodontitis is 
induced through infection with periodontal pathogens, either through spiking of drinking 
water, or introduction of pathogens with alveolar gavage. (Examples of mouse models of 
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periodontitis can be seen in Yamaguchi et al. 2016; Settem et al. 2012.) Mice would then be 
treated with sialidase inhibitors and any differences in gingival recession and alveolar bone 
loss observed. The pharmacology of the inhibitor would have to be taken into account 
during design of such experiments: The inhibitor would probably have to be present 
systemically in order to reach the periodontal pocket, since applying oral patches, chips, or 
gels to mice might be problematic. While this does not present an issue for inhibitors such 
as oseltamivir (oral administration) the inhibitor zanamivir might have to be administered 
differently to achieve systemic concentrations at which it is effective against pathogens. 
A less direct approach might be taken to study the ability of sialidase inhibitors to reduce 
periodontal pathogen levels in the oral cavity or at the periodontium in humans: The 
sialidase inhibitor oseltamivir is administered orally, and reaches 0.34 µg/ml systemically  
during conventional anti-flu therapy (Widmer et al. 2010), and clinical trials using 
intravenous (systemic) zanamivir are also performed (Fritz et al. 1999; Marty et al. 2013), 
where zanamivir can reach up to ~50 µg/ml (~17 µM) in serum (Marty et al. 2013). 
Presumably the GCF and saliva of patients undergoing these anti-flu therapies also contains 
the sialidase inhibitors, thus exposing the periodontal microbiota to zanamivir or 
oseltamivir. In addition to confirming the presence of inhibitors in the GCF and/or saliva, it 
would theoretically be possible to compare the periodontal microbiota of patients before 
or at an early stage of treatment with their microbiota post-treatment, and assess the 
relative levels of periodontal pathogens before and after treatment. In such studies it 
probably would not be appropriate to take detailed clinical assessments of periodontal 
health, since clinical assessments or periodontitis are usually made a few months apart. 
Any observed impact of sialidase inhibitors on periodontal pathogen abundance in these 
patients would provide a stronger case for developing sialidase inhibitors for periodontitis 
therapy. 
5.4.2 Formulation of Products Containing Sialidase Inhibitors 
Commonly used formulations of consumer products for oral hygiene or treatment products 
include pastes, mouthwashes, and (less commonly) gels, which can be applied to the teeth, 
oral cavity and oral mucosa, and these retain their position for a short amount of time. 
(minutes, gels persist longer than toothpaste and mouthwash). In the case of toothpaste 
and mouthwash, the concentration of active ingredients in saliva is mostly lost within the 
first 30-60 minutes after toothbrushing, though some is retained in the oral tissues and is 
gradually released into saliva over the course of several hours (Duckworth 2013). 
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 More specialised formulations used (or under development for use) in the clinic or for 
patient-specific therapy include these and other formulations, such as oral patches and 
chips. Patches are placed on the oral mucosa, retained in position, and release the active 
ingredient over a longer time scale (minutes-hours), and chips, which are similar devices 
that can be positioned in the periodontal pocket, where they release the active ingredient 
over a longer time period (days-weeks (Soskolne et al. 1998)). Periodontal chips have been 
developed that incorporate and release the antibacterial agent chlorhexidine, and when 
used as an adjunct to periodontitis therapy (scaling and root planing) their use can result in 
improvements in clinical parameters and inhibition of pathogen recolonisation compared 
to patients who do not receive the adjunct (John et al. 2015).  
Currently characterised sialidase inhibitors are competitive, i.e. they compete with other 
ligands in binding to the sialidase. This implies that a continuous concentration of inhibitor 
needs to be maintained at the periodontal pocket or gingival crevice-where periodontal 
pathogens colonise and cause disease, in order to continuously inhibit the virulence of 
periodontal pathogens. This is in contrast to more conventional active ingredients that 
affect bacteria, such as chlorhexidine, which require only a short timescale to display 
bactericidal effects. 
Given this, a conventional oral healthcare formulation-mouthwash or toothpaste-is unlikely 
to be useful as this would result in intermittent, short term exposure of pathogens to the 
inhibitor. Gels and patches applied to the periodontium are a possible formulation, as they 
remain in position for a longer time period. These could potentially be sold as consumer 
products, or be available on prescription, but importantly these formulations do not 
require a clinician to apply the therapeutic. Chips, placed in the periodontal pocket, are 
another possible formulation. Since these are retained and would release the sialidase 
inhibitor over the longest time period, these could also be useful for administration of 
sialidase inhibitors. However, such a product would be limited to clinical use only, due to 
the requirement for a clinician or trained professional in placing the chip. 
Considering the above, sialidase inhibitors could be developed as gels, patches, or chips. 
The latter two could possibly be sold directly to consumers, but a chip formulation would 
be a specialist product for use in the clinic only. 
5.4.3 Regulation of Consumer Products 
Oral healthcare consumer products for sale in the European Union (EU) can be considered 
to belong to one of three regulatory categories: Cosmetics, medical devices, or medicines. 
296 
 
*Currently available at: 
 http://eur-ex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1976L0768:20100301:en:PDF 
These have different levels of safety and efficacy testing associated with them, and the 
classification of a product also affects the types of claims that can be made about what the 
product does. The United States of America (USA) have different regulatory requirements 
compared to the EU, with considerations concerning novel active ingredients (discussed 
below). However, the categories a product containing a sialidase inhibitor might fall under 
remain the almost the same; cosmetics, medical devices, or drugs (“drugs” being analogous 
to the EU “medicines” category). 
 Cosmetics 5.4.3.1
Governed by EU directive 76/768/EEC*, a cosmetic product “shall mean  any  substance… 
intended to be placed in contact with the various external parts of the human body 
(epidermis, hair system, nails, lips and external genital organs) or with the teeth and the 
mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, 
perfuming them, changing their appearance and/or correcting body odours and/or 
protecting them or keeping them in good condition” (EU directive 76/768/EEC, Article 1, 
page 5). Oral cosmetic products can tread a fine line between this classification and medical 
device or medicine classifications, as cleaning of the oral cavity and disruption of plaque is 
required for oral health, but active ingredients with these properties might also be 
considered a treatment for a given condition. 
In an oral health context, toothpastes and mouthwashes often fall into the cosmetics 
category. However, the presence of certain active ingredients in these formulations, such 
as chlorhexidine, or high concentrations of other active ingredients, such as fluoride, might 
result in the product classified as a medical device or medicine, since the nature of the 
active ingredient is no longer considered to be simply maintaining appearance or odour, 
and instead could be considered a treatment or preventative of disease. 
The nature of the cosmetics category limits the types of claims that can be made about the 
benefits of a product to maintenance of appearance/odour. This is why the claims made 
regarding daily, cosmetic toothpastes are limited to using words such as “cleaning”, 
“freshness”, or “whitening activity” to describe their activity. Given that sialidase inhibitors 
inhibit virulence of pathogens, it is unlikely that a product containing them as an active 
would fall into the cosmetics category. Furthermore, the potential benefits of sialidase 
inhibitors are not limited to cosmetic applications-they prevent virulence- and from a 
commercial standpoint this might represent a unique selling point, and these claims about 
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the product could only be made if the sialidase inhibitor-product is classified as a medical 
device or medicine. 
 Medical Devices 5.4.3.2
Governed by EU directive 3/42/EEC*, medical device “means any instrument, apparatus, 
appliance, software, material or other article… to be used specifically for diagnostic and/or 
therapeutic purposes… and which does not achieve its principal intended action in or on 
the human body by pharmacological, immunological or metabolic means, but which may 
be assisted in its function by such means.” (EU directive 3/42/EEC, Article 1, pages 5-6). 
In terms of oral healthcare consumer products, toothpastes and mouthwashes may fall 
under this classification if they have a perceived therapeutic or preventative benefit. An 
example of medical devices in this context is the Corsodyl ® (Trademark GlaxoSmithKline, 
UK) range of daily toothpastes. These have undergone clinical trials to prove that they do 
have therapeutic and/or preventative benefits: Corsodyl® toothpaste has been shown to 
“reduce levels of plaque”, “stop bleeding gums”, and appears to “maintain healthy gingiva” 
(https://www.gsk-dentalprofessionals.co.uk/our-brands/corsodyl-toothpaste/corsodyl-
daily-toothpaste/). Since these are considered to be mechanical effects, Corsodyl® daily is 
defined as a medical device. 
Sialidase inhibitor-products may fall under the classification of medical devices if they are 
deemed to have similar modes of action, i.e. mechanical rather than pharmacological. It 
could be argued that since sialidase inhibitors inhibit virulence by preventing bacterial 
attachment, biofilm formation, and host-bacteria interactions without killing bacteria 
directly, that they do have a mechanical mode of action. Indeed, a clinical trial of a sialidase 
inhibitor-product might have similar findings to the ones stated above for Corsodyl® daily 
products.  
   Medical devices are further subdivided into invasive (placed inside the body) and non-
invasive devices (placed externally or on the oral mucosa). The duration of device 
placement is also taken into account, including transient (<60 minutes), short term (<30 
days), and long term (<30 days) (EU directive 3/42/EEC, Annex IX, pages 51-54). The precise 
type of medical device that a sialidase inhibitor-product falls under would be governed 
largely by its formulation and directions for application: A gel based formulation might be 
classified as non-invasive, transient or short term. An oral mucosa-patch might be non-
invasive transient or short term, while a chip-based formulation might be classified as 
invasive since it would be placed inside the periodontal pocket. On the other hand, the EU 
*Currently available at:  
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009
/10/WC500004481.pdf 
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*Currently available at: 
http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:01993L0042-20071011&from=EN 
directive governing medical devices states specifically that devices may be considered non-
invasive if they are placed above the pharynx ((EU directive 3/42/EEC, Annex IX, page 54, 
section 2.1). 
It might be the case that sialidase inhibitors are deemed to have a primarily 
pharmacological mode of action, in which case they would be governed by rules concerned 
with medicinal products. The EU directive governing medical devices appears to recognise 
the difficulty in distinguishing between these two classifications when it states that 
“medicinal products [are] covered by Directive 2001/83/EC. In deciding whether a product 
falls under that Directive or this Directive, particular account shall be taken of the principal 
mode of action of the product.” (EU directive 3/42/EEC, Article 1, page 8). 
 Medicines, or Medicinal Products 5.4.3.3
Governed by EU Directive 2001/83/EC*, medicinal products include “Any substance or 
combination of substances presented as having properties for treating or preventing 
disease in human beings… Any substance or combination of substances which may be used 
in or administered to human beings with a view to restoring, correcting, or modifying 
physiological functions by exerting a pharmacological, immunological, or metabolic action” 
(EU Directive 2001/83/EC, article 1, page 13).  
Certainly, it might be considered likely that a sialidase inhibitor-active ingredient could fall 
under this regulation, especially if (like zanamivir) it inhibits human sialidases. However, if 
the inhibitor is mainly considered to act through mechanical, non-invasive means, such as 
reducing levels of plaque or stopping bleeding gums with an oral gel or mouthwash, then 
such a product might fall under the medical device category. If zanamivir were to be 
applied to a product, it would probably be classified as a medicine since it is already 
licensed as a medicine for treatment of flu, and also inhibits human sialidases (Hata et al. 
2008) as well as those of the periodontal pathogens.  
Candidate-products applying for regulation as a medicine have the most stringent 
requirements -appendix 7.9 contains some of these, the rest can be viewed in EU Directive 
2001/83/EC*, “Title III, Placing on the Market, Chapter I”-making them the most difficult to 
apply for. This chapter of EU Directive 2001/83/EC does make reference to the possibility of 
foregoing the submission of clinical trials data to the regulatory authority (which would 
make the regulatory process slightly easier) if the new product is suitably similar to a 
reference product that has been on the market for at least eight years. Zanamivir has been 
sold in the anti-flu drug Relenza for that period of time. Unfortunately for a theoretical 
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zanamivir-containing product for treatment of periodontitis, there is a requirement for the 
reference product to be “of the same pharmaceutical form as the reference product”, so 
this provision is of little use in terms of more rapidly-progressing a theoretical zanamivir-
based product to market.  
5.5 In Conclusion 
Ultimately, the results of this project expand our knowledge of the molecular microbiology 
of periodontal pathogens and the pathogenicity of T. forsythia and P. gingivalis. 
Furthermore, the results advocate the potential for sialidase inhibitors as anti-virulence 
therapeutics for treatment of periodontal disease. Though more research with alternative 
inhibitors is probably required, and ultimately this project raised more questions than it 
answered. 
However, the discovery of a potential immunomodulatory role for the pathogen sialidases 
and further characterisation of these enzymes paves the way for further developments in 
this exciting area of research, and with tenacity this is likely to yield promising results which 
can be applied to the discovery of new therapeutics. Or in other words- “Do you know what 
happens to lads who ask too many questions? ...Damned if I know. Probably they get 
answers, and serve 'em right.” –Terry Pratchett, Mort (1987). 
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7.1 Full Sequences of sialidases closely related to NanH from 92.A2 
 
> Sialidase T.forsythia 92.A2 NCBI Reference Sequence: WP_014225510.1  
MKKFFWIIGLFASMQMTRAADSVYVQNPQIPILVDRTDNVLFRIRIPDATKGDVLNRLTIRFGNEDKLSE
VKAVRLFYAGTEAATKGRSRFAPVTYVSSHNIRNTRSANPSYSIRQDEVTTVANTLTLKTRQPMVKGINY
FWVSVEMDRNTSLLSKLTSTVTEVVINDKPAVIAGEQAAVRRMGIGVRHAGDDGSASFRIPGLVTTNK
GTLLGVYDVRYNNSVDLQEHIDVGLSRSTDKGQTWEPMRIAMSFGETDGLPSGQNGVGDPSILVDERT
NTVWVVAAWTHGMGNARAWTNSMPGMTPDETAQLMMVKSTDDGRTWSESTNITSQVKDPSWC
FLLQGPGRGITMRDGTLVFPIQFIDSLRVPHAGIMYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLM
LNMRDNRGGSRAVSITRDLGKSWTEHSSNRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHI
TIKASLDGGVTWLPAHQVLLDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
 
> Sialidase T.forsythia 3313 NCBI Reference Sequence: WP_060828620.1 
MKRFFLIVGLLASMQMTRAADSVYVQNPQIPILIDRTDNVLFRISIPDATKGDVLNRLTIRFGNEDKLSEV
KAVRLFYAGTEAATKGRSRFAPVTYVSSHNIRNTRSANPSYSVRQDEVTTVANTLTLKTRQPMVKGINYF
WVSVEMDRNTSLLSKLTPTVTEAVINDKPAVIAGEQAAVRRMGIGVRHAGDDGSASFRIPGLVTTNKG
TLLGVYDVRYNNSVDLQEHVDVGLSRSTDKGQTWEPMRIAMSFGETDGLPSGQNGVGDPSILVDERT
NTVWVVAAWTHGMGNARAWTNSMPGMTPDETAQLMMVKSTDDGRTWSEPTNITSQVKDPSWC
FLLQGPGRGITMRDGTLVFPIQFIDSLRVPHAGIMYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLM
LNMRDNRGGSRAVSITRDLGKSWTEHSSNRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHI
TIKASLDGGVTWLPAHQVLLDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
 
> Sialidase T.forsythia 43037 NCBI Reference Sequence: WP_046826229.1 
MKKFFWIIGLFISMQMTRAADSVYVQNPQIPILIDRTDNVLFRIRIPDATKGDVLNRLTIRFGNEDKLSEV
KAVRLFYAGTEAATKGRSRFAPVTYVSSHNIRNTRSANPSYSVRQDEVTTAANTLTLKTRQPMVKGINYF
WVSVEMDRNTSLLSKLTPTVTEAVINDKPAVIAGEQAAVRRMGIGVRHAGDDGSASFRIPGLVTTNEG
TLLGVYDVRYNNSVDLQEHVDVGLSRSTDKGQTWEPMRIAMSFGETDGLPSGQNGVGDPSILVDERT
NTVWVVAAWTHGMGNARAWTNSMPGMTPDETAQLMMVKSTDDGRTWSEPINITSQVKNPSWC
FLLQGPGRGITMRDGTLVFPIQFIDSLRVPHAGIMYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLM
LNMRDNRGGSRAVSITRDLGKSWTEHSSNRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHI
TIKASLDGGVTWLPAHQVLLDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
> Sialidase T.forsythia KS16 NCBI Reference Sequence: WP_060831273.1 
MKKFFLIVGLFASMQIIRAADSVYVQNPQIPILVDRTDNVLFRIRIPDATKGDVLNRLTIRFGNEDKLSEVK
AVRLFYAGTEAATKGRSRFAPVTYVSSHNIRNTRSANPSYSVRQDEVTTVANTLTLKTRQPMVKGINYF
WVSVEMDRNTSLLSKLTPTVTEAVINDKPAVIAGEQAAVRRMGIGVRHAGDDGSASFRIPGLVTTNEG
TLLGVYDVRYNNSVDLQEHVDVGLSRSTDKGQTWEPMRIAMSFGETDGLPSGQNGVGDPSILVDERT
NTVWVVAAWTHGMGNARAWTNSMPGMTRDETPQLMMVRSTDDGRTWSEPINITSQVKDPSWCF
LLQGPGRGITMRDGTLVFPIQFIDSVRVPHAGIMYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLML
NMRDNRGGSRAVSITRDLGKSWTEHSSNRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHI
TIKASLDGGVTWLPAHQVLLDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
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>Sialidase Parabacteroides gordonii NCBI Reference Sequence: 
WP_028730084.1 
 
MKKSIFYLCLLFIAQTAFAADSLYVREQQIPILIDRTDNVLLEMRIPAQKGDVLNKFTLQFGNETNLSDIKAI
RLFYSGTEAPAREGTHFNPVTYVTSFTPGKTRVANPSYSVKQDEVTAPANTITLTSKQPMVKGPNYFWV
SIEMKPETSLLSRVSFTMPEAVINNKPAAIAWKGKAEAPRRVGVGVRQAGDDGSAAFRIPGMVTTNN
GTLLGVYDIRYNSSVDLQEMVDIGVSRSTDKGQTWEPMQVAMTFGETGGLPHAQNGVGDPSILVDEK
TNTIWIVAAWTHGMGNGRAWWNSMPGMTPDETAQLVLVKSEDDGKTWSEPINITSQVKDPSWYFL
LQGPGRGITMQDGTLVFPIQFIDATRIPNAGVMYSKDRGKTWHIHNLARTNTTEAQVAEVEPGVLML
NMRDNRGGSRAVATTKDLGKTWTEHPSSRSALPEPVCMASLIKVDADDNITGKKLLLFSNPNTTKGRN
HITIKASLDGGLTWPAEHQVLLDEAEGWGYTCLSMIDKETVGIFYESSVAHMTFQAIKISDLIKE 
 
>sialidase Parabacteroides distasonis ATCC 8503 NCBI Reference Sequence: 
WP_011967072.1 
MKKTFLYFCLLFIVQTAFAADSIYVREQQIPILIDRIDNVLYEMRIPAQKGDVLNEITIQIGDNVDLSDIQAI
RLFYSGVEAPSRKGEHFSPVTYISSHIPGNTRKALESYSVRQDEVTAPLSRTVKLTSKQPMLKGINYFWVSI
QMKPETSLLAKVATTMPNAQINNKPINITWKGKVDERHVGIGVRQAGDDGSAAFRIPGLVTTNNGTLL
GVYDIRYNSSVDLQEKIDIGVSRSTDKGQTWEPMRVAMTFKQTDGLPHGQNGVGDPSILVDEKTNTI
WVVAAWTHGMGNERAWWNSMPGMTPDETAQLMLVKSEDDGKTWSEPINITSQVKDPSWYFLLQ
GPGRGITMQDGTLVFPIQFIDATRVPNAGIMYSKDRGKTWHLHNLARTNTTEAQVAEVEPGVLMLN
MRDNRGGSRAVATTKDLGKTWTEHPSSRSALQESVCMASLIKVNAKDNITGKDLLLFSNPNTTKGRNH
ITIKASLDGGLTWPTEHQVLLDEAEGWGYSCLSMIDKETVGIFYESSVAHMTFQAVKLQDLIHQ 
>Allistipes spp. bNR/Asp-box repeat protein [Alistipes sp. 
CAG:435] 
MMKRTFWLIALSLLSLTLSASDSLRIHNPQIPILLDRMDNVLFQIRVPDAVQGDVLESLTVEFGPDTDIKS
MAELRLFYSGTEAVRRQGLRFSPVEYISAHNVWNTRSANPSYSVMQEQVSKIGRKVVLHSRQPMVGGI
NYYWVSVRMNPDASLLTELRARVSEVVVNGKKIPVACDSRDVVRRMGYGVRHAGDDHSMAYRIPGL
VTTNSGSLIGVYDVRWNSSVDLQERIDIGVSRSTDKGQTWEPMRIAMSFADVDGLPSGQNGVGDPAV
LVDEKTGTIWVMAAWTHGMGNGRAWTNSMPGMEPMETPQLMLARSDDDGRTWSEPINITKQVK
DPSWCFLLQGPGRGITMRDGTLVFAIQFIDKDRMPHAGIIFSKDHGETWHIHNPARSNTTEAQVAEVE
PGVLMLNMRDNRGGARAVMTTRDLGRTWNEHVSHRTTLREPVCMASLIAVPAEKNVLGKDLLLFSN
PDTTDGRRDITIKASLDGGVTWPYSLLLDEGDSWGYSCLTMIDSQTVGILYESSVAHITFQVVKLKDIVR 
 
>Sialidase Porphyromonas sp. 31_2 Genbank: KEJ85713.1 
MEFTYLLISTYKQKHHEKTFLYFCLLFIVQTAFAADSLYVREQQIPILIDRIDNVLYEMRIPAQKGDVLNEITI
QIGDNVDLSDIQAIRLFYSGVEAPSRKGEHFSPVTYISSHIPGNTRKALESYSVRQDEVTTPLSRTVKLTSK
QPMLKGINYFWVSIQMKPETSLLAKVATTMPNAQINNKPIDITWKGKVDERHVGIGVRQAGDDGSAA
FRIPGLVTTNNGTLLGVYDIRYNSSVDLQEKIDIGVSRSTDKGQTWEPMRVAMTFKQTDGLPHGQNGV
GDPSILVDEKTNTIWVVAAWTHGMGNERAWWNSMPGMTPDETAQLMLVKSEDDGKTWSEPINITS
QVKDPSWYFLLQGPGRGITMQDGTLVFPIQFIDATRVPNAGIMYSKDRGKTWHLHNLARTNTTEAQV
AEVEPGVLMLNMRDNRGGSRAVATTKDLGKTWTEHPSSRSALQESVCMASLIKVNAKDNITGKDLLLF
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SNPNTTKGRNHITIKASLDGGLTWPTEHQVLLDEAEGWGYSCLSMIDKETVGIFYESSVAHMTFQAIKL
QDIIHQ 
>Sialidase B. fragilis str. 3976T8 WP_032598086.1 
MKKAVILFSLFCFLCAIPVVQAADTIFVRETRIPILIERQDNVLFYLRLDAKESQTLNDVVLNLGEGVNLSEI
QSIKLYYGGTEALQDSGKKRFAPVGYISSNTPGKTLAANPSYSIKKSEVTNPGNQVVLKGDQKLFPGINYF
WISLQMKPGTSLTSKVTADIASITLDGKKALLDVVSENGIEHRMGVGVRHAGDDNSAAFRIPGLVTTNK
GTLLGVYDVRYNSSVDLQEHVDVGLSRSTDGGKTWEKMRLPLAFGEFGGLPAGQNGVGDPSILVDTKT
NNVWVVAAWTHGMGNQRAWWSSHPGMDMNHTAQLVLAKSTDDGKTWSAPINITEQVKDPSWY
FLLQGPGRGITMSDGTLVFPTQFIDSTRVPNAGIMYSKDGGKNWKMHNYARTNTTEAQVAEVEPGVL
MLNMRDNRGGSRAVAITKDLGKTWTEHESSRKALPESVCMASLISVKAKDNVLGKDLLIFSNPNTTKG
RYNTTIKISLDGGVTWSPEHQLLLDEGDNWGYSCLSMIDKETIGILYESSVAHMTFQAVKLKDIIK 
>Sialidase B. thetaiotaomicron str. 2789STDY5834899 GenBank: CUP73670.1 
MKRNHYLFTLILLLGCSIFVKASDTVFVHQTQIPILIERQDNVLFYFRLDAKESRMMDEIVLDFGRSVNLS
DVQAVKLYYGGTEALQDRGKNRFAPVDYISSHRPGNTLAAIPSYSIKCAEVLQPSAKVVLKSHYKLFPGIN
FFWISLQMKPETSLFTKISSELQSVKIDGKEAICEERSPKDIIHRMAVGVRHAGDDGSASFRIPGLVTSNK
GTLLGVYDVRYNSSVDLQEYVDVGLSRSTDGGKTWEKMRLPLSFGEYDGLPAAQNGVGDPSILVDTQT
NTIWVVAAWTHGMGNQRAWWSSHPGMDLYQTAQLVMAKSTDDGKTWSKPINITKQVKDPSWYF
LLQGPGRGITMSDGTLVFPTQFIDSTRVPNAGIMYSKDRGKTWKMHNMARTNTTEAQVVEIEPGVLM
LNMRDNRGGSRAVAITKDLGKTWTEHPSSRKALQEPVCMASLIHVEAKDNVLDKDILLFSNPNTTRGR
NHITIKASLDDGLTWLPEHQLMLDEGEGWGYSCLTMIDRETIGILYESSAAHMTFQAVKLKDLIR 
 
>Sialidase Dysgonomonas sp. HGC4 NCBI Reference Sequence: 
WP_050709261.1MKNLFLSFFLLLSLTINSASDTVKIKAPQIPILTDRQDNVLFYIRLDAANSKVLNNVKV
NLDKEVNLNEIKSIKLYYSGTECVQREGKTFYAPVQYISKDVPGNTFAANSSYSVKKTELSTLKNEITLTAD
QPLFPGINYFWVSIEMKPNASLLSNVQANITDVILDNKSAIIAFDKERSVSRKLGIGVRHAGDDKAAAYRI
PGLATSNKGTMLGVYDVRYNNSADLQEYVHVGLSRSVDKGQTWEPMRIIMDFDEYGGLPKAQNGVG
DPAILVDKTTGTIWVVAAWTHGMGNGRAWFNSQQGMGIDQTAQLVMVKSDDDGKTWSKPINVTP
QLKDPSWYFLLQGPGNGITMQDGTIVFASQFIDSERIPNAGIIYSKDHGKTWQTHNYARTNTTEAQVV
EIEPGVLMLNMRDNRGGSRAVATTKDMGKTWTEHPSSRSALQEPVCMASIIKVAAKDNVLKKDILLFS
NPNTTKERKDITIKASLDGGNTWLPEQQILLDEDYSWGYSCLSMIDKETVGIFYESSVAHMTFQAIKLSDI
IKK 
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7.2 Full Sequences of Sialidases Closely Related to SiaPG from ATCC 
33277 
> sialidase Porphyromonas gingivalis_ATCC33277 NCBI Reference 
Sequence: WP_012458403.1 
MANNTLLAKTRRYVCLVVFCCLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPPGAKQIR
IGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADSVAGRCFFYLAAD
IGPVASFSRSDTLTARVEELAVDGRPLPLKELSPASRRLYREYEALFVPGDGGSRNYRIPSILKTANG
TLIAMADRRKYNQTDLPEDIDIVMRRSTDGGKSWSDPRIIVQGEGRNHGFGDVALVQTQAGKLLMIFV
GGVGLWQSTPDRPQRTYISESRDEGLTWSPPRDITHFIFGKDCADPGRSRWLASFCASGQGLVLPSGR
VMFVAAIRESGQEYVLNNYVLYSDDEGGTWQLSDCAYHRGDEAKLSLMPDGRVLMSVRNQGRQESRQR
FFALSSDDGLTWERAKQFEGIHDPGCNGAMLQVKRNGRNQMLHSLPLGPDGRRDGAVYLFDHVSGRWS
APVVVNSGSSAYSDMTLLADGTIGYFVEEDDEISLVFIRFVLDDLFDARQ 
 
> sialidase Porphyromonas gingivalis_A7A1-28 NCBI Reference 
Sequence: WP_058019243.1 
MANNTLLAKTRRSVCLVVFCCLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPPGAKQIR
IGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADSVAGRCFFYLAAD
IGPVASFSRSDTLTARVEELAVDGRPLPLKELSPASRRLYREYEALFVPGDGGSRNYRIPSILKTANG
TLIAMADRRKYNQTDLPEDIDIVMRRSTDGGKSWSDPRIIVQGEGRNHGFGDVALVQTQAGKLLMIFV
GGVGLWQSTPDRPQRTYISESRDEGLTWSPPRDITHFIFGKDCADPGRSRWLASFCASGQGLVLPSGR
VMFVAAIRESGQEYVLNNYVLYSDDEGGTWQLSDCAYHRGDEAKLSLMPDGRVLMSVRNQGRQESRQR
FFALSSDDGLTWERAKQFEGIHDPGCNGAMLQVKRNGRNQMLHSLPLGPDGRRDGAVYLFDHVSGRWS
APVVVNSGSSAYSDMTLLADGTIGYFVEEDDEISLVFIRFVLDDLFDARQ 
 
> sialidase Porphyromonas gingivalis_W4087 NCBI Reference 
Sequence: WP_043894535.1 
MANNTLLAKTRRSVCLVVFCCLMAMMHLSGQEVTVCGDSHGVAPNQMYRTLVKVALSESLPPGAKQIR
IGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADSVAGRRFFYLAAD
IGPVASFSRSDTLTARVEELAVDGRPLPLKELSPASRRLYREYEALFVPGDGGSRNYRIPAILKTANG
TLIAMADRRKYNQTDLPEDIDIVMRRSTDGGKSWSDPRIIVQGEGRNHGFGDVALVQTQAGKLLMIFV
GGVGLWQSTPDRPQRTYISESRDEGLTWSPPRDITHFIFGKDCADPGRSRWLASFCASGQGLVLPSGR
IMFVAAIRESGQEYVLNNYVLYSDDEGDTWQLSDCAYRRGDEAKLSLMPDGRVLMSIRNQGRQESRQR
FFALSSDDGLTWERAKQFEGIHDPGCNGAMLQVKRNGRDQVLHSLPLGPDGRRDGAVYLFDHTSGRWS
APVVVNSGSSAYSDMTLLADGTIGYFVEEDDEISLVFIWFVLDDLFDARQ 
 
> sialidase, Putative Porphyromonas gingivalis_W83 Genbank: 
AAQ65563.1 
MANNTLLAKTRRYVCLVGFCWLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPP
GAKQIRIGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADS
VAGRRFFYLAADIGPVASFSRSDTLTARVEEVAVDGRPLPLKELSPASRRLYRGYEALFVPG
DGGSRNYRIPAILKTANGTLIAMADRRKYNQTDLPEDIDIVMRRSTDGGKSWSDPRIIVQGE
GRNHGFGDVALVQTQAGKLLMIFVGGVGLWQSTPDRPQRTYISESRDEGLTWSPPRDITHFI
FGKDCADPGRSRWLASFCASGQGLVLPSGRITFVAAIRESGQEYVLNNYVLYSDDEGDTWQL
SDCAYRRGDEAKLSLMPDGRVLMSIRNQGRQESRQRFFALSSDDGLTWERAKQFEGIHDPGC
NGAMLQVKRNGRDQVLHSLPLGPDGRRDGAVYLFDHVSGRWSAPVVVNSGSSAYSDMTLLAD
GTIGYFVEEGDEISLVFIRFVLDDLFDVRQ 
 
> “Hypothetical Protein” Porphyromonas gingivalis_F0570 NCBI 
Reference Sequence: 
WP_021665936.1MANNTLLAKTRRYVCLVGFCWLMAMMHLSGQEVTMWGDSHGVAPNQVR
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RTLVKVALSESLPPGAKQIRIGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFP
ISKEDRTTALSADSVAGRRFFYLAADIGPVASFSRSDTLTARVEEVAVDGRPLPLKELSPAS
RRLYRGYEALFVPGDGGSRNYRIPAILKTANGTLIAMADRRKYNQTDLPEDIDIVMRRSTDG
GKSWSDPRIIVQGEGRNHGFGDVALVQTQAGKLLMIFVGGVGLWQSTPDRPQRTYISESRDE
GLTWSPPRDITHFIFGKDCADPGRSRWLASFCASGQGLVLPSGRITFVAAIRESGQEYVLNN
YVLYSDDEGDTWHLSDCAYRRGDEAKLSLMPDGRVLMSVRNQGRQESRQRFFALSSDDGLTW
ERAKQFEGIHDPGCNGAMLQVKRNGRDQVLHSLPLGPDGRRDGAVYLFDHTSGRWSAPVVVN
SGSSAYSDMTLLADGRIGYFVEEGDEISLVFIRFVLDDLFDARQ 
 
> “Hypothetical Protein” Porphyromonas gingivalis_AJW4 NCBI 
Reference Sequence: 
WP_053444411.1MANNTLLAKTRRYVCLVGFCWLMAMMHLSGQEVTMWGDSHGVAPNQVR
RTLVKVALSESLPPGAKQIRIGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFP
ISKEDRTTAFSADSVAGRRFFYLAADIGPVASFSRSDTLTARVEEVAVDGRPLPLKELSPAS
RHLYRGYEALFVPGDGGSRNYRIPAILKTANGTLIAMADRRKYNQTDLPEDIDIVMRRSTDG
GKSWSDPRIIVQGEGRNHGFGDVALVQTQAGKLLMIFVGGVGLWQSTPDRPQRTYISESRDE
GLTWSPPRDITHFIFGKDCADPGRSRWLASFCASGQGLVLPSGRITFVAAIRESGQEYVLNN
YVLYSDDEGDTWHLSDCAYRRGDEAKLSLMPDGRVLMSVRNQGRQESRQRFFALSSDDGLTW
ERAKQFEGIHDPGCNGAMLQVKRNGRDQVLHSLPLGPDGRRDGAVYLFDHTSGRWSAPVVVN
SGSSAYSDMTLLADGTIGYFVEEGDEISLVFIRFVLDDLFDARQ 
 
> Sialidase Porphyromonas gulae_COT-052 OH4119 GenBank: 
KGN74638.1 
MANNTLLARTLRSVCLVVFCCLVAMLRLTAQEVAVWGDKHGVAPDQAHRTLVKIVLSEPLPP
NAKQIRISYSFPQDTKDKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDCVITLSADS
VAGRRFFYLAADIGPVASFSPSDTLTARVEEVAVDGRPLPFKEVSPASRRLYRGYEALFVPG
DGGSRNYRIPAILKTAKGTLIAMADRRKYNQTDLPEDIDIVMRRSTNGGRSWSDPRIIVQGE
GRNHGFGDVALVQTKARKLLMIFVGGVGLWQSTPDRPQRTYVSESRDEGLTWSPPRDITRFI
FGKDCADPGRSRWLASFCASGKGLLLPSGRIMFVAAIRESGQEYVLKNYVLYSDDEGSTWHL
SDCAYRRGDEAKLSLMPDGRVLMSVRNQGRQEERQRFFALSSDDGLTWERAKQFESIHDPGC
NGAMLQLKWNGRDQMLHSLPLGPDGRRDGAVYLFDHASVRWSTPVVVNSGSSAYSDMTLLAD
GTIGYFVEEDDEISLVFIRFALDDLFDAGL 
 
>sialidase Porphyromonas gulae COT-052 OH2179 NCBI Reference 
Sequence: WP_039431766.1 
MLRLTAQEVAVWGDKHGVAPDQAHRTLVKIALSEPLPPNAKQIRIRYSFPQDTKDKVTALYL
LVSDSLAVRDLPDYKGRVSYDSFPISKEDCVITLSADSVAGRRFFYLAADIGPVASFSRSDT
LTARVQEVAVDGRPLPLKELSPASRRLYRGYEALFVPGDDGSRNYRIPAILKTAKGTLIAMA
DRRKYNQTDLPEDIDIVMRRSTNGGRSWSDPRIIVQGEGRNHGFGDVALVQTQAGKLLMIFV
GGVGLWQSTPDRPQRTYISESRDEGLTWSPPRDITHFIFGKDCADPGRSRWLASFCASGQGL
VLPSGRITFVAAIRESGQEYVLNNYVLYSDDEGGTWQLSDCAYHRGDEAKLSLMPDGRVLMS
VRNQGRQESRQRFFALSSDDGLTWERAKQFEGIHDPGCNGAMLQVERSGRNQMLHSLPLGPD
GRRDGAVYLFDHTSGRWSTPVVVNSGSSAYSDMTLLADGTIGYFVEEDDEISLVFIRFALDD
LFDAGQ 
 
>glycosyl hydrolase, partial [Bacteroidetes bacterium OLB8] 
GenBank: KXK20028.1 
AGPVLSEVHLNFKGTSHLKDITQCRIYNTGNVNAFNPGKPSGNLLATARIRRSELTLKTREN
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LLPGDNHLWLTVDVSPKAVEGNKIDVALKSIRVDDRNYPIVNGNPEGSREILLKRVLVLAPG
DYGSKNYRIPAIITADDHSLVILTDKRKDNSIDLPEDIDIIAQRSTDGGKTWSEPVTVAKGE
GRYKGYGDACITRTLSGKLVALYVGGPGLWNSTSEKPQGHYMSVSDDNGKSWSDPVDITGQL
YGINCPDSVRRHWQSSFFGSGRGLTLRDGRIMAVIAVRESKENHKLNNYVVYSDDEGTTWHV
SQKAIDGGDEAKVVELNDGTILLSSRTAGNRLWAKSTDRGVTWGPKNTWHEIWGNACDADII
RYTSTRDGYDKDRILHTLPNAKNRTNVSMWLSYDEGTTWPVRKTICKGESAYSSITILPDGT
IGVYVEEDESVPYKMYFLNFSLDWLTDGKDHFRKAGG 
 
>uncharacterized protein BN523_00027 [Bacteroides sp. CAG:189] 
GenBank: CCY52158.1 
MKHYISLISILVLMSILPLWGQSGQSLVLNGTDQLMKIASHDDFNVSAEESFTVACWVKVNR
WLDGQRFVAKRSMTGTPKSGYELWGGQSSSKFYANNAPNTAGNHDNSMSVWSTEFGSLDTWA
HVAFVVDRVNGKMYLYHNGKQVGNSGIKDIGPWYVENDYDVTVGTGRASAMEYAYYLKGEID
NLRFWKRALSLEEINADKVDEMPASEGLVAAYDFENIDGLTVPDVSGNGHNGVLVNYPVDGP
CKVASASVVQDSNFTGRGNEDEVVLKAVLDMEGTDPVQCNKLTLNMDGTTNVQDVKSIKVYS
TGNINSFDARYAAVTATLLGSCKPASGEINCELTGELTSGTNYLWITYDIADNATEGNKVDA
NIVSITTADETYAFTEGSVEGERTILLKRKLLFAPGDAGSKNYRIPAIITAADGSLVVATDK
RKNNQGDLPEDIDVVIRRSEDGGITWSEPQTIAEGTGARRGFGDAGLVHTTEENGLLCIFVG
GEGIFNNSSPSNPTRTYVCKSTDNGKTWSAPRDITEQLYGTACTVTERQGWYASFCASGNGL
LTKNGRIMFVAAVRENSASTLSNFVYYSDDNGETWNVSKRAKLGGDESKVVELSDGTILMSI
RRQSKGPRYYTKSTDGGITWGEVSEWTEMLEPNCNGDIIRYTSVNDGYEKNRLLHSIPNDAA
NRRNVSVFVSYDEGQTWPVKKSICPTGSAYSSLTILPDGTIGAYVEENYDTDNMSLYFNNFS
LDWLTDGADIYYAAGETEVVKSPTFSAPEGEYENSVAIELTTATDGASIYYTLDGNTPNERS
ILYEGLITIEETTTVKAIAVKDGLANSEIATATYTITHPGEYCIWDEDAYPRTNTDRVVQSL
SVSGASQGGIAQDFTTVVAGIGAKTQSKINFDNTADVLNATIGNELFLTVADFNLYWTHYYV
YVDYNQNGVFESNEVVSYTHYSEDDGTYHDSKGDVVDAGKVQRDLPSFIIPDNAKLGETRIR
FKADWNSLDPCGDASLASNRGTICDFTINIHEAVMGVVSFEQTEGATLQIMNGEEEVTNGTR
LPLGTVLSVNAEVTSDDYIIRAILVNGEELESNTFVLAEDATVSLDIIKGKLVNYQVEGNGI
LSVSDNSSNEIASGAIVYKGSVVVIKVTPDENYHVESVLINGDDKTEECVSDAGYSLVVNEH
LDIIAKFAIDSYSLNYSCNEEFGKMIVQKSNGDDVISGDLIPYNEKVTFTLQPAVRCYVASV
MIDGEEKMDEILTNKSFSLNITKETTVQVVYEAEKYSLTLANDTPKKGKLMVKRLSDDIELE
DQSEIIYDEELLIAWLPEEGCELAELWIKEGEDDEYDLIEAGLLEELGDSKEFSYQVFANVA
LRAVFSGTVSITNTEIANTTVYTKDGKLIVKDGKVGCEVFVYDVLGQVVKSFIIENALETVQ
LGTTSSLYLVKIVDGADCIVKKVGNM 
 
>sialidase [Bacteroides salyersiae] strain 2789STDY5608871 
GenBank: CUM75333.1 
MKHYISLISILVLMSILPLWGQSGQSLVLNGTDQLMKIASHDDFNVSAEESFTVACWVKVNR
WLDGQRFVAKRSMTGTPKSGYELWGGQSSSKFYANNAPNTAGNHDNSMSVWSTEFGSLDTWA
HVAFVVDRVNGKMYLYHNGKQVGNSGIKDIGPWYVENDYDVTVGTGRASAMEYAYYLKGEID
NLRFWKRALSLEEINADKVDEMPASEGLVAAYDFENIDGLTVPDVSGNGHNGVLVNYPVDGP
CKVASASVVQDSNFTGRGNEDEVVLKAVLDMEGTDPVQCNKLTLNMDGTTNVQDVKSIKVYS
TGNINSFDARYAAVTATLLGSCKPASGKINCELTGELTSGTNYLWITYDIADNATEGNKVDA
NIVSITTADETYAFTEGSVEGERTILLKRKLLFAPGDAGSKNYRIPAIITAADGSLVVATDK
RKNNQGDLPEDIDVVIRRSEDGGITWSEPQTIAEGTGARRGFGDAGLVHTTEENGLLCIFVG
GEGIFNNSSPSNPTRTYVCKSTDNGKTWSAPRDITEQLYGTACTVTERQGWYASFCASGNGL
LTKNGRIMFVAAVRENSASTLSNFVYYSDDNGETWNVSKRAKLGGDESKVVELSDGTILMSI
RRQSKGPRYYTKSTDGGITWGEVSEWTEMLEPNCNGDIIRYTSVNDGYEKNRLLHSIPNDAA
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NRRNVSVFVSYDEGQTWPVKKSICPTGSAYSSLTILPDGTIGAYVEENYDTDNMSLYFNNFS
LDWLTDGADIYYAAGETEVVKSPTFSAPEGEYENSVAIELTTATDGASIYYTLDGNTPNERS
ILYEGLITIEETTTVKAIAVKDGLANSEIATATYTITHPGEYCIWDEDAYPRTNTDRVVQSL
SVSGASQGGIAQDFTTVVAGIGAKTQSKINFDNTADVLNATIGNELFLTVADFNLYWTHYYV
YVDYNQNGVFESNEVVSYTHYSEDDGTYHDSKGDVVDAGKVQRDLPSFIIPDNAKLGETRIR
FKADWNSLDPCGDASLASNRGTICDFTINIHEAVMGVVSFEQTEGATLQIMNGEEEVTNGTR
LPLGTVLSVNAEVTSDDYIIRAILVNGEELESNTFVLAEDATVSLDIIKGKLVNYQVEGNGI
LSVSDNSSNEIASGAIVYKGSVVVIKVTPDENYHVESVLINGDDKTEECVSDVGYSLVVNEH
LDIIAKFAIDSYSLNYSCNEEFGKMIVQKSNGDDVISGDLIPYNEKVTFTLQPAVRCYVASV
MIDGEEKMDEILTNKSFSLNITKETTVQVVYEAEKYSLTLANDTPKKGKLMVKRLSDDIELE
DQSEIIYDEELLIAWLPEEGCELAELWIKEGEDDEYDLIEAGLLEELGDSKEFSYQVFANVA
LRAVFSGTVSITNTEIANTTVYTKDGKLIVKDGKVGCEVFVYDVLGQVVKSFIIENALETVQ
LGTTSSLYLVKIVDGADCIVKKIGNM 
 
>T9SS C-terminal target domain-containing protein Barnesiella 
viscericola DSM 
18177MHLAMVINRADNTVSLYRDGQQGNWKQNAALNSWTVVNNNPIYLGCGSTTGTPDHLM
DGKLANVRFWSKALTAAEVAADMTATVGPDTEALIAAYDFANISGLTVPDISGHGHDATLSG
FDPVGSDVAIYSATSKADTNFTGRGNTNEIASSMAVAITGQEGTYTFGNLSLDLTGTTNVQD
ITAIKVYMTDQNSFDPRKAGEAELLGTCTPTENTVECALTGESPVGTKYLWVTFDVSETAAE
GNRVAIKPTMLDEKAVSAITTGSREILLGRTLLFAPGDYGSVAYRIPGIITAWDGSLVAITD
KRKYNQSDIPEDIDIVVRRSTDNGKTWSEPVTMAQGTGQYHGYGDAAIVRTNTENELLCIFI
GGNGLFASTTSNRIRTYISRSTDNGQSWSAPQDITDQIFRGERASWTASFCAAGNGLKTRNG
VLMFVAAMRHDSGNTLYNHVVYSNDNGVTWNVSNCAMVGGDESKVVELNDGRILMSVRRQSK
GARYYTISDNVPSTTEAVSWTQKNTSTVSSWAEMVEPACNGDIVRYTSTLDGYDKDRILHTL
PNDGANRQNLTVFLSYDEGRTWSVKKSICPTGSAYSSIAILEDGTIGVYAEENYNTDKYSTY
FMNFSLDWLTNQADTYIEPGVEAVAAPVFSVPAGYYTEAQTLEITTATEGAQIYYTLDGSTP
TANSTLYEDPITLSETVTVNAIAMKEGMSNSVMTSAEYTFLTEWEHPTGTIHDTESRYVTSA
TTTGAVEDLNYTLSSKPSTVFIDTQSAFTVEAGQEFTLRVQCTEQMIWCHAVLFADWNRDFD
FDDEGEMITKVGIDSYEDTDQTLSANGNTMMKDFSVNITVPAEAKVAETRLRIQFSDAWHNK
SAHEHTAMDNIDKGGCYDFVMNIEPSSDLPSGIDDDRTAHTMVYPTLFTEGVTLFATGNGEA
RIFDLAGRLLSRVEVSEGENYIEGTTLPAGSLIMVVTTDEGTKSFRVVKK 
 
>uncharacterized protein BN693_00676 [Prevotella sp. CAG:5226] 
GenBank: 
CDA42204.1MKRNYFNGLLAALTLFGLGTSQAWADKIVTSTAENPKWFRIYTPNRSNLSLI
SKGVGVAMQNTKTFEKPYSASQLWRLEAGSTDGTYKIVNMSGEYISPSSTVKPNNNAAFAPV
KSGAGDWTITDLSDDTYTITSGSVQFNTSQDGPNYYLYNWGSGTNKEDAGCKYRFEAVSLTE
LETAQAKALSVLNETEEGTNPGQYPAEVRTTFTNAIKAATTVDAITAAQTTYSAAMVQVAAG
KTYYIVSDKSVGYCQGKYIYSAGSEAQPKWGNKVVSAAYGWTFTDAGNGQFYVQNYGTKEYI
EPNSTDVNGATKTTATPATKYTVTSLGQGVFNIKPDGKNPLHAQNDGAVLVMWAGGIGSASA
WRLIEIPESDLTATPTFNSINVAPGFQTYAAGNKEQVLLTFQTEVAGFNGNVVGKSLKLNLG
ATNVAGLENIKVFTSKNANFVSNGQRDAALIGQVATVSGNEVEVAFDNALEMPSGTTRFYVT
ADITDKAVVGDSVDAALVSFTYGDNKVFTVNNGNPEGIARVYKVQSVPFMPNDLGTAFWRIP
SMVVLHNQKGANASKNGRVVTMADNRFNHGGDLPSHIDVYERHSDDNGKTWSAHKWVVGNET
DEALVASKDGKHKGFGDVTMVETASGKIIALMVGGQGYFYSTNEDGNRIVPVIITSTDGGDT
WSQARALTDELYKGVYEQGQVLGSFAGSGRGICLQRQKDAKLNGRVMFAMSHRFATGAIQEY
IIYSDDEGETWKMSPKSAYNGGDESKLVELADGTVMISVRQNGQRGFNTSTDGGMTWGTQTT
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NADINGNPCNADILYYNNKVLLHSYINNGSRKNVTVKASFDNGKTWGHPVVICAPSSCYSTM
DITKDGDIAIFYEDNACTQGYALNYAVFPIDWIVPGGDPSAKAFQEALAKAKAATTNEGYTD
EATAKAGQYSQEAIDNVKSLIATYEASVTDYEAATAALNAAVEAMGKTACTVDGYYNETTFT
ISSLSTISSLEGAGYISADAKAKSEADNTAEWQIVPATVAGQVYIKLKDADSYIFRSGNTLA
ASAAPQAWKLVKNDGFYNLIAVHKAENSYLVINVGTGEFNWWTSAAGDNTWSTKFVLTAKTV
VTDINNATVANGSEKAVRYYDLQGRRVLNPTKGLFITNTGKKVIK 
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7.3 CBM/NTD Sequences of Sialidases Closely Related to SiaPG from 
ATCC 33277 
> sialidase Porphyromonas gingivalis_ATCC33277 NCBI Reference 
Sequence: WP_012458403.1 
MANNTLLAKTRRYVCLVVFCCLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPPGAKQIR
IGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADSVAGRCFFYLAAD
IGPVASFSRSDTLTARVEELAVDGRPLPLKELSPASRRLYRE 
 
> sialidase Porphyromonas gingivalis_A7A1-28 NCBI Reference 
Sequence: WP_058019243.1 
MANNTLLAKTRRSVCLVVFCCLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPPGAKQIR
IGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADSVAGRCFFYLAAD
IGPVASFSRSDTLTARVEELAVDGRPLPLKELSPASRRLYRE 
 
> sialidase Porphyromonas gingivalis_W4087 NCBI Reference 
Sequence: WP_043894535.1 
MANNTLLAKTRRSVCLVVFCCLMAMMHLSGQEVTVCGDSHGVAPNQMYRTLVKVALSESLPPGAKQIR
IGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADSVAGRRFFYLAAD
IGPVASFSRSDTLTARVEELAVDGRPLPLKELSPASRRLYRE 
 
> sialidase, Putative Porphyromonas gingivalis_W83 Genbank: 
AAQ65563.1 
MANNTLLAKTRRYVCLVGFCWLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPP
GAKQIRIGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADS
VAGRRFFYLAADIGPVASFSRSDTLTARVEEVAVDGRPLPLKELSPASRRLYRG 
 
> “Hypothetical Protein” Porphyromonas gingivalis_F0570 NCBI 
Reference Sequence: WP_021665936.1 
MANNTLLAKTRRYVCLVGFCWLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPP
GAKQIRIGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADS
VAGRRFFYLAADIGPVASFSRSDTLTARVEEVAVDGRPLPLKELSPASRRLYRG 
 
> “Hypothetical Protein” Porphyromonas gingivalis_AJW4 NCBI 
Reference Sequence: WP_053444411.1 
MANNTLLAKTRRYVCLVGFCWLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPP
GAKQIRIGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTAFSADS
VAGRRFFYLAADIGPVASFSRSDTLTARVEEVAVDGRPLPLKELSPASRHLYRG 
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7.4 Prediction of Secretion Sequences Using SignalP 
 
NanH 
 
SiaPG 
 
 
Reference: Thomas Nordahl Petersen, Søren Brunak, Gunnar von Heijne & Henrik Nielsen 
 “SignalP 4.0: discriminating signal peptides from transmembrane regions” 
Nature Methods, 8:785-786, 2011  
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7.5 Details of DNA and Protein Sequences Concerning T. forsythia 
NanH  
 
Whole Gene-Stain 92A2 NCBI Accession number: NC_016610.1 
ATGAAAAAGTTTTTTTGGATTATTGGTTTGTTTGCATCGATGCAGATGACACGCGCGGCGGA
CAGTGTTTACGTACAAAACCCACAGATCCCCATCCTCGTCGATCGGACGGACAATGTGCTGT
TCCGTATCCGTATTCCTGACGCGACGAAAGGCGATGTGCTGAACCGGCTGACCATACGCTTC
GGTAACGAAGACAAGCTGTCGGAGGTGAAAGCCGTTCGTCTGTTTTATGCCGGTACGGAAGC
GGCCACAAAAGGCCGTTCCCGTTTTGCGCCGGTGACGTATGTCTCTTCGCACAATATTCGTA
ACACGCGTTCGGCCAACCCGTCCTATTCCATCCGGCAGGATGAAGTGACGACCGTTGCAAAT
ACATTGACGCTGAAAACACGTCAGCCGATGGTGAAAGGCATCAACTATTTTTGGGTGAGTGT
GGAGATGGATCGTAACACTTCGCTACTGTCGAAGCTCACCTCGACGGTGACGGAAGTGGTTA
TCAACGATAAGCCGGCCGTTATTGCCGGCGAACAGGCCGCTGTGCGCCGTATGGGGATCGGG
GTGCGTCATGCGGGCGACGACGGATCAGCCTCTTTCCGTATTCCCGGATTAGTGACAACGAA
CAAAGGAACATTGCTCGGGGTCTATGATGTACGTTACAATAACAGTGTAGATTTACAGGAGC
ATATCGACGTGGGGCTGAGCCGCAGCACCGACAAAGGTCAGACATGGGAACCGATGCGCATT
GCCATGTCGTTCGGTGAGACCGACGGATTACCGTCGGGGCAGAATGGAGTCGGCGATCCGTC
CATCCTCGTCGATGAACGCACGAACACCGTCTGGGTTGTTGCCGCATGGACGCACGGGATGG
GCAATGCGCGCGCATGGACCAATTCCATGCCCGGAATGACACCCGATGAAACAGCCCAACTG
ATGATGGTGAAAAGTACGGACGACGGCCGAACATGGAGCGAATCGACCAACATCACGTCTCA
GGTGAAAGATCCTTCGTGGTGCTTCCTGCTGCAAGGTCCGGGAAGAGGAATCACAATGCGGG
ACGGCACGCTTGTCTTCCCGATCCAGTTTATCGACTCCCTACGTGTCCCTCACGCGGGTATT
ATGTACAGCAAAGACCGTGGAGAGACGTGGCATATCCATCAGCCGGCGCGTACCAACACGAC
GGAGGCGCAAGTGGCCGAGGTAGAGCCGGGCGTGCTCATGCTGAACATGCGTGACAATCGTG
GCGGCAGCCGTGCCGTCAGCATTACACGCGACTTGGGAAAAAGTTGGACGGAACACTCGTCG
AACCGCAGCGCCTTGCCGGAATCGATCTGTATGGCGAGCCTGATCAGCGTCAAAGCGAAAGA
TAACATCATCGGGAAAGACCTGTTGCTCTTCTCGAATCCCAACACGACGGAAGGACGCCATC
ACATCACCATCAAGGCGAGCCTCGACGGAGGTGTTACGTGGCTTCCTGCACATCAGGTACTT
CTCGACGAAGAAGACGGATGGGGCTACTCGTGTCTGTCGATGATCGACCGCGAAACGGTCGG
GATATTTTACGAATCGAGTGTGGCACACATGACCTTTCAGGCTGTTAAAATCAAAGACCTGA
TACGA 
NanH Whole protein-92A2 
MKFFGLSCKNTCRMKKFFWIIGLFASMQMTRAADSVYVQNPQIPILVDRTDNVLFRIRIPDA
TKGDVLNRLTIRFGNEDKLSEVKAVRLFYAGTEAATKGRSRFAPVTYVSSHNIRNTRSANPS
YSIRQDEVTTVANTLTLKTRQPMVKGINYFWVSVEMDRNTSLLSKLTSTVTEVVINDKPAVI
AGEQAAVRRMGIGVRHAGDDGSASFRIPGLVTTNKGTLLGVYDVRYNNSVDLQEHIDVGLSR
STDKGQTWEPMRIAMSFGETDGLPSGQNGVGDPSILVDERTNTVWVVAAWTHGMGNARAWTN
SMPGMTPDETAQLMMVKSTDDGRTWSESTNITSQVKDPSWCFLLQGPGRGITMRDGTLVFPI
QFIDSLRVPHAGIMYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLMLNMRDNRGGSRAVSI
TRDLGKSWTEHSSNRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHITIKASL
DGGVTWLPAHQVLLDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
 
  
333 
 
Whole Gene-Strain ATCC43037 (not currently available in the NCBI database) 
ATGAAAAAGTTTTTTTGGATTATTGGTTTATTTATATCGATGCAGATGACACGGGCGGCGGA
CAGTGTTTACGTACAAAACCCACAGATCCCCATCCTCATCGATCGGACGGACAATGTGCTGT
TCCGTATCCGTATTCCTGACGCGACGAAAGGCGATGTGCTGAACCGGCTGACCATACGCTTC
GGTAACGAAGACAAGTTGTCGGAGGTGAAAGCCGTTCGTCTGTTTTATGCCGGTACGGAAGC
GGCCACAAAAGGCCGTTCCCGTTTTGCACCGGTGACGTATGTCTCTTCGCACAATATCCGTA
ACACGCGTTCGGCCAACCCGTCCTATTCCGTCCGGCAGGATGAAGTGACGACCGCTGCAAAT
ACATTGACGCTGAAAACACGTCAGCCGATGGTGAAAGGCATCAACTATTTTTGGGTGAGTGT
GGAGATGGATCGTAACACTTCGCTACTGTCGAAGCTCACCCCGACGGTGACGGAAGCGGTTA
TCAACGATAAGCCGGCCGTTATTGCCGGCGAACAGGCCGCTGTGCGCCGTATGGGGATCGGG
GTGCGTCATGCGGGCGACGACGGATCGGCCTCTTTCCGTATTCCCGGATTAGTGACAACGAA
CGAAGGAACATTGCTCGGGGTCTATGATGTACGTTACAATAACAGTGTAGATTTGCAGGAGC
ATGTCGACGTAGGGCTGAGCCGCAGCACCGACAAAGGTCAGACATGGGAACCGATGCGCATT
GCCATGTCGTTCGGTGAGACCGACGGATTACCGTCGGGGCAGAATGGAGTCGGCGATCCGTC
CATCCTCGTCGATGAACGCACGAACACCGTCTGGGTTGTTGCCGCATGGACGCACGGGATGG
GCAATGCGCGCGCATGGACCAATTCCATGCCCGGAATGACACCCGATGAAACAGCCCAACTG
ATGATGGTAAAAAGTACGGACGACGGCCGAACATGGAGCGAACCGATCAACATCACGTCGCA
GGTGAAAAATCCTTCGTGGTGCTTCCTGCTGCAAGGTCCGGGAAGAGGAATCACAATGCGGG
ACGGTACGCTTGTCTTCCCGATCCAGTTTATCGACTCCCTACGTGTCCCTCACGCGGGTATT
ATGTACAGCAAAGACCGTGGAGAGACGTGGCATATCCATCAGCCGGCGCGTACCAACACGAC
GGAGGCGCAAGTGGCTGAGGTGGAGCCGGGCGTGCTCATGCTGAACATGCGTGACAATCGTG
GCGGCAGCCGTGCCGTCAGCATTACACGCGACTTGGGAAAAAGTTGGACGGAACACTCGTCG
AACCGCAGCGCCTTGCCGGAATCGATCTGTATGGCGAGCCTGATCAGCGTCAAAGCGAAAGA
CAACATCATCGGGAAAGACCTGTTGCTCTTCTCGAATCCCAACACGACGGAAGGACGTCATC
ACATCACCATCAAGGCGAGCCTCGACGGAGGTGTTACGTGGCTTCCTGCGCATCAGGTACTT
CTCGACGAAGAAGACGGATGGGGCTACTCGTGTCTGTCGATGATCGACCGGGAAACGGTCGG
GATATTTTACGAATCGAGTGTGGCACACATGACCTTTCAGGCTGTTAAAATCAAAGATCTGA
TACGA 
 
Whole Protein 
MKKFFWIIGLFISMQMTRAADSVYVQNPQIPILIDRTDNVLFRIRIPDATKGDVLNRLTIRF
GNEDKLSEVKAVRLFYAGTEAATKGRSRFAPVTYVSSHNIRNTRSANPSYSVRQDEVTTAAN
TLTLKTRQPMVKGINYFWVSVEMDRNTSLLSKLTPTVTEAVINDKPAVIAGEQAAVRRMGIG
VRHAGDDGSASFRIPGLVTTNEGTLLGVYDVRYNNSVDLQEHVDVGLSRSTDKGQTWEPMRI
AMSFGETDGLPSGQNGVGDPSILVDERTNTVWVVAAWTHGMGNARAWTNSMPGMTPDETAQL
MMVKSTDDGRTWSEPINITSQVKNPSWCFLLQGPGRGITMRDGTLVFPIQFIDSLRVPHAGI
MYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLMLNMRDNRGGSRAVSITRDLGKSWTEHSS
NRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHITIKASLDGGVTWLPAHQVL
LDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
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NanH whole Gene Synthesis-Based on 92A2 
 
Nucleotide, with NdeI and XhoI Restriction Sites Highlighted in yellow. ˅=cleavage site. 
 
CACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCCGCATCA˅TATGGCCGATAGCGTTTATGTTCAG
AATCCGCAGATTCCGATTCTGGTTGATCGTACCGATAATGTGCTGTTTCGTATTCGTATTCCGGATGC
AACCAAAGGTGATGTTCTGAATCGTCTGACCATTCGCTTTGGCAATGAAGATAAACTGAGCGAAGTTA
AAGCAGTGCGTCTGTTTTATGCAGGCACCGAAGCAGCCACCAAAGGTCGTAGCCGTTTTGCACCGGTT
ACCTATGTTAGCAGCCATAACATTCGTAATACCCGTAGCGCAAATCCGAGCTATAGCATTCGTCAGGA
TGAAGTTACCACCGTTGCAAATACCCTGACCCTGAAAACCCGTCAGCCGATGGTTAAAGGTATTAACT
ATTTTTGGGTGAGTACCCTGACCCTGAAAACCCGTCAGCCGATGGTTAAAGGTATTAACTATTTTTGG
GTGAGTGTGATTAATGATAAACCGGCAGTTATTGCCGGTGAACAGGCAGCAGTTCGTCGTATGGGTAT
TGGTGTTCGTCATGCCGGTGATGATGGTAGCGCAAGCTTTCGCATTCCGGGTCTGGTTACCACCAATA
AAGGCACCCTGCTGGGTGTTTATGATGTGCGTTATAACAATAGCGTGGATCTGCAAGAACATATTGAT
GTTGGTCTGAGCCGTAGCACCGATAAAGGCCAGACCTGGGAACCGATGCGTATTGCAATGAGCTTTGG
TGAAACCGATGGTCTGCCGAGCGGTCAAATGGTGTTGGTGATCCGAGCATTCTGGTGGATGAACGTAC
CAATACCGTTTGGGTTGTTGCAGCATGGACCCATGGTATGGGTAATGCACGTGCCTGGACCAATAGCA
TGCCTGGTATGACACCGGATGAAACCGCACAGCTGATGATGGTTAAAAGCACCGATGATGGTCGTACC
TGGTCAGAAAGCACCAATATTACCAGCCAGGTTAAAGATCCGAGCTGGTGTTTTCTGCTGCAGGGTCC
GGGTCGTGGTATTACCATGCGTGATGGCACCCTGGTTTTTCCGATTCAGTTTATTGATAGCCTGCGTG
TTCCGCATGCAGGTATTATGTATAGCAAAGATCGCGGTGAAACCTGGCATATTCATCAGCCTGCACGT
ACAAATACCACCGAAGCCCAGGTTGCCGAAGTTGAACCGGGTGTTCTGATGCTGAATATGCGTGATAA
TCGTGGTGGTAGCCGTGCAGTTAGCATTACCCGTGATCTGGGTAAAAGCTGGACCGAACATAGCAGCA
ATCGTAGCGCACTGCCGGAAAGCATTTGTATGGCAAGCCTGATTAGCGTTAAAGCCAAAGATAACATC
ATCGGCAAAGATCTGCTGCTGTTTAGCAATCCGAATACCACAGAAGGTCGTCATCATATTACCATTAA
AGCAAGCCTGGATGGTGGTGTTACCTGGCTGCCTGCACATCAGGTGCTGCTGGATGAAGAAGATGGTT
GGGGTTATAGCTGTCTGAGCATGATTGATCGTGAAACCGTGGGTATCTTTTATGAAAGCAGCGTTGCA
CACATGACCTTTCAGGCAGTTAAAATCAAAGACCTGATTCGCC˅TCGAGCTGGGCCTCATGGGCCTTC
CGCTCACTGCCCGCTTTCCAG 
Protein expression of ORF, reported by Manufacturer 
  
ADSVYVQNPQIPILVDRTDNVLFRIRIPDATKGDVLNRLTIRFGNEDKLSEVKAVRLFYAGTEAATKG
RSRFAPVTYVSSHNIRNTRSANPSYSIRQDEVTTVANTLTLKTRQPMVKGINYFWVSVEMDRNTSLLS
KLTSTVTEVVINDKPAVIAGEQAAVRRMGIGVRHAGDDGSASFRIPGLVTTNKGTLLGVYDVRYNNSV
DLQEHIDVGLSRSTDKGQTWEPMRIAMSFGETDGLPSGQNGVGDPSILVDERTNTVWVVAAWTHGMGN
ARAWTNSMPGMTPDETAQLMMVKSTDDGRTWSESTNITSQVKDPSWCFLLQGPGRGITMRDGTLVFPI
QFIDSLRVPHAGIMYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLMLNMRDNRGGSRAVSITRDLGK
SWTEHSSNRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHITIKASLDGGVTWLPAHQV
LLDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
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7.6 Details of DNA and Protein Sequences Concerning P. gingivalis 
SiaPG 
 
Whole SiaPG gene-from P. gingivalis ATCC 33277 
TCATTGCCGGGCATCGAAGAGATCGTCAAGGACGAACCGAATGAAAACCAATGAGATCTCAT
CGTCTTCTTCGACAAAATAACCGATCGTTCCATCCGCCAACAGAGTCATATCCGAGTAGGCA
CTCGATCCTGAATTGACAACAACGGGAGCGGACCAGCGGCCGGAGACATGATCGAAGAGATA
GACAGCCCCATCGCGACGCCCATCCGGGCCGAGAGGCAGGGAGTGCAGCATTTGATTCCTTC
CATTCCTTTTCACTTGAAGCATAGCTCCATTACAGCCGGGGTCATGGATGCCCTCGAACTGC
TTGGCTCTCTCCCAAGTAAGGCCATCGTCGGAGGAGAGAGCGAAGAAACGCTGTCGGCTCTC
CTGCCTTCCCTGATTGCGTACGCTCATCAGTACCCTGCCATCAGGCATCAATGAGAGCTTTG
CCTCGTCGCCACGGTGGTATGCACAGTCGGAAAGCTGCCATGTACCTCCCTCGTCGTCGCTA
TAGAGGACATAGTTGTTCAGGACGTACTCCTGCCCTGATTCGCGGATGGCAGCCACAAACAT
GACACGACCGGATGGAAGCACAAGCCCTTGTCCCGAAGCACAAAAGGAGGCCAACCAGCGAC
TGCGTCCCGGATCGGCACAATCCTTGCCGAAGATGAAATGGGTTATATCCCGAGGAGGCGAC
CAGGTGAGGCCTTCGTCCCGACTTTCCGATATATAAGTGCGCTGAGGACGATCGGGGGTAGA
CTGCCACAAGCCTACTCCACCGACAAAGATCATCAGGAGCTTTCCTGCTTGAGTTTGCACCA
GGGCTACATCGCCAAAGCCATGATTGCGTCCCTCTCCCTGTACGATAATCCGGGGATCGCTC
CACGATTTCCCTCCGTCCGTACTGCGCCGCATGACTATATCTATATCCTCCGGCAGATCCGT
CTGATTATATTTTCGTCTGTCGGCCATCGCTATGAGTGTTCCATTGGCCGTTTTCAAAATGG
ACGGGATACGATAGTTGCGCGATCCGCCATCACCGGGTACAAAGAGGGCCTCATACTCCCTA
TACAGACGACGGGAGGCAGGCGACAGCTCTTTCAACGGCAAAGGACGGCCATCGACAGCCAG
CTCTTCCACACGGGCAGTCAGCGTATCGGATCGGGAAAAAGAAGCGACAGGCCCTATATCCG
CAGCCAAATAAAAGAAGCAGCGTCCGGCTACCGAATCCGCAGAAAGGGCTGTGGTACGATCT
TCCTTTGAGATCGGGAAGCTATCGTAAGAGACTCGCCCTTTGTAGTCCGGCAAGTCGCGCAC
CGCTAAAGAATCACTCACAAGGAGATATAGGGCGGTGACTTTTTCCTCCGTTTCTTTCGGAA
GAGAGAATCCGATACGAATCTGTTTTGCACCCGGAGGAAGGGATTCACTTAAGGCTACCTTC
ACCAGCGTTCGGCGCACTTGGTTCGGCGCCACTCCATGGCTGTCCCCCCACATAGTGACTTC
CTGTCCAGAGAGGTGCATCATCGCCATGAGACAACAAAAAACGACAAGGCAGACATAACGTC
GAGTCTTCGCCAAAAGAGTATTATTAGCCAT 
 
Whole Protein 
MANNTLLAKTRRYVCLVVFCCLMAMMHLSGQEVTMWGDSHGVAPNQVRRTLVKVALSESLPP
GAKQIRIGFSLPKETEEKVTALYLLVSDSLAVRDLPDYKGRVSYDSFPISKEDRTTALSADS
VAGRCFFYLAADIGPVASFSRSDTLTARVEELAVDGRPLPLKELSPASRRLYREYEALFVPG
DGGSRNYRIPSILKTANGTLIAMADRRKYNQTDLPEDIDIVMRRSTDGGKSWSDPRIIVQGE
GRNHGFGDVALVQTQAGKLLMIFVGGVGLWQSTPDRPQRTYISESRDEGLTWSPPRDITHFI
FGKDCADPGRSRWLASFCASGQGLVLPSGRVMFVAAIRESGQEYVLNNYVLYSDDEGGTWQL
SDCAYHRGDEAKLSLMPDGRVLMSVRNQGRQESRQRFFALSSDDGLTWERAKQFEGIHDPGC
NGAMLQVKRNGRNQMLHSLPLGPDGRRDGAVYLFDHVSGRWSAPVVVNSGSSAYSDMTLLAD
GTIGYFVEEDDEISLVFIRFVLDDLFDARQ 
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SiaPG- whole Gene Synthesis-Based on 92A2 
 
Nucleotide, with NdeI and XhoI Restriction Sites Highlighted in yellow. ˅=cleavage site. 
CACTATAGGGCGAATTGGCGGAAGGCCGTCAAGGCCGCATCA˅TATGGAAGTTACCATGTGGGGTGAT
AGCCATGGTGTTGCACCGAATCAGGTTCGTCGTACCCTGGTTAAAGTTGCACTGAGCGAAAGCCTGCC
TCCGGGTGCAAAACAAATTCGTATTGGTTTTAGCCTGCCGAAAGAAACCGAAGAAAAAGTTACCGCAC
TGTATCTGCTGGTTAGCGATAGCCTGGCAGTTCGTGATCTGCCGGATTATAAAGGTCGTGTTAGCTAT
GATAGCTTCCCGATTAGCAAAGAAGATCGTACCACCGCACTGAGTGCAGATAGCGTTGCAGGTCGTCG
TTTTTTCTATCTGGCAGCAGATATTGGTCCGGTTGCAAGCTTTAGCCGTAGCGATACCCTGACCGCAC
GTGTTGAAGAGGTTGCAGTTGATGGTCGTCCGCTGCCGCTGAAAGAACTGAGTCCGGCAAGCCGTCGT
CTGTATCGTGGTTATGAAGCACTGTTTGTTCCGGGTGATGGTGGTAGCCGTAATTATCGTATTCCGGC
AATTCTGAAAACCGCAAATGGCACCCTGATTGCAATGGCAGATCGTCGCAAATATAACCAGACCGATC
TGCCTGAAGATATTGATATTGTTATGCGTCGTAGCACCGATGGTGGCAAAAGCTGGTCAGATCCGCGT
ATTATTGTTCAGGGTGAAGGTCGTAATCATGGTTTTGGTGATGTTGCACTGGTTCAGACCCAGGCAGG
TAAACTGCTGATGATTTTTGTTGGTGGTGTTGGTCTGTGGCAGAGCACACCGGATCGTCCGCAGCGTA
CCTATATTAGCGAAAGTCGTGATGAAGGCCTGACCTGGTCACCGCCTCGTGACATTACCCATTTTATC
TTTGGTAAAGATTGTGCAGATCCGGGTCGTAGCCGTTGGCTGGCAAGCTTTTGTGCAAGTGGTCAGGG
TCTGGTTCTGCCGAGCGGTCGTATTACCTTTGTTGCAGCAATTCGTGAAAGCGGTCAAGAATATGTGC
TGAATAACTATGTTCTGTATAGCGACGATGAAGGTGATACCTGGCAGCTGAGCGATTGTGCATATCGT
CGCGGTGATGAAGCAAAACTGAGCCTGATGCCGGATGGTCGTGTTCTGATGAGCATTCGTAATCAGGG
TCGTCAAGAAAGCCGTCAGCGTTTTTTTGCCCTGAGCAGTGATGATGGTCTGACATGGGAACGTGCCA
AACAGTTTGAAGGTATTCATGATCCGGGTTGTAATGGTGCAATGCTGCAGGTTAAACGTAATGGTCGT
GATCAGGTTCTGCATAGTCTGCCGCTGGGTCCGGATGGCCGTCGTGATGGTGCCGTTTACCTGTTTGA
TCATGTTAGCGGTCGTTGGAGCGCACCGGTTGTTGTTAATAGCGGTAGCAGCGCATATAGCGATATGA
CCCTGCTGGCAGATGGCACCATTGGTTATTTTGTTGAAGAAGGTGACGAAATCAGCCTGGTGTTTATT
CGTTTTGTTCTGGATGACCTGTTCGATGTTCGTCAGC˅TCGAGCTGGGCCTCATGGGCCTTCCGCTCA
CTGCCCGCTTTCCAG 
Protein expression of ORF, reported by Manufacturer 
 
ADSVYVQNPQIPILVDRTDNVLFRIRIPDATKGDVLNRLTIRFGNEDKLSEVKAVRLFYAGTEAATKG
RSRFAPVTYVSSHNIRNTRSANPSYSIRQDEVTTVANTLTLKTRQPMVKGINYFWVSVEMDRNTSLLS
KLTSTVTEVVINDKPAVIAGEQAAVRRMGIGVRHAGDDGSASFRIPGLVTTNKGTLLGVYDVRYNNSV
DLQEHIDVGLSRSTDKGQTWEPMRIAMSFGETDGLPSGQNGVGDPSILVDERTNTVWVVAAWTHGMGN
ARAWTNSMPGMTPDETAQLMMVKSTDDGRTWSESTNITSQVKDPSWCFLLQGPGRGITMRDGTLVFPI
QFIDSLRVPHAGIMYSKDRGETWHIHQPARTNTTEAQVAEVEPGVLMLNMRDNRGGSRAVSITRDLGK
SWTEHSSNRSALPESICMASLISVKAKDNIIGKDLLLFSNPNTTEGRHHITIKASLDGGVTWLPAHQV
LLDEEDGWGYSCLSMIDRETVGIFYESSVAHMTFQAVKIKDLIR 
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7.7 SignalP Predictions of secretion sequence 
NanH 
SiaPG 
 
Reference:  Thomas Nordahl Petersen, Søren Brunak, Gunnar von Heijne & Henrik Nielsen 
“SignalP 4.0: discriminating signal peptides from transmembrane regions” Nature Methods, 
8:785-786, 2011 
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7.8 An Alignment of NanH from T. forsythia strains 43037 and 92.A2, 
Performed using ESPript 
 
97.96% homology (Clustal Omega).
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7.9 Partial List of EU Requirments to be Submitted before 
Liscensing of a Product under the “Medicine” Classification 
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Chatchawal Phansopa*, Radoslaw P. Kozak†, Li Phing Liew†, Andrew M. Frey*, Thomas Farmilo*, Jennifer L. Parker*,
David J. Kelly‡, Robert J. Emery†, Rebecca I. Thomson§, Louise Royle†, Richard A. Gardner†, Daniel I.R. Spencer† and
Graham P. Stafford*1, 2
*Integrated BioSciences, School of Clinical Dentistry, University of Sheffield, Sheffield, S10 2TA, U.K.
†Ludger Ltd, Culham Science Centre, Oxfordshire OX14 3EB, U.K.
‡Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, U.K.
§Reading School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AP, U.K.
Tannerella forsythia, a Gram-negative member of the
Bacteroidetes has evolved to harvest and utilize sialic acid.
The most common sialic acid in humans is a mono-N-
acetylated version termed Neu5Ac (5-N-acetyl-neuraminic acid).
Many bacteria are known to access sialic acid using sialidase
enzymes. However, in humans a high proportion of sialic acid
contains a second acetyl group attached via an O-group, i.e.
chiefly O-acetylated Neu5,9Ac2 or Neu5,4Ac2. This diacetylated
sialic acid is not cleaved efficiently by many sialidases and
in order to access diacetylated sialic acid, some organisms
produce sialate-O-acetylesterases that catalyse the removal of
the second acetyl group. In the present study, we performed
bioinformatic and biochemical characterization of a putative
sialate-O-acetylesterase from T. forsythia (NanS), which contains
two putative SGNH-hydrolase domains related to sialate-O-
acetylesterases from a range of organisms. Purification of
recombinant NanS revealed an esterase that has activity against
Neu5,9Ac2 and its glycolyl form Neu5Gc,9Ac. Importantly, the
enzyme did not remove acetyl groups positioned at the 4-O
position (Neu5,4Ac2). In addition NanS can act upon complex
N-glycans released from a glycoprotein [erythropoietin (EPO)],
bovine submaxillary mucin and oral epithelial cell-bound glycans.
When incubated with its cognate sialidase, NanS increased sialic
acid release from mucin and oral epithelial cell surfaces, implying
that this esterase improves sialic acid harvesting for this pathogen
and potentially other members of the oral microbiome. In
summary, we have characterized a novel sialate-O-acetylesterase
that contributes to the sialobiology of this important human
pathogen and has potential applications in the analysis of sialic
acid diacetylation of biologics in the pharmaceutical industry.
Key words: acetlyesterase, Bacteroidetes, carbohydrate-active
enzyme, glycans, oral cavity, sialic acid.
INTRODUCTION
The oral-dwelling pathogen Tannerella forsythia is a member of
a small group of bacteria that is associated with the prevalent
oral disease of periodontitis [1]. It is a member of a wider
family of Gram-negative anaerobic human-colonizing bacteria
of the phylum Bacteroidetes. The Bacteroidetes, with Tannerella
being no exception, are well adapted to life in the human body
with a wide array of metabolic adaptations to their gut and oral
environments respectively [2,3]. In particular, our recent work
and that of others on the physiology of Tannerella revealed that it
has an extensive array of glycan-harvesting capabilities encoded
in its genome [3] with its ability to harvest and utilize sialic
acid from glycoproteins present on human epithelial surfaces and
secretory fluids most relevant, alongside potential dietary sources.
This ability to utilize sialic acid is possibly the most pertinent
in vivo and certainly the most well-studied growth substrate for
this enigmatic organism [4].
This ability to harvest and utilize sialic acid is encoded by a
genetic locus in Tannerella that contains not only putative sialic
acid catabolic genes (nanA,E), but also a unique sialic acid-uptake
system that is dependent on the periplasm-spanning TonB protein
and can thus be considered a sialic acid-specific polysaccharide
utilization system (PUL) [5,6]. However, the substrate for
this transport system, unlike many other Bacteroidetes, is the
monomeric form of the sugar, rather than an oligosaccharide that
is then acted upon by periplasmic sialidases and other enzymes
before catabolism commences [7].
The sialic acid specific PUL of Tannerella secretes a sialidase
enzyme of the glycosyl hydrolase 33 (GH33) family [8] with
the ability to cleave sialic acids from fetuin and less efficiently
from human and bovine mucin sources [9]. One possible reason
for this lower efficiency of cleavage from mucins has been
hypothesized to be the high level of diacetylation of sialic
acid present that inhibits functional access of sialidases and
slows cleavage rates for many sialidases [10,11]. This high
level of diacetylation is widespread in humans [12] and would
represent a wasted nutritional source for oral bacteria such as
T. forsythia. The diacetylated sialic acids are also important
in viral infections with several viruses using the main form of
Abbreviations: 2-AB, 2-aminobenzamide; CCA, Cancer antennarius agglutinin; CHO, Chinese hamster ovary; DMB, 1,2-diamino-4,5-
methylenedioxybenzene ·2HCl; EPO, erythropoietin; HILIC, hydrophilic interaction liquid chromatography; MFI, mean fluorescence intensity; PNGase
F, peptide N-glycosidase F; pNP, p-nitrophenol; pNP-Ac, p-nitrophenyl acetate; PUL, polysaccharide utilization system; rH-EPO, recombinant human EPO;
SNA, Sambucus nigra agglutinin; SRP, sialic acid reference panel; TBA, thiobarbituric acid.
1 Ludger and Graham Stafford have a licensing agreement centred on the use of NanS commercially.
2 To whom correspondence should be addressed (email g.stafford@sheffield.ac.uk).
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diacetylated sialic acid, Neu5,9,Ac2, as a receptor, e.g. influenza
C and several coronaviruses [13,14]. In addition both viruses and
humans possess sialate-O-acetylesterase enzymes which in the
case of the viruses act as receptor-destroying enzymes involved
in the infection cycle and in the case of humans are used for
the modulation of diacetylation of sialic acids on both internal
and external proteins with biological roles in development and
autoimmunity among others [15,16], including certain leukaemias
and cancers [17,18]. These enzymes are members of a large family
of SGNH-serine esterases whose activity acts to remove O-acetyl
groups from sialic acids, generally having specificity for acetyl
groups at the 9- or 4-positions. In addition, evidence suggests that
bacteria are also capable of producing sialate-O-acetylesterases
that may be involved in survival in mucin-rich environments [12]
and the sialic acid catabolism operon of Tannerella appears to
contain such an enzyme [19]. However, information on this class
of enzymes lags behind that of the sialidases and other classes of
carbohydrate-active enzymes.
In addition, this class of enzymes has potential value in the
study and design of recombinant biopharmaceuticals. An example
of this is the biological drug human erythropoietin (EPO) which
is highly glycosylated with most glycans terminating in sialic
acid residues which can contain two or more extra O-acetyl
groups [20] which could consequently have an impact on the
efficacy of the drug. As the specific structures of the glycans on a
biopharmaceutical can be critical to the efficacy of the drug, it is
essential to ensure that glycosylation is optimized and consistent
from batch to batch. Thus, the availability of enzymes specific
for additional O-acetylation on sialic acids could aid both the
identification and the quality control of glycosylation on such
drugs.
In the present study, we set out to characterize the putative
sialate-O-acetylesterase (NanS) from the oral pathogen T.
forsythia and investigate its activity and ability to act on
experimental and physiologically relevant diacetylated sialic acid
substrates. The data presented show that NanS from T. forsythia
is a novel, highly active, neutral sialate-O-acetylesterase that acts
to remove 9-O-acetyl groups (and potentially those at 7-O and 8-
O positions but not 4-O-acetylated sialic acid) from diacetylated
sialic acids in mucinous and epithelial cell glycoproteins and on
released highly branched N-glycans from EPO. We also provide
evidence that it can work in concert with its cognate sialidase
in the release of sialic acid from mucin and oral epithelial cell
surfaces, suggesting that in vivo it might act to increase sialic
acid release by sialidases for T. forsythia and other bacteria in its
environmental niche.
MATERIALS AND METHODS
Bacterial cell culture
Escherichia coli BL21 (DE3) strains were cultured in LB broth at
37 ◦C or on solid LB medium containing 1.5% bacteriological
agar (Oxoid). Selective antibiotics were added to appropriate
concentrations (i.e. 50 μg/ml ampicillin).
Cloning of nanS for expression
The predicted mature TF0037 (nanS) ORF (i.e. lacking the
putative secretion sequence of TF0037) from T. forsythia
genomic DNA was PCR-amplified using primers (NanS–GST–
Bam-For 5′ -AAAGGATCCCAGAAGACTGTGAAAGTGGC-3′
and NanS–GST–Eco-Rev 5′ -AAAGAATTCTTATTCAATCA-
CAGCCTGAAACG-3′ ) using Phusion Polymerase according
to the manufacturer’s instructions. The gene was cloned into
pGEX-4T-3 using BamHI and EcoR1 to produce pGEX-NanS
and its sequence was verified by DNA sequencing (Core
Genomic Facility, University of Sheffield); N.B. this revealed
four differences from the published genome sequence, but none
in active-site regions which is now known to be from strain T.
forsythia 92A.2 (ATCC-BAA-2717; see Supplementary Figure
S1 for alignment) [21].
Production of recombinant NanS
E. coli BL21 (DE3) Origami B was transformed with the pGEX-
NanS plasmid, grown in LB broth and induced at mid-exponential
growth phase (D600 = 0.6) with 1 mM IPTG (Sigma–Aldrich) for
5 h at 37 ◦C with agitation. Cells were harvested, resuspended
in purification buffer (50 mM Tris/HCl, pH 8.0, 150 mM NaCl
and 2.5 mM CaCl2), disrupted using a French pressure cell (three
times at 7245 kPa; Thermo Scientific) and soluble fractions were
clarified by further centrifugation (40000 g, 30 min, 4 ◦C). The
N-terminally GST-tagged protein was purified by applying the
cell-free extract on a 1-ml GSTrap column (GE Healthcare)
at 1 ml/min, following which unbound proteins were removed
by washing with 20 column volumes of purification buffer.
The GST-tag of bound NanS was proteolytically removed by
incubating the column in 1 unit/μl thrombin (Sigma–Aldrich)
in the purification buffer, sealed and left to stand at room
temperature for 5 h. Cleaved NanS was eluted with two bed
volumes of purification buffer, then mixed gently with 50 μl of p-
aminobenzamidine–agarose (Sigma–Aldrich) that had been pre-
equilibrated in the same buffer to remove thrombin. The purified
protein was extensively dialysed against a dialysis buffer (50 mM
sodium phosphate, pH 7.4, and 150 mM NaCl) and concentration
determined using the Pierce BCA protein assay kit (Thermo
Scientific).
Reaction kinetics and pH optimum of purified NanS
The pH optimum of NanS was determined using the chromogenic
esterase substrate p-nitrophenyl acetate (pNP-Ac; Sigma–
Aldrich) by incubating 2.5 nM purified NanS with 0.1 mM
pNP-Ac in 20 mM sodium citrate (pH 3.0–6.0), 20 mM sodium
phosphate (pH 6.4–8.8) or 20 mM sodium carbonate (pH 9.2)
buffers and the presence of free p-nitrophenol (pNP) measured
and expressed as the mean change in absorbance per min, +−
S.D. pNP-Ac hydrolysis was monitored every 15 s by removal
of an aliquot of enzyme reaction, followed by heat inactivation
(98 ◦C, 90 s), after which, an equal volume of quenching buffer
(2 M sodium carbonate, pH 10.5) was added and the release
of free pNP recorded by measuring its absorbance (A405) in a
spectrophotometer (Tecan M200).
For Km determination, purified NanS was pre-incubated at 25 ◦C
for 15 min in 50 mM sodium/potassium phosphate buffer, pH 7.4,
and 150 mM NaCl, at a final concentration of 2.5 nM. pNP-Ac
was then added at a range of final concentrations (2.5–1000 μM)
and pNP-Ac hydrolysis was monitored as above. Time course data
from each concentration of the pNP-Ac substrate were examined
for linearity by plotting the data, followed by the calculation of
the slope of the tangent. Known concentrations of pNP in the
same buffer mixed with an equal volume of quenching buffer was
measured as above to obtain a standard curve. Kinetic parameters
Km and Vmax were calculated by fitting data from three biological
replicates in Prism 6 (GraphPad Software) to eqn (1):
V0 = Vmax · Z/(Km + Z) (1)
c© 2015 Authors; published by Portland Press Limited
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in which V0 is the steady-state rate of pNP-Ac substrate turnover
by NanS, Vmax is the maximum rate (μmol/min per mg of NanS
protein) Z is the concentration of pNP-Ac (μM) in the reaction
mixture and Km is the Michaelis–Menten constant (μM) at which
the reaction rate is half of Vmax. We also used the equation Vmax/[E]
to determine kcat.
Quantification of sialic acid release from mucin
A modified version of the thiobarbituric acid (TBA) assay [20,23]
was used to assess hydrolysis of sialic acid from mucin. Mucin
at 3 μM was incubated with 0.1 μM NanH, NanS or NanH +
NanS in PBS, pH 7.4 (Sigma–Aldrich), for 30 min at 37 ◦C, in
a total reaction volume of 50 μl before addition of 25 μl of
25 mM sodium periodate (Sigma–Aldrich) in 500 mM H2SO4.
This was incubated for 30 min at 37 ◦C before oxidation of
free sialic acid was halted by addition of 2% (w/v) sodium
arsenite (Sigma–Aldrich) in 500 mM HCl. Formation of the red
chromophore was completed by the addition of 200 μl of 100 mM
TBA (Sigma–Aldrich), pH 9, and incubated for 7.5 min at 95 ◦C.
The chromophore was extracted by addition of 500 μl of acidified
butanol [butan-1-ol with 5% (v/v) 600 mM HCl], before vortex-
mixing and centrifugation at 10000 g for 3 min. A 100 μl sample
of the butanol phase was then added to a clear 96-well plate
(Greiner) and the absorbance at 549 nm was measured using a
Tecan infinite M200 plate reader. Free sialic acid (Carbosynth)
was used to generate a standard curve.
Lectin staining of oral epithelial cells
The oral squamous carcinoma cell line H357 was cultured in
175 cm2 tissue culture flasks (Greiner), in Dulbecco’s modified
Eagle’s medium (DMEM, Sigma–Aldrich) supplemented with
10% (v/v) FBS (Sigma–Aldrich) and 2 mM L-glutamine (Sigma–
Aldrich), 100 units/ml penicillin and 100 μg/ml streptomycin
(Sigma–Aldrich). Cells were seeded at 100000 cells/ml into 24-
well tissue culture plates (Greiner) containing glass coverslips
(VWR), with 1 ml of cell suspension/well and incubated at
37 ◦C in 5% CO2 for 14–24 h. To stain for cellular Neu5,9Ac2,
cells were incubated with either PBS or 50 nM NanS in PBS
for 2 h at 37 ◦C, washed twice with 500 μl of PBS and fixed
using 2% paraformaldehyde for 15 min at 37 ◦C. Fixed cells
were washed twice with 500 μl of PBS, incubated with 2 μg/ml
biotinylated Cancer antennarius agglutinin (CCA) or Sambucus
nigra agglutinin (SNA) lectin (EY Laboratories) for 30 min at
37 ◦C, washed twice with 500 μl of PBS, then stained with
2 μg/ml streptavidin–FITC (Vector Laboratories) for 30 min at
37 ◦C. To stain for cellular α2,6-linked Neu5Ac (5–N–acetyl-
neuraminic acid), cells were incubated with PBS, 50 nM NanS,
50 nM NanH or 50 nM NanH and 50 mM NanS, all in PBS, for
30 min at 37 ◦C, washed twice with 500 μl of PBS and fixed
using 2% paraformaldehyde for 15 min at 37 ◦C. Coverslips
with stained cells were mounted on glass slides using Prolong
Gold Antifade mountant with DAPI (Life Technologies). Cells
were visualized using an Axiovert 200M fluorescence microscope
(Zeiss) and Axiovision software. Fiji/ImageJ software (NIH)
was used to process images with three fields of view from
two biological replicates assessed [24]. Neu5,9Ac2 staining was
expressed as: mean pixel brightness (FITC staining only)/number
of cells = mean fluorescence intensity (MFI) per cell. FITC
image acquisition was carried out using the same exposure time
and percentage weight for each condition and parameters during
image analysis were kept constant between conditions.
Treatment of diacetylated sialic acids with NanS
A Neu5,9Ac2 (Ludger Ltd), Neu5,4Ac2 (Carbosynth) and sialic
acid reference panel (SRP; derived from bovine submaxillary
mucin, Ludger Ltd) were incubated with 1 μl of NanS enzyme
(0.7 mg/ml) in a final volume of 10 μl (1× PBS, pH 7.2) for 16 h
at 25 ◦C. Sialic acid standards (1 μg of each sialic acid) were
labelled with 1,2-diamino-4,5-methylenedioxybenzene · 2HCl
(DMB) using a Ludger DMB sialic acid release and labelling
kit according to the product guide. Briefly, dried standards were
incubated with 20 μl of labelling reagent in the dark for 3 h at
50 ◦C. The reaction was terminated upon the addition of 480 μl
of water. The DMB-labelled samples were analysed by reverse-
phase HPLC using a LudgerSep-R1 column (4.6 mm × 150 mm,
Ludger Ltd) at 30 ◦C on a Waters 2795 HPLC with a 2475
fluorescence detector (λex = 373 nm, λem = 448 nm), controlled
by Empower software (Waters). Isocratic run conditions were at a
flow rate of 0.5 ml/min with solvent acetonitrile/methanol/water
(9:7:84 by volume). Then 10 μl of sample was injected undiluted
on to the HPLC. The SRP standard was used as a system suitability
standard as well as an external calibration standard to allocate
sialic acid structures.
Treatment of N-glycans from rH-EPO with NanS
N-glycans were released from 10 μg of recombinant human EPO
(rH-EPO) expressed from Chinese hamster ovary (CHO) cells
(a gift from Antonio Vallin, Center for Molecular Immunology,
La Habana, Cuba) using peptide N-glycosidase F (PNGase F)
(E-PNG01; Ludger Ltd). The EPO (in 17.5 μl) was denatured
following addition of 6.25 μl of 2% SDS and 1 M 2-
mercaptoethanol by heating at 100 ◦C for 5 min, before incubation
at 37 ◦C for 16 h with 1 μl of PNGase F and 1.25 μl of 15% (w/v)
Triton X-100. Released N-glycans were fluorescently labelled
with 2-aminobenzamide (2-AB) according to Bigge et al. [25]
using a Ludger 2-AB Glycan Labelling Kit. The released glycans
were incubated with labelling reagents for 3 h at 65 ◦C. The 2-AB-
labelled glycans were cleaned up using LudgerClean S Cartridges
(Ludger Ltd). NanS enzyme digestions were performed according
to Royle et al. [26]. The 2-AB-labelled N-glycans were incubated
with 1 μl of NanS enzyme (0.7 mg/ml) in a final volume of
10 μl (50 mM sodium acetate buffer, pH 5.5) for 16 h at 37 ◦C.
NanS was removed by binding to a protein-binding plate LC-
PBM-96 (Ludger Ltd.) before analysis by HILIC–UPLC. 2-
AB-labelled samples were analysed by hydrophilic interaction
liquid chromatography (HILIC)-UPLC (ultra performance liquid
chromatography) using an ACQUITY UPLC® BEH-Glycan
1.7 μm, 2.1 mm× 150 mm column at 40 ◦C on an ACQUITY
UPLC H Class instrument with a fluorescence detector (excitation
250 nm and emission 428 nm), controlled by Empower software
version 2, build 2154 (Waters). Solvent A was 50 mM ammonium
formate, pH 4.4, and solvent B was acetonitrile. Samples were
injected in 28% aqueous/72% acetonitrile; injection volume
25 μl. Gradient conditions were 0–54 min, 28–48% A; 54–
57 min, 48–100% A; 57–58 min, 100% A; 58–59 min, 100–
28% A; 59–60 min, 28% A; at a flow rate of 0.4 ml/min. Waters
GPC software with a cubic spline fit was used to allocate GU
values to peaks. 2-AB-labelled glucose homopolymer (CAB-
GHP-30, Ludger Ltd) was used as a system suitability standard
as well as an external calibration standard for GU allocation [25].
Basic bioinformatic analysis
The nanS gene sequence and its product NanS was analysed
for the presence of a signal sequence using PSORTb and
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Figure 1 Basic bioinformatic analysis of T. forsythia NanS
(A) Domain architecture of NanS, illustrating predicted signal sequence (light grey), SGNH domain (type I, dark grey) and DUF303 domain (black; to scale). (B) Amino acid sequence alignments
of the conserved sequence blocks of the SGNH type I and DUF303 domains of confirmed and putative sialate-O-acteylesterases from a range of organisms: T. forsythia 92A.2 (WP_014225512.1),
B. fragilis NCTC 9343 (WP_005808991.1), P. denticola (Pr.dent; WP_013672182.1), P. distastonis (P. dista; WP_011967074.1), C. sputigena (C. sputi; WP_002678445.1), human SIAE1 enzyme
(Hs SIAE1), E. coli O157:H7 (WP_000991449), influenza C (P07975.1). Residue numbers from T. forsythia 92A.2 are shown.
Cello. Alignments were generated using Multalin [27].
Accession numbers for the genes used are: T. forsythia 92A.2
(WP_014225512.1), Bacteroides fragilis (WP_005808991.1),
Prevotella denticola (WP_013672182.1), Parabacteroides
distastonis (WP_011967074.1), Capnocytophaga sputigena
(WP_002678445.1), human SIAE1 enzyme (NP_733746.1), E.
coli O157:H7 (E. coli-WP_000991449), influenza C (P07975).
RESULTS
NanS is a predicted sialate-O-acetylesterase containing putative
SGHN type I and II domains
In our initial work on the sialic acid utilization operon of
T. forsythia, we noted the presence of a potential sialate-O-
acetylesterase based on BLAST search data [6]. The predicted
size of the full-length NanS protein is 78.6 kDa; however, it has
a strong putative N-terminal secretion signal with a potential
cleavage site after alanine 18 (P-SORT) in the primary amino
acid sequence meaning the size of the mature protein would
be 76.3 kDa. Therefore, this protein at the very least enters the
periplasm, but we assume, given its potential role in sialic acid
harvesting, that it is secreted from the cell, similar to the NanH
sialidase of this organism [28].
A more detailed bioinformatics analysis of the NanS amino
acid sequence of T. forsythia indicates the presence of two distinct
domains, both of which are related to different classes of SGNH-
serine hydrolase family of enzymes (Figure 1A) [29]. The SGNH-
hydrolases are a group of enzymes responsible for hydrolysis
of a range of substrate types that includes both carbohydrate
esterases and lipases where the catalytic action in both cases
involves hydrolysis of ester bonds via use of a catalytic serine
residue in the active site [29]. Within the primary amino acid
sequence of the T. forsythia NanS, residues 1–180 of the mature
protein have homology with members of the SGNH-hydrolase
superfamily with all the conserved sequence features present
(Figure 1B) [30]. It is worth noting that, at least in the signature
sequence blocks, this domain can be aligned with viral sialate-O-
acetylesterase active-site residues such as those identified for the
haemagglutinin esterase from influenza C virus but that homology
outside this region is very low [31,32].
In contrast, residues 260–564 seem to be related to the DUF303
pfam grouping (PF03629) whose founder member is the E.
coli NanS sialate-O-acetylesterase [30,33]. All SGNH proteins
contain several signature motifs with the presence of the invariant
residues within conserved blocks spread throughout the amino
acid sequence: serine (block I), glycine (block II), asparagine
(block III) and a catalytic histidine (block V) [26]. However,
work by Rangarajan et al. [30] identified two types of SGNH-
hydrolases, based on differences in the signature sequences in
blocks I, II, III and V between classic SGNH-hydrolases and the
DUF303 type, which they termed type I and II. As indicated
in Figure 1, the NanS from T. forsythia displays a domain
architecture not reported in the SIAE family to date, i.e. it contains
both SGNH family I and II domains linked within one protein.
As mentioned above the C-terminal domain of the protein has
strong homology with the type II SGNH enzymes identified
by Rangarajan et al. [30] (Figure 1A). However, although it
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is possible to align the NanS from T. forsythia and other
Bacteroidetes based on the sequence blocks first characterized by
Rangarajan et al. [30] (Figure 1B) with high levels of conservation,
the identity with the E. coli sequence that is the founder member
of the group is low. When one examines the presence of the
conserved sequence blocks it is clear that the Bacteroidetes NanS
C-terminal domains contain the signature extended GQSN motif
(block I), the conserved glycine in block II, which actually seems
to be part of a larger GGS motif and the QGES motif of block III.
Unlike E. coli, which lacks an obvious asparagine residue within
the SGNH schema, the Bacteroidetes, the Capnocytophaga and
the human sequence all contain a putative catalytic asparagine
residue (Asn403 in T. forsythia); however, its role in these enzymes
is unclear given its absence from E. coli NanS, which is fully
active. One absentee from the Bacteroidetes, Capnocytophaga
and human sequences, however, is an obvious catalytic histidine
(His301 within RSSH motif in E. coli), although we suggest
that the DVH motif that is conserved across the Bacteroidetes
group might represent a variant on the DXXH present in group
I SGNH hydrolases, although this has not yet been confirmed
experimentally by point mutagenesis or other means. It is also
of note that at least in the conserved blocks these bacterial
domains also align well with the human SIAE (SiAlate Esterase)
gene (Figure 1) [31], indicating that this GQSN-containing SIAE
domain may well represent a common catalytic domain for SIAE
activity in biology.
Purified NanS enzyme is a highly active sialate-O-acetylesterase
To test our hypothesis that nanS encodes an esterase enzyme
with specificity for acetyl groups contained within diacetylated
sialic acids (i.e. Neu5,9Ac2 or Neu5,4Ac2), we first investigated
whether purified NanS was active against the model and widely
used esterase substrate pNP-Ac. To achieve this, we cloned NanS
into a GST-fusion vector and expressed it in E. coli before
purification via GST-affinity chromatography and release of the
soluble untagged protein via thrombin cleavage of the NanS
protein from its GST-fusion partner (Supplementary Figure S2).
When pNp-Ac was incubated with NanS protein, we observed
rapid cleavage of this substrate via measurement of release of
free pNP at 405 nm (results not shown). In order to more fully
characterize activity of NanS, we then assessed its ability to
cleave pNP-Ac over a range of pH values by incubating NanS
(25 nM) in the presence of 0.1 mM pNP-Ac. As illustrated in
Figure 2(A), NanS is active over a wide range pH values (6–8.4)
with an optimum in the neutral range 7.2–7.6. Purified NanS was
also highly stable, with only marginal loss of activity when the
enzyme was incubated at ambient temperature for 72 h (results
not shown). We then set out to establish the kinetic parameters
of the enzyme with this pNP-Ac by assessing initial reaction
velocity (V0, μmol/min per mg of NanS) over a range of substrate
concentrations as illustrated in Figure 2(B). These data reveal
that the enzyme seems to obey Michaelis–Menten type, one-step
binding kinetics with the pNP-Ac substrate over the range of
concentrations used with a Km of 51.2 μM (+−1.9 μM) and a Vmax
of 166.6 μmol/min per mg of NanS (+−0.004 μM). In addition
we calculated kcat at 111 s− 1 and a specificity constant (kcat/Km) of
2.2 × 106 M− 1·s− 1. Despite the presence of two potential catalytic
domains, we found no evidence, using pNP-Ac as substrate, that
any co-operativity between these potential domains existed from
a Hill plot of the data [i.e. log(v/Vmax – v)] which revealed a Hill
number of 0.97 (results not shown).
In order to assess whether NanS in fact acted upon
its hypothesized in vivo substrate, albeit in its monomeric
Figure 2 Biochemical characterisation of NanS with p-nitrophenol acetate
(pNP-Ac)
(A) pH optimum of NanS with pNP-Ac (0.1 mM) using 2.5 nM NanS. Released pNP was
measured at 405 nM. A combination of buffers was used to assay across pH ranges with
reactions quenched with 1 M Na2CO3. Experiments were performed with three separate protein
preparations each in triplicate, mean and S.D. are shown. (B) Initial reaction velocities of NanS
(2.5 nM) with pNP-Ac substrate (concentrations indicated) in 50 mM phosphate, 150 mM NaCl
(pH 7.4). Rates were established using a pNP standard curve that were used to derive values for
K m. Experiments were performed with three separate protein preparations with mean and S.D.
shown.
unconjugated form, i.e. the diacetylated sialic acid of Neu5,9Ac2
we performed hydrolysis reactions by incubating NanS (1 μl,
0.7 mg/ml) with (DMB-)Neu5,9Ac2 standards at 25 ◦C overnight,
i.e. to completion. These sialic acids were then labelled with
the fluorophore DMB before analysis by reverse-phase Ultra
High Perfomance Liquid Chromatography (UHPLC). The data
revealed that the Neu5,9Ac2 was completely transformed into
Neu5Ac by NanS (Figure 3). It is also of note that the Neu5,9Ac2
standard contained a small amount of another contaminating
peak in the standard trace which is also degraded by NanS
(indicated in middle panel of Figure 3) which we propose are
Neu5,8Ac2 and Neu5.7Ac2. In order to establish whether NanS
acted upon the other prominent mammalian sialic acid Neu5,4Ac2,
we performed a similar experiment with a pure preparation of
Neu5,4Ac2 and revealed that no degradation of the Neu5,4Ac2
peak at approximately 16.5 min occurred and indicating that NanS
does not act upon this sugar.
To investigate the substrate specificity more thoroughly, we
incubated NanS with a SRP sample that contains a range of
diacetylated NeuAc and NeuGc monosaccharides (Figure 4).
These data revealed that NanS caused the disappearance of
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Figure 3 Activity of NanS against mono-O-acetylated sialic acid standards
Fluorescently labelled (DMB) (A) Neu5,9Ac2 and (B) Neu5,4Ac2 was incubated overnight (25◦C) with 5 μl (0.7mg/ml) of NanS (bottom) and compared with DMB–Neu5Ac standards (not shown)
by UHPLC. Elution times are shown on the x-axis and relative intensity as stacked images.
not only Neu5,9Ac2 peaks, but also Neu5Gc,9Ac alongside
Neu5,7Ac2 and Neu5,8Ac2 peaks, although Neu5,7 and
Neu5,8Ac2 may not be acted upon directly, but rather reflect
transesterification occurring in the samples. At this point, we
have no knowledge of its action on triacetylated forms.
NanS potentiates activity of Tannerella sialidase activity on
physiologically relevant substrates
Based on genomic data, our hypothesis was that the role of NanS
in vivo is to aid in the efficient harvest of sialic acid from human
glycoproteins in the oral cavity for uptake and utilization by
T. forsythia. We therefore designed an experiment to test whether
NanS enhanced the action of the T. forsythia NanH sialidase
enzyme in removing sialic acids from the highly sialylated and
diacetylated substrate, bovine submaxillary mucin where 25–
80% of sialic acid is 9-O-acetylated depending on the batch
[10,34,35] and which we had previously shown was a less efficient
substrate for NanH than a non-diacetylated substrate such as fetuin
[9].
As illustrated in Figure 5(A), incubation of mucin with NanS
alone resulted in no release of sialic acid as measured by the
TBA assay [23]. However, on the addition of 100 nM NanH, only
90 pmol/min was released per min, whereas addition of equimolar
amounts of NanS (100 nM) resulted in the amount of sialic acid
released increasing over 4-fold, indicating that NanS allows more
access to sialic acid for cleavage by NanH. In addition these data
reveal indirectly that NanS is able to release sialic acid from an
intact glycoprotein containing Neu5,9Ac2 and other variants.
NanS acts upon gingival cell-associated diacetylated sialic acid
To further test the ability of NanS to deacetylate sialic acids
from protein substrates, we also tested the ability of NanS to
cleave acetyl groups from the surface of oral epithelial cells
by incubating NanS with H357 oral squamous cell carcinoma
(tongue) cells, followed by staining with the diacetylated sialic
acid-specific lectin CCA (green channel). Figure 4(B) shows that
upon addition of NanS, CCA-specific green staining is lost from
the surface of H357 cells. When this green fluorescence was
measured in relation to the number of cells, this visual observation
was corroborated (Figures 5B and 5C), further illustrating the
ability of NanS to access potential in vivo substrates on relevant
human cell lines.
To further elucidate the potential role for NanS in vivo in
interactions with sialic acids on the surface of human cells, we
next asked whether NanS would increase the removal of sialic
acid from human oral epithelial cells by its cognate sialidase
NanH (much like the mucin experiment outlined above). In this
case, we performed staining of the cells with the α-2,6-linkage-
specific Neu5Ac lectin SNA and then treated cells with NanS or
NanH alone or NanH plus NanS in concert, revealing an increase
in sialic acid release from the surface of these cells as assayed by
means of mean fluorescence per cell (Figures 5D and 5E).
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Figure 4 Activity of NanS against a sialic acid reference panel
DMB-labelled Ludger Sialic acid Reference panel (SRP) was incubated with overnight (25◦C)
with 1 μl (0.7 mg/ml) of NanS (bottom) and compared with undigested standards (top) by
reverse-phase HPLC. Elution times are shown on the x-axis and relative intensity as stacked
images. Sugars are described using standard nomenclature.
NanS activity against total N-glycans from a heavily glycosylated
human protein
We next tested the ability of NanS to remove acetyl groups
from diacetylated sialic acids from a well-characterized human
glycoprotein, namely rH-EPO. Following digestion of the 2-AB,
labelled N-glycans released from rH-EPO with NanS in vitro
overnight at 37◦C samples were analysed by HILIC–UPLC. We
observed that a number of the peaks either disappear (peaks 10, 19
and 23a in Figure 6; Supplementary Table S1) or reduce following
treatment with NanS enzyme. When the glycan structure of these
peaks was assessed from the undigested samples by MS, they
were revealed to contain one O-acetyl group within the three
or four terminal sialic acid residues of these triantennary and
complex tetrantennary glycan structures (Figure 6, upper panel;
Supplementary Table S2). Since NanS is unable to act upon
Neu5,4Ac2, we can infer that these peaks contain Neu5,9 (7 or
8) and that NanS can act upon native complex human type N-
glycans, such as those known to be present in rH-EPO [20].
DISCUSSION
In the present paper, we report the initial characterization of
a novel type of sialate-acetylesterase from the oral pathogen
T. forsythia. Activity of the purified enzyme, NanS, was high
with the model esterase substrate pNP-Ac where the enzyme
displayed a neutral pH optimum, which one might expect given
the physiological environment in which Tannerella finds itself
in vivo, i.e. in the periodontal pocket, where pH is known to
be neutral to alkaline [36]. This pH optimum is typical of other
sialate-O-acetylesterases from both viral and mammalian sources
[37]. It displays a similarly high affinity (μM) for pNP-Ac when
compared with other sialate-O-acetylesterases from viral sources
[38,39], but differs in that it is able, based on evidence of the
present study, to target mucin-conjugated diacetylated sialic acids,
in keeping with the potential role of T. forsythia NanS in enabling
release of sialic acids from mucinous sources in their environment.
We also established that NanS is able to hydrolyse acetyl
groups from a diacetylated Neu5,9Ac2 monosaccharide standard,
but not Neu5,4Ac2, as assayed using DMB-labelled derivatives
(Figure 3). Both the main Neu5,9Ac2 peak and the two additional
peaks that are Neu5,8Ac2 and Neu5,7Ac2 [15] disappeared
after incubation of monosaccharide with NanS. However, it
is unclear whether the enzyme acts directly on Neu5,8Ac2 or
Neu5,7Ac2 because these exist in equilibrium with Neu5,9Ac2
and can spontaneously convert into Neu5,9Ac2 under the neutral
conditions and long incubation times used here [40]. Thus we
propose that NanS is likely to be specific for Neu5,9Ac2, although
we cannot rule out Neu5,7Ac2 and Neu5,8Ac2-specific activity.
In the present study we also show activity of NanS against both
cell-bound glycoproteins, as evidenced by loss of CCA lectin
staining on H357 cells and mucinous secretions alongside released
human N-glycans. It is also of note that NanS can act upon the
glycolyl-containing Neu5Gc,9Ac, a form of sugar that is prevalent
in mammalian hosts but also likely to be present in secretions and
cell-surface glycans in the oral cavity due to cross-feeding of oral
glycans from dietary sources.
In addition we show that NanS is active in deacetylation of
diacetylated sialic acids on three highly branched triantennary
and tetrantennary glycans (FA3G3S3Ac1, FA4G4S4Ac1 and
FA4G4Lac1S4Ac1) from the important pharmaceutical protein
EPO, which is heavily N-glycosylated and contains a high
amount of terminally sialylated glycans including a significant
amount of diacetylated sialic acids [41,42]. Several brands of
EPO are produced in CHO cells which have been identified
as capable of acetylating sialic acids with up to six extra
acetyl groups in this biopharamaceutical [20]. The NanS enzyme
could be a useful tool in identifying the structures present on
recombinant EPO with respect to the presence of different variants
of diacetylated sialic acids, as changes in the glycan fingerprints
for EPO need to be monitored for batch to batch consistency
for biopharmaceutical productions and in identification of
microheterogeneity in glycan fingerprints of EPO produced from
different sources that are important in monitoring anti-doping
activity [42,43]. Taken together, although we do not have kinetic
data for these complex substrates, it is clear from our evidence
that NanS can act on physiologically relevant complex N- and
O-glycans in free (monosaccharide) as protein-conjugated or free
glycans.
Our hypothesis at the beginning of the present study was
that the sialate acetylesterase activity of NanS contributed to
opening up the accessibility of sialic acid for cleavage by the
T. forsythia sialidase NanH. Thus it was reassuring to find that
when the NanH sialidase is co-incubated with NanS, its ability
to catalyse the release of sialic acid from mucin was increased
significantly (Figure 5). This is of importance not only to T.
forsythia where this ability to access diacetylated sialic acid
means T. forsythia maximizes its ability to harvest and utilize
sialic acid in its environmental niche in the oral cavity, but
also to the oral microbial community. For example, although
several cohabiting organisms possess sialidases enzymes, namely
Porphyromonas gingivalis and Treponema denticola, they do not
possess NanS homologues raising the possibility that Tannerella
may contribute to the overall community ability to access sialic
acids, i.e. a ‘public-good’ phenotype. Our data also hint that NanS
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Figure 5 Action of NanS (and NanH sialidase) on mucinous and human epithelial cell sialloglycans
(A) Co-incubation of 3 μM bovine submaxillary mucin with 100 nM T. forsythia NanH and NanS, as indicated. Reactions were incubated for 30 min at 37◦C before free sialic acid was assayed
using a modified TBA (see the Materials and method section). Free Neu5Ac was used to generate a standard curve. Assays are shown from triplicate enzyme reactions with S.D. displayed. One-way
ANOVA was used to test statistical significance (*P < 0.001). (B) Oral squamous cell carcinoma H357 cells were incubated with NanS (50 nM) for 1 h at 37◦C, fixed and stained with FITC- (green)
labelled CCA lectin and DAPI (blue). Exposure time and weighting for both DAPI and FITC fluorescence was kept consistent between conditions. (C) Images were processed in ImageJ; background
subtraction and MFI per cell calculations were carried out using the same parameters for each condition; MFI per cell is shown with S.D. for three fields of view (approximately 60 cells), Student’s
t test was used to assess significance (P = 0.0276). (D) Oral squamous cell carcinoma H357 cells were incubated with NanS (50 nM) or NanS and NanH (50 nM each) for 30 min at 37◦C, stained
with FITC- (green) labelled SNA lectin and DAPI (blue) before fixing. During fluorescent microscopy, exposure time and weighting for both DAPI and FITC fluorescence was kept consistent between
conditions. (E) Images were processed in ImageJ; background subtraction and MFI per cell calculations were carried out using the same parameters for each condition and MFI per cell shown with
S.D. for three fields of view (approximately 60 cells), Student’s t test was used to assess significance (P = 0.0219).
may contribute to human cell interactions since they both access
human glycan diacetylated sialic acid and potentiate sialidase
access when incubated with human cells. This co-activity of a
sialate esterase and sialidases is not unprecedented in biology,
since there is evidence that the influenza C virus uses sialate-
O-acetylesterase not only as a receptor-destroying enzyme but
also to enhance the activity of its neuraminidase, but certainly
this is the first example in the context of bacteria in oral cavity
community [44]. At a mechanistic level our previous work has
suggested that the Nan operon of T. forsythia should be considered
a sialic acid-specific PUL that contains catabolic, transport and
harvesting genes [3,5]. It is therefore tempting to speculate that
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Figure 6 Characterisation of specific glycans targetted by NanS within the N-glycan complement of Erythropoietin (EPO)
Plots of HILIC–UHLPC profiles of 2-AB-labelled N-glycans released from EPO using PNGase F after overnight incubation of EPO with (middle) or without (upper) 1 μl of NanS (0.7 mg/ml). An
overlaid plot is also shown (lower) and peaks of interest that are assumed to contain Neu5,9Ac2 are highlighted with a circle and their glycan structures (as derived by MS of procainamide-labelled
N-glycans; Supplementary Table S2) are depicted according to the CFG notation; blue square, N-acetylglucosamine; green circle, mannose; yellow circle, galactose; red triangle, fucose; purple
diamond, sialic acid. Acetyl group present on one of the sialic acids is also labelled as Ac1.
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NanS might interact with either or both the NanH sialidase and
the NanOU transport system either being localized on the cell
surface or in a secreted form, as seems to be the case for NanH
and NanU [3]. These questions are currently under investigation
in our laboratory.
Another biological consequence of NanS activity on top of its
potential importance to the nutritional physiology of T. forsythia
is that the ability to produce a sialate-O-acetylesterase might
influence the immune response to this organism. Specifically there
is evidence that conversion of Neu5,9Ac2 paraformaldehyde for
15 min at 37 ◦C., to Neu5Ac on the surface of B-cells influences
several autoimmune diseases [16], leading one to speculate
that this might also be occurring in periodontal disease where
alterations in immune responses are known to influence not only
the local symptoms of the disease, but also its systemic sequelae
[45,46]. A role for the influence of diacetylation of sialic acids in
cancer is also documented, although how this might be influenced
by bacterial enzymes either in the oral cavity or elsewhere is not
clear [18,47].
As mentioned above, analysis of the predicted domain
structure of NanS, suggests a novel domain architecture that
differs from the only other characterized bacterial sialate-
O-acetylesterase, namely the NanS from E.coli [30,33]. In
short, NanS from T. forsythia contains two putative sialate-O-
acetylesterase domains, one of SGNH type I and one of SGNH
type II, proposed recently in relation to NanS from E. coli [30].
This domain architecture seems to be present in a range of
bacteria of the phylum Bacteroidetes, which includes Prevetolla,
Capnocytophaga, Bacteroides and Parabacteroides spp. among
others, but not outside this group. The type I SGNH sialate
esterase domains contain the invariant SGNH residues with the
Bacteroidetes sequences clustering closely but also sharing these
with viral enzymes. In contrast, the type II SGNH sialate-O-
acetylesterases contain conserved sequence motifs that are shared
across sialate esterases from Bacteroidetes, Enterobacteriaciae
and humans, namely GQSN and QGES (blocks I and III).
However, many questions remain, namely which is the catalytic
histidine residue in the Bacteroidetes type II domain and more
importantly what the role of the two putative acetylesterase
domains is in interaction with and hydrolysis of diacetylated sialic
acids.
In summary, we have begun to characterize a novel prototype
member of a two-domain class of sialate-O-acetylesterases that
may play a role in both the in vivo physiology of human
pathogens and the commensals in the oral cavity and potentially
the gut. This ability to harvest diacetylated sialic acids might
confer an advantage on T. forsythia and other oral organisms in
harvesting sialic acid for nutrition. In addition, there is much
evidence that sialic acid is the key to the interaction of many
human bacterial and viral pathogens with human cells in both
epithelial layers [28] and the immune system, and one assumes
that possessing sialate-O-acetylesterase activity contributes to this
process. Whether this hypothesis is true or not, it is likely that
oral bacteria encounter diacetylated sialic acids in abundance with
both secreted and membrane-bound mucins containing significant
amounts of diacetylated sialic acids, but also the presence of
diacetylated sialic acid epitopes present on oral epithelial cells
as evidenced by CCA lectin staining and co-incubations with
sialidases reducing SNA staining. One observation in the present
study is that the enzyme characterized here bears strong homology
with other putative enzymes encoded in the chromosomes of
several gut-dwelling Bacteroidetes, such as B. fragilis, indicating
that this ability to harvest diacetylated sialic acids is also important
in the mucin-rich environment that is the human gut [12], as well
as the oral cavity.
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